0001437749-17-003640.txt : 20170302 0001437749-17-003640.hdr.sgml : 20170302 20170302131355 ACCESSION NUMBER: 0001437749-17-003640 CONFORMED SUBMISSION TYPE: S-1 PUBLIC DOCUMENT COUNT: 15 FILED AS OF DATE: 20170302 DATE AS OF CHANGE: 20170302 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AmeriCann, Inc. CENTRAL INDEX KEY: 0001508348 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742] IRS NUMBER: 274336843 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: S-1 SEC ACT: 1933 Act SEC FILE NUMBER: 333-216397 FILM NUMBER: 17657878 BUSINESS ADDRESS: STREET 1: 3200 BRIGHTON BLVD. STREET 2: UNIT 114 CITY: DENVER STATE: CO ZIP: 80216 BUSINESS PHONE: 303-898-9832 MAIL ADDRESS: STREET 1: 3200 BRIGHTON BLVD. STREET 2: UNIT 114 CITY: DENVER STATE: CO ZIP: 80216 FORMER COMPANY: FORMER CONFORMED NAME: Americann, Inc. DATE OF NAME CHANGE: 20140516 FORMER COMPANY: FORMER CONFORMED NAME: Nevada Health Scan, Inc. DATE OF NAME CHANGE: 20101220 S-1 1 acan20170208_s1.htm FORM S-1 acan20170208_s1.htm

As filed with the Securities and Exchange Commission on ______, 2017

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S-1

 

Registration Statement Under

THE SECURITIES ACT OF 1933

 

        AMERICANN, INC.          
(Exact name of registrant as specified in charter)

 

Delaware

 

000-54231

 

27-4336843

(State or other jurisdiction

of incorporation)

 

(Primary Standard Classi-

fication Code Number)

 

(IRS Employer

 I.D. Number)

 

 

3200 Brighton Blvd., Unit 144
Denver, CO 80216

                     (303) 862-9000                    

(Address and telephone number of principal executive offices)

 

 

3200 Brighton Blvd., Unit 144
                              Denver, CO 80216                         

(Address of principal place of business or intended principal place of business)

 

 

Timothy Keogh

3200 Brighton Blvd., Unit 144
Denver, CO 80216

                    (303) 862-9000                  

(Name, address and telephone number of agent for service)

 

Copies of all communications, including all communications sent

to the agent for service, should be sent to:

 

William T. Hart, Esq.

Hart & Hart, LLC

1624 Washington Street

Denver, Colorado 80203

303-839-0061

 

As soon as practicable after the effective date of this Registration Statement

APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC:

 

 
 

 

  

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: [x]

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    [  ]

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.    [  ]

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.     [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b2 of the Exchange Act.

 

Large accelerated filer [  ]

Accelerated filer [  ]

 

 

Non-accelerated filer   [  ]

Smaller reporting company [X]

(Do not check if a smaller reporting company)

 

 

CALCULATION OF REGISTRATION FEE  
                             

Title of each

         

Proposed

   

Proposed

         

Class of

         

Maximum

   

Maximum

         

Securities

 

Securities

   

Offering

   

Aggregate

   

Amount of

 

to be

 

to be

   

Price Per

   

Offering

   

Registration

 

Registered

 

Registered

   

Share (1)

   

Price

   

Fee

 
                                 

Common Stock (2)

    4,150,000       $4.15       $17,222,500       $2,002  

 


 

(1)

Offering price computed in accordance with Rule 457.

 

(2)

Shares of common stock offered by selling shareholders.

 

 

 

The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of l933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

 

 

 

 

PROSPECTUS

AMERICANN, INC

 

Common Stock

 

 

By means of this prospectus, a number of our shareholders are offering to sell up to:

 

 

2,000,000 shares of our common stock which they acquired in a private offering, or which they may acquire upon the exercise of our Series I warrants;

 

 

2,000,000 shares of our common stock exercisable upon the exercise of our Series I warrants, which the investors acquired in the private offering; and

 

 

150,000 shares of our common stock which three of our shareholders may acquire upon the exercise of our Series II and III warrants.

 

 

Although we will receive proceeds if any of the warrants are exercised, we will not receive any proceeds from the sale of the common stock by the selling stockholders. We will pay for the expenses of this offering which are estimated to be $50,000.

 

Our common stock is traded on the over-the-counter market under the symbol ACAN. On February 23, 2017 the closing price for our common stock was $5.05.

 

As of the date of this prospectus there was no public market for our warrants, and we do not expect a market to develop in the future.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.

 

These securities are speculative and involve a high degree of risk. For a description of certain important factors that should be considered by prospective investors, see "Risk Factors" beginning on page 8 of this Prospectus.

 

 

 

 

 

 

 

 

 

 

 

The date of this prospectus is February ___, 2017.

 

 
1

 

  

PROSPECTUS SUMMARY

 

AmeriCann plans to offer a comprehensive, turnkey package of services that includes consulting, design, construction and financing to approved and licensed marijuana operators throughout the United States. Our business plan is based on the anticipated growth of the regulated marijuana market in the United States.

 

AmeriCann’s team includes board members, consultants, engineers and architects who specialize in real estate development, traditional horticulture, lean manufacturing, medical research, facility construction, regulatory compliance, security, marijuana cultivation and genetics, extraction processes, and infused product development.

 

The expanding cannabis industry requires extensive real estate to meet the growing needs of the market for cannabis products. AmeriCann assists our Preferred Partners with the identification, design, permitting, acquisition, development and operation of scalable infrastructure to cultivate and to dispense medical cannabis in regulated markets.

 

The Offering

 

Between October 27, 2016 and November 7, 2016, we sold 2,000,000 units to investors in a private offering at a price of $1.00 per unit. Each unit consisted of one share of our common stock and one Series I warrant. Each Series I warrant allows the holder to purchase one share of our common stock at a price of $3.00 per share at any time on or before November 4, 2020.

 

On September 15, 2016, the Company borrowed $75,000 from three unrelated parties. The notes bear interest at 12% per year, are unsecured, and are due and payable on January 14, 2017. At the option of the holder, the notes may be converted into shares of the Company’s common stock at a conversion price of $0.75 per share. As additional consideration for the loans, the Company issued 75,000 Series II warrants and 75,000 Series III warrants to the lenders. Each Series II warrant allows the holder to purchase one share of our common stock at a price of $0.75 per share. Each Series III warrant allows the holder to purchase one share of our common stock at a price of $1.25 per share. The Series II and Series III warrants expire on December 15, 2020.

 

By means of this prospectus:

 

 

a number of shareholders are offering to sell up to:

 

 

-

2,000,000 shares of our common stock, as well as up to 2,000,000 shares of our common stock which are issuable upon the exercise of our Series I warrants, which they acquired in a private offering; and

 

 

-

150,000 shares of our common stock which are issuable upon the exercise of our Series II and III warrants.

 

See the section of this prospectus entitled “Selling Shareholders” for more information.

 

 
2

 

 

As of February 23, 2017 we had 19,131,000 outstanding shares of common stock. The number of our outstanding shares does not include:

 

 

shares issuable upon the exercise of the Series I, II or III warrants; or

 

 

shares issuable upon the exercise of options and warrants granted to our officers, directors and other persons. See the section of this prospectus captioned “Market For Our Common Stock” for more information concerning these securities.

 

The purchase of the securities offered by this prospectus involves a high degree of risk. Risk factors include the lack of any relevant operating history, losses since we were incorporated, and the possible need us to sell shares of our common stock to raise capital. See “Risk Factors” section of this prospectus below for additional Risk Factors.

 

Forward-Looking Statements

 

This prospectus contains or incorporates by reference "forward-looking statements," as that term is used in federal securities laws, concerning our financial condition, results of operations and business. These statements include, among others:

 

 

statements concerning the benefits that we expect will result from our business activities; and

 

 

statements of our expectations, beliefs, future plans and strategies, anticipated developments and other matters that are not historical facts.

 

You can find many of these statements by looking for words such as "believes," "expects," "anticipates," "estimates" or similar expressions used in this prospectus.

 

These forward-looking statements are subject to numerous assumptions, risks and uncertainties that may cause our actual results to be materially different from any future results expressed or implied in those statements. Because the statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied. We caution you not to put undue reliance on these statements, which speak only as of the date of this prospectus. Further, the information contained in this prospectus, or incorporated herein by reference, is a statement of our present intention and is based on present facts and assumptions, and may change at any time.

 

RISK FACTORS

 

Investors should be aware that this offering involves certain risks, including those described below, which could adversely affect the value of our common stock. We do not make, nor have we authorized any other person to make, any representation about the future market value of our common stock. In addition to the other information contained in this prospectus, the following factors should be considered carefully in evaluating an investment in our securities.

 

 
3

 

 

We have a limited operating history, and may never be profitable. Since we have only limited operations and have an unproven business plan, it is difficult for potential investors to evaluate our business. There can be no assurance that we will be profitable or that the securities which may be sold in this offering will have any value.

 

We need additional capital to implement our business plan. We need additional capital to construct the first phase of the MMCC project (approximately $18,000,000), as well as to offer our full range of planned services to the cannabis industry. However, we will not receive any proceeds from the sale of our common stock by the selling shareholders. We do not know what the terms of any future capital raising may be but any future sale of our equity securities will dilute the ownership of existing stockholders and could be at prices substantially below the market price of our common stock. Our failure to obtain the capital which we require may result in the slower implementation of our business plan.

 

We may be unable to acquire the properties that are critical to our proposed business. Our business plan involves the acquisition of properties which will be sold or leased to licensed marijuana growers and dispensary owners for their operations. There can be no assurance that we will be able to obtain the capital needed to purchase any properties.

 

Our proposed business is dependent on laws pertaining to the marijuana industry. Continued development of the marijuana industry is dependent upon continued legislative authorization of marijuana at the state level.  Any number of factors could slow or halt progress in this area.  Further, progress for the industry, while encouraging, is not assured.  While there may be ample public support for legislative action, numerous factors impact the legislative process.  Any one of these factors could slow or halt use of marijuana, which would negatively impact our proposed business.

 

As of January 31, 2017, 28 states and the District of Columbia allow its citizens to use medical marijuana. Voters in the states of Colorado, Washington, Alaska, Oregon and the District of Columbia have approved ballot measures to legalize cannabis for adult use. The state laws are in conflict with the federal Controlled Substances Act, which makes marijuana use and possession illegal on a national level. The former Obama administration has effectively stated that it is not an efficient use of resources to direct law federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws allowing the use and distribution of medical marijuana. However, there is no guarantee that the administration will not change its stated policy regarding the low-priority enforcement of federal laws. Additionally, the new Trump administration could change this policy and decide to enforce the federal laws strongly. Any such change in the federal government’s enforcement of current federal laws could cause significant financial damage to us and our shareholders.

 

Further, and while we do not intend to harvest, distribute or sell cannabis, if we lease buildings to growers of marijuana we could be deemed to be participating in marijuana cultivation, which remains illegal under federal law, and exposes us to potential criminal liability, with the additional risk that our properties could be subject to civil forfeiture proceedings.

 

 
4

 

 

The marijuana industry faces strong opposition. It is believed by many that large well-funded businesses may have a strong economic opposition to the marijuana industry.  We believe that the pharmaceutical industry clearly does not want to cede control of any product that could generate significant revenue.  For example, medical marijuana will likely adversely impact the existing market for the current “marijuana pill” sold by mainstream pharmaceutical companies.  Further, the medical marijuana industry could face a material threat from the pharmaceutical industry, should marijuana displace other drugs or encroach upon the pharmaceutical industry’s products.  The pharmaceutical industry is well funded with a strong and experienced lobby that eclipses the funding of the medical marijuana movement.  Any inroads the pharmaceutical industry could make in halting or impeding the marijuana industry could have a detrimental impact on our proposed business.

 

Marijuana remains illegal under Federal law. Marijuana is a schedule-I controlled substance and is illegal under federal law.  Even in those states in which the use of marijuana has been legalized, its use remains a violation of federal law. Since federal law criminalizing the use of marijuana preempts state laws that legalize its use, strict enforcement of federal law regarding marijuana would likely result in our inability to proceed with our business plan.

 

Laws and regulations affecting the medical marijuana industry are constantly changing, which could detrimentally affect our proposed operations. Local, state and federal medical marijuana laws and regulations are broad in scope and subject to evolving interpretations, which could require us to incur substantial costs associated with compliance or alter our business plan. In addition, violations of these laws, or allegations of such violations, could disrupt our business and result in a material adverse effect on our operations. In addition, it is possible that regulations may be enacted in the future that will be directly applicable to our proposed business.   We cannot predict the nature of any future laws, regulations, interpretations or applications, nor can we determine what effect additional governmental regulations or administrative policies and procedures, when and if promulgated, could have on our business.  

 

Potential competitors could duplicate our business model. There is no aspect of our business which is protected by patents, copyrights, trademarks, or trade names. As a result, potential competitors could duplicate our business model with little effort.

 

We are dependent on our management team and the loss of any of these individuals would harm our business. Our future success depends largely upon the management experience, skill, and contacts of our officers and directors. The loss of the services of either of these officers, whether as a result of death, disability or otherwise, may have a material adverse effect upon our business.

 

We have been named as a defendant in an arbitration claim. An unrelated third party filed an arbitration claim against us seeking damages for failure to deliver a stock option agreement. In filing an answer to the arbitration claim, we intend to assert the defense that the unrelated third party has not been damaged since the exercise price of the options far exceeds the market value of our common stock.

 

 
5

 

 

The applicability of "penny stock rules" to broker-dealer sales of our common stock may have a negative effect on the liquidity and market price of our common stock. Trading in our shares is subject to the "penny stock rules" adopted pursuant to Rule 15g-9 of the Exchange Act, which apply to companies that are not listed on an exchange and whose common stock trades at less than $5.00 per share or which have a tangible net worth of less than $5,000,000, or $2,000,000 if they have been operating for three or more years. The penny stock rules impose additional sales practice requirements on broker-dealers which sell such securities to persons other than established customers and institutional accredited investors. For transactions covered by this rule, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser's written consent to the transaction prior to sale. Consequently, the penny stock rules may affect the ability of broker-dealers to sell shares of common stock and may affect the ability of shareholders to sell their shares in the secondary market, as compliance with such rules may delay and/or preclude certain trading transactions. The rules could also have an adverse effect on the market price of our common stock.

 

These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for our common stock. Many brokers may be unwilling to engage in transactions in our common stock because of the added disclosure requirements, thereby making it more difficult for shareholders to dispose of their shares. You may also find it difficult to obtain accurate information about, and/or quotations as to the price of our common stock.

 

We may issue shares of preferred stock that would have a liquidation preference to our common stock. Our articles of incorporation currently authorize the issuance of 20,000,000 shares of our preferred stock. The board has the power to issue shares without shareholder approval, and such shares can be issued with such rights, preferences, and limitations as may be determined by our board of directors. The rights of the holders of common stock will be subject to, and may be adversely affected by, the rights of any holders of preferred stock that may be issued in the future. We presently have no commitments or contracts to issue any shares of preferred stock. Authorized and unissued preferred stock could delay, discourage, hinder or preclude an unsolicited acquisition of our company, could make it less likely that shareholders receive a premium for their shares as a result of any such attempt, and could adversely affect the market prices of, and the voting and other rights, of the holders of outstanding shares of our common stock.

 

Our auditors have expressed doubt as to our ability to continue in business. The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $6,421,696 and $5,904,931 at December 31, 2016 and September 30, 2016, respectively, and had a net loss of $516,765 for the three months ended December 31, 2016. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern. While the Company is attempting to increase operations and generate additional revenues, the Company's cash position may not be significant enough to support the Company's daily operations.

 

 
6

 

  

Market for OUR Common STOCK.

 

Our common stock is quoted on the OTCQX and OTC Bulletin Board under the trading symbol “ACAN”.  There has been limited trading of our common stock since trading began on July 10, 2014.

  

Shown below is the range of high and low closing prices for our common stock as reported by the OTCQX or OTC Bulletin Board for the periods presented: 

 

Quarter Ended

 

High

   

Low

 
                 

December 31, 2014

  $ 1.45     $ 0.55  

March 31, 2015

  $ 1.01     $ 0.55  

June 30, 2015

  $ 0.96     $ 0.30  

September 30, 2015

  $ 0.90     $ 0.40  
                 

December 31, 2015

  $ 0.74     $ 0.46  

March 31, 2016

  $ 0.55     $ 0.40  

June 30, 2016

  $ 1.21     $ 0.55  

September 30, 2016

  $ 1.16     $ 0.52  
                 

December 31, 2016

  $ 3.65     $ 0.62  

 

Holders of our common stock are entitled to receive dividends as may be declared by the Board of Directors.  Our Board of Directors is not restricted from paying any dividends but is not obligated to declare a dividend.  No cash dividends have ever been declared and it is not anticipated that cash dividends will ever be paid.  We currently intend to retain any future earnings to finance future growth.  Any future determination to pay dividends will be at the discretion of our directors and will depend on our financial condition, results of operations, capital requirements and other factors the board of directors considers relevant.

 

Our Articles of Incorporation authorize the Board of Directors to issue up to 20,000,000 shares of preferred stock.  The provisions in the Articles of Incorporation relating to the preferred stock allow our directors to issue preferred stock with multiple votes per share and dividend rights, which would have priority over any dividends paid to the holders of our common stock.  The issuance of preferred stock with these rights may make the removal of management difficult even if the removal would be considered beneficial to shareholders generally, and will have the effect of limiting shareholder participation in certain transactions such as mergers or tender offers if these transactions are not favored by management.

 

As of February 22, 2017, we had 163 shareholders of record and 19,131,000 outstanding shares of common stock.

 

Other Shares Which May Be Issued

 

The following table lists additional shares of our common stock which may be issued as the result of the exercise of outstanding options or warrants:

 

   

Number of

 

Note

   

Shares

 

Reference

           

Shares issuable upon exercise of Series I Warrants

    2,000,000  

A

           

Shares issuable upon the exercise of Series II and Series III Warrants

    150,000  

B

 

 
7

 

 

   

Number of

 

Note

   

Shares

 

Reference

           

Shares issuable upon exercise or exchange of Series A Warrants sold in private offering

    1,186,500  

C

 

         

Shares issuable upon exercise of options and warrants held by our current officers, a former officer and a related party

    4,800,000  

D

 

         

Shares issuable upon exercise of options granted to third parties

    105,000  

E

 

         

Shares issuable upon conversion of note held by Strategic Capital Partners

    800,000  

F

 

         

Shares issuable upon exercise of warrants held by Massachusetts Medical Properties, LLC

    3,640,000  

G

 

A.     Between October 27, 2016 and November 7, 2016 we sold 2,000,000 units at a price of $1.00 per unit. Each unit consisted of one share of our common stock and one Series I Warrant. Each Series I Warrant entitles the holder to purchase one share of our common stock at a price of $3.00 per share at any time on or before November 4, 2020.

 

B.     On September 15, 2016 we borrowed $75,000 from three unrelated parties. The notes bear interest at 12% per year, are unsecured, and are due and payable on January 14, 2017. At the option of the holder, the notes may be converted into shares of our common stock at a conversion price of $0.75 per share. As additional consideration for the loans, we issued 75,000 Series II warrants and 75,000 Series III warrants to the lenders. Each Series II warrant allows the holder to purchase one share of our common stock at a price of $0.75 per share. Each Series III warrant allows the holder to purchase one share of our common stock at a price of $1.25 per share. The Series II and Series III warrants expire on December 15, 2020.

 

C.     In 2014 we sold 791,000 Units at a price of $3.00 per Unit. Each Unit consisted of one share of our common stock and one Series A Warrant. Each Series A Warrant entitles the holder to purchase one share of our common stock at a price of $8.00 per share. We intend to offer the holders of the Series A Warrants 1.5 shares of our common stock in exchange for each Series A Warrant. If all Series A Warrants are exchanged, the total shares outstanding will increase by 1,186,500. As of the date of this Prospectus, no shares of common stock had been issued in exchange for the Series A Warrants.

 

 
8

 

 

D.     The Company has issued warrants/options to the persons and upon the terms shown below:

 

       

Shares issuable

           
   

Date of

 

upon exercise of

   

Exercise

 

Expiration

Name

 

Issuance

 

warrants/options

   

price

 

date

                       

Strategic Capital

 

2/14/14

    1,200,000     $ 8.00  

1/22/18

Partners, LLC (1)

 

2/14/14

    600,000     $ 12.00  

1/22/18

Timothy Keogh

 

3/25/14

    800,000     $ 8.00  

1/22/18

Timothy Keogh

 

3/25/14

    400,000     $ 12.00  

1/22/18

Former officer and director

 

3/19/14

    100,000     $ 8.00  

3/28/18

Former officer and director

 

3/19/14

    100,000     $ 12.00  

3/28/18

Strategic Capital Partners, LLC (1)(2)

 

7/14/16

    800,000     $ 1.50  

6/30/20

Strategic Capital Partners, LLC (1)(2)

 

7/14/16

    800,000     $ 3.00  

6/30/20

 

(1)

Strategic Capital Partners is controlled by Benjamin J. Barton, an officer and director of the Company.

 

(2)

See “Business – Transactions with Strategic Capital Partners” for information concerning the grant of these options.

 

E.     Options are held by third parties, are exercisable at a price of $0.75 per share, and expire in 2018.

 

F.     The Note is in the principal amount of $1,000,000, bears interest 9.5% per year and matures on December 31, 2019. The Note can be converted at any time into shares of our common stock at a conversion price of $1.25 per share.

 

G.     In connection with the sale of the property to Massachusetts Medical Properties, LLC and the lease described in the “Business” section of this prospectus, we entered into an agreement with MMP pursuant to which we issued to MMP 100,000 shares of our common stock, and a warrant to purchase up to 3,640,000 shares of common stock at an exercise price of $1.00 per share. The warrant can be exercised at any time on or after October 17, 2018 and on or before October 17, 2020.

 

We may sell additional shares of our common stock, warrants, convertible notes or other securities to raise additional capital. We have not yet determined the amount of securities which we may sell, or the price at which the securities may be sold. We do not have any commitments or arrangements from any person to purchase any of our securities and there can be no assurance that we will be successful in selling any additional securities.

 

 
9

 

 

Management’s discussion and Analysis

AND plan of operation

 

Results of Operations

 

Year ended September 30, 2016

 

Total Revenues

 

During the year ended September 30, 2016, we generated $60,000 in revenue, as compared to $140,000 for the year ended September 30, 2015. The reduction in revenues reflects our amendment to reduce our consulting fees for 4900 Jackson, LLC (and its predecessor) from $10,000 per month to $5,000 per month in May 2015, and the cessation of consulting fee revenues from WGP in 2015.

 

Advertising and Marketing Expenses

 

Advertising and marketing expenses were $21,312 for the year ended September 30, 2016, as compared to $15,172 for the year ended September 30, 2015. The increase is due to increased print marketing and advertising efforts to raise the profile and awareness of the company and pursue new opportunities in our national expansion program. 

 

Professional Fees

 

Professional fees were $571,141 for the year ended September 30, 2016, as compared to $640,326 for the year ended September 30, 2015. The decrease in professional fees is primarily due to a decrease in legal expenses associated with our operations, partially offset by an increase in planning, design, and permitting costs associated with the Massachusetts Medical Cannabis Center.  

 

General and Administrative Expenses

 

General and administrative expenses were $583,739 for the year ended September 30, 2016, as compared to $835,501 for the year ended September 30, 2015.  The decrease is attributable primarily to a decrease in stock based compensation and option expense as many of our stock-based awards were granted in 2014 and were subject to short vesting periods.  This decrease was partially offset by increases in salaries and other general and administrative expenses as we continue to develop our business and expand our operations.

 

Provision for Doubtful Accounts

 

Provision for doubtful accounts was $13,229 for the year ended September 30, 2016, as compared to $456,470 for the year ended September 30, 2015.  The provision was established in 2015 and represented all amounts owed by WGP at that time (including related interest) that are not covered by a formal security agreement. Activity in 2016 represents additional reserves on related accrued interest owed by WGP.

 

 
10

 

 

Interest Income

 

Interest income was $183,255 for the year ended September 30, 2016, as compared to $213,665 for the year ended September 30, 2015. The decrease is attributable to decreases in amounts owed on our notes receivable. 

 

Interest Expense

 

Interest expense was $272,659 for the year ended September 30, 2016, as compared to $135,540 for the year ended September 30, 2015. The increase is attributable to the financing of our recent investing and operating activities primarily with debt.

 

Loss on Extinguishment of Debt

 

Loss on extinguishment of debt was $991,939 for the year ended September 30, 2016, as compared to $0 for the year ended September 30, 2015. The loss recognized in the current year is a result of the debt modifications discussed in Note 4 to the financial statements which are a part of this prospectus.

 

Net Loss

 

We had a net loss of $2,210,764 for the year ended September 30, 2016, as compared to a net loss of $1,729,344 for the year ended September 30, 2015. The increase in net loss is attributable to changes in revenues, operating expenses, interest income and expense, and loss on extinguishment of debt, each of which is described above.

 

Three months ended December 31, 2016 and 2015

 

Total Revenues

 

During the three months ended December 31, 2016 and 2015, we generated $15,000 in revenue. For both periods, all of the Company’s revenue was earned from one customer, 4900 Jackson, LLC.

 

Advertising and Marketing Expenses

 

Advertising and marketing expenses were $2,247 and $2,098 for the three months ended December 31, 2016 and 2015, respectively. The Company continues to use print marketing and advertising efforts to raise the profile and awareness of the company and pursue new opportunities in our national expansion program. 

 

Professional Fees  

 

Professional fees were $150,404 and $218,329 for the three months ended December 31, 2016 and 2015, respectively. The decrease is attributable primarily to a decrease in consulting fees associated with the planning, design and permitting of the Massachusetts Medical Cannabis Center which received unanimous Site Plan approval by the Freetown Planning Board in December of 2015.

 

 
11

 

 

General and Administrative Expenses

 

General and administrative expenses were $288,433 and $175,145 for the three months ended December 31, 2016 and 2015, respectively. The increase is attributable primarily lease expense associated with the lease agreement that commenced in October 2016.

 

Provision for doubtful accounts

 

Provision for doubtful accounts was $3,325 for the three months ended December 31, 2016 and 2015.

 

Interest Income

 

Interest income was $27,187 and $48,295 for the three months ended December 31, 2016 and 2015, respectively. The decrease is attributable to decreases in amounts owed from our clients.

 

Interest Expense

 

Interest expense was $114,543 and $53,814 for the three months ended December 31, 2016 and 2015, respectively. The increase is primarily attributable to increased interest rates and the amortization of debt discounts that are associated with the debt modifications that occurred in 2016. 

 

Net Operating Loss 

 

We had a net loss of $(516,765) and $(389,416) for the three months ended December 31, 2016 and 2015, respectively. The increase in net loss is attributable to changes in revenues, operating expenses and interest income and expense, each of which is described above.

 

Liquidity and Capital Resources

  

As of September 30, 2016, we had borrowed $2,024,297 from a Company controlled by Benjamin J. Barton, one of our officers and directors. The balance consists of two separate notes, as follows:

 

 

 ●

Convertible note of $1,000,000, net of premium of $284,229. Bears interest at 9.5% payable quarterly. The total outstanding principal balance and any accrued and unpaid interest is due on December 31, 2019. SCP has the option to convert all or any part of the principal amount into fully paid and non-assessable shares of the Company’s common stock at a conversion price of $1.25.

 

 

Secured note of $931,646, net of discount of $211,578. Bears interest at 8% payable quarterly. The total outstanding principal balance and any accrued and unpaid interest is due on December 31, 2019. The note is secured by: 1) a second lien on the Company’s property in Denver, Colorado, and 2) the Company’s claims against WGP.

 

As of September 30, 2016, we had borrowed $990,000 from a third party. The loan bears interest at 18% and is due March 15, 2017.

 

 
12

 

 

As of September 30, 2016, we had borrowed $203,247 from various third parties. As of January 31, 2017, these loans had been repaid.

 

In November 2016, we sold 2,000,000 Units at a price of $1.00 per Unit. The Units were sold in a private offering to a group of accredited investors. Each Unit consists of one share of our common stock and one Series I Warrant. Each Series I Warrant allows the holder to purchase one share of our common stock at a price of $3.00 per share at any time on or before November 4, 2020. The offering provided us with $2,000,000 in gross proceeds and the potential for an additional $6,000,000 in proceeds from the exercise of the Series I Warrants. The proceeds from the placement will be used for our MMCC development, to pursue new opportunities in California, Pennsylvania, Florida and other states, and for general corporate purposes.

  

During the year ended September 30, 2016, our cash used in operations was $540,863 as compared to net cash used in operations of $792,534 for the year ended September 30, 2015. This was primarily due to an increase in accounts payable and accrued expenses.

 

Cash flows used in investing activities were $632,510 for the year ended September 30, 2016, consisting primarily of deposits on land and advances made on related party notes receivable, offset by payments received from notes receivable. Cash flows used in investing activities were $849,075 for the year ended September 30, 2015, consisting of deposits on land, advances made on notes receivable and website development expenditures, partially offset by payments received from notes receivable.

 

Cash flows from financing activities were $972,044 for the year ended September 30, 2016, consisting of proceeds from notes payable and notes payable - related parties. Cash flows from financing activities were $1,669,006 for the year ended September 30, 2015, consisting of proceeds from notes payable, partially offset by payments on notes payable.

 

During the three months ended December 31, 2016, our net cash flows used in operations were $786,520 as compared to net cash flows used in operations of $217,603 for the three months ended December 31, 2015. The increase is primarily due to decreases in accounts payable, accrued expenses, and interest payable funded by the proceeds from our private equity offering during the three months ended December 31, 2016.

 

Cash flows provided by investing activities were $6,238 for the three months ended December 31, 2016, consisting of advances made on notes receivable of $79,993, offset by $86,231 of payments received from notes receivable. Cash flows used in investing activities were $123,453 for the three months ended December 31, 2015, consisting of a $200,000 deposit on land and minor purchases of fixed assets, partially offset by $80,876 of payments received from notes receivable. 

 

Cash flows provided by financing activities were $1,583,027 for the three months ended December 31, 2016, consisting of net proceeds from the issuance of common stock of $1,806,274, proceeds from notes payable of $24,657, offset by payments on notes payable to related parties of $20,000 and payments on notes payable of $227,904. Cash flows provided by financing activities were $180,000 for the three months ended December 31, 2015, consisting of proceeds from notes payable to related parties.

 

 
13

 

 

We do not have any firm commitments from any person to provide us with any capital.

 

As of December 31, 2016, we did not have any off balance sheet arrangements. 

 

Trends

 

The factors that will most significantly affect our future operating results, liquidity and capital resources will be:

 

 

Government regulation of the marijuana industry;

 

Revision of Federal banking regulations for the marijuana industry; and

 

Legalization of the use of marijuana for medical or recreational use in other states.

 

Other than the foregoing, we do not know of any trends, events or uncertainties that have had, or are reasonably expected to have, a material impact on:

 

 

revenues or expenses;

 

any material increase or decrease in liquidity; or

 

expected sources and uses of cash.

 

Capital requirements

 

Our material capital commitments for the twelve months ending December 31, 2017 are:

 

Description

 

Amount

 

Due Date

           

Repayment of loan

  $ 990,000  

03/15/17

First phase of construction at MMCC

  $ 2,600,000  

04/17/17

 

Recent Accounting Pronouncements

 

Recent accounting pronouncements which may be applicable to us are described in Note 1 to the September 30, 2016 financial statements included as part of this prospectus.

 

Significant Accounting Policies

 

Our significant accounting policies are set forth below. We have consistently applied these policies in all material respects. We do not believe that our operations to date have involved uncertainty of accounting treatment, subjective judgment, or estimates, to any significant degree, except as it pertains to our provision for doubtful accounts associated with amounts due from WGP described in the notes to our financial statements.

 

 
14

 

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent  assets and  liabilities at the date of the financial  statements and the  reported  amounts of revenues  and expenses  during the  reporting  period. The more significant estimates and assumptions made by management are valuation of equity instruments, deferred tax asset valuation and allowance and collectability of long-lived assets. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.  See Note 3 in the Notes to the Financial Statements included as part of this prospectus for a discussion of our provision for doubtful accounts for amount amounts owed from WGP.

 

Cash and Cash Equivalents

 

Cash and cash equivalents includes cash on hand, demand deposit accounts and temporary cash investments with maturities of ninety days or less at the date of purchase.

 

Income Taxes

 

In accordance with Accounting Standards Codification (ASC) 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements.  The resulting deferred tax assets or liabilities have been adjusted to reflect changes in tax laws as they occur.  A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.

 

We expect to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a "more-likely-than-not" threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of September 30, 2016, we had no uncertain tax positions. We recognize interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. We currently have no federal or state tax examinations nor have we had any federal or state examinations since our inception. To date, we have not incurred any interest or tax penalties.

 

For federal tax purposes, our 2012 through 2016 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.

 

Concentration of Credit Risks and Significant Customers

 

Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash, notes receivables, deposits, accounts receivables and notes receivable. We place our cash with high credit quality financial institutions. As of September 30, 2016, we had outstanding notes receivable of $247,378 with 4900 Jackson, LLC, notes receivable of $117,693 with Coastal Compassion Inc., and notes and other receivables in the amount of $1,250,014 with WGP (exclusive of provision for doubtful accounts of $469,699).  See Note 3 in the Notes to the Financial Statements included as part of this prospectus for a discussion of our provision for doubtful accounts for amounts owed from WGP.

 

 
15

 

 

For the year ended September 30, 2016, all of the Company’s revenue was earned from one customer, 4900 Jackson, LLC. For the year ended September 30, 2015, revenue earned from 4900 Jackson, LLC was $100,000, or 71% of total revenues.

 

Financial Instruments and Fair Value of Financial Instruments

 

We adopted ASC Topic 820, Fair Value Measurements and Disclosures, for assets and liabilities measured at fair value on a recurring basis. ASC Topic 820 establishes a common definition for fair value to be applied to existing US GAAP that requires the use of fair value measurements that establishes a framework for measuring fair value and expands disclosure about such fair value measurements. 

 

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Topic 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

 

 

Level 1:

Observable inputs such as quoted market prices in active markets for identical assets or liabilities

 

 

Level 2:

Observable market-based inputs or unobservable inputs that are corroborated by market data

 

 

Level 3:

Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

 

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. We had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared.

 

Derivative Liabilities

 

We evaluate stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. We determined that none of our financial instruments meet the criteria for derivative accounting as of September 30, 2016 and 2015.

 

 
16

 

 

Fixed Assets

 

Our long-lived assets consisted of property and equipment and are reviewed for impairment in accordance with the guidance of the FASB Topic ASC 360, Property, Plant, and Equipment, and FASB Topic ASC 205, Presentation of Financial Statements. We test for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management's estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. Through September 30, 2016, we had not experienced impairment losses on our long-lived assets. However, there can be no assurances that demand for our products or services will continue, which could result in an impairment of long-lived assets in the future.

 

Website Development Costs

 

We recognized the costs associated with developing a website in accordance with ASC Subtopic 350-50, Website Development Cost. The website development costs are divided into three stages, planning, development and production. The development stage can further be classified as application and infrastructure development, graphics development and content development. In short, website development cost for internal use should be capitalized except content input and data conversion costs in content development stage. Costs associated with the website consist of website development costs paid to third parties. Website development amortization expense was $13,833 for the year ended September 30, 2016, and $1,153 for the year ended September 30, 2015.

 

Deferred Financing Costs

 

Deferred financing costs represent costs incurred in the connection with obtaining debt financing. These costs are amortized ratably and charged to financing expenses over the term of the related debt.

 

Equity Instruments Issued to Non-Employees for Acquiring Goods or Services

 

Issuances of our common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a "performance commitment" which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete.  

 

 
17

 

 

Although situations may arise in which counter performance may be required over a period of time, the equity award granted to the party performing the service is fully vested and non-forfeitable on the date of the agreement. As a result, in this situation in which vesting periods do not exist if the instrument is fully vested on the date of agreement, we determine such date to be the measurement date and will record the estimated fair market value of the instruments granted as a prepaid expense and amortize such amount to general and administrative expense in the accompanying statement of operations over the contract period. When it is appropriate for us to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values at each of those interim financial reporting dates.

 

Non-Cash Equity Transactions

 

Shares of equity instruments issued for noncash consideration are recorded at the estimated fair market value of the consideration granted based on the estimated fair market value of the equity instrument, or at the estimated fair market value of the goods or services received, whichever is more readily determinable.

 

Stock-Based Compensation

 

We account for share-based awards to employees in accordance with ASC 718 “Stock Compensation”. Under this guidance, stock compensation expense is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the estimated service period (generally the vesting period) on the straight-line attribute method. Share-based awards to non-employees are accounted for in accordance with ASC 505-50 “Equity”, wherein such awards are expensed over the period in which the related services are rendered.

 

Related Parties

 

A party is considered to be related to us if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with us. Related parties also include our principal owners, our management, members of the immediate families of our principal owners and our management and other parties with which we may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties, or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests, is also a related party.

 

 
18

 

 

Revenue Recognition

 

We recognize revenue on consulting at the time the service is rendered and collectability is reasonably assured.

 

Advertising Expense

 

Advertising, promotional and selling expenses consisted of sales and marketing expenses, and promotional activity expenses. Expenses are recognized when incurred.

 

General and Administrative Expense

 

General and administrative expenses consisted of professional service fees, rent and utility expenses, meals, travel and entertainment expenses, and other general and administrative overhead costs. Expenses are recognized when incurred.

 

Loss per Share

 

We compute net loss per share in accordance with the FASB ASC 260. The ASC specifies the computation, presentation and disclosure requirements for loss per share for entities with publicly held common stock.

 

Basic loss per share amounts is computed by dividing the net loss by the weighted average number of common shares outstanding. Shares issuable upon the exercise of equity instruments such as warrants and options were not included in the loss per share calculations because the inclusion would have been anti-dilutive.

 

Going Concern

 

Management believes that the actions presently being taken to further implement its business plan and generate additional revenues provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate additional revenues and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company's ability to further implement its business plan and generate additional revenues. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

Off-Balance Sheet Arrangements

 

As of December 31, 2016, we did not have any off-balance sheet arrangements.

 

Notes Payable

 

See Notes 4 and 5 to the December 31, 2016 financial statements included as part of this prospectus for information concerning our notes payable

 

 
19

 

 

Contractual Obligations

 

The Company leases an automobile under an operating lease commencing October 4, 2014 for 39 months at $611 per month. The lease expense was $7,483 and $7,953 for the years ended September 30, 2016 and 2015, respectively.  At December 31, 2016, the future rental payments required under operating leases are as follows:

 

2017

  $ 7,483  

2018

    910  

2019

    -  

2020

    -  

2021

    -  

Total

  $ 8,393  

 

 

BUSINESS

 

AmeriCann's business plan is to offer a comprehensive, turnkey package of services that includes consulting, design, construction and financing to approved and licensed marijuana operators throughout the United States. Our business plan is based on the anticipated growth of the regulated marijuana market in the United States.

 

AmeriCann’s team includes board members, consultants, engineers and architects who specialize in real estate development, traditional horticulture, lean manufacturing, medical research, facility construction, regulatory compliance, security, marijuana cultivation and genetics, extraction processes, and infused product development.

 

To support local businesses that seek to serve cannabis patients in their communities we initiated the AmeriCann Preferred Partner Program. Currently, we have one Preferred Partner in Colorado, which is 4900 Jackson, LLC and one Preferred Partner in Massachusetts, which is Coastal Compassion, Inc. Through this program, we plan to provide an essential set of resources including advanced cultivation facilities, access to a team of experts and in certain cases, capital for our partner’s businesses. In addition, AmeriCann’s team has assisted applicants in obtaining cannabis licenses in competitive application processes in Massachusetts and Illinois. This support is designed to assist our Preferred Partners in newly regulated markets.

 

 AmeriCann plans to lease facilities to its Preferred Partners that will be designed with AmeriCann’s propriety cultivation and processing system called “Cannopy.” AmeriCann developed Cannopy with experts from traditional horticulture, lean manufacturing, regulatory compliance and cannabis cultivation. Cannopy includes automation throughout the production life-cycle, customized workflow processes, monitoring and controls, and top-line security systems. Cannopy empowers Preferred Partners to consistently produce medical marijuana for patients at the lowest cost in the most efficient, compliant manner. We provide initial and on-going training, policies, practices and procedures to operate the state-of-the-art facilities.

 

The expanding cannabis industry requires extensive real estate to meet the growing needs of the market for cannabis products. AmeriCann assists our Preferred Partners with the identification, design, permitting, acquisition, development and operation of scalable infrastructure to cultivate and to dispense medical cannabis in regulated markets.

 

 
20

 

 

Company History

 

The Company was incorporated in Delaware on June 25, 2010. The Company was established as part of the Chapter 11 reorganization of AP Corporate Services, Inc. ("AP"). Under AP's Plan of Reorganization, as confirmed by the U.S. Bankruptcy Court for the Central District of California, the Company was incorporated to: (i) receive and own any interest which AP had in the development of an MRI scanning facility; and (ii) issue shares of its common stock to AP's general unsecured creditors, to its administrative creditors, and to its shareholders.

 

Lacking the resources to effectively develop an MRI facility, in June 2012 the Company decided to promote medical tourism by providing information on a website for those seeking to travel abroad for healthcare services. The Company planned to generate revenue by selling advertising to healthcare providers and related businesses including hotels and travel agencies.

 

In September 2013, the Company abandoned its business plan relating to promoting medical tourism.

 

On January 17, 2014, Strategic Capital Partners, LLC (“SCP”) a firm controlled by Benjamin J. Barton, one of our officers and directors, acquired 14,950,000 shares of our outstanding common stock from a group of our shareholders.

 

On February 21, 2014, we changed our name from Nevada Health Scan, Inc. to AmeriCann, Inc. and declared a stock dividend in the amount of four shares of common stock for each issued and outstanding share of common stock.

 

On February 24, 2014, SCP returned 65,750,000 shares of our common stock to us. These shares were cancelled and returned to the status of authorized and unissued shares.

 

4900 Jackson, LLC

 

During the summer of 2014 we entered into a Financing and Consulting Agreement with a licensed Colorado cannabis cultivator. The agreements called for us to loan $1,000,000 to the Preferred Partner, 4900 Jackson, LLC, to convert an existing 15,000 square foot warehouse into a new cannabis growing and processing facility.  The growing and processing facility was completed in 2015.  As of September 30, 2016, we have received $1,158,000 in principal, interest and consulting payments from the operator of the facility. These payments are scheduled to continue through May of 2017. 

 

Monaco Street Property

 

On July 31, 2014, we closed on an all cash purchase of a five-acre parcel of land located in north central Denver, Colorado. The total purchase price for the property was $2,250,000.  The property is currently zoned for cannabis cultivation and processing by the City and County of Denver. We received concept approval from the City and County of Denver for the construction of a 125,000 square foot cannabis cultivation, processing, and administration facility on this property.  We estimate the cost to construct this facility will be approximately $12,500,000.  This property serves as collateral for a $990,000 loan which is due and payable on March 15, 2017. This property is held for resale, and we have no plans to develop on it.

 

 
21

 

 

Massachusetts Medical Cannabis Center

 

On January 14, 2015, we entered into an agreement to purchase a 52.6 acre parcel of undeveloped land in Freetown, Massachusetts. The property is located approximately 47 miles southeast of Boston. We plan to develop the property as the Massachusetts Medical Cannabis Center "MMCC". Plans for the MMCC include the construction of sustainable greenhouse cultivation and processing facilities that will be leased to Registered Marijuana Dispensaries under the Massachusetts Medical Marijuana Program. Additional plans for the MMCC may include a testing laboratory, a research facility, a training center, an infused product production facility and corporate offices. 

 

On December 8, 2015, The Town of Freetown Planning Board unanimously approved our site plan application for the MMCC.  The site plan application requested 977,000 square feet of infrastructure for medical marijuana cultivation, processing, testing and associated administration in Freetown's Industrial Park. 

 

On March 29, 2016, the Department of Public Health (“DPH”) for the Commonwealth of Massachusetts approved our consulting agreement and development agreement relating to the MMCC's first tenant and Preferred Partner, Coastal Compassion, Inc.

 

On April 7, 2016, we signed agreements with Coastal Compassion Inc. (“CCI”). CCI is one of a limited number of non-profit organizations that has received a provisional or final registration to cultivate, process and sell medical cannabis by the Massachusetts Department of Public Health. CCI has agreed to become the initial tenant in our planned MMCC. Tim Keogh, our Chief Executive Officer, is a Board Member of CCI.

 

Pursuant to the agreements, we agreed to provide CCI with financing of up to $2.5 million for a five-year term at 18% interest per year for construction and working capital required for CCI’s approved dispensary and cultivation center in Fairhaven, MA. For a three- year period beginning April 1, 2016, we agreed to consult with CCI in the design, construction and operation of the Fairhaven facility. CCI will pay us $10,000 each month for these consulting services. The DPH has approved our agreement with CCI relating to the consulting, the loan, and the development and lease terms for Building A of the MMCC.

 

On October 17, 2016, we assigned the property rights to the property in Freetown, Massachusetts to Massachusetts Medical Properties, LLC (“MMP”), for a nominal fee and MMP purchased the 52.6-acre parcel of land in Freetown, Massachusetts. The deposits of $925,000 previously paid by us to the seller, Boston Beer Company (“BBC”), were credited against the total purchase price of $4,475,000. The remaining balance of $3,550,000 was paid to BBC by MMP.

 

As part of a simultaneous transaction, we entered into a lease agreement by which MMP agreed to lease the property to us for an initial term of fifty years. We have the option to extend the term of the lease for four additional ten year periods. The lease is a triple net lease, whereby we will pay all real estate taxes, repairs, maintenance and insurance.

 

The lease payments will be the greater of (a) $30,000 per month; (b) $0.38 per square foot per month of any structure built on the property; or (c) 1.5% of all gross monthly sales of products sold by us, any of our assignees, or any of our subtenants. The lease payments will be adjusted up (but not down) every five years by any increase in the Consumer Price Index.

 

 
22

 

 

Between October 17, 2016 and April 17, 2017, the monthly lease payments will accrue, with all accrued lease payments to be paid to MMP on April 17, 2017.

 

Under the terms of the lease, we have six months to obtain capital funding for the construction of the first phase building. In the event that we are unable to raise these funds within this six month period, we have an additional six month period to do so; provided, that we have paid accrued lease payments and closing costs. If we are then unable to raise the funds on or before twelve months from October 17, 2016, the lease will terminate.

 

We will receive credit for the $925,000 paid towards the purchase price in the form of discounted lease payments. For the initial fifty (50) year term of the lease, the lease payments will be reduced by $1,541.67 each month.

 

In connection with our agreements with MMP, we issued to MMP 100,000 shares of our common stock and a warrant to purchase up to 3,640,000 shares of common stock at an exercise price of $1.00 per share. The warrant can be exercised at any time on or after October 17, 2018 and on or before October 17, 2020.

 

B Corp Certification

 

We received B Corp certification in June 2016. This certification is an acknowledgment of our commitment to social and environmental ethics, transparency and accountability.

 

We join over 1,700 Certified B corporations globally, including 71 others in Colorado, that have met the rigorous standards that measure a company’s impact on its employees, suppliers, community, and the environment. Notable B corporations include Ben & Jerry’s, Patagonia, Warby Parker, and Etsy, Inc.

 

The B Corp certification was granted by B Lab, a nonprofit organization that serves a global movement of people using business as a force for good. Its vision is that one day all companies will compete to be best for the world and that society will enjoy a more shared and durable prosperity.

 

B Corp promotes robust standards that can be used by policymakers, investors and the general public to evaluate companies and their business practices. B Corp certification is to business what Fair Trade certification is to coffee or USDA Organic certification is to milk.

 

We successfully completed a rigorous application and review process in obtaining this prestigious certification.

 

We believe that this certification, and its endorsement of our environmental standards, community focus and ethics, will provide us with a competitive advantage over potential competitors that lack this accreditation.

 

Concurrent with receiving B Corp certification, we committed to become a Public Benefit Corporation within two years. If we do not accomplish this, we may lose our B Corp certification.

 

 
23

 

 

Market Conditions

 

According to ArcView Market Research’s 4th Edition of The State of Legal Marijuana Markets report, “The strong growth in demand for legal cannabis over the past two years is expected to continue in the years ahead. Twenty-eight states already permit medical cannabis use and eight states and the District of Columbia have passed ballot measures to allow for full adult use of cannabis. With 8 of 9 ballot measures for medical and adult-use cannabis laws passing in November, 2016 has proven to be a significant year for the cannabis industry. A majority of U.S. states have transitioned from cannabis prohibition to some form of regulated legal markets.”   Sales of legal medical and adult use marijuana were $4.6 billion in 2014, $5.7 billion in 2015 and are expected to grow to $22.8 billion by 2020. The cannabis industry was the fastest growing industry in the United States between 2014 and 2015 (74% growth) and is projected to grow faster than any other industry in the country over the next decade.

 

While the industry is growing rapidly, the cannabis industry faces four major obstacles that challenge its growth and profitability. First, the cultivation of cannabis is a very capital-intensive enterprise. Many cannabis entrepreneurs do not have access to the capital required to build the infrastructure required to meet growing demand and sales projections. Traditional sources of financing, such as banks, are not available currently to cannabis producers and retailers. Second, there is a significant shortage of knowledge related to virtually all areas of the cannabis business. When new states are added to the list of regulated cannabis markets, there will be a scarcity of experience and expertise to serve the needs of growers and retailers in these states. Third, the majority of states do not allow access to medical cannabis for its patients. This presents an obstacle to the medical cannabis industry and requires financial resources and dedicated advocacy to change regulations on the state level. Fourth, as explained below, marijuana is illegal under federal law.

 

Government Regulation

 

Marijuana is a Schedule-I controlled substance and is illegal under federal law.  Even in those states in which the use of marijuana has been legalized, its use remains a violation of federal law.

 

A Schedule I controlled substance is defined as a substance that has no currently accepted medical use in the United States, a lack of safety for use under medical supervision and a high potential for abuse.  The Department of Justice defines Schedule 1 controlled substances as “the most dangerous drugs of all the drug schedules with potentially severe psychological or physical dependence.”  If the federal government decides to enforce the Controlled Substances Act in Colorado with respect to marijuana, persons that are charged with distributing, possessing with intent to distribute, or growing marijuana could be subject to fines and terms of imprisonment, the maximum being life imprisonment and a $50 million fine.

 

 
24

 

 

As of January 31, 2017, 28 states and the District of Columbia allow their citizens to use Medical Marijuana.  Additionally, voters in the states of Colorado, Washington, Alaska, Oregon, Nevada, California, Massachusetts, Maine and the District of Columbia approved ballot measures to legalize cannabis for recreational use by adults.  The state laws are in conflict with the federal Controlled Substances Act, which makes marijuana use and possession illegal on a national level. The Obama administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws allowing the use and distribution of medical marijuana.   However, there is no guarantee that the administration will not change its stated policy regarding the low-priority enforcement of such federal laws. Additionally, the Trump administration that follows could change this policy and decide to enforce the federal laws strongly.  Any such change in the federal government’s enforcement of current federal laws could cause significant financial damage to us and our shareholders.  While we do not intend to harvest, distribute or sell cannabis, we may be irreparably harmed by a change in enforcement by the federal government or the enactment of new and more restrictive laws.

 

Competition

 

Currently, there are a number of other companies that are involved in the marijuana industry, many of which we consider to be our competition. Many of these companies provide services similar to those which we provide or plan to provide.  We expect that other companies will recognize the value of serving the marijuana industry and become our competitors.

 

Change in Accountants

 

On January 19, 2016, we dismissed Hartley Moore Accountancy Corporation (“Hartley Moore”) as our independent registered accounting firm. There were no disagreements with Hartley Moore on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement(s), if not resolved to Hartley Moore's satisfaction, would have caused them to refer to the subject matter of the disagreement(s) in connection with their reports; and there were no "reportable events" as defined in Item 304(a)(1) of Regulation S-K of the Securities and Exchange Commission. On January 19, 2016, we engaged Malone Bailey, LLP as our independent registered public accounting firm. The change in our independent accountants was approved by our Board of Directors.

 

General

 

Our offices are located at 3200 Brighton Blvd., Unit 144 Denver, CO 80216. We lease this space located on a month-to-month basis at a rate of $2,870 per month.

 

As of February 23, 2017 we had two full time employees, that being Timothy Keogh, our Chief Executive Officer and Jane Roach, our Office Manager.  As of September 30, 2016, Mr. Keogh was spending approximately 90% of his time on our business and Jane Roach was spending approximately 100% of her time on our business.  Ben Barton, our Chief Financial Officer, plans to spend approximately 95% of his time on our business.

 

 
25

 

  

MANAGEMENT

 

Name

Age

Position

     

Timothy Keogh

37

Chief Executive Officer and a Director

Benjamin J. Barton

52

Chief Financial and Accounting Officer and a Director

  

The following is a brief summary of the background of each officer and director including their principal occupation during the five preceding years.  All directors will serve until their successors are elected and qualified or until they are removed.

 

Timothy Keogh was appointed our Chief Executive Officer and a director on March 25, 2014. As our Chief Executive Officer, Mr. Keogh has developed sustainable practices and traditional horticultural approaches to the production of medical cannabis to benefit patients in regulated markets. Prior to joining AmeriCann, Mr. Keogh was the Chief Executive Office and a director of Coastal Compassion, Inc., a non-profit corporation that has entered the medical marijuana business in Massachusetts. This effort began in September of 2012 and was formalized under Massachusetts G.L. Chapter 180 in August of 2013.  Under the direction of Mr. Keogh, Coastal Compassion, Inc. received 1 a limited number of provisionally approved licenses in Massachusetts.

 

 Between November 2010 and November 2013 Mr. Keogh owned and managed Dock Promotions, LLC, a company which provided consulting services to waterfront developments and marinas in the areas of design, construction, and operations.   Between 2003 and 2010, Mr. Keogh was the Director of Business Services for Marina Management Services, Inc., a corporation which provided management and consulting solutions to waterfront developments, marinas and boatyards throughout the Americas and the Caribbean. 

 

Mr. Keogh is an advisory board member of the Rhode Island Patient Advocacy Coalition, and an active member and invited speaker for the National Cannabis Industry Association.  Mr. Keogh holds a Bachelor of Science in Business Administration from Mount St. Mary’s College.

 

Ben Barton was appointed a director on January 14, 2014 and Chief Financial Officer on January 22, 2014. Since 1986, Mr. Barton has been active in all aspects of venture capital and public stock offerings. Since 2005, Mr. Barton has been the Managing Director of Strategic Capital Partners, LLC, a private investment company specializing in emerging companies. Mr. Barton was one of the founders of Synergy Resources Corporation, an energy company that trades on the NYSE. Prior to earning an MBA in Finance from UCLA, Mr. Barton received his Bachelor of Science degree in Political Science from Arizona State University.

 

Effective March 25, 2014, we entered into an employment agreement with Mr. Keogh.  The agreement has an initial term of three years and provides that we will pay Mr. Keogh $12,000 per month during the term of the agreement.  Pursuant to the employment agreement, Strategic Capital Partners, LLC, our largest shareholder, sold 1,200,000 shares of our common stock to Mr. Keogh at a price of $0.001 per share.

 

Of these 1,200,000 shares, 300,000 shares are subject to the following vesting requirements.  

 

 
26

 

 

Provided Mr. Keogh is employed by us as of the date of vesting, 300,000 shares will vest on the earlier March 19, 2017 or the date we receive at least $45,000,000 from the sale of our debt or equity securities.  For purposes of the foregoing, traditional financing from banks or similar financial institutions will not be given effect and the required amounts to be raised will be cumulative.

 

All shares that are not vested at the time of termination of Mr. Keogh’s employment, will be repurchased by us at a price of $0.001 per share.  Any shares which are not vested and which are purchased by us will be returned to treasury and cancelled.

 

See “Principal Shareholders” for information concerning options granted to Mr. Keogh.

 

Our directors serve until the next annual meeting of our shareholders and until their successors have been duly elected and qualified.  Our officers serve at the discretion of our directors.  

 

We believe our directors are qualified to act as such for the following reasons:

 

Timothy Keogh – experience in marijuana industry

Benjamin J. Barton – experience in the capital markets

 

Timothy Keogh and Benjamin J. Barton are not independent as that term is defined in Section 803 of the NYSE MKT Company Guide.

 

We do not have a financial expert as that term is defined by the Securities and Exchange Commission.

 

Our Board of Directors does not have standing audit, nominating or compensation committees, committees performing similar functions, or charters for such committees. Instead, the functions that might be delegated to such committees are carried out by our Board of Directors, to the extent required. Our Board of Directors believes that the cost of associated with such committees, has not been justified under our current circumstances.

 

Given our lack of operations to date, our Board of Directors believes that its current members have sufficient knowledge and experience to fulfill the duties and obligations of an audit committee. None of the current Board members is an “audit committee financial expert” within the meaning of the rules and regulations of the Securities and Exchange Commission. The Board has determined that each of its members is able to read and understand fundamental financial statements and has substantial business experience that results in that member’s financial sophistication.

 

Our Board of Directors does not have a “leadership structure” since each board member is free to introduce any resolution at any meeting of our directors and is entitled to one vote at any meeting.

 

Holders of our common stock may send written communications to our entire board of directors, or to one or more board members, by addressing the communication to “the Board of Directors” or to one or more directors, specifying the director or directors by name, and sending the communication to our offices in Denver, Colorado.  Communications addressed to the Board of Directors as whole will be delivered to each board member.  Communications addressed to a specific director (or directors) will be delivered to the director (or directors) specified.

 

 
27

 

 

Security holder communications not sent to the Board of Directors as a whole or to specified board members will be relayed to board members.

 

During the years ended September 30, 2016 and 2015 we did not compensate any person for serving as a director.

 

Executive Compensation

 

During the years ended September 30, 2016 and 2015 we paid the following compensation to our officers:

 

Name

 

Year

 

Salary

   

Bonus

   

Options

   

Total

 
                                     

Timothy Keogh

 

2016

  $ 144,000       -       -     $ 144,000  

Chief Executive Officer

 

2015

  $ 144,000       -       -     $ 144,000  
                                     

Benjamin J. Barton

 

2016

    -       -       -       -  

Chief Financial Officer

 

2015

    -       -       -       -  

 

The following shows the amounts we expect to pay to our officers during the year ending September 30, 2017 and the amount of time these persons expect to devote to us.

 

           

Percent of time

 
   

Projected

   

to be Devoted to the

 

Name

 

Compensation

   

Company’s Business

 
                 

Timothy Keogh

  $ 144,000       90%  

Benjamin J. Barton

    -       95%  

 

Transactions With Related Parties

 

During March and April 2014, we sold 1,000,000 shares of our common stock to private investors at a price of $0.75 per share. Benjamin J. Barton, one of our officers and directors, purchased 400,000 of these shares.

 

During July 2014, we raised $2,373,000 through a private sale of 791,000 Units at a price of $3.00 per Unit. Each Unit consisted of one share of common stock and one warrant. Each warrant allows the holder to purchase one share of our common stock at a price of $8.00 per share anytime on or before April 30, 2018.  Mr. Barton purchased 666,667 of these Units for cash.

 

 
28

 

 

As of September 30, 2015, the Company had borrowed $1,682,849 from SCP a Company controlled by Mr. Barton. Through June 20, 2016, we borrowed an additional $227,500 from SCP, and on July 14, 2016, SCP assumed our note payable to an unrelated third party of $521,297. Simultaneously, we modified the note payable to SCP. Principal and interest of $500,000 was converted into 400,000 shares of our common stock. In addition, we issued SCP warrants to purchase 800,000 shares of our common stock, exercisable at a price of $1.50 per share, and warrants to purchase an additional 800,000 shares of common stock, exercisable at a price of $3.00 per share. Both sets of warrants expire on June 30, 2020. The remaining $1,931,646 owed to SCP was divided into two promissory notes. The first note, in the principal amount of $1,000,000, bears interest at 9.5% per year and matures on December 31, 2019. Interest is payable quarterly with the first interest payment due on September 30, 2016. The Note can be converted at any time into shares of our common stock, initially at a conversion price of $1.25 per share. The conversion price will be proportionately adjusted in the event of any stock split or capital reorganization. The note is not secured. The second note, in the principal amount of $931,646, bears interest at 8% per year and matures on December 31, 2019. Interest is payable quarterly, with the first interest payment due on September 30, 2016. The note is not convertible into shares of our common stock, and is secured by a second lien on our property in Denver, Colorado and a first lien on all amounts due to us by Wellness Group Pharms. Any payments received from the sale, lease or commercialization of the property in Denver, and any amounts received from Wellness Group Pharms, will be applied to the principal amount of the Note. Otherwise, all unpaid principal and interest will be due on December 31, 2019. The Company evaluated the debt modification and convertible debt issued in accordance with ASC 470, Debt, and recorded a loss on extinguishment of debt of $901,939, debt discount on secured notes payable – related party of $211,578, and a debt premium on convertible debt of $284,229.

 

In a separate transaction, the Company borrowed an additional $20,000 from SCP. As of September 30, 2016, the Company owed SCP $2,024,297, net of premiums and discounts.

 

On April 7, 2016, we signed agreements with Coastal Compassion Inc. (“CCI”). CCI is one of a limited number of non-profit organizations that has received a provisional or final registration to cultivate, process and sell medical cannabis by the Massachusetts Department of Public Health. CCI has agreed to become the initial tenant in our planned MMCC. Tim Keogh, our Chief Executive Officer, is a Board Member of CCI.

 

Pursuant to the agreements, we agreed to provide CCI with financing of up to $2.5 million for a five-year term at 18% interest per year for construction and working capital required for CCI’s approved dispensary and cultivation center in Fairhaven, MA. For a three-year period beginning April 1, 2016, we agreed to consult with CCI in the design, construction and operation of the Fairhaven facility. CCI will pay us $10,000 each month for these consulting services. Although the DPH has approved our agreement with CCI relating to the development and lease terms of the MMCC, the actual lease agreement with CCI has not been finalized or approved by the DPH. We will need to secure significant capital to provide the financing to CCI.

 

 As of September 30, 2016, we have provided financing to CCI of $117,693, which includes accrued consulting fees of $60,000, construction and working capital advances of $52,001, and accrued interest of $5,692.

 

 
29

 

  

PRINCIPAL SHAREHOLDERS

 

The following table shows the ownership, as of February 23, 2017, of those persons owning beneficially 5% or more of our common stock and the number and percentage of outstanding shares owned by each of our directors and officers and by all officers and directors as a group.  Each owner has sole voting and investment power over their shares of common stock.

      

Name

 

Shares

Owned

   

Percent of

Outstanding Shares

 
                 

Timothy Keogh (1)

    1,200,000       6.3 %

Benjamin J. Barton

    --       0.0 %

Strategic Capital Partners, LLC (2)

    8,966,667       46.9 %
                 

All officers and directors as a Group (2 persons)

    10,166,667       53.2 %

 

(1)

Of these 1,200,000 shares, 300,000 shares are subject to vesting requirements.  See the “Management” section of this prospectus for further details regarding Mr. Keogh’s employment agreement.

 

(2)

Strategic Capital Partners, LLC, is controlled by Mr. Barton.

  

Options and Warrants

 

We have issued warrants/options to the persons and upon the terms shown below:

  

       

Shares Upon

           
   

Date of

 

Exercise of

   

Exercise

 

Expiration

Name

 

Issuance

 

Warrants or Options

   

Price

 

Date

                       

Strategic Capital Partners, LLC (1)

 

02/14/14

    1,200,000     $ 8.00  

01/22/18

 

 

02/14/14

    600,000     $ 12.00  

01/22/18

   

09/09/14

    666,667     $ 8.00  

04/30/18

   

07/14/16

    800,000     $ 1.25  

12/31/19

   

07/14/16

    800,000     $ 1.50  

06/30/20

   

07/14/16

    800,000     $ 3.00  

06/30/20

                       

Timothy Keogh

 

03/25/14

    800,000     $ 8.00  

01/22/18

   

03/25/14

    400,000     $ 12.00   01/22/18

Former director and officer

 

03/19/14

    100,000     $ 8.00  

03/28/18

   

03/19/14

    100,000     $ 12.00  

03/28/18

                       

Massachusetts Medical Properties, LLC

 

10/17/16

    3,640,000     $ 1.00  

10/17/20

                       
                       

Unrelated lenders

 

09/15/16

    75,000     $ 0.75  

09/15/20

   

09/15/16

    75,000     $ 1.25  

09/15/20

   

09/15/16

    100,000     $ 0.75  

01/31/17

 

(1)

Strategic Capital Partners, LLC, is controlled by Mr. Barton.

 

 
30

 

 

We have also granted options to a number of persons which allow for the purchase of up to 105,000 shares of common stock at a price of $0.75 per share.

 

To date, no warrants or options have been issued under shareholder approved plans and no shareholder approved plans currently exist.

 

SELLING SHAREHOLDERS

 

The persons listed in the following table plan to offer the shares shown opposite their respective names by means of this prospectus. The owners of the shares to be sold by means of this prospectus are referred to as the “selling shareholders”. The selling shareholders acquired their shares in the transactions described below.

 

Private Offering. Between October 27, 2016 and November 7, 2016 we sold 2,000,000 units to a group of investors in a private offering at a price of $1.00 per unit. Each unit consisted of one share of our common stock and one Series I warrant. Each Series I Warrant entitles the holder to purchase one share of our common stock at a price of $3.00 per share at any time on or before November 4, 2020.

 

Convertible Notes. On September 15, 2016, we borrowed $75,000 from three unrelated parties. The notes bear interest at 12% per year, are unsecured, and are due and payable on January 14, 2017. At the option of the holder, the notes may be converted into shares of our common stock at a conversion price of $0.75 per share. As additional consideration for the loans we issued 75,000 Series II warrants and 75,000 Series III warrants to the lenders. Each Series II warrant allows the holder to purchase one share of our common stock at a price of $0.75 per share. Each Series III warrant allows the holder to purchase one share of our common stock at a price of $1.25 per share. The Series II and Series III warrants expire on December 15, 2020.

 

We will not receive any proceeds from the sale of the securities by the selling shareholders. We will pay all costs of registering the securities offered by the selling shareholders. These costs, based upon the time related to preparing this section of the prospectus, are estimated to be $2,000. The selling shareholders will pay all sales commissions and other costs of the sale of the securities offered by them.

 

 
31

 

 

           

Shares

   

Shares

   

Shares

                 
           

Issuable

   

Issuable

   

Issuable

                 
           

Upon

   

Upon

   

Upon

           

Share

 
           

Exercise

   

Exercise

   

Exercise

   

Shares to

   

Ownership

 

Name of

 

Shares

   

of Series I

   

of Series II

   

of Series III

   

Be Sold In

   

After

 

Selling Shareholder

 

Owned

   

Warrants

   

Warrants

   

Warrants

   

This Offering

   

Offering

 
                                                 

Angyalfy Family Trust

    50,000       50,000                       100,000          

BCS Capital, LLC

    55,000       55,000                       110,000          

Margaret Bathgate

    100,000       100,000                       200,000          

The Gary S. Berlin Trust

    20,000       20,000                       40,000          

Michael E. Donnelly

    25,000       25,000                       50,000          

Vicki Edwards-Barone

    50,000       50,000                       100,000          

Duane L. Femrite Revocable Family Trust

    25,000       25,000                       50,000          

James Greenwell

    15,000       15,000                       30,000          

David Gregarek

    25,000       25,000       25,000       25,000       100,000       --  

GKG Investments, LLC

    75,000       75,000       25,000       25,000       200,000       --  

Genuine Partners

    25,000       25,000       25,000       25,000       100,000       --  

Tysadco Partners

    27,000       27,000                       54,000          

David and Stephanie Kenkel

    55,000       55,000                       110,000          

Grace M. Kenkel Revocable Trust

    60,000       60,000                       120,000          

John B. Kenkel Revocable Trust

    35,000       35,000                       70,000          

Timothy Keogh

    1,205,000       5,000                       10,000       1,200,000  

Jon B. Kruljac

    75,000       75,000                       150,000          

Lang Family Revocable Living Trust

    10,000       10,000                       20,000          

Hayden IR, LLC

    8,000       8,000                       16,000          

Wilbert L. Miles

    15,000       15,000                       30,000          

William D. Moreland

    500,000       500,000                       1,000,000          

Brian J. Morgan

    200,000       200,000                       400,000          

David R. Morgan

    100,000       100,000                       200,000          

Rajnikant N. Patel

    25,000       25,000                       50,000          

Walter R. Pedigo

    15,000       15,000                       30,000          

Kathy Pudelko

    25,000       25,000                       50,000          

George Resta Living Trust

    50,000       50,000                       100,000          

Kevin J. Shields

    100,000       100,000                       200,000          

Victor Sibilla

    10,000       10,000                       20,000          

Thomas H. Smith

    25,000       25,000                       50,000          

Alva Terry Staples

    25,000       25,000                       50,000          

Rob Ware

    25,000       25,000                       50,000          

Ian Whitmore

    40,000       40,000                       80,000          

Cinnamon Wing

    10,000       10,000                       20,000          

Thomas D. Wolf

    10,000       10,000                       20,000          

Sara Yassin

    50,000       50,000                       100,000          

Robert J. Zappa

    10,000       10,000                       20,000          

Alan Budd Zuckerman

    25,000       25,000                       50,000          

 

The controlling persons of the non-individual selling shareholders are:

 

Name of Shareholder

Controlling Person

   

Angyalfy Family Trust

William B. Angyalfy

BCS Capital, LLC

Katherine Barton

Gary S. Berlin Trust

Gary S. Berlin

Duane L. Femrite Revocable Family Trust

Duane L. Femrite

GKG Investments, LLC

Matt Gregarek

Genuine Partners

Tim Jay Brasel

Tysadco Partners

Glenn Levit

Grace M. Kenkel Revocable Trust

David Kenkel

John B. Kenkel Revocable Trust

David Kenkel

Lang Family Revocable Living Trust

Lanny R. and Carol V. Lang

Hayden IR, LLC

Brett Maas

George Resta Living Trust

George Resta

   

 

With the exception of Timothy Keogh, no selling shareholder has, or had, any material relationship with us or our officers or directors.

 

Margaret Bathgate is the wife of Steven Bathgate. Steven Bathgate, Michael Donnelly and Vicki Edwards-Barone are affiliated with GVC Capital, LLC. John B. Kruljac is affiliated with G Select, LLC. Victor Sibilla is affiliated with West Park Capital, Inc. GVC Capital, West Park Capital and G Select, LLC are securities brokers. To our knowledge, no other selling shareholder is affiliated with a securities broker.

 

 
32

 

 

The shares of common stock to be sold by the selling shareholders may be sold by means of this prospectus from time to time as market conditions permit.

 

The shares of common stock may be sold by one or more of the following methods, without limitation:

 

 

a block trade in which a broker or dealer so engaged will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;

 

 

purchases by a broker or dealer as principal and resale by such broker or dealer for its account pursuant to this prospectus;

 

 

ordinary brokerage transactions and transactions in which the broker solicits purchasers; and

 

 

face-to-face transactions between sellers and purchasers without a broker/dealer.

 

In completing sales, brokers or dealers engaged by the selling shareholders may arrange for other brokers or dealers to participate. Brokers or dealers may receive commissions or discounts from selling shareholders in amounts to be negotiated. As to any particular broker-dealer, this compensation might be in excess of customary commissions. Neither we nor the selling stockholders can presently estimate the amount of such compensation. Notwithstanding the above, no FINRA member will charge commissions that exceed 8% of the total proceeds from the sale.

 

The selling shareholders and any broker/dealers who act in connection with the sale of their securities may be deemed to be "underwriters" within the meaning of §2(11) of the Securities Acts of 1933, and any commissions received by them and any profit on any resale of the securities as principal might be deemed to be underwriting discounts and commissions under the Securities Act.

 

If any selling shareholder enters into an agreement to sell his or her securities to a broker-dealer as principal, and the broker-dealer is acting as an underwriter, we will file a post-effective amendment to the registration statement, of which this prospectus is a part, identifying the broker-dealer, providing required information concerning the plan of distribution, and otherwise revising the disclosures in this prospectus as needed. We will also file the agreement between the selling shareholder and the broker-dealer as an exhibit to the post-effective amendment to the registration statement.

 

The selling shareholders may also sell their shares pursuant to Rule 144 under the Securities Act of 1933.

 

We have advised the selling shareholders that they, and any securities broker/dealers or others who sell the common stock or warrants on behalf of the selling shareholders, may be deemed to be statutory underwriters and will be subject to the prospectus delivery requirements under the Securities Act of 1933. We have also advised each selling shareholder that in the event of a "distribution" of the securities owned by the selling shareholder, the selling shareholder, any "affiliated purchasers", and any broker/dealer or other person who participates in the distribution may be subject to Rule 102 of Regulation M under the Securities Exchange Act of 1934 ("1934 Act") until their participation in that distribution is completed. Rule 102 makes it unlawful for any person who is participating in a distribution to bid for or purchase securities of the same class as is the subject of the distribution. A "distribution" is defined in Rule 102 as an offering of securities "that is distinguished from ordinary trading transactions by the magnitude of the offering and the presence of special selling efforts and selling methods". We have also advised the selling shareholders that Rule 101 of Regulation M under the 1934 Act prohibits any "stabilizing bid" or "stabilizing purchase" for the purpose of pegging, fixing or stabilizing the price of the common stock in connection with this offering.

 

 
33

 

 

DESCRIPTION OF SECURITIES

 

Common Stock

 

We are authorized to issue 100,000,000 shares of common stock. Holders of our common stock are each entitled to cast one vote for each share held of record on all matters presented to the shareholders. Cumulative voting is not allowed; hence, the holders of a majority of our outstanding common shares can elect all directors.

 

Holders of our common stock are entitled to receive such dividends as may be declared by our Board of Directors out of funds legally available and, in the event of liquidation, to share pro rata in any distribution of our assets after payment of liabilities. Our Board of Directors is not obligated to declare a dividend. It is not anticipated that dividends will be paid in the foreseeable future.

 

Holders of our common stock do not have preemptive rights to subscribe to additional shares if issued. There are no conversion, redemption, sinking fund or similar provisions regarding the common stock. All outstanding shares of common stock are fully paid and non-assessable.

 

Preferred Stock

 

We are authorized to issue 20,000,000 shares of preferred stock. Shares of preferred stock may be issued from time to time in one or more series as may be determined by our Board of Directors. The voting powers and preferences, the relative rights of each such series and the qualifications, limitations and restrictions of each series will be established by the Board of Directors. Our directors may issue preferred stock with multiple votes per share and dividend rights which would have priority over any dividends paid with respect to the holders of our common stock. The issuance of preferred stock with these rights may make the removal of management difficult even if the removal would be considered beneficial to shareholders generally, and will have the effect of limiting shareholder participation in transactions such as mergers or tender offers if these transactions are not favored by our management. As of the date of this prospectus, we had not issued any shares of preferred stock.

 

Options and Warrants

 

See the “Market For Our Common Stock” section of this prospectus for information concerning our outstanding options and warrants.

 

 
34

 

 

Transfer Agent

 

Island Stock Transfer, Inc.

15500 Roosevelt Boulevard, Suite 301

Clearwater, FL 33760

(727) 289-0010

 

LEGAL PROCEEDINGS

 

Beginning September 21, 2014, we entered into a series of agreements with Wellness Group Pharms, LLC (“WGP”), an entity that was pursuing licenses to operate marijuana cultivation facilities under the Illinois Compassionate Use of Medical Cannabis Pilot Program Act.  As amended on February 22, 2015, these agreements provided for the following:

 

 

We were to replace WGP as the purchasing party under an existing contract to acquire a 16.1 acre parcel in Anna, Illinois as WGP was to take the necessary legal steps to assign to us the right to acquire ownership to the property. Subsequent to the amendment WGP purchased the land. To date we have not received title to the land.

 

 

We were to construct on this parcel a marijuana cultivation facility (consisting of a 27,000 square foot warehouse and a total developable footprint of 285,000 square feet which would be built in future phases according to demand) in accordance with terms specified in WGP’s license application with the State of Illinois.

 

 

WGP was to lease and operate the facility from us at a base monthly rent of $6.00 per square foot plus 25% of gross monthly sales of cannabis and 20% of gross monthly sales of cannabis infused products.

 

 

We were to provide working capital advances up to a maximum borrowing amount of $2,772,724, with any advances accruing interest at a rate of 18% per annum.  No principal or interest payments were due until WGP had cash on hand of $250,000, but in any event all principal and interest is due December 31, 2017.

 

 

We were to receive consulting fees of $20,000 per month, with any unpaid amounts accruing interest at a rate of 18% per annum.

  

Between February 2015 and April 2015, both parties operated under this agreement.  We made working capital advances totaling $673,294 (inclusive of the deposit of $100,000 made under the initial WGP agreements) and we recognized consulting revenues of $40,000.  We also incurred construction costs totaling $332,357 to begin developing the facility in connection with its obligations under the amended agreement.  However, WGP did not assign its rights to acquire the 16.1 acre parcel to us as required under the amended agreement.  Instead, WGP acquired the property directly.  We have notified WGP that we have fulfilled our obligations pursuant to our agreements with WGP but due to WGP's breach of contract, and repeated lack of good faith and fair dealing, the agreement was terminated.  WGP has claimed that our construction costs were unauthorized.  We dispute WGP’s claim.

 

Included in Note and Other Receivables – WGP in our balance sheet at September 30, 2016 are working capital advances of $673,294, accrued consulting fees of $40,000, construction advances of $332,357 and accrued interest of $204,363 for a total of $1,250,014. 

 

 
35

 

 

We have a formal security agreement covering $600,000 of the advances made to WGP (and related interest), whereby the indebtedness is secured by all real and personal property of WGP.  We believe all other amounts owed by WGP are due and payable.  However, given the current dispute with WGP, we have established a provision for doubtful accounts of $469,699 as of September 30, 2016, representing all amounts owed by WGP (including related interest) that are not covered by a formal security agreement.  This provision is reflected as a separate component of operating expense within our accompanying statement of operations.

 

We have not filed any formal litigation but have provided legal notice that our loans to WGP are immediately due and payable.  By contract, our process for resolving any disputes with WGP is to be resolved via binding arbitration.  We are aggressively pursuing collection of all amounts owed by WGP.  See Note 3 in the Notes to the Financial Statements for a discussion regarding our ongoing dispute with WGP.

 

In October 2016, we were named as a Defendant in an arbitration proceeding brought by Jay Czarkowski, one of our former officers and directors. In his claim, Mr. Czarkowski claims that we failed to grant him stock options to purchase 200,000 shares of the Company’s common stock pursuant to our March 2014 settlement agreement with Mr. Czarkowski. We have denied Mr. Czarkowski claim since our 10-K reports have disclosed that we have granted these options to Mr. Czarkowski.

 

In October 2016, an unrelated third party filed an arbitration claim against us seeking damages for failure to deliver a stock option agreement. In filing an answer to the arbitration claim, we intend to assert the defense that the unrelated third party has not been damaged since the exercise price of the options far exceeds the market value of our common stock.

 

Other than the foregoing, we are not involved in any legal proceedings and we do not know of any legal proceedings which are threatened or contemplated. 

 

INDEMNIFICATION

 

Our Bylaws authorize indemnification of a director, officer, employee or agent against expenses incurred by him in connection with any action, suit, or proceeding to which he is named a party by reason of his having acted or served in such capacity, except for liabilities arising from his own misconduct or negligence in performance of his duty. In addition, even a director, officer, employee, or agent found liable for misconduct or negligence in the performance of his duty may obtain such indemnification if, in view of all the circumstances in the case, a court of competent jurisdiction determines such person is fairly and reasonably entitled to indemnification. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our directors, officers, or controlling persons pursuant to these provisions, we have been informed that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Act and is therefore unenforceable.

 

AVAILABLE INFORMATION

 

We have filed with the Securities and Exchange Commission a Registration Statement on Form S-1 (together with all amendments and exhibits) under the Securities Act of 1933, as amended, with respect to the securities offered by this prospectus. This prospectus does not contain all of the information in the Registration Statement, certain parts of which are omitted in accordance with the rules and regulations of the Securities and Exchange Commission. For further information, reference is made to the Registration Statement which may be read and copied at the Commission’s Public Reference Room.

 

 
36

 

 

We are subject to the requirements of the Securities Exchange Act of l934 and are required to file reports and other information with the Securities and Exchange Commission. Copies of any such reports and other information (which includes our financial statements) filed by us can be read and copied at the Commission's Public Reference Room.

 

The public may obtain information on the operation of the Public Reference Room by calling the Commission at 1-800-SEC-0330. The Public Reference Room is located at 100 F. Street, N.E., Washington, D.C. 20549.

 

Our Registration Statement and all reports and other information we file with the Securities and Exchange Commission are available at www.sec.gov, the website of the Securities and Exchange Commission.

 

 
37

 

 

Financial Statements

 
   

Reports of Independent Registered Public Accounting Firms

F-1

Balance Sheets

F-3

Statements of Operations

F-4

Statement of Stockholders' Equity (Deficit)

F-5

Statements of Cash Flows

F-6

Notes to the Financial Statements

F-7

 

 
38

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

   

To the Board of Directors and Stockholders of AmeriCann, Inc.

 

We have audited the accompanying balance sheet of AmeriCann, Inc. (the “Company”) as of September 30, 2016, and the related statements of operations, changes in stockholders’ equity and cash flows for the year then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.

 

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform an audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

 

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of AmeriCann, Inc. as of September 30, 2016, and the results of their operations and their cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company suffered recurring losses from operations and has an accumulated deficit. These conditions raise significant doubt about the Company’s ability to continue as a going concern. Management’s plans in this regard are described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

/s/ Malone Bailey, LLP

 

www.malonebailey.com

Houston, Texas

January 12, 2017

 

 
F-1

 

 

Hartley Moore Accountancy Corporation

17981 Sky Park Circe, Suite H

Irvine, CA 92614

Tel: (949) 438-4730

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

Board of Directors and Stockholders of

AmeriCann, Inc. (fka Nevada Health Scan, Inc.)

 

 

We have audited the accompanying balance sheet of AmeriCann, Inc. (fka Nevada Health Scan, Inc.) as of September 30, 2015, and the related statements of operations, changes in stockholders’ deficit, and cash flows for the year ended September 30, 2015. These financial statements are the responsibility of the entity’s management. Our responsibility is to express an opinion on these financial statements based on our audit.

 

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States of America).  Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement.  The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.  Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.  An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall consolidated financial statement presentation.  We believe that our audit provides a reasonable basis for our opinion.

 

In our opinion, the financial statements referred to the above present fairly, in all material respects, the financial position of AmeriCann, Inc. (fka Nevada Health Scan, Inc.) as of September 30, 2015, and the results of its operations and its cash flows for the year ended September 30, 2015, in conformity with accounting principles generally accepted in the United States of America.

 

The accompanying financial statements have been prepared assuming that the entity will continue as a going concern.  As discussed in Note 2 to the financial statements, the entity has suffered recurring losses from operations that raises substantial doubt about its ability to continue as a going concern.  Management’s plans in regard to these matters are also described in Note 2.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

/s/ Hartley Moore Accountancy Corporation

Hartley Moore Accountancy Corporation

 

Irvine, California

January 13, 2016

 

 
F-2

 

  

AMERICANN, INC.

BALANCE SHEETS

     

   

September 30,

   

September 30,

 
   

2016

   

2015

 
                 

Assets

               

Current Assets:

               

Cash and cash equivalents

  $ 24     $ 201,353  

Interest receivable

    2,521       5,975  

Deposits on land

    -       200,000  

Prepaid expenses

    11,726       35,758  

Land held for resale

    -       2,250,809  

Note receivable

    247,378       -  

Total current assets

    261,649       2,693,895  
                 

Land held for resale

    2,250,809       -  

Furniture and equipment (net of depreciation of $2,581 and $1,458)

    5,276       6,399  

Notes and other receivables (net of allowance of $469,699 and $456,470)

    780,315       1,251,105  

Note receivable - related party

    117,693       -  

Website development costs (net of amortization of $14,986 and $1,153)

    26,514       40,347  

Deposits on land

    925,000       -  

Security deposit

    3,110       3,110  

Total assets

  $ 4,370,366     $ 3,994,856  
                 

Liabilities and Stockholders' Equity

               

Current Liabilities:

               

Accounts payable and accrued expenses

  $ 385,380     $ 85,298  

Interest payable (including $109,825 and $0 to related parties)

    118,749       -  

Other payables

    14,927       11,716  

Deferred revenue

    60,000       -  

Notes payable

    1,157,997       900,000  

Total current liabilities

    1,737,053       997,014  
                 

Note payable - related party

    2,024,297       1,682,849  

Total liabilities

    3,761,350       2,679,863  
                 

Commitments and contingencies - see Note 9

               
                 

Stockholders' Equity:

               

Preferred stock, $0.0001 par value; 20,000,000 shares authorized; no shares issued and outstanding

    -       -  

Common stock, $0.0001 par value; 100,000,000 shares authorized; 17,031,000 and 16,631,000 shares issued and outstanding as of September 30, 2016 and 2015, respectively

    1,703       1,663  

Additional paid in capital

    6,512,244       5,007,497  
                 

Accumulated deficit

    (5,904,931 )     (3,694,167 )

Total stockholders' equity

    609,016       1,314,993  

Total liabilities and stockholders' equity

  $ 4,370,366     $ 3,994,856  

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

 
F-3

 

 

AMERICANN, INC.

STATEMENTS OF OPERATIONS

 

   

Year Ended September 30,

 
   

2016

   

2015

 

Revenues:

               

Consulting fees

  $ 60,000     $ 140,000  

Total revenues

    60,000       140,000  
                 

Operating expenses:

               

Advertising and marketing

    21,312       15,172  

Professional fees

    571,141       640,326  

General and administrative expenses

    583,739       835,501  

Provision for doubtful accounts

    13,229       456,470  

Total operating expenses

    1,189,421       1,947,469  
                 

Loss from operations

    (1,129,421 )     (1,807,469 )
                 

Other income (expense):

               

Interest income

    183,255       213,665  

Interest expense

    (162,834 )     (73,198 )

Loss on extinguishment of debt

    (991,939 )     -  

Interest expense - related party

    (109,825 )     (62,342 )

Total other income (expense)

    (1,081,343 )     78,125  
                 

Net loss

  $ (2,210,764 )   $ (1,729,344 )
                 

Basic and diluted loss per common share

  $ (0.13 )   $ (0.10 )
                 

Weighted average common shares outstanding

    17,031,000       16,622,507  

 

See accompanying notes to financial statements. 

 

 
F-4

 

   

AMERICANN, INC.

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

 

                                   

Additional

                 
   

Preferred Stock

   

Common Stock

   

Paid In

   

Accumulated

         
   

Shares

   

Amount

   

Shares

   

Amount

   

Capital

   

Deficit

   

Total

 
                                                         

Balances, September 30, 2014

    -     $ -       16,581,000     $ 1,658     $ 4,606,718     $ (1,964,823 )   $ 2,643,553  

Stock-based compensation expense

    -       -       -       -       299,602       -       299,602  

Stock option expense

    -       -       -       -       66,932       -       66,932  

Stock issued for services in process

    -       -       50,000       5       34,245               34,250  

Net loss

    -       -       -       -       -       (1,729,344 )     (1,729,344 )

Balances, September 30, 2015

    -     $ -       16,631,000     $ 1,663     $ 5,007,497     $ (3,694,167 )   $ 1,314,993  

Stock-based compensation expense

    -       -       -       -       131,075       -       131,075  

Stock option expense

    -       -       -       -       9,173       -       9,173  

Stock issued for debt modification

    -       -       400,000       40       1,364,499       -       ,364,539  

Net loss

    -       -       -       -       -       (2,210,764 )     (2,210,764 )

Balances, September 30, 2016

    -       -       17,031,000     $ 1,703     $ 6,512,244     $ (5,904,931 )   $ 609,016  

 

See accompanying notes to financial statements. 

 

 
F-5

 

 

AMERICANN, INC.

STATEMENTS OF CASH FLOWS

 

   

Year Ended September 30,

 
   

2016

   

2015

 

Cash flows from operating activities:

               

Net loss

  $ (2,210,764 )   $ (1,729,344 )

Adjustments to reconcile net loss to net cash used in operating activities:

               

Depreciation and amortization

    14,956       2,217  

Provision for doubtful accounts

    13,229       456,470  

Stock based compensation and option expense

    140,249       366,534  

Loss on extinguishment of debt

    991,939       -  

Amortization of deferred financing costs

    -       27,772  

Amortization of stock issued for prepaid services

    -       28,542  

Changes in operating assets and liabilities:

               

Interest receivable

    3,454       (5,975 )

Prepaid expenses

    24,032       (25,050 )

Accounts payable and accrued expenses

    300,082       59,783  

Related party payables

    -       (16,357 )

Interest payable

    8,924       -  

Interest payable - related party

    109,825       44,657  

Other payables

    3,211       9,957  

Deferred revenue

    60,000       (11,740 )

Net cash flows used in operations

    (540,863 )     (792,534 )

Cash flows from investing activities:

               

Capitalization of website development costs

    -       (41,500  

Deposit on land

    (725,000 )     (200,000 )

Payments received on notes receivable

    338,927       413,695  

Advances made on notes receivable - related party

    (117,693 )     -  

Advances made on notes receivable - WGP

    (128,744 )     (1,021,270 )

Net cash flows used in investing activities

    (632,510 )     (849,075 )

Cash flows from financing activities:

               

Proceeds from note payable

    724,544       861,006  

Proceeds from note payable - related party

    247,500       1,015,000  

Payments on note payable - related party

    -       (207,000 )

Net cash flows provided by financing activities

    972,044       1,669,006  

Net increase (decrease) in cash and cash equivalents

    (201,329 )     27,397  

Cash and cash equivalents at beginning of period

    201,353       173,956  

Cash and cash equivalents at end of period

  $ 24     $ 201,353  

Supplementary Disclosure of Cash Flow Information:

               

Cash paid for interest

  $ 151,925     $ 36,357  

Cash paid for income taxes

  $ -     $ -  

Deferred financing costs

  $ -     $ 27,772  

Property tax paid directly from escrow

  $ -     $ 11,222  

Pay off of loan entered into on March 21, 2015, from loan proceeds entered into on September 15, 2015

  $ -     $ 650,000  
                 

Non-Cash Investing and Financing Activities:

               

Common stock issued for related party debt settlement

    500,000       -  

Debt discount on new debt

    35,250       -  

Reclass note payable to related party (3rd party debt was released and assumed by related party)

    521,297       -  

Debt discount/premium due to debt modification

    72,651       -  

Warrants issued with debt modification

    756,637       -  

Accrued interest added to note payable related party

    -       49,849  

Advance from deposit reclassed to note receivable - WGP

    -       100,000  

Shares issued for prepaid services

    -       34,250  

   

 See accompanying notes to financial statements

 

 
F-6

 

 

AMERICANN, INC.

 NOTES TO FINANCIAL STATEMENTS

  

NOTE 1.

DESCRIPTION OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES

 

Description of Business

 

AmeriCann, Inc. ("the Company" or "the Issuer") was organized under the laws of the State of Delaware on June 25, 2010. The Company was established as part of the Chapter 11 reorganization of AP Corporate Services, Inc. ("AP"). Under AP's Plan of Reorganization, as confirmed by the U.S. Bankruptcy Court for the Central District of California, the Company was incorporated to: (i) receive and own any interest which AP had in the development of an MRI scanning facility; and (ii) issue shares of its common stock to AP's general unsecured creditors, to its administrative creditors, and to its shareholders.

 

Since the Company lacked the resources to effectively develop an MRI facility, in June 2012 the Company decided to promote medical tourism by providing information on a website for those seeking to travel abroad for healthcare services. The Company planned to generate revenue by selling advertising to healthcare providers and related businesses including hotels and travel agencies.

 

In September 2013, the Company abandoned its business plan relating to promoting medical tourism.

 

On January 17, 2014, a privately held limited liability company acquired approximately 93% of the Company's outstanding shares of common stock from several of the Company's shareholders which resulted in a change in control of the Company.

 

The Company's new business plan is to offer a comprehensive, turnkey package of services that includes consulting, design, construction and financing to approved and licensed marijuana operators throughout the United States. The Company's business plan is based on the anticipated growth of the regulated marijuana market in the United States.

 

The Company's activities are subject to significant risks and uncertainties including failure to secure funding to expand its operations. 

 

Certain prior period amounts have been reclassified to conform with current period presentation. These reclassifications have no impact on net loss.

 

Summary of Significant Accounting Policies

 

This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States and have been consistently applied in the preparation of the financial statements.

 

Use of Estimates

 

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets  and  liabilities  and disclosure  of contingent  assets and  liabilities at the date of the financial  statements and the  reported  amounts of revenues  and expenses  during the  reporting  period. The more significant estimates and assumptions made by management are valuation of equity instruments, deferred tax asset valuation and allowance and collectability of long-lived assets. Actual results could differ from those estimates as the current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.  See Note 3 in the Notes to the Financial Statements included as part of this report for a discussion of our provision for doubtful accounts for amount amounts owed from WGP.

 

Cash and Cash Equivalents

 

Cash and cash equivalents includes cash on hand, demand deposit accounts and temporary cash investments with maturities of ninety days or less at the date of purchase.

 

 
F-7

 

 

Income Taxes

 

In accordance with Accounting Standards Codification (ASC) 740 - Income Taxes, the provision for income taxes is computed using the asset and liability method. The liability method measures deferred income taxes by applying enacted statutory rates in effect at the balance sheet date to the differences between the tax basis of assets and liabilities and their reported amounts on the financial statements.  The resulting deferred tax assets or liabilities have been adjusted to reflect changes in tax laws as they occur.  A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized.

 

We expect to recognize the financial statement benefit of an uncertain tax position only after considering the probability that a tax authority would sustain the position in an examination. For tax positions meeting a "more-likely-than-not" threshold, the amount to be recognized in the financial statements will be the benefit expected to be realized upon settlement with the tax authority. For tax positions not meeting the threshold, no financial statement benefit is recognized. As of September 30, 2016, we had no uncertain tax positions. We recognize interest and penalties, if any, related to uncertain tax positions as general and administrative expenses. We currently have no federal or state tax examinations nor have we had any federal or state examinations since our inception. To date, we have not incurred any interest or tax penalties.

 

For federal tax purposes, our 2014 through 2016 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.

 

Concentration of Credit Risks and Significant Customers

 

Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash, notes receivables, deposits, accounts receivables and notes receivable. We place our cash with high credit quality financial institutions. As of September 30, 2016, we had outstanding notes receivable of $247,378 with 4900 Jackson, LLC, notes receivable of $117,693 with Coastal Compassion Inc., and a note and a receivable in the amount of $1,250,014 with WGP (exclusive of provision for doubtful accounts of $469,699).  See Note 3 in the Notes to the Financial Statements included as part of this report for a discussion of our provision for doubtful accounts for amounts owed from WGP.

 

For the year ended September 30, 2016, all of the Company’s revenue was earned from one customer, 4900 Jackson, LLC. For the year ended September 30, 2015, revenue earned from 4900 Jackson, LLC was $100,000, or 71% of total revenues.

 

Financial Instruments and Fair Value of Financial Instruments

 

We adopted ASC Topic 820, Fair Value Measurements and Disclosures, for assets and liabilities measured at fair value on a recurring basis. ASC Topic 820 establishes a common definition for fair value to be applied to existing US GAAP that requires the use of fair value measurements that establishes a framework for measuring fair value and expands disclosure about such fair value measurements. 

 

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC Topic 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

 

 

Level 1:

Observable inputs such as quoted market prices in active markets for identical assets or liabilities

 

Level 2:

Observable market-based inputs or unobservable inputs that are corroborated by market data

 

Level 3:

Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.

 

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. We had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared.

 

 
F-8

 

 

Derivative Liabilities

 

We evaluate stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity’s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date. We determined that none of our financial instruments meet the criteria for derivative accounting as of September 30, 2016 and 2015.

 

Fixed Assets

 

Our long-lived assets consisted of property and equipment and are reviewed for impairment in accordance with the guidance of the FASB Topic ASC 360, Property, Plant, and Equipment, and FASB Topic ASC 205, Presentation of Financial Statements. We test for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management's estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. Through September 30, 2016, we had not experienced impairment losses on our long-lived assets. However, there can be no assurances that demand for our products or services will continue, which could result in an impairment of long-lived assets in the future.

 

Website Development Costs

 

We recognized the costs associated with developing a website in accordance with ASC Subtopic 350-50, Website Development Cost. The website development costs are divided into three stages, planning, development and production. The development stage can further be classified as application and infrastructure development, graphics development and content development. In short, website development cost for internal use should be capitalized except content input and data conversion costs in content development stage. Costs associated with the website consist of website development costs paid to third parties. Website development amortization expense was $13,833 for the year ended September 30, 2016, and $1,153 for the year ended September 30, 2015.

 

Deferred Financing Costs

 

Deferred financing costs represent costs incurred in the connection with obtaining debt financing. These costs are amortized ratably and charged to financing expenses over the term of the related debt.

 

Equity Instruments Issued to Non-Employees for Acquiring Goods or Services

 

Issuances of our common stock or warrants for acquiring goods or services are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. The measurement date for the fair value of the equity instruments issued to consultants or vendors is determined at the earlier of (i) the date at which a commitment for performance to earn the equity instruments is reached (a "performance commitment" which would include a penalty considered to be of a magnitude that is a sufficiently large disincentive for nonperformance) or (ii) the date at which performance is complete.  

 

 
F-9

 

 

Although situations may arise in which counter performance may be required over a period of time, the equity award granted to the party performing the service is fully vested and non-forfeitable on the date of the agreement. As a result, in this situation in which vesting periods do not exist if the instruments is fully vested on the date of agreement, we determine such date to be the measurement date and will record the estimated fair market value of the instruments granted as a prepaid expense and amortize such amount to general and administrative expense in the accompanying statement of operations over the contract period. When it is appropriate for us to recognize the cost of a transaction during financial reporting periods prior to the measurement date, for purposes of recognition of costs during those periods, the equity instrument is measured at the then-current fair values at each of those interim financial reporting dates.

 

Non-Cash Equity Transactions

 

Shares of equity instruments issued for noncash consideration are recorded at the estimated fair market value of the consideration granted based on the estimated fair market value of the equity instrument, or at the estimated fair market value of the goods or services received, whichever is more readily determinable.

 

Stock-Based Compensation

 

We account for share-based awards to employees in accordance with ASC 718 “Stock Compensation”. Under this guidance, stock compensation expense is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the estimated service period (generally the vesting period) on the straight-line attribute method. Share-based awards to non-employees are accounted for in accordance with ASC 505-50 “Equity”, wherein such awards are expensed over the period in which the related services are rendered.

 

Related Parties

 

A party is considered to be related to us if the party directly or indirectly or through one or more intermediaries, controls, is controlled by, or is under common control with us. Related parties also include our principal owners, our management, members of the immediate families of our principal owners and our management and other parties with which we may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. A party which can significantly influence the management or operating policies of the transacting parties, or if it has an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests, is also a related party.

 

Revenue Recognition

 

We recognize revenue on consulting at the time the service is rendered and collectability is reasonably assured.

 

Advertising Expense

 

Advertising, promotional and selling expenses consisted of sales and marketing expenses, and promotional activity expenses. Expenses are recognized when incurred.

 

General and Administrative Expense

 

General and administrative expenses consisted of professional service fees, rent and utility expenses, meals, travel and entertainment expenses, and other general and administrative overhead costs. Expenses are recognized when incurred.

 

Loss per Share

 

We compute net loss per share in accordance with the FASB ASC 260. The ASC specifies the computation, presentation and disclosure requirements for loss per share for entities with publicly held common stock.

 

Basic loss per share amounts is computed by dividing the net loss by the weighted average number of common shares outstanding. Shares issuable upon the exercise of equity instruments such as warrants and options were not included in the loss per share calculations because the inclusion would have been anti-dilutive.

 

 
F-10

 

 

Recent Accounting Pronouncements

 

In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers, which will supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five-step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. As amended by the FASB in July 2015, the standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our financial statements and have not yet determined the method by which we will adopt the standard in 2018.

 

In August 2014, the FASB issued guidance that requires management to evaluate whether there are conditions or events that raise substantial doubt about an entity's ability to continue as a going concern. If such conditions or events exist, disclosures are required that enable users of the financial statements to understand the nature of the conditions or evens, management's evaluation of the circumstances and management's plans to mitigate the conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. We will be required to perform an annual assessment of our ability to continue as a going concern when this standard becomes effective on January 1, 2017; however, the adoption of this guidance is not expected to impact our financial position, results of operations or cash flows.

 

In November 2015, the FASB issued ASU No. 2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet rather than being separated into current and noncurrent. ASU 2015-17 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. Early adoption is permitted and the standard may be applied either retrospectively or on a prospective basis to all deferred tax assets and liabilities. We early adopted ASU 2015-17 during our first quarter of fiscal year 2016 on a retrospective basis. The adoption of 2015-17 had no impact on our financial statements.

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), to provide guidance on recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements, specifically differentiating between different types of leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from all leases. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous GAAP. There continues to be a differentiation between finance leases and operating leases. However, the principal difference from previous guidance is that the lease assets and lease liabilities arising from operating leases should be recognized in the balance sheet. The accounting applied by a lessor is largely unchanged from that applied under previous GAAP. The amendments will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and early adoption is permitted. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The modified retrospective approach includes a number of optional practical expedients that entities may elect to apply. These practical expedients relate to the identification and classification of leases that commenced before the effective date, initial direct costs for leases that commenced before the effective date, and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset. An entity that elects to apply the practical expedients will, in effect, continue to account for leases that commence before the effective date in accordance with previous GAAP unless the lease is modified, except that lessees are required to recognize a right-of-use asset and a lease liability for all operating leases at each reporting date based on the present value of the remaining minimum rental payments that were tracked and disclosed under previous GAAP. The Company is currently evaluating the impact of these amendments on its financial statements.

 

In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations, to clarify the implementation guidance on principal versus agent considerations and address how an entity should assess whether it is the principal or the agent in contracts that include three or more parties. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). The Company is currently evaluating the impact of these amendments on its financial statements.

 

 
F-11

 

 

In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, to reduce complexity in accounting standards involving several aspects of the accounting for employee share-based payment transactions, including (1) the income tax consequences, (2) classification of awards as either equity or liabilities, and (3) classification on the statement of cash flows. The amendments will be effective for financial statements issued for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, and early adoption is permitted. Amendments related to the timing of when excess tax benefits are recognized, minimum statutory withholding requirements, forfeitures, and intrinsic value should be applied using a modified retrospective transition method, amendments related to the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares to meet the minimum statutory withholding requirement should be applied retrospectively, amendments requiring recognition of excess tax benefits and tax deficiencies in the income statement and the practical expedient for estimating expected term should be applied prospectively, and amendments related to the presentation of excess tax benefits on the statement of cash flows can be applied using either a prospective transition method or a retrospective transition method. An entity that elects early adoption must adopt all of the amendments in the same period. The Company is currently evaluating the impact of these amendments on its financial statements.

 

In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, to clarify the following two aspects of Topic 606: 1) identifying performance obligations, and 2) the licensing implementation guidance. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). The Company is currently evaluating the impact of these amendments on its financial statements.

 

In May 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, to clarify certain core recognition principles including collectability, sales tax presentation, noncash consideration, contract modifications and completed contracts at transition and disclosures no longer required if the full retrospective transition method is adopted. The effective date and transition requirements for these amendments are the same as the effective date and transition requirements of ASU 2014-09 (discussed above). The Company is currently evaluating the impact of these amendments on its financial statements.

 

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, to clarify how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The amendments should be applied using a retrospective transition method, and are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company is currently evaluating the impact of these amendments on its financial statements.

 

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force), to provide guidance on the presentation of restricted cash or restricted cash equivalents in the statement of cash flow. The amendments should be applied using a retrospective transition method, and are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company is currently evaluating the impact of these amendments on its financial statements.

  

NOTE 2.

GOING CONCERN

 

The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $5,904,931 and $3,694,167 at September 30, 2016 and 2015, respectively, and had a net loss of $2,210,764 for the year ended September 30, 2016. Further, the amount due from WGP of $1,250,014 (before an allowance of $469,699) may not be collectible. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern. While the Company is attempting to increase operations and generate additional revenues, the Company's cash position may not be significant enough to support the Company's daily operations. Management intends to raise additional funds through the sale of its securities.

 

Management believes that the actions presently being taken to further implement its business plan and generate additional revenues provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate additional revenues and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company's ability to further implement its business plan and generate additional revenues. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

 
F-12

 

 

NOTE 3.

NOTES RECEIVABLE

 

Notes and Other Receivables consisted of the following: 

 

   

September 30,

   

September 30,

 
   

2016

   

2015

 

Note receivable from 4900 Jackson, LLC, a licensed dispensary, interest rate of 12.0%; monthly principal and interest payments of $50,000, with a balloon payment of $182,531 due on May 1, 2017; collateralized by the borrower's assets.

  $ 247,378     $ 586,305  
                 

Notes and other receivables from WGP, a licensed medical marijuana cultivator; $673,294 note secured by real and personal property of the borrower, interest rate of 18.0%; accrued consulting fees of $40,000, construction advances of $332,357 and accrued interest of $204,363. Net of reserves of $469,699 and $456,470. All amounts are due and payable immediately.

    780,315       664,800  
                 

Related party note receivable from CCI, a non-profit corporation, financing of up to $2.5 million through April 2021, interest rate of 18.0%; monthly principal and interest payments commencing the sixth month after CCI begins to generate sales; accrued consulting fees of $60,000, construction and working capital advances of $52,001, and accrued interest of$5,692; unsecured.

    117,693       --  
      1,145,386       1,251,105  

Less: Current portion

    247,378       --  
    $ 898,008     $ 1,251,105  

 

The notes and other receivables from WGP are classified as long term due to ongoing disputes between the Company and WGP.

 

Beginning September 21, 2014, we entered into a series of agreements with WGP, an entity that was pursuing licenses to operate marijuana cultivation facilities under the Illinois Compassionate Use of Medical Cannabis Pilot Program Act.  As amended on February 22, 2015, these agreements provided for the following:

 

 

We were to replace WGP as the purchasing party under an existing contract to acquire a 16.1 acre parcel in Anna, Illinois as WGP was to take the necessary legal steps to assign to us the right to acquire ownership to the property.  Subsequent to the amendment WGP purchased the land.  To date we have not received title to the land.

 

 

We were to construct on this parcel a marijuana cultivation facility (consisting of a 27,000 square foot warehouse and a total developable footprint of 285,000 square feet which would be built in future phases according to demand) in accordance with terms specified in WGP’s license application with the State of Illinois.

 

 

WGP was to lease and operate the facility from us at a base monthly rent of $6.00 per square foot plus 25% of gross monthly sales of cannabis and 20% of gross monthly sales of cannabis infused products.

 

 

We were to provide working capital advances up to a maximum borrowing amount of $2,772,724, with any advances accruing interest at a rate of 18% per annum.  No principal or interest payments were due until WGP had cash on hand of $250,000, but in any event all principal and interest is due December 31, 2017.

 

 

We were to receive consulting fees of $20,000 per month, with any unpaid amounts accruing interest at a rate of 18% per annum.

 

 
F-13

 

 

Between February 2015 and April 2015, both parties operated under this agreement.  We made working capital advances totaling $673,294 (inclusive of the deposit of $100,000 made under the initial WGP agreements) and we recognized consulting revenues of $40,000.  We also incurred construction costs totaling $332,357 to begin developing the facility in connection with its obligations under the amended agreement.  However, WGP did not assign its rights to acquire the 16.1 acre parcel to us as required under the amended agreement.  Instead, WGP acquired the property directly.  We have notified WGP that we have fulfilled our obligations pursuant to our agreements with WGP but due to WGP's breach of contract, and repeated lack of good faith and fair dealing, the agreement was terminated.  WGP has claimed that our construction costs were unauthorized.  We dispute WGP’s claim.

 

Included in Note and Other Receivables – WGP in our balance sheet at September 31, 2016 are working capital advances of $673,294, accrued consulting fees of $40,000, construction advances of $332,357 and accrued interest of $204,363 for a total of $1,250,014. 

 

We have a formal security agreement covering $600,000 of the advances made to WGP (and related interest), whereby the indebtedness is secured by all real and personal property of WGP.  We believe all other amounts owed by WGP are due and payable.  However, given the current dispute with WGP, we have established a provision for doubtful accounts of $469,699 as of September 30, 2016, representing all amounts owed by WGP (including related interest) that are not covered by a formal security agreement.  This provision is reflected as a separate component of operating expense within our accompanying statement of operations.

 

We have not filed any formal litigation but have provided legal notice that our loans to WGP are immediately due and payable.  By contract, our process for resolving any disputes with WGP is to be resolved via binding arbitration.  We are aggressively pursuing collection of all amounts owed by WGP.

 

NOTE 4.

NOTES PAYABLE

 

Unrelated

 

On March 21, 2015, the Company closed on a $650,000 loan from a third party. The loan was due September 21, 2015 and was secured by the land held for sale the Company owns at 4200 Monaco Street, Denver, Colorado. The annual interest rate for the loan was 14%. This note was repaid as described below.

 

On September 15, 2015, a potential buyer loaned the Company $900,000. The loan bears interest at 12% per year and was due and payable on March 16, 2016. The Company used $650,000 of the proceeds to repay the existing loan that was secured by the property. On April 6, 2016, the loan was modified as follows:

 

 

The principal balance of the loan was increased to $990,000;

 

The interest rate was increased to 18% per year; and

 

The maturity date of the loan was extended to March 15, 2017.

 

We considered ASC Subtopic 470-50, Debt Modifications and Extinguishments, and determined that the modification was an extinguishment and therefore, recognized a loss on the extinguishment of the original debt of $90,000 in the year ended September 30, 2016. We may repay the loan at any time without penalty. The loan is secured by a first lien on the five-acre parcel of land in Denver. At September 30, 2016, accrued interest on this note payable was $8,924. Interest expense was $150,497 and $80,623 for the years ended September 30, 2016 and 2015, respectively.

 

As of September 30, 2016, we had borrowed $203,247 from various unrelated parties, exclusive of debt discounts. The interest rates on these notes range from 8% to 18%, due dates range from December 14, 2016, through January 15, 2017, and $75,000 is convertible into the Company’s common stock at a conversion price of $0.75. In addition to the notes, we issued warrants to purchase 75,000 shares of our common stock, exercisable at a price of $0.75 per share, and warrants to purchase an additional 75,000 shares of common stock, exercisable at a price of $1.25 per share. Both sets of warrants expire on September 15, 2020. We allocated the new proceeds to the warrants, stock options, and the convertible debt based on their relative fair values, as determined by the Black Scholes option pricing model. Based on the Black Scholes option pricing model, $35,250 was allocated to the warrants which are reflected in additional paid-in-capital and $35,250 was allocated to a debt discount. The debt discount is being amortized on a straight-line basis over the term of the note. See Note 8 in the Notes to these Financial Statements for additional information on the warrants.

 

 
F-14

 

 

Related Party

 

On February 1, 2016, the Company entered into an agreement with an unrelated party which provides the Company with borrowing capacity of $200,000. On May 1, 2016, the agreement was amended to increase the borrowing capacity to $1,000,000. On July 14, 2016, Strategic Capital Partners (“SCP”) assumed the $521,297 loan borrowed against this credit line, increasing the total balance owed to SCP by the Company to $2,431,646. SCP is controlled by Benjamin J. Barton, one of our officers and directors and a principal shareholder. The amounts borrowed from SCP were used to fund our operations.

 

On July 14, 2016, the Company entered into a debt modification agreement whereby a portion of the debt was converted into common stock and the remaining debt was renegotiated into two promissory notes.

 

Of the amounts owed to SCP, $500,000 was converted into 400,000 shares of our common stock ($1.25 conversion rate).

 

The remaining $1,931,646 owed to SCP was divided into two promissory notes.

 

The first note, in the principal amount of $1,000,000, bears interest at 9.5% per year and matures on December 31, 2019. Interest is payable quarterly with the first interest payment due on September 30, 2016. The note can be converted at any time, at the option of the lender, into shares of our common stock, initially at a conversion price of $1.25 per share. The conversion price will be proportionately adjusted in the event of any stock split or capital reorganization. The note is not secured. At September 30, 2016, accrued interest on this note payable was $20,301.

 

If the average closing price of our common stock is at least $2.50 for twenty consecutive trading days, and the average daily volume of trades of our common stock during the twenty trading days is at least 100,000 shares, we may, within 10 days of the end of such twenty-day period, notify SCP that its right to convert the note into shares of our common stock will end 45 days after the date of the notice to SCP.

 

The second note, in the principal amount of $931,640, bears interest at 8% per year and matures on December 31, 2019. Interest is payable quarterly, with the first interest payment due on September 30, 2016. The note is not convertible into shares of our common stock. The note is secured by a second lien on our property in Denver, Colorado and a first lien on all amounts due to us by WGP. Any payments received from the sale, lease or commercialization of the property in Denver, and any amounts received from WGP, will be applied to the principal amount of the note. Otherwise, all unpaid principal and interest will be due on December 31, 2019. At September 30, 2016, accrued interest on this note payable was $15,297.

 

In connection with the debt modification agreement, we issued SCP warrants to purchase 800,000 shares of our common stock, exercisable at a price of $1.50 per share, and warrants to purchase an additional 800,000 shares of common stock, exercisable at a price of $3.00 per share. Both sets of warrants expire on June 30, 2020. See Note 8 in the Notes to these Financial Statements for additional information on the warrants.

 

The Company analyzed the modification of the note under ASC 470, Debt, and concluded that the modification was an extinguishment and therefore, recognized a loss on the extinguishment of the original debt of $901,939 as follows:

     

   

Present Value as

 
    of 7/14/16  

Reacquisition Price of Debt:

 

 

 

Common stock issued

  $ 408,000  

Warrants

    921,288  

$1.0M convertible note

    1,284,229  

$0.9M secured note

    720,068  

Reacquisition Price of Debt:

  $ 3,333,585  

Net Carrying Amount of Extinguished Debt:

    2,431,646  

Gain/(loss) on extinguishment of debt:

  $ (901,939 )

 

The Company allocated the reacquisition price to the warrants, stock options, and the convertible debt based on their relative fair values, as determined by the Black Scholes option pricing model. Based on the Black Scholes option pricing model, $921,288 was allocated to the warrants which are reflected in additional paid-in-capital, $284,229 was allocated to a debt premium on the convertible debt, and $211,578 was allocated to a debt discount on the secured note. Both the debt premium and discount are being amortized on a straight-line basis over the term of the note.

 

In a separate transaction, the Company borrowed an additional $20,000 from SCP. As of September 30, 2016, the Company owed SCP $2,024,297, net of premiums and discounts.

 

 
F-15

 

 

NOTE 5.

RELATED PARTY TRANSACTIONS

 

Strategic Capital Partners. At September 30, 2016 and 2015, we had outstanding notes payable to SCP, of $2,024,297 and $1,682,849, respectively. On July 14, 2016, $500,000 of the amount owed to SCP was converted into 400,000 shares of our common stock, and the remaining $1,931,646 owed to SCP was divided into two promissory notes. See Notes 4 and 8 in the Notes to these Financial Statements.

 

Interest expense was $109,825 and $62,342 for the years ended September 30, 2016 and 2015, respectively. Interest payable – related party of $109,825 and $0 was included in the accompanying balance sheets at September 30, 2016 and September 30, 2015, respectively.  The Company made no interest payments during 2016 associated with this related party notes payable.  During 2016, the Company received advances of $247,500 and made no payments. During 2015, the Company received advances of $1,015,000 and made payments of $207,000.

 

During the year ended September 30, 2015, SCP paid expenses of $37,720 on behalf of the Company of which the Company repaid all related amounts as of September 30, 2015. There were no similar transactions during the year ended September 30, 2016.

 

Coastal Compassion. On April 7, 2016, we signed agreements with Coastal Compassion Inc. (“CCI”). CCI is one of a limited number of non-profit organizations that has received a provisional or final registration to cultivate, process and sell medical cannabis by the Massachusetts Department of Public Health. CCI has agreed to become the initial tenant in our planned MMCC. Tim Keogh, our Chief Executive Officer, is a Board Member of CCI.

 

Pursuant to the agreements, we agreed to provide CCI with financing of up to $2.5 million for a five-year term at 18% interest per year for construction and working capital required for CCI’s approved dispensary and cultivation center in Fairhaven, MA. For a three- year period beginning April 1, 2016, we agreed to consult with CCI in the design, construction and operation of the Fairhaven facility. CCI will pay us $10,000 each month for these consulting services. Although the DPH has approved our agreement with CCI relating to the development and lease terms of the MMCC, the actual lease agreement with CCI has not been finalized or approved by the DPH. We will need to secure significant capital to provide the financing to CCI.

 

As of September 30, 2016, we have provided financing to CCI of $117,693, which includes accrued consulting fees of $60,000, construction and working capital advances of $52,001, and accrued interest of $5,692. At September 30, 2016, we had deferred revenue of $60,000 from consulting services provided to CCI.

 

NOTE 6.

EARNINGS PER SHARE

 

The following table sets forth the computation of basic and diluted net loss per share: 

 

   

Year Ended September 30,

 
   

2016

   

2015

 
                 

Net loss attributable to common stockholders

  $ (2,210,764 )   $ (1,729,344 )
                 

Basic weighted average outstanding shares of common stock

    17,031,000       16,622,507  

Dilutive effects of common share equivalents

    -       -  

Dilutive weighted average outstanding shares of common stock

    17,031,000       16,622,507  
                 

Basic and diluted net loss per share of common stock

  $ (0.13 )   $ (0.10 )

 

 
F-16

 

 

NOTE 7.

INCOME TAXES

 

Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses. These loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur. The Company accounts for income taxes pursuant to FASB Statement Accounting Standards Codification ASC 740. The Company has made an early adoption of ASU 2015-17, Balance Sheet Classification of Deferred Taxes.

 

Deferred income taxes arise from the temporary differences between financial statement and income tax recognition of net operating losses and other items. Loss carryovers are limited under the Internal Revenue Code should a significant change in ownership occur.

 

The components of the deferred income tax assets and liabilities arising under ASC No. 740 were as follows:

 

   

Year Ended September 30,

 
   

2016

   

2015

 
                 

Deferred tax assets

  $ -     $ -  

Deferred tax liabilities

    -       -  

Net deferred tax assets/(liabilities)

  $ -     $ -  

 

The types of temporary differences between the tax basis of assets and their financial reporting amounts that give rise to a significant portion of the deferred assets and liabilities are as follows:

 

   

September 30,

 
   

2016

   

2015

 
   

Temporary

           

Temporary

         
   

Difference

   

Tax Effect

   

Difference

   

Tax Effect

 
                                 

Deferred tax assets

                               

Net operating loss

  $ 1,156,331     $ 428,536     $ 916,345     $ 339,597  

Other temporary differences

    9,261       3,432       175,325       64,975  

Net deferred tax assets

    1,165,592       431,968       1,091,670       404,572  

Valuation allowance

    (1,165,592 )     (431,968 )     (1,091,670 )     (404,572 )

Total deferred tax asset

    -       -       -       -  
                                 

Deferred tax liabilities

                               

Total deferred liability

    -       -       -       -  
                                 

Total net deferred tax asset

  $ -     $ -     $ -     $ -  

 

At September 30, 2016 and September 30, 2015, the Company had approximately and $2,551,748 and $1,395,417 respectively, in unused federal net operating loss carryforwards, which begin to expire principally in the year 2034. A deferred tax asset at each date of approximately $431,968 and $404,572 resulting from the loss carryforwards and other temporary differences has been offset by a 100% valuation allowance. The change in the valuation allowance for the period ended September 30, 2016 and September 30, 2015 was approximately $27,396 and $227,029.

 

A reconciliation of the U.S. statutory federal income tax rate to the effective tax rate is as follows:

 

   

Year Ended September 30,

 
   

2016

   

2015

 
                 

U.S. Federal statutory graduated rate

    34.00 %     34.00 %

State income tax rate, net of federal benefit

    3.06 %     3.06 %

Total rate

    37.06 %     37.06 %
                 

Less: Net operating loss for which no benefit is currently available

    (37.06 )%     (37.06 )%

Net effective rate

    0.00 %     0.00 %

 

 
F-17

 

 

The Company’s income tax filings are subject to audit by various taxing authorities. The Company’s open audit periods are September 30, 2014, 2015, and 2016. In evaluating the Company’s provisions and accruals, future taxable income, and reversal of temporary differences, interpretations and tax planning strategies are considered. The Company believes its estimates are appropriate based on current facts and circumstances.

 

NOTE 8.

EQUITY

 

Preferred Stock

 

The Company has authorized 20,000,000 shares of $.0001 par value preferred stock. No preferred shares were outstanding at September 30, 2016 and 2015.

 

Common Stock

 

On January 17, 2014, SCP acquired 14,950,000 shares of the Company's outstanding common stock.

 

In connection with the acquisition:

 

 

Benjamin J. Barton, the owner of SCP, was appointed as a director of the Company; and

 

 

Dean Konstantine, Josephine Resma and Howard Behling resigned as officers and directors of the Company.

 

On February 21, 2014, the Company’s board of  directors  declared a stock dividend  in the  amount  of four  shares of common  stock for each  issued  and outstanding share of common stock and issued 64,400,000 shares as a result. As the Company has an accumulated deficit the stock dividend resulted in no amounts being capitalized out of retained earnings and only the par value amount being capitalized out of paid in capital. On March 20, 2014 SCP, returned 65,750,000 shares to the Company.

 

On July 14, 2016, $500,000 of a note payable to SCP was converted into 400,000 shares of the Company’s common stock ($1.25 conversion rate) as part of an overall debt modification. See Note 4.

 

Shares Issued to Officer

 

In connection with an employment agreement described in Note 9, SCP, the Company's largest shareholder, sold 1,200,000 shares of the Company's common stock to Mr. Keogh at a price of $0.001 per share. The estimated fair market value of the stock was $.75 per share based the then current Private Placement Memorandum in place resulting in an aggregate stock based compensation of $898,800 for the difference between the estimated fair market value of $.75 and the purchase price of $0.001 per share. As the Company expects the shares to be earned over the vesting period, the Company will amortize the entire amount to stock based compensation in the Company's statement of operations over the vesting period. Stock based compensation expense for these shares was $131,075 and $299,602 for the years ended September 30, 2016 and 2015, respectively.  As of September 30, 2016, unrecognized stock based compensation expense associated with this award was $37,450 which is expected to be recognized over a weighted average period of 0.29 years.

 

Of these 1,200,000 shares, 300,000  shares  vested on March 25, 2014 and 900,000 are subject to the following vesting requirements provided  that Mr. Keogh is employed the Company on the applicable vesting date: (i) 300,000 Shares will vest on the earlier of March 20,  2015 or the date the Company  receives at least $15,000,000 from the sale of its debt or equity  securities;  (ii) 300,000 Shares will  vest on the  earlier  of March  20,  2016 or the date the  Company receives at least  $30,000,000  from the sale of its debt or equity  securities; and (iii) 300,000 Shares will vest on the earlier March 19, 2017 or the date the Company  receives  at least  $45,000,000  from  the  sale of its debt or  equity to be raised will be cumulative. As of September 30, 2016, 900,000 shares have vested.

 

If during the term of the employment agreement, Mr.  Keogh is terminated other than for cause, there is a change in control, or Mr. Keogh terminates the employment agreement for good reason, then, all shares which have not yet vested will immediately vest.

 

All shares that are not vested at the time of termination of Mr. Keogh's employment, if such termination is a termination for cause or a voluntary termination, will be repurchased by the Company at a price of $0.001 per share. Any shares which are not vested and which are not required to be purchased by the Company will be returned to treasury and cancelled.

 

 
F-18

 

 

Shares Issued to Consultants

 

On February 19, 2015, the Company issued 50,000 shares of common stock in connection with an investment relation services agreement dated December 1, 2014 whereby 25,000 shares vested immediately and 25,000 shares vested on the six-month anniversary of the agreement. Services are for a period of 12 months. These shares had an aggregate value of $34,250 based on the fair market value of the stock on the vesting date.  As of September 30, 2015, there was $5,708 in the prepaid expense account. Amortization of the prepaid expense for these shares was $5,708 and $28,542 for the years ended September 30, 2016 and 2015, respectively, and recognized in general and administrative expenses.

 

Stock Options

 

Options Issuances in 2015

 

As part of its amended agreement with WGP, the Company issued options which allow WGP to purchase up to 100,000 shares of the Company's common stock at a price of $4.00 per share. The options were valued at $19,139 using the Black Scholes option pricing model with the following assumptions: $.70 value of stock on grant date; $4.00 exercise price immediate vesting; .75 risk free interest rate; 100% volatility factor; and 0% dividend yield. The options expire in February 2018.  As these options were fully vested at grant date, the full value was recognized immediately as stock based compensation expense and no further expense will be recognized associated with these awards.

 

Options Issuances in 2016

 

There were no stock options granted in 2016.

 

Summary Option Activity

 

Stock option activity for the year ended September 30, 2016 and 2015 is presented below: 

 

                   

Weighted

         
           

Weighted

   

Average

         
           

Average

   

Contractual

   

Aggregate

 
   

Number of

   

Exercise

   

Term

   

Intrinsic

 
   

Shares

   

Price

   

(Years)

   

Value

 
                                 

Outstanding at September 30, 2014

    1,105,000     $ 9.12       2.0     $ -  

Granted

    100,000       4.00       -       -  

Cancelled

    -       -       -       -  

Exercised

    -       -       -       -  

Outstanding at September 30, 2015

    1,205,000     $ 8.70       2.5     $ -  

Granted

    -       -       -       -  

Cancelled

    -       -       -       -  

Exercised

    -       -       -       -  

Outstanding as of September 30, 2016

    1,205,000     $ 8.70       1.5     $ -  

Vested and expected to vest at September 30, 2016

    1,205,000     $ 8.70       1.5     $ -  

Exercisable at September 30, 2016

    1,205,000     $ 8.70       1.5     $ -  

 

Stock based compensation expense related to the options was $9,173 and $66,932 for the years ended September 30, 2016 and 2015, respectively. At September 30, 2016, there is no remaining unrecognized stock-based compensation associated with stock options.

 

 
F-19

 

 

Warrants

 

On July 14, 2016, $500,000 of the amount owed to SCP discussed in Note 4 was converted into 400,000 shares of our common stock. In connection with the conversion, we issued SCP warrants to purchase 800,000 shares of our common stock, exercisable at a price of $1.50 per share, and warrants to purchase an additional 800,000 shares of common stock, exercisable at a price of $3.00 per share. Both sets of warrants expire on June 30, 2020. The first set of warrants was valued at $510,960 using the Black Scholes option pricing model with the following assumptions: $1.02 value of stock on grant date; $1.25 exercise price; 4-year vesting; 0.96% risk free interest rate; 100% volatility factor; and 0% dividend yield. The second set of warrants was valued at $410,328 using the Black Scholes option pricing model with the following assumptions: $1.02 value of stock on grant date; $3.00 exercise price; 4-year vesting; 0.96% risk free interest rate; 100% volatility factor; and 0% dividend yield.

 

The warrants to purchase the first 800,000 shares of our common stock will expire 45 days after written notice to SCP that the average closing price of our common stock was at least $3.00 for twenty consecutive trading days, and the average daily volume of trades of our common stock during the twenty trading days was at least 100,000 shares, provided a registration statement is in effect with respect to the shares issuable upon the exercise of the Warrants.

 

The warrants to purchase the additional 800,000 shares of our common stock will expire 45 days after written notice to SCP that the average closing price of our common stock was at least $4.80 for twenty consecutive trading days, and the average daily volume of trades of our common stock during the twenty trading days was at least 100,000 shares, provided a registration statement is in effect with respect to the shares issuable upon the exercise of the Warrants.

 

On September 15, 2016, we borrowed $25,000 each from three unrelated parties. In connection with these notes, we issued warrants to purchase a total of 75,000 shares of our common stock, exercisable at a price of $0.75 per share, and warrants to purchase an additional 75,000 shares of common stock, exercisable at a price of $1.25 per share. Both sets of warrants expire on September 15, 2020.

 

The following table shows the warrant activity for the years ended September 30, 2016 and 2015: 

 

   

Shares

   

Weighted

   

Average

         
   

Issuable

   

Average

   

Remaining

         
   

Upon

   

Exercise

   

Contract

   

Intrinsic

 
   

Exercise

   

Price

   

Term

   

Value

 
                                 

Outstanding at September 30, 2014

    2,591,000     $ 8.92       3.7     $ -  

Granted

    -       -       -          

Exercised

    -       -       -          

Cancelled

    -       -       -          

Outstanding at September 30, 2015

    2,591,000     $ 8.92       2.7     $ -  

Granted

    1,750,000       2.14       3.8       -  

Exercised

    -       -       -       -  

Cancelled

    -       -       -       -  

Outstanding at September 30, 2016

    4,341,000     $ 6.19       2.3     $ -  

Exercisable at September 30, 2016

    4,341,000     $ 6.19       2.3     $ -  

 

 
F-20

 

 

NOTE 9.

COMMITMENTS AND CONTINGENCIES

 

Officer Employment Agreement.  On March 25, 2014, the Company entered into an employment agreement with Mr. Keogh. The agreement: (i) has an initial term of three years; (ii) requires that Mr. Keogh devote at least 50% of his time to the Company and; (iii) provides that the Company will pay Mr. Keogh $12,000 per month during the term of the agreement. In connection with this employment agreement the Company granted Mr. Keogh shares of common stock and options.  See Note 8 in the Notes to these Financial Statements.

 

Investment Relations Consulting Agreement. On December 1, 2014, the Company entered into an investment relation services agreement where the Company pays $4,000 per month in exchange for services.  For the year ended September 30, 2015, the total amount paid was $32,000. There were no such transactions during the year ended September 30, 2016. As of September 30, 2015, $12,000 was recorded in accrued liabilities on the balance sheet. Common stock was also issued related to this agreement.  See Note 8 in the Notes to these Financial Statements.

 

Consulting Agreement. On December 1, 2014, the Company entered into a consulting agreement with a community relations and public affairs company.  Pursuant to the agreement, the Company pays $4,000 per month in exchange for services.  The agreement may be terminated by either party with 30 days written notice. For the year ended September 30, 2015 the total amount paid was $24,000. There were no such transactions during the year ended September 30, 2016. At September 30, 2015, $12,000 was recorded in accrued liabilities on the balance sheet.

 

MMCC.  On January 14, 2015, we entered into an agreement to purchase a 52.6 acre parcel of undeveloped land in Freetown, Massachusetts. The property is located approximately 47 miles southeast of Boston. We plan to develop the property as the Massachusetts Medical Cannabis Center "MMCC". Plans for the MMCC may include the construction of sustainable greenhouse cultivation and processing facilities that will be leased or sold to Registered Marijuana Dispensaries under the Massachusetts Medical Marijuana Program. We paid the seller $100,000 upon the signing of the agreement which amount will be applied toward the purchase price at the closing.

 

Between August 2015 and September 2016, there were several amendments to the Agreement to extend the closing date to October 14, 2016. As consideration for the extensions, the Company, at closing, agreed to increase the purchase price to $4,325,000 and paid the seller $725,000, which was applied to the purchase price of the land. As of September 30, 2016, the Company had paid $925,000 that was applied to the purchase price of the land at closing. On October 17, 2016, the Company closed on the land purchase via a sales-leaseback transaction. See Note 10 in the Notes to these Financial Statements for additional information.

 

Operating Leases. The Company leases its office space located at 3200 Brighton Boulevard, Denver, Colorado for $2,870 per month on a month-to-month basis.

 

Upon signing the lease, the Company paid a refundable deposit of $3,110. The lease expense was $35,145 and $34,140 for the year ended September 30, 2016 and 2015, respectively.

 

The Company leases an automobile under an operating lease commencing October 4, 2014 for 39 months at $611 per month. The lease expense was $7,483 and $7,953 for the year ended September 30, 2016 and 2015, respectively.  At September 30, 2016, the future rental payments required under operating leases are as follows:

  

2017

  $ 7,483  

2018

    910  

2019

    -  

2020

    -  

2021

    -  

Total

  $ 8,393  

 

NOTE 10.

SUBSEQUENT EVENTS

 

MMCC.  On October 17, 2016, the Company assigned the property rights to a 52.6-acre parcel of undeveloped land in Freetown, Massachusetts to Massachusetts Medical Properties, LLC (“MMP”), and MMP purchased the land from the seller. The deposits of $925,000 previously paid by the Company to the seller, Boston Beer Company (“BBC”), were credited against the total purchase price of $4,475,000. The remaining balance of $3,550,000 was paid to BBC by MMP. The property is located approximately 47 miles southeast of Boston. The Company plans to develop the property as the Massachusetts Medical Cannabis Center (the “MMCC”). Plans for the MMCC include the construction of sustainable greenhouse cultivation, processing, and infused product facilities that will be leased or sold to Registered Marijuana Dispensaries under the Massachusetts Medical Marijuana Program.

 

As part of a simultaneous transaction, the Company entered into a lease, pursuant to which MMP agreed to lease the property to the Company for an initial term of fifty (50) years. The Company has the option to extend the term of the lease for four (4) additional ten (10) year periods. The lease is a triple net lease, with the Company paying all real estate taxes, repairs, maintenance and insurance.

 

 
F-21

 

 

The lease payments will be the greater of (a) $30,000 per month; (b) $0.38 per square foot per month of any structure built on the property; or (c) 1.5% of all gross monthly sales of products sold by the Company, any assignee of the Company, or any subtenant of the Company. The lease payments will be adjusted up (but not down) every five (5) years by any increase in the Consumer Price Index.

 

Between October 17, 2016 and April 17, 2017, the monthly lease payments will accrue, with all accrued lease payments to be paid to MMP on April 17, 2017. On April 17, 2017, the Company will reimburse MMP’s costs and expenses associated with the acquisition of the property, the lease, and the acquisition of the shares and the warrant from the Company (as further described below).

 

Under the terms of the lease, the Company has six (6) months to obtain capital funding for the construction of the first phase building. In the event that the Company is unable to raise these funds within the six (6) month period, the Company will have an additional six (6) month period to do so; provided, that the Company has paid accrued lease payments and closing costs. If the Company is then unable to raise these funds on or before twelve (12) months from October 17, 2016, the lease will terminate.

The Company shall receive credit for the $925,000 paid towards the purchase price in the form of discounted lease payments. For the initial fifty (50) year term of the lease, the lease payments will be reduced by $1,541.67 each month.

 

In connection with the sale of the property to MMP and the lease, the Company and MMP entered into a Share Purchase Agreement pursuant to which the Company issued to MMP 100,000 shares of its common stock, par value $0.0001 (“Common Stock”), and a warrant to purchase up to 3,640,000 shares of Common Stock at an exercise price of $1.00 per share. The warrant can be exercised at any time on or after October 17, 2018 and on or before October 17, 2020. The warrant does not contain a cashless exercise provision.

 

Unregistered Sale of Equity Securities. On November 7, 2016, we accepted subscriptions for $2,000,000 in equity financing through the sale of 2,000,000 Units at a price of $1.00 per Unit. The Units were sold in a private offering to a group of accredited investors. Each Unit consisted of one share of our common stock and one Series I Warrant. Each Series I Warrant allows the Holder to purchase one share of our common stock at a price of $3.00 per share at any time on or before November 4, 2020.

  

The offering will provide the Company with $2,000,000 in gross proceeds and the potential for an additional $6,000,000 in proceeds with the exercise of the Series I Warrants.

 

The proceeds from the placement will be utilized for the Company’s Massachusetts Medical Cannabis Center (the “MMCC”) development, to pursue new opportunities in California, Pennsylvania, Florida and other states, and general corporate purposes.

 

 
F-22

 

 

AMERICANN, INC.

 

INTERIM FINANCIAL STATEMENTS

 

DECEMBER 31, 2016

 

UNAUDITED

 

 

 

 

 

 

 

 

 

 

 
F-23

 

 

AMERICANN, INC.

BALANCE SHEETS

 

   

December 31, 2016 (unaudited)

   

September 30,

2016

 
                 

Assets

               

Current Assets:

               

Cash and cash equivalents

  $ 802,769     $ 24  

Interest receivable

    -       2,521  

Prepaid land lease

    53,906       -  

Prepaid expenses and other current assets

    11,726       11,726  

Note receivable

    176,147       247,378  

Total current assets

    1,044,548       261,649  
                 

Land held for resale

    2,250,809       2,250,809  

Furniture and equipment (net of depreciation of $2,862 and $2,581)

    4,995       5,276  

Notes and other receivables (net of allowance of $473,024 and $469,699)

    789,098       780,315  

Note receivable - related party

    182,686       117,693  

Website development costs (net of amortization of $18,445 and $14,986)

    23,055       26,514  

Prepaid land lease and related deposits

    2,627,950       925,000  

Security deposit

    3,110       3,110  

Total assets

  $ 6,926,251     $ 4,370,366  
                 

Liabilities and Stockholders' Equity

               

Current Liabilities:

               

Accounts payable and accrued expenses

  $ 151,672     $ 385,380  

Interest payable (including $0 and $109,825 to related parties)

    -       118,749  

Other payables

    16,281       14,927  

Deferred revenue

    90,000       60,000  

Notes payable (net of discount of $3,819 and $35,250)

    986,181       1,157,997  

Total current liabilities

    1,244,134       1,737,053  
                 

Note payable - related party (net of discount of $62,888 and $72,651)

    1,994,534       2,024,297  
                 

Total liabilities

    3,238,668       3,761,350  
                 

Commitments and contingencies - see Note 9

               
                 

Stockholders' Equity:

               

Preferred stock, $0.0001 par value; 20,000,000 shares authorized; no shares issued and outstanding

    -       -  

Common stock, $0.0001 par value; 100,000,000 shares authorized; 19,131,000 and 17,031,000 shares issued and outstanding as of December 31, 2016 and September 30, 2016, respectively

    1,913       1,703  

Additional paid in capital

    10,107,366       6,512,244  

Accumulated deficit

    (6,421,696 )     (5,904,931 )

Total stockholders' equity

    3,687,583       609,016  
                 

Total liabilities and stockholders' equity

  $ 6,926,251     $ 4,370,366  

 

See accompanying notes to unaudited financial statements.

 

 
F-24

 

 

AMERICANN, INC.

STATEMENTS OF OPERATIONS

(unaudited)

 

   

Three Months Ended December 31,

 
   

2016

   

2015

 
                 

Revenues:

               

Consulting fees

  $ 15,000     $ 15,000  

Total revenues

    15,000       15,000  
                 
                 

Operating expenses:

               

Advertising and marketing

    2,247       2,098  

Professional fees

    150,404       218,329  

General and administrative expenses

    288,433       175,145  

Provision for doubtful accounts

    3,325       3,325  

Total operating expenses

    444,409       398,897  
                 

Loss from operations

    (429,409 )     (383,897 )
                 

Other income (expense):

               

Interest income

    27,187       48,295  

Interest expense

    (81,575 )     (31,956 )

Interest expense - related party

    (32,968 )     (21,858 )

Total other income (expense)

    (87,356 )     (5,519 )
                 

Net loss

  $ (516,765 )   $ (389,416 )
                 

Basic and diluted loss per common share

  $ (0.03 )   $ (0.02 )
                 

Weighted average common shares outstanding

    18,286,435       16,631,000  
 

See accompanying notes to unaudited financial statements.

 

 
F-25

 

 

AMERICANN, INC.

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

(unaudited)

 

                                   

Additional

                 
   

Preferred Stock

   

Common Stock

   

Paid In

   

Accumulated

         
   

Shares

   

Amount

   

Shares

   

Amount

   

Capital

   

Deficit

   

Total

 
                                                         

Balances, September 30, 2016

    -     $ -       17,031,000     $ 1,703     $ 6,512,244     $ (5,904,931 )   $ 609,016  

Stock-based compensation expense

    -       -       -       -       18,725       -       18,725  

Shares and warrants issued to lessor

    -       -       100,000       10       1,770,323       -       1,770,333  

Stock issued for cash, net

    -       -       2,000,000       200       1,806,074       -       1,806,274  

Net loss

    -       -       -       -       -       (516,765 )     (516,765 )

Balances, December 31, 2016

    -     $ -       19,131,000     $ 1,913     $ 10,107,366     $ (6,421,696 )   $ 3,687,583  
 

See accompanying notes to unaudited financial statements.

 

 
F-26

 

 

AMERICANN, INC.

STATEMENTS OF CASH FLOWS

(unaudited)

 

   

Three Months Ended December 31,

 
   

2016

   

2015

 
                 

Cash flows from operating activities:

               

Net loss

  $ (516,765 )   $ (389,416 )

Adjustments to reconcile net loss to net cash used in operating activities:

               

Depreciation and amortization

    3,740       3,740  

Provision for doubtful accounts

    3,325       3,325  

Stock based compensation and option expense

    18,725       51,722  

Amortization of debt discount/(premium)

    21,668       -  

Changes in operating assets and liabilities:

               

Interest receivable

    2,521       990  

Amounts due from WGP

    (12,108 )     (32,362 )

Prepaid expenses

    13,477       24,032  

Accounts payable and accrued expenses

    (233,708 )     68,090  

Interest payable

    (8,924 )     31,956  

Interest payable - related party

    (109,825 )     21,858  

Other payables

    1,354       (1,538 )

Deferred revenue

    30,000       -  

Net cash flows used in operations

    (786,520 )     (217,603 )
                 

Cash flows from investing activities:

               

Purchase of fixed assets

    -       (4,329 )

Deposit on land

    -       (200,000 )

Payments received on notes receivable

    86,231       80,876  

Advances made on notes receivable - related party

    (64,993 )     -  

Advances made on notes receivable

    (15,000 )     -  

Net cash flows provided by (used in) investing activities

    6,238       (123,453 )
                 

Cash flows from financing activities:

               

Common stock issued for cash, net

    1,806,274       -  

Proceeds from note payable

    24,657       -  

Proceeds from note payable - related party

    -       180,000  

Payments on note payable - related party

    (20,000 )     -  

Payments on note payable

    (227,904 )     -  

Net cash flows provided by financing activities

    1,583,027       180,000  
                 

Net increase (decrease) in cash and cash equivalents

    802,745       (161,056 )
                 

Cash and cash equivalents at beginning of period

    24       201,353  
                 

Cash and cash equivalents at end of period

  $ 802,769     $ 40,297  
                 
                 

Supplementary Disclosure of Cash Flow Information:

               
                 

Cash paid for interest (including $152,556 to related parties)

  $ 164,450     $ -  

Cash paid for income taxes

  $ -     $ -  
                 

Non-Cash Investing and Financing Activities:

               
                 

Shares and warrants issued to lessor as consideration for land lease

    1,770,333       -  
 

See accompanying notes to unaudited financial statements.

 

 
F-27

 

  

AMERICANN, INC.

Notes To Unaudited Financial Statements

 

 

NOTE 1. NATURE OF BUSINESS AND BASIS OF PRESENTATION

 

AmeriCann, Inc. ("the Company", “we”, “our” or "the Issuer") was organized under the laws of the State of Delaware on June 25, 2010.

 

On January 17, 2014, a privately held limited liability company acquired approximately 93% of the Company's outstanding shares of common stock from several of the Company's shareholders, which resulted in a change in control of the Company.

 

The Company's business plan is to offer a comprehensive, turnkey package of services that includes consulting, design, construction and financing to approved and licensed marijuana operators throughout the United States. The Company's business plan is based on the anticipated growth of the regulated marijuana market in the United States.

 

The Company's activities are subject to significant risks and uncertainties including failure to secure funding to properly expand its operations.

 

Basis of Presentation

 

The (a) balance sheet as of September 30, 2016, which has been derived from audited financial statements, and (b) the unaudited financial statements as of and for the three months ended December 31, 2016 and 2015, have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission ("SEC"), and should be read in conjunction with the audited financial statements and notes thereto contained in the Company's Form 10-K filed with the SEC on January 12, 2017. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for future quarters or for the full year. Notes to the financial statements which substantially duplicate the disclosure contained in the audited financial statements for fiscal 2016 as reported in the Form 10-K have been omitted.

 

Certain prior period amounts have been reclassified to conform with current period presentation. These reclassifications have no impact on net loss.

 

Recent Accounting Pronouncements

 

Between May 2014 and December 2016, the Financial Accounting Standards Board(FASB) has issued several Accounting Standards Updates(ASU) on Revenue from Contracts with Customers (Topic 606). These updates will supersede nearly all existing revenue recognition guidance under current U.S. generally accepted accounting principles (GAAP). The core principle is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. A five-step process has been defined to achieve this core principle, and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standards are effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standards in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting the standards recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of its pending adoption of these standards on its financial statements and has not yet determined the method by which it will adopt the standard in 2018.

 

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force), to provide guidance on the presentation of restricted cash or restricted cash equivalents in the statement of cash flow. The amendments should be applied using a retrospective transition method, and are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company is currently evaluating the impact of these amendments on its financial statements.

 

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, to clarify how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The amendments should be applied using a retrospective transition method, and are effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company is currently evaluating the impact of these amendments on its financial statements.

 

 
F-28

 

 

In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, to reduce complexity in accounting standards involving several aspects of the accounting for employee share-based payment transactions, including (1) the income tax consequences, (2) classification of awards as either equity or liabilities, and (3) classification on the statement of cash flows. The amendments will be effective for financial statements issued for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, and early adoption is permitted. Amendments related to the timing of when excess tax benefits are recognized, minimum statutory withholding requirements, forfeitures, and intrinsic value should be applied using a modified retrospective transition method, amendments related to the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares to meet the minimum statutory withholding requirement should be applied retrospectively, amendments requiring recognition of excess tax benefits and tax deficiencies in the income statement and the practical expedient for estimating expected term should be applied prospectively, and amendments related to the presentation of excess tax benefits on the statement of cash flows can be applied using either a prospective transition method or a retrospective transition method. An entity that elects early adoption must adopt all of the amendments in the same period. The Company is currently evaluating the impact of these amendments on its financial statements.

 

In February 2016, the FASB issued ASU No. 2016-02, Leases: (Topic 842), to provide guidance on recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements, specifically differentiating between different types of leases. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from all leases. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous GAAP. There continues to be a differentiation between finance leases and operating leases. However, the principal difference from previous guidance is that the lease assets and lease liabilities arising from operating leases should be recognized in the balance sheet. The accounting applied by a lessor is largely unchanged from that applied under previous GAAP. The amendments will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and early adoption is permitted. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. The modified retrospective approach includes a number of optional practical expedients that entities may elect to apply. These practical expedients relate to the identification and classification of leases that commenced before the effective date, initial direct costs for leases that commenced before the effective date, and the ability to use hindsight in evaluating lessee options to extend or terminate a lease or to purchase the underlying asset. An entity that elects to apply the practical expedients will, in effect, continue to account for leases that commence before the effective date in accordance with previous GAAP unless the lease is modified, except that lessees are required to recognize a right-of-use asset and a lease liability for all operating leases at each reporting date based on the present value of the remaining minimum rental payments that were tracked and disclosed under previous GAAP. The Company is currently evaluating the impact of these amendments on its financial statements.

 

NOTE 2. GOING CONCERN 

 

The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had an accumulated deficit of $6,421,696 and $5,904,931 at December 31, 2016 and September 30, 2016, respectively, and had a net loss of $516,765 for the three months ended December 31, 2016. Further, the amount due from WGP of $1,262,122 (before an allowance of $473,024) may not be collectible. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern. While the Company is attempting to increase operations and generate additional revenues, the Company's cash position may not be significant enough to support the Company's daily operations. Management intends to raise additional funds through the sale of its securities.

  

Management believes that the actions presently being taken to further implement its business plan and generate additional revenues provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate additional revenues and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company's ability to further implement its business plan and generate additional revenues. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

 
F-29

 

 

NOTE 3. NOTES AND OTHER RECEIVABLES

 

Notes and Other Receivables as of December 31, 2016 and September 30, 2016, consisted of the following: 

 

   

December 31,

2016

   

September 30,

2016

 
                 
Note receivable from 4900 Jackson, LLC, a licensed dispensary, interest rate of 12.0%; monthly principal and interest payments of $50,000, with a balloon payment of $182,531 due on May 1, 2017; collateralized by the borrower's assets.   $ 176,147     $ 247,378  
                 
Notes and other receivables from WGP, a licensed medical marijuana cultivator; $673,294 note secured by real and personal property of the borrower, interest rate of 18.0%; accrued consulting fees of $40,000, construction advances of $332,357 and accrued interest of $216,471. Net of reserves of $473,024. All amounts are due and payable immediately.     789,098       780,315  
                 
Related party note receivable from CCI, a non-profit corporation, financing of up to $2.5 million through April 2021, interest rate of 18.0%; monthly principal and interest payments commencing the sixth month after CCI begins to generate sales; accrued consulting fees of $90,000, construction and working capital advances of $80,089, and accrued interest of $12,597; unsecured.     182,686       117,693  
      1,147,931       1,145,386  

Less: Current portion

    176,147       247,378  
    $ 971,784     $ 898,008  

 

The notes and other receivables from WGP are classified as long term due to ongoing disputes between the Company and WGP.

 

NOTE 4.  NOTES PAYABLE

 

Unrelated

 

On September 15, 2015, an unrelated third party loaned the Company $900,000. The loan bore interest at 12% per year and was due and payable on March 16, 2016. The Company used $650,000 of the proceeds to repay existing loans that were secured by the land held for sale. On April 6, 2016, the loan was modified as follows: 

 

 

The principal balance of the loan was increased to $990,000;

 

The interest rate was increased to 18% per year; and

 

The maturity date of the loan was extended to March 15, 2017.

 

The Company considered ASC Subtopic 470-50, Debt Modifications and Extinguishments, and determined that the modification was an extinguishment and therefore, recognized a loss on the extinguishment of the original debt of $90,000. The Company may repay the loan at any time without penalty. The loan is secured by a first lien on the five-acre parcel of land in Denver. Accrued interest on this note payable at December 31, 2016 and September 30, 2016 was $0 and $8,924, respectively.

 

In September 2016, we had borrowed funds from various unrelated parties. The interest rates on these notes ranged from 8% to 18%, due dates ranged from December 14, 2016, through January 15, 2017, and $75,000 was convertible into the Company’s common stock at a conversion price of $0.75. In addition to the notes, we issued warrants to purchase 75,000 shares of our common stock, exercisable at a price of $0.75 per share, and warrants to purchase an additional 75,000 shares of common stock, exercisable at a price of $1.25 per share. Both sets of warrants expire on September 15, 2020. We allocated the new proceeds to the warrants, stock options, and the convertible debt based on their relative fair values, as determined by the Black Scholes option pricing model. Based on the Black Scholes option pricing model, $35,250 was allocated to the warrants which are reflected in additional paid-in-capital and $35,250 was allocated to a debt discount. The debt discount is being amortized on a straight-line basis over the term of the note. At December 31, 2016, there was no outstanding principle or interest, and unamortized debt discount was $3,819.

 

 
F-30

 

 

Related Party

 

On February 1, 2016, we entered into an agreement with an unrelated party which provided us with borrowing capacity of $200,000. On May 1, 2016, the agreement was amended to increase the borrowing capacity to $1,000,000. On July 14, 2016, Strategic Capital Partners (“SCP”) assumed the $521,297 loan borrowed against this credit line, increasing the total balance owed to SCP to $2,431,646. SCP is controlled by Benjamin J. Barton, one of our officers and directors and a principal shareholder. The amounts borrowed from SCP were used to fund our operations.

 

On July 14, 2016, we entered into a debt modification agreement whereby a portion of the debt was converted into common stock and the remaining debt was renegotiated into two promissory notes.

 

Of the amounts owed to SCP, $500,000 was converted into 400,000 shares of our common stock ($1.25 conversion rate).

 

The remaining $1,931,646 owed to SCP was divided into two promissory notes.

 

The first note, in the principal amount of $1,000,000, bears interest at 9.5% per year and matures on December 31, 2019. Interest is payable quarterly. The note can be converted at any time, at the option of the lender, into shares of our common stock, initially at a conversion price of $1.25 per share. The conversion price will be proportionately adjusted in the event of any stock split or capital reorganization. The note is not secured. Accrued interest on this note payable at December 31, 2016 and September 30, 2016 was $0 and $20,301, respectively.

 

If the average closing price of our common stock is at least $2.50 for twenty consecutive trading days, and the average daily volume of trades of our common stock during the twenty trading days is at least 100,000 shares, we may, within 10 days of the end of such twenty-day period, notify SCP that its right to convert the note into shares of our common stock will end 45 days after the date of the notice to SCP.

 

The second note, in the principal amount of $931,640, bears interest at 8% per year and matures on December 31, 2019. Interest is payable quarterly. The note is not convertible into shares of our common stock. The note is secured by a second lien on our property in Denver, Colorado and a first lien on all amounts due to us by WGP. Any payments received from the sale, lease or commercialization of the property in Denver, and any amounts received from WGP, will be applied to the principal amount of the note. Otherwise, all unpaid principal and interest will be due on December 31, 2019. Accrued interest on this note payable at December 31, 2016 and September 30, 2016 was $0 and $15,297, respectively.

 

In connection with the debt modification agreement, we issued SCP warrants to purchase 800,000 shares of our common stock, exercisable at a price of $1.50 per share, and warrants to purchase an additional 800,000 shares of common stock, exercisable at a price of $3.00 per share. Both sets of warrants expire on June 30, 2020.

 

NOTE 5. RELATED PARTY TRANSACTIONS

 

Strategic Capital Partners. At December 31, 2016 and September 30, 2016, we had outstanding notes payable to SCP of $1,994,534 and $2,024,297, respectively.

 

Interest expense was $32,968 and $21,858 for the three months ended December 31, 2016 and 2015, respectively. Interest payable – related party of $0 and $109,825 was included in the accompanying balance sheets at December 31, 2016 and September 30, 2016, respectively.  We made interest payments of $152,556 during 2017, and made no interest payments during 2016 associated with this related party notes payable.  During the three months ended December 31, 2016, we received advances of $0 and made payments of $20,000. During the three months ended December 31, 2015, we received advances of $180,000 and made no payments.

  

Coastal Compassion. On April 7, 2016, we signed agreements with Coastal Compassion Inc. (“CCI”). CCI is one of a limited number of non-profit organizations that has received a provisional or final registration to cultivate, process and sell medical cannabis by the Massachusetts Department of Public Health. CCI has agreed to become the initial tenant in our planned MMCC. Tim Keogh, our Chief Executive Officer, is a Board Member of CCI.

 

 
F-31

 

 

Pursuant to the agreements, we agreed to provide CCI with financing of up to $2.5 million for a five-year term at 18% interest per year for construction and working capital required for CCI’s approved dispensary and cultivation center in Fairhaven, MA. For a three- year period beginning April 1, 2016, we agreed to consult with CCI in the design, construction and operation of the Fairhaven facility. CCI will pay us $10,000 each month for these consulting services. Although the DPH has approved our agreement with CCI relating to the development and lease terms of the MMCC, the actual lease agreement with CCI has not been finalized or approved by the DPH. We will need to secure significant capital to provide the financing to CCI.

 

As of December 31, 2016, we have provided financing to CCI of $182,686, which includes accrued consulting fees of $90,000, construction and working capital advances of $80,089, and accrued interest of $12,597. At December 31, 2016, we had deferred revenue of $90,000 from consulting services provided to CCI.

 

NOTE 6. LOSS PER SHARE

 

The following table sets forth the computation of basic and diluted net loss per share:

 

   

Three Months Ended

 
   

December 31,

 
   

2016

   

2015

 
                 
                 

Net loss attributable to common stockholders

  $ (516,765 )   $ (389,416 )
                 

Basic weighted average outstanding shares of common stock

    18,286,435       16,631,000  

Dilutive effects of common share equivalents

    -       -  

Dilutive weighted average outstanding shares of common stock

    18,286,435       16,631,000  
                 

Basic and diluted net loss per share of common stock

  $ (0.03 )   $ (0.02 )

 

We have excluded 1,205,000 of stock options from the computation of diluted net loss per share since the effects are anti-dilutive.

 

NOTE 7. INCOME TAXES

 

We did not record any income tax expense or benefit for the three months ended December 31, 2016. We increased our valuation allowance and reduced its net deferred tax assets to zero. Our assessment of the realization of its deferred tax assets has not changed, and as a result we continue to maintain a full valuation allowance for our net deferred assets as of December 31, 2016.

 

As of December 31, 2016, we did not have any unrecognized tax benefits. There were no significant changes to the calculation since September 30, 2016.

 

NOTE 8. STOCK BASED COMPENSATION

 

Restricted Stock Awards. We use restricted stock awards to compensate certain key executives and other individuals. At December 31, 2016, we had 300,000 outstanding unvested restricted stock awards which vest on March 20, 2017. Stock-based compensation expense associated with restricted stock awards was $18,725 and $46,813 for the three months ended December 31, 2016 and 2015. As of December 31, 2016, unrecognized stock-based compensation associated with restricted stock awards totaled $18,725, which is to be recognized over a weighted average period of 0.2 years.

 

 
F-32

 

 

Stock Options. Stock option activity as of and for the three months ended December 31, 2016 is as follows: 

 

                   

Weighted

         
           

Weighted

   

Average

         
           

Average

   

Contractual

   

Aggregate

 
   

Number of

   

Exercise

   

Term

   

Intrinsic

 
   

Shares

   

Price

   

(Years)

   

Value

 
                                 

Outstanding at September 30, 2016

    1,205,000     $ 8.70       1.5     $ -  

Granted

    -       -       -       -  

Cancelled

    -       -       -       -  

Exercised

    -       -       -       -  

Outstanding as of December 31, 2016

    1,205,000     $ 8.70       1.2     $ -  

Vested and expected to vest at December 31, 2016

    1,205,000     $ 8.70       1.2     $ -  

Exercisable at December 31, 2016

    1,205,000     $ 8.70       1.2     $ -  
 

Stock-based compensation expense associated with stock options totaled $0 and $4,909 for the three months ended December 31, 2016 and 2015, respectively. At December 31, 2016, there is no remaining unrecognized stock-based compensation associated with stock options.

 

NOTE 9.  COMMITMENTS AND CONTIGENCIES

 

Coastal Compassion. On April 7, 2016, we signed agreements with Coastal Compassion Inc. (“CCI”). CCI is one of a limited number of non-profit organizations that has received a provisional or final registration to cultivate, process and sell medical cannabis by the Massachusetts Department of Public Health. CCI has agreed to become the initial tenant in our planned MMCC. Tim Keogh, our Chief Executive Officer, is a Board Member of CCI.

 

Pursuant to the agreements, we agreed to provide CCI with financing of up to $2.5 million for a five-year term at 18% interest per year for construction and working capital required for CCI’s approved dispensary and cultivation center in Fairhaven, MA. For a three- year period beginning April 1, 2016, we agreed to consult with CCI in the design, construction and operation of the Fairhaven facility. CCI will pay us $10,000 each month for these consulting services. Although the DPH has approved our agreement with CCI relating to the development and lease terms of the MMCC, the actual lease agreement with CCI has not been finalized or approved by the DPH. We will need to secure significant capital to provide the financing to CCI.

 

As of December 31, 2016, we have provided financing to CCI of $182,686, which includes accrued consulting fees of $90,000, construction and working capital advances of $80,089, and accrued interest of $12,597.

 

 
F-33

 

 

Operating Leases

 

Land

 

On October 17, 2016, the Company closed the previously announced acquisition of a 52.6-acre parcel of undeveloped land in Freetown, Massachusetts. The deposits of $925,000 previously paid by the Company to the seller, Boston Beer Company (“BBC”), were credited against the total purchase price of $4,475,000. The remaining balance of $3,550,000 was paid to BBC by Massachusetts Medical Properties, LLC (“MMP”). The property is located approximately 47 miles southeast of Boston. The Company plans to develop the property as the Massachusetts Medical Cannabis Center (the “MMCC”). Plans for the MMCC include the construction of sustainable greenhouse cultivation, processing, and infused product facilities that will be leased or sold to Registered Marijuana Dispensaries under the Massachusetts Medical Marijuana Program.

 

As part of a simultaneous transaction, the Company assigned the property rights to MMP for a nominal fee and entered a lease agreement pursuant to which MMP agreed to lease the property to the Company for an initial term of fifty (50) years. We have the option to extend the term of the lease for four (4) additional ten (10) year periods. The lease is a triple net lease, with the Company paying all real estate taxes, repairs, maintenance and insurance.

 

The lease payments will be the greater of (a) $30,000 per month; (b) $0.38 per square foot per month of any structure built on the property; or (c) 1.5% of all gross monthly sales of products sold by the Company, any assignee of the Company, or any subtenant of the Company. The lease payments will be adjusted up (but not down) every five (5) years by any increase in the Consumer Price Index.

 

Between October 17, 2016 and April 17, 2017, the monthly lease payments will accrue, with all accrued lease payments to be paid to MMP on April 17, 2017. On April 17, 2017, the Company will reimburse MMP’s costs and expenses associated with the acquisition of the property, the lease, and the acquisition of the shares and the warrant from the Company (as further described below).

 

Under the terms of the lease, the Company has six (6) months to obtain capital funding for the construction of the first phase building. In the event that the Company is unable to raise these funds within the six (6) month period, the Company will have an additional six (6) month period to do so; provided, that the Company has paid accrued lease payments and closing costs. If the Company is then unable to raise these funds on or before twelve (12) months from October 17, 2016, the lease will terminate.  

The Company shall receive credit for the $925,000 paid towards the purchase price of the land in the form of discounted lease payments. For the initial fifty (50) year term of the lease, the lease payments will be reduced by $1,542 each month.

 

In connection with the sale of the property to MMP and the lease, the Company and MMP entered into a Share Purchase Agreement pursuant to which the Company issued to MMP 100,000 shares of its common stock at par value of $0.0001 (“Common Stock”), and a warrant to purchase up to 3,640,000 shares of Common Stock at an exercise price of $1.00 per share. The warrant can be exercised at any time on or after October 17, 2018 and on or before October 17, 2020. The warrant does not contain a cashless exercise provision. The fair value of the warrant was established using the Black Scholes option pricing model using the following assumptions:

 

 

Risk-free interest rate – 1.12 percent

 

Expected term – 4.0 years

 

Volatility – 100 percent

  

The Company allocated $1,697,333 to the warrant which is reflected in additional paid-in-capital and was allocated to prepaid land lease. The fair value of the common stock on the date of the agreement was $73,000, which is also reflected in additional paid-in-capital and was allocated to prepaid land lease. The prepaid land lease is being amortized on a straight-line basis over the term of the lease.

 

The lease expense was $98,852 and $0 for the three months ended December 31, 2016 and 2015, respectively.  At December 31, 2016, the future rental payments required under this lease are $450,000 for the remainder of fiscal 2017, $360,000 for fiscal years 2018 through 2012, and $16,110,000 thereafter.

 

Office space

 

The Company leases its office space located at 3200 Brighton Boulevard, Denver, Colorado for $2,870 per month under a month-to-month lease.

 

The Company leases an automobile under an operating lease commencing October 4, 2014 for 39 months at $611 per month. At December 31, 2016, the future rental payments required under this lease are $5,650 for the remainder of fiscal 2017 and $910 for fiscal 2018.


Except as described above, the Company has no other non-cancelable lease commitments.

 

 
F-34

 

 

NOTE 10.  SHAREHOLDERS’ EQUITY

 

Sale of Equity Securities. On November 7, 2016, we issued 2,000,000 shares of common stock through the sale of 2,000,000 Units at a price of $1.00 per Unit. The Units were sold in a private offering to a group of accredited investors. Each Unit consisted of one share of our common stock and one Series I Warrant. Each Series I Warrant allows the Holder to purchase one share of our common stock at a price of $3.00 per share at any time on or before November 4, 2020. The relative fair value of the warrants issued was approximately 41% of the proceeds received.

  

The offering provided us with $2,000,000 in gross proceeds and the potential for an additional $6,000,000 in proceeds with the exercise of the Series I Warrants. The proceeds from the placement will be utilized for the MMCC development, to pursue new opportunities in California, Pennsylvania, Florida and other states, and general corporate purposes.

 

Shares issued to lessor. As described in Note 9, we entered into a Share Purchase Agreement with MMP pursuant to which we issued to MMP 100,000 shares of our common stock at par value of $0.0001 (“Common Stock”), and a warrant to purchase up to 3,640,000 shares of Common Stock at an exercise price of $1.00 per share. The warrant can be exercised at any time on or after October 17, 2018 and on or before October 17, 2020. The warrant does not contain a cashless exercise provision.

 

Warrants. Warrant activity as of and for the three months ended December 31, 2016 is as follows: 

 

                   

Weighted

         
           

Weighted

   

Average

         
           

Average

   

Contractual

   

Aggregate

 
   

Number of

   

Exercise

   

Term

   

Intrinsic

 
   

Shares

   

Price

   

(Years)

   

Value

 
                                 

Outstanding at September 30, 2016

    4,341,000     $ 6.19       2.1     $ -  

Granted

    5,640,000     $ 1.71       3.8     $ -  

Cancelled

    -       -       -       -  

Exercised

    -       -       -       -  

Outstanding as of December 31, 2016

    9,981,000     $ 3.66       3.1     $ -  

Vested and expected to vest at December 31, 2016

    9,981,000     $ 3.66       3.1     $ -  

Exercisable at December 31, 2016

    9,981,000     $ 3.66       3.1     $ -  

 

 
F-35 

 

 

TABLE OF CONTENTS

 

 

 

Page

PROSPECTUS SUMMARY

2
   

RISK FACTORS

3
   

MARKET FOR OUR COMMON STOCK

7
   

MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION

10

 

 

BUSINESS

20
   

MANAGEMENT

26
   

PRINCIPAL SHAREHOLDERS

30
   

SELLING SHAREHOLDERS

31
   

DESCRIPTION OF SECURITIES

34
   

LEGAL PROCEEDINGS

35
   

INDEMNIFICATION

36
   

AVAILABLE INFORMATION

36
   

FINANCIAL STATEMENTS

38

 

No dealer, salesperson or other person has been authorized to give any information or to make any representation not contained in this prospectus, and if given or made, such information or representations must not be relied upon as having been authorized by AmeriCann, Inc. This prospectus does not constitute an offer to sell, or a solicitation of an offer to buy, any of the securities offered in any jurisdiction to any person to whom it is unlawful to make an offer by means of this prospectus.

 

 

 

 

 

 

 

 

 

 

 

 

AmeriCann Prospectus 1-18-17

 

 

 

 

PART II

Information Not Required in Prospectus

Item 13.

Other Expenses of Issuance and Distribution.

 

The following table shows the costs and expenses payable by the Company in connection with this registration statement.

 

SEC Filing Fee 

  $ 2,002  

Blue Sky Fees and Expenses     

    1,000  

Printing Expenses    

     1,000  

Legal Fees and Expenses

    35,000  

Accounting Fees and Expenses

    10,000  

Miscellaneous Expenses

    998  

TOTAL

  $ 50,000  

 

All expenses other than the SEC filing fee are estimated.

 

Item 14.

Indemnification of Officers and Directors     

 

The Delaware General Corporation Code provides that the Company may indemnify any and all of its officers, directors, employees or agents or former officers, directors, employees or agents, against expenses actually and necessarily incurred by them, in connection with the defense of any legal proceeding or threatened legal proceeding, except as to matters in which such persons shall be determined to not have acted in good faith and in the Company’s best interest.

 

Item 15.

Recent Sales of Unregistered Securities.

 

 

 

 Note

Reference

During March and April 2014 the Company sold 1,000,000 shares of its common stock to twenty-nine private investors at a price of $0.75 per share.

 

A.C.

 

 

 

During July 2014, the Company sold 791,000 Units to fifteen investors at a price of $3.00 per Unit. Each Unit consisted of one share of common stock and one warrant. Each warrant allows the holder to purchase one share of the Company’s common stock at a price of $8.00 per share anytime on or before April 30, 2018. 

 

 B.

 

 

 

On February 19, 2015, the Company issued 50,000 shares of its common stock, valued at $34,250, to Stratcon Partners for providing investor relations services to the Company.

 

A. C.

 

 

 

In October 2016, the Company issued 100,000 shares of its common stock and a warrant to purchase up to 3,640,000 shares of common stock to Massachusetts Medical Properties, LLC. The warrant can be exercised at a price of $1.00 per share any time on or after October 17, 2018 and on or before October 17, 2020.

 

 

B.C.

 

 

 

In November 2016, the Company sold 2,000,000 Units, at a price of $1.00 per Unit, to a group of accredited investors. Each Unit consists of one share of our common stock and one Series I Warrant. Each Series I Warrant allows the holder to purchase one share of our common stock at a price of $3.00 per share at any time on or before November 4, 2020. We paid commissions to GVC Capital, LLC and West Park Capital, Inc. in connection with the sale of these Units.

 

B.

 

 
1

 

 

A.     The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 with respect to the issuance of these shares. The persons who acquired these shares were sophisticated investors and were provided full information regarding the Company. There was no general solicitation in connection with the offer or sale of these securities. The persons who acquired these shares acquired them for their own accounts. The certificates representing these shares bear a restricted legend providing that they cannot be sold except pursuant to an effective registration statement or an exemption from registration.

 

B.     The Company relied upon the exemption provided by Rule 506 of the Securities and Exchange Commission with respect to the issuance of these securities. The persons who acquired these securities were sophisticated investors and were provided full information regarding the Company. There was no general solicitation in connection with the offer or sale of these securities. The persons who acquired these securities acquired them for their own accounts. The certificates representing these securities bear a restricted legend providing that they cannot be sold except pursuant to an effective registration statement or an exemption from registration.

 

C.      No commission or other form of remuneration was given to any person in connection with the issuance of these securities.

 

Item 16.

Exhibits and Financial Statement Schedules

 

The following exhibits are filed with this Registration Statement:

 

3.1.1

Certificate of Incorporation

(1)

     

3.1.2

Certificate of Ownership and Merger (name change to AmeriCann)

(2)

     

3.2

Bylaws

 
     

4.1

Form of Series I Warrant

 
     

4.2

Form of Series II Warrant

 
     

4.3

Form of Series III Warrant

 
     

5

Opinion of Counsel

 
     

10.1

Employment Agreement with Timothy Keogh

 

 

10.2

Agreements with Wellness Group Pharms

 

 

 
2

 

 

10.3

Loan Modification Agreement with Strategic Capital Partners, LLC, together with Warrants and Promissory Notes

 
     

10.4

Agreements with 4900 Jackson, LLC

 
     

10.5

Agreements with Coastal Compassion, Inc.

 
     

10.6

Share Purchase Agreement with Massachusetts Medical Properties, LLC, together with Warrant and Ground Lease

 
     

23.1

Consent of Attorneys

 
     

23.2

Consents of Accountants

 

 

(1)

Incorporated by reference to Exhibit 3.1 filed with the Company’s Registration Statement on Form 10.

 

(2)

Incorporated by reference to Exhibit 3.1.2 filed with the Company’s annual report on Form 10-K for the year ended September 30, 2015.

 

Item 17.

Undertakings

 

The undersigned registrant hereby undertakes:

 

(1)     To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

 

(i)      To include any prospectus required by Section l0 (a)(3) of the Securities Act:

 

(ii)     To reflect in the prospectus any facts or events which, individually or together, represent a fundamental change in the information in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

 

(iii)    To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

 

(2)     That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

 
3

 

 

(3)     To remove from registration by means of a post-effective amendment any of the securities that remain unsold at the termination of the offering.

 

Insofar as indemnification for liabilities arising under the Securities Act of l933 (the “Act”) may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

 

(5)     That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:

 

(i)     If the registrant is relying on Rule 430B:

 

(A)     Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

 

(B)     Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or

 

(ii)     If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

 

 
4

 

 

(6)     That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities:

 

The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

 

(i)     Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

 

(ii)     Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

 

(iii)      The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

 

(iv)     Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser

 

 
5

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Act of l933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Denver, Colorado on the 1st day of March 2017.

 

 

AMERICANN, INC.

 

 

 

 

 

 

 

 

 

 

By:

/s/ Timothy Keogh

 

 

 

Timothy Keogh, Chief Executive Officer

 

       

 

 

 

 

  By: /s/ Benjamin J. Barton  
    Benjamin J. Barton, Chief Financial and Accounting Officer  

 

 

In accordance with the requirements of the Securities Act of l933, this registration statement has been signed by the following persons in the capacities and on the dates indicated:

 

 

Signature  

Title

      Date

 

 

 

 

 

 

/s/ Timothy Keogh    

 

 

Timothy Keogh  

Chief Executive Officer and a Director  

 March 1, 2017 

 

 

 

     

/s/ Benjamin J. Barton

Chief Financial and Accounting

 March 1, 2017

Benjamin J. Barton      

Officer and a Director  

 

    

 

 

 

6

EX-3.2 2 ex3-2.htm EXHIBIT 3.2 ex3-2.htm

  

 

 

 

 

 

EXHIBIT 3.2

 

 

 

 

 

 

 

 

 

 
 

 

 

BYLAWS

OF

AMERICANN, INC.

 

 

ARTICLE I

OFFICES

 

Section l. Offices:

 

The principal office of the Corporation shall be determined by the Board of Directors, and the Corporation shall have other offices at such places as the Board of Directors may from time to time determine.

 

ARTICLE II

STOCKHOLDER'S MEETINGS

 

Section l. Place:

 

The place of stockholders' meetings shall be the principal office of the Corporation unless another location shall be determined and designated from time to time by the Board of Directors.

 

Section 2. Annual Meeting:

 

The annual meeting of the stockholders of the Corporation for the election of directors to succeed those whose terms expire, and for the transaction of such other business as may properly come before the meeting, shall be held no later than one year after the end of the Corporation’s fiscal year on a date to be determined by the Board of Directors.

 

Section 3. Special Meetings:

 

Special meetings of the stockholders for any purpose or purposes may be called by the President, the Board of Directors, or the holders of ten percent (l0%) or more of all the shares entitled to vote at such meeting, by the giving of notice in writing as hereinafter described.

 

Section 4. Voting:

 

At all meetings of stockholders, voting may be viva voce; but any qualified voter may demand a stock vote, whereupon such vote shall be taken by ballot and the Secretary shall record the name of the stockholder voting, the number of shares voted, and, if such vote shall be by proxy, the name of the proxy holder. Voting may be in person or by proxy appointed in writing, manually signed by the stockholder or his duly authorized attorney-in-fact. No proxy shall be valid after eleven months from the date of its execution, unless otherwise provided therein.

 

 
1

 

 

Each stockholder shall have such rights to vote as the Articles of Incorporation provide for each share of stock registered in his name on the books of the Corporation. The Corporation may establish a record date, not to exceed, in any case, fifty (50) days preceding the meeting, for the determination of stockholders entitled to vote. The Secretary of the Corporation shall make, at least ten (l0) days before each meeting of stockholders, a complete list of the stockholders entitled to vote at such meeting or any adjournment thereof, arranged in alphabetical order, with the address of and the number of shares held by each, which list, for a period of ten (l0) days prior to such meeting, shall be kept on file at the principal office of the Corporation and shall be subject to inspection by any stockholder at any time during usual business hours. Such list shall also be produced and kept open at the time and place of the meeting and shall be subject to the inspection of any stockholder during the whole time of the meeting.

 

Section 5. Order of Business:

 

The order of business at any meeting of stockholders shall be as follows:

 

 

l.

Calling the meeting to order.

 

 

2.

Calling of roll.

 

 

3.

Proof of notice of meeting.

 

 

4.

Report of the Secretary of the stock represented at the meeting and the existence or lack of a quorum.

 

 

5.

Reading of minutes of last previous meeting and disposal of any unapproved minutes.

 

 

6.

Reports of officers.

 

 

7.

Reports of committees.

 

 

8.

Election of directors, if appropriate.

 

 

9.

Unfinished business.

 

 

10

New business.

 

 

11.

Adjournment.

 

 

12.

To the extent that these Bylaws do not apply, Roberts' Rules of Order shall prevail.

 

 
2

 

 

Section 6. Notices:

 

Written or printed notice stating the place, day, and hour of the meeting and, in case of a special meeting, the purpose or purposes for which the meeting is called, shall be delivered not less than l0 nor more than 60 days before the date of the meeting, either personally or by mail, by or at the direction of the President, the Secretary, or the officer or persons calling the meeting, to each stockholder of record entitled to vote at such meeting. If mailed, such notice shall be deemed to be delivered when deposited in the United States mail addressed to the shareholder at his address as it appears on the stock transfer books of the Corporation, with postage thereon prepaid.

 

Section 7. Quorum:

 

A quorum at any annual or special meeting shall consist of the representation in person or by proxy of 33 1/3% of the issued and outstanding capital stock of the Corporation entitled to vote at such meeting. In the event a quorum be not present, the meeting may be adjourned by those present for a period not to exceed sixty (60) days at any one adjournment; and no further notice of the meeting or its adjournment shall be required.

 

ARTICLE III

BOARD OF DIRECTORS

 

Section l. Organization and Powers:

 

The Board of Directors shall constitute the policy-making or legislative authority of the Corporation. Management of the affairs, property, and business of the Corporation shall be vested in the Board of Directors, which shall consist of not less than one nor more than ten members, who shall be elected at the annual meeting of stockholders by a plurality vote for a term of one (l) year, and shall hold office until their successors are elected and qualify. The number of directors shall be established from time-to-time by a resolution of the directors. Directors need not be stockholders. Directors shall have all powers with respect to the management, control, and determination of policies of the Corporation that are not limited by these Bylaws, the Articles of Incorporation, or by statute, and the enumeration of any power shall not be considered a limitation thereof.

 

Section 2. Vacancies:

 

Any vacancy in the Board of Directors, however caused or created, shall be filled by the affirmative vote of a majority of the remaining directors, though less than a quorum of the Board, or at a special meeting of the stockholders called for that purpose. The directors elected to fill vacancies shall hold office for the unexpired term and until their successors are elected and qualify.

 

 
3

 

 

Section 3. Regular Meetings:

 

A regular meeting of the Board of Directors shall be held, without other notice than this Bylaw, immediately after and at the same place as the annual meeting of stockholders or any special meeting of stockholders at which a director or directors shall have been elected. The Board of Directors will meet quarterly.

 

Section 4. Special Meetings:

 

Special meetings of the Board of Directors may be held at the principal office of the Corporation, or such other place as may be fixed by resolution of the Board of Directors for such purpose, at any time on call of the President or of any member of the Board, or may be held at any time and place without notice, by unanimous written consent of all the members, or with the presence and participation of all members at such meeting. A resolution in writing signed by all the directors shall be as valid and effectual as if it had been passed at a meeting of the directors duly called, constituted, and held.

 

Section 5. Notices:

 

Notices of both regular and special meetings, save when held by unanimous consent or participation, shall be mailed by the Secretary to each member of the Board not less than three days before any such meeting and notices of special meetings may state the purposes thereof. No failure or irregularity of notice of any regular meeting shall invalidate such meeting or any proceeding thereat.

 

Section 6. Quorum and Manner of Acting:

 

A quorum for any meeting of the Board of Directors shall be a majority of the Board of Directors as then constituted. Any act of the majority of the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors. Any action of such majority, although not at a regularly called meeting, and the record thereof, if assented to in writing by all of the other members of the Board, shall always be as valid and effective in all respects as if otherwise duly taken by the Board of Directors.

 

Section 7. Executive Committee:

 

The Board of Directors may by resolution of a majority of the Board designate two (2) or more directors to constitute an executive committee, which committee, to the extent provided in such resolution, shall have and may exercise all of the authority of the Board of Directors in the management of the Corporation; but the designation of such committee and the delegation of authority thereto shall not operate to relieve the Board of Directors, or any member thereof, of any responsibility imposed on it or him by law.

 

 
4

 

 

Section 8. Order of Business:

 

The order of business at any regular or special meeting of the Board of Directors, unless otherwise prescribed for any meeting by the Board, shall be as follows:

 

 

l.

Reading and disposal of any unapproved minutes.

 

 

2.

Reports of officers and committees.

 

 

3.

Unfinished business.

 

 

4.

New business.

 

 

5.

Adjournment.

 

 

6.

To the extent that these Bylaws do not apply, Roberts' Rules of Order shall prevail.

 

ARTICLE IV

OFFICERS

 

Section 1. Officers:

 

The officers of the Corporation shall be those designated by the Board of Directors. The officers shall have the powers, responsibilities and duties as may be designed by the Board or the Corporation’s Chief Executive Officer. In the discretion of the Board, one person may hold more than one office and two or more persons may serve in any one office.

 

Notwithstanding the above, the Chief Executive Officer or the Secretary will have responsibility for the preparation and maintenance of minutes of the directors’ and shareholders’ meetings and other records and information required to be kept by the Corporation pursuant to C.R.S. 7-116-101 and for authenticating records of the Corporation.

 

Section 2. Vacancies or Absences:

 

If a vacancy in any office arises in any manner, the directors then in office may choose, by a majority vote, a successor to hold office for the unexpired term of the officer. If any officer shall be absent or unable for any reason to perform his duties, the Board of Directors, to the extent not otherwise inconsistent with these Bylaws, may direct that the duties of such officer during such absence or inability shall be performed by such other officer or subordinate officer as seems advisable to the Board.

 

 
5

 

 

ARTICLE V

STOCK

 

Section 1. Regulations:

 

The Board of Directors shall have power and authority to take all such rules and regulations as they deem expedient concerning the issue, transfer, and registration of certificates for shares of the capital stock of the Corporation. The Board of Directors may appoint a Transfer Agent and/or a Registrar and may require all stock certificates to bear the signature of such Transfer Agent and/or Registrar.

 

Section 2. Restrictions on Stock:

 

The Board of Directors may restrict any stock issued by giving the Corporation or any stockholder "first right of refusal to purchase" the stock, by making the stock redeemable or by restricting the transfer of the stock, under such terms and in such manner as the directors may deem necessary and as are not inconsistent with the Articles of Incorporation or by statute. Any stock so restricted must carry a stamped legend setting out the restriction or conspicuously noting the restriction and stating where it may be found in the records of the Corporation.

 

ARTICLE VI

DIVIDENDS AND FINANCES

 

Section l. Dividends:

 

Dividends may be declared by the directors and paid out of any funds legally available therefor, as may be deemed advisable from time to time by the Board of Directors of the Corporation. Before declaring any dividends, the Board of Directors may set aside out of net profits or earned or other surplus such sums as the Board may think proper as a reserve fund to meet contingencies or for other purposes deemed proper and to the best interests of the Corporation.

 

Section 2. Monies:

 

The monies, securities, and other valuable effects of the Corporation shall be deposited in the name of the Corporation in such banks or trust companies as the Board of Directors shall designate and shall be drawn out or removed only as may be authorized by the Board of Directors from time to time.

 

Section 3. Fiscal Year:

 

The Board of Directors by resolution shall determine the fiscal year of the Corporation.

 

 
6

 

 

ARTICLE VII

AMENDMENTS

 

These Bylaws may be altered, amended, or repealed by the Board of Directors by resolution of a majority of the Board.

 

ARTICLE VIII

INDEMNIFICATION

 

The Corporation shall indemnify any and all of its directors or officers, or former directors or officers, or any person who may have served at its request as a director or officer of another corporation in which this Corporation owns shares of capital stock or of which it is a creditor and the personal representatives of all such persons, against expenses actually and necessarily incurred in connection with the defense of any action, suit, or proceeding in which they, or any of them, were made parties, or a party, by reason of being or having been directors or officers or a director or officer of the Corporation, or of such other corporation, except in relation to matters as to which any such director or officer or person shall have been adjudged in such action, suit, or proceeding to be liable for negligence or misconduct in the performance of any duty owed to the Corporation. Such indemnification shall not be deemed exclusive of any other rights to which those indemnified may be entitled, independently of this Article, by law, under any Bylaw agreement, vote of stockholders, or otherwise.

 

ARTICLE IX

CONFLICTS OF INTEREST

 

No contract or other transaction of the Corporation with any other persons, firms or corporations, or in which the Corporation is interested, shall be affected or invalidated by the fact that any one or more of the directors or officers of the Corporation is interested in or is a director or officer of such other firm or corporation; or by the fact that any director or officer of the Corporation, individually or jointly with others, may be a party to or may be interested in any such contract or transaction.

 

ARTICLE X

SHAREHOLDER CLAIMS

 

In the event that any shareholder initiates or asserts a claim against the Corporation, or any officer or director of the Corporation, including any derivative claim or claim purportedly filed on behalf of the Corporation, and the shareholder does not obtain a judgment on the merits that substantially achieves, in substance and amount, the full remedy sought, then such shareholder shall be obligated (jointly and severally in the event the claim us brought by more than one shareholder) to reimburse the Corporation and any officer or director of the Corporation for all fees, costs and expenses of every kind and description (including, but not limited to, all reasonable attorney’s fees and other litigation expenses) that the Corporation or its officers or directors may incur in connection with such claim.

 

 

Americann Bylaws 7-15-14

 

 

7

EX-4.1 3 ex4-1.htm EXHIBIT 4.1 ex3-2.htm

 

 

 

 

 

EXHIBIT 4.1 

 

 

 

 

 

 

 

 

 

 
 

 

 

AMERICANN, INC.

 

SERIES I WARRANT

 

 

This is to certify that, FOR VALUE RECEIVED, _______________, or registered assigns (“Holder”) is the holder of ______________ Series I Warrants of AmeriCann, Inc. (the “Company”). Each Warrant allows the holder to purchase one share of the Company’s Common Stock at a price of $3.00 per share. The number of shares of Common Stock to be received upon the exercise of this Warrant, and the price to be paid for a share of Common Stock, may be adjusted from time to time as hereinafter set forth. The shares of Common Stock deliverable upon such exercise, as may be adjusted from time to time, are hereinafter sometimes referred to as “Warrant Stock”, and the exercise price of a share of Common Stock in effect at any time, and as may be adjusted from time to time, is hereinafter sometimes referred to as the "Exercise Price."

 

(a) Exercise of Warrant. This Warrant may be exercised in whole or in part at any time or from time to time but not later than 5.00 P.M., Mountain time, November 4, 2020 (the “Expiration Date”). If November 4, 2020 is a day on which banking institutions are authorized by law to close, then this Warrant may be exercised on the next succeeding day which shall not be such a day, by presentation and surrender of this Warrant to the Company or at the office of its stock transfer agent, if any, with the Purchase Form annexed hereto duly executed and accompanied by payment of the Exercise Price for the number of Shares of Warrant Stock specified in such form, together with all Federal and state taxes applicable upon such exercise.

 

Nothwithstanding the above, this Warrant will expire 30 days after written notice to the holder that the average closing price of the Company’s common stock was at least $4.50 for ten consecutive trading days and the average daily volume of trades of the Company’s common stock during the ten trading days was at least 150,000 shares.

 

If this Warrant should be exercised in part only, the Company, upon surrender of this Warrant for cancellation, shall execute and shall deliver a new Warrant evidencing the right of the Holder to purchase the balance of the Shares of Warrant Stock purchaseable hereunder. Upon receipt by the Company of this Warrant at the office or the agency of the Company, in proper form for exercise, the Holder shall be deemed to be the Holder of record of the Shares of Warrant Stock issuable upon such exercise, notwithstanding that the stock transfer books of the Company shall then be closed or that certificates representing such Shares of Warrant Stock shall not then be actually delivered to the Holder.

 

(b) Reservation of Shares of Warrant Stock. The Company hereby agrees that, at all times, there shall be reserved for issuance and/or delivery upon exercise of this Warrant such number of shares of its Common Stock as shall be required for issuance or delivery upon exercise of this Warrant.

 

(c) Fractional Shares. No fractional Shares of Warrant Stock or scrip representing fractional Shares of Warrant Stock shall be issued upon the exercise of this Warrant. With respect to any fraction of a Share of Warrant Stock called for upon any exercise hereof, the Company shall pay to the Holder an amount in cash equal to such fraction multiplied by the current market value of such fractional share determined as follows:

 

 
 

 

 

(i)     If the Company's Common Stock is publicly traded, the average daily closing prices for 30 consecutive trading days immediately preceding the date of exercise of this Warrant. The closing price for each day shall be the last sale price regular-way or, in case no such sale takes place on such date, the average of the closing bid and asked prices regular-way, on the principal national securities exchange in which the Company's Common Stock is listed or admitted to trading, or if it is not listed or admitted to trading on any national securities exchange, the last sale price of such Common Stock on the consolidated transaction reporting system of the Financial Institution Regulatory Authority (“FINRA”), if such last sale information is reported on such system, or if not so reported, the average of the closing bid and asked prices of such Common Stock on the National Association of Securities Dealers Automatic Quotation system ("NASDAQ"), or any comparable system, or if the Common Stock is not listed on NASDAQ, or a comparable system, the average of the closing bid and asked prices as furnished by two members of the NASD selected from time to time by the Company for that purpose.

 

(ii)     If the Company's Common Stock is not publicly traded, the current value shall be an amount, not less than the book value, determined in such reasonable manner as may be prescribed by the Board of Directors of the Company, such determination to be final and binding on the Holder.

 

(d)     Exchange, Assignment or Loss of Warrant. This Warrant is exchangeable, without expense, at the option of the Holder, upon presentation and surrender hereof to the Company or at the office of its stock transfer agent, if any, for other Warrants of different denominations entitling the Holder thereof to purchase in the aggregate the same number of Shares of Warrant Stock purchasable hereunder. This Warrant may not be sold, hypothecated, assigned, or transferred prior to the date this Warrant is first exercisable. Any assignment shall be made subject to the provisions of Section (j) by surrender of this Warrant to the Company or at the office of its stock transfer agent, if any, with the Assignment Form annexed hereto duly executed and with funds sufficient to pay any transfer tax; whereupon, the Company, without charge, shall execute and shall deliver a new Warrant in the name of the assignee named in such instrument of assignment and this Warrant shall promptly be cancelled.

 

This Warrant may be divided or may be combined with other Warrants which carry the same rights upon presentation hereof at the office of the Company or at the office of its stock transfer agent, if any, together with a written notice specifying the names and the denominations in which new Warrants are to be issued and signed by the Holder hereof. The term "Warrant" as used herein includes any Warrants issued in substitution for or replacement of this Warrant or into which this Warrant may be divided or exchanged. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction, or mutilation of this Warrant, and (in the case of loss, theft, or destruction) of reasonably satisfactory indemnification, and upon surrender and cancellation of this Warrant, if mutilated, the Company will execute and will deliver a new Warrant of like tenor and date. Any such new Warrant executed and delivered shall constitute an additional contractual obligation on the part of the Company, whether or not this Warrant so lost, stolen, destroyed or mutilated shall be at any time enforceable by anyone.

 

(e)     Rights of the Holder. The Holder, by virtue hereof, shall not be entitled to any rights of a stockholder in the Company, either at law or in equity, and the rights of the Holder are limited to those expressed in the Warrant and are not enforceable against the Company except to the extent set forth herein.

 

 
 

 

 

(f)     Anti-Dilution Provisions.

 

(i) Adjustment of Price. Anything in this Section (f) to the contrary notwithstanding, if the Company shall issue, at any time, Common Stock or convertible securities by way of dividend, forward stock split or other distribution on any stock of the Company or subdivide or combine the outstanding shares of Stock, the Exercise Price shall be proportionately decreased in the case of such issuance, forward stock split, or distribution (on the day following the date fixed for determining shareholders entitled to receive such additional shares) or proportionately increased in the case of such combination (on the date that such combination shall become effective), provided, however, should the Company cancel or fail to make such dividend or other distribution or other issuance, the Exercise Price shall be forthwith adjusted to the price which would have prevailed prior to the Company setting such record date.

 

(ii) No Adjustment for Small Amounts. Anything in this Section to the contrary notwithstanding, the Company shall not be required to give effect to any adjustment in the Exercise Price unless and until the net effect of one or more adjustments, determined as above provided, shall have required a change of the Exercise Price by at least one cent, but when the cumulative net effect of more than one adjustment so determined shall be to change the actual Exercise Price by at least one cent, such change in the Exercise Price shall thereupon be given effect.

 

(iii) Number of Shares Adjusted. Upon any adjustment of the Exercise Price, the Holder of this Warrant shall thereafter (until another such adjustment) be entitled to purchase, at the new Exercise Price, the number of Warrant Stock, calculated to the nearest full shares, obtained by multiplying the number of shares of Stock initially issuable upon exercise of this Warrant by the Exercise Price in effect on the date hereof and dividing the product so obtained by the new Exercise Price.

 

(g)     Officer's Certificate. Whenever the Exercise Price shall be adjusted as required by the provisions of Section (f) hereof, the Company shall forthwith file with its Secretary or an Assistant Secretary at its principal office, and with its stock transfer agent, if any, an Officer's Certificate showing the adjusted Exercise Price, determined as herein provided, and setting forth in reasonable detail the facts requiring such adjustment. Each such Officer's Certificate shall be made available at all reasonable times for inspection by the Holder; and the Company, after each such adjustment, shall forthwith deliver a copy of such certificate to the Holder. Such certificate shall be conclusive as to the correctness of such adjustment.

 

(h)     Notices to Warrant Holders. So long as this Warrant shall be outstanding and unexercised (i) if the Company shall pay any dividend or shall make any distribution upon the Common Stock or (ii) if the Company shall offer to the holders for subscription or purchase by them any shares of stock of any class or any other rights or (iii) if any capital reorganization of the Company; reclassification of the capital stock of the Company; consolidation or merger of the Company with or into another corporation; sale, lease or transfer of all or substantially all of the property and assets of the Company to another corporation; or voluntary or involuntary dissolution, liquidation, or winding up of the Company shall be effected, then, in any such case, the Company shall cause to be delivered to the Holder, at least ten (l0) days prior to the date specified in (x) or (y) below, as the case may be, a notice containing a brief description of the proposed action and stating the date on which (x) a record is to be taken for the purpose of such dividend, distribution, or rights, or (y) such reclassification, reorganization, consolidation, merger, conveyance, lease, dissolution, liquidation, or winding up is to take place and the date, if any, is to be fixed, as of which the holders of record shall be entitled to exchange their Shares for securities or other property deliverable upon such reclassification, reorganization, consolidation, merger, conveyance, dissolution, liquidation, or winding up.

 

 
 

 

 

(i)     Reclassification, Reorganization or Merger. In case of any Reclassification, or capital reorganization (other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of an issuance of Common Stock by way of dividend or other distribution or of a subdivision or combination), or in case of any consolidation or merger of the Company with or into another corporation (other than a merger with a subsidiary, in which merger the Company is the continuing corporation and which does not result in any reclassification, or capital reorganization) or in case of any sale or conveyance to another corporation of the property of the Company as an entirety or substantially as an entirety, the Company shall cause effective provision to be made so that the Holder shall have the right thereafter, by exercising this Warrant, to purchase the kind and amount of shares of Stock and other securities and property receivable upon such reclassification; capital reorganization; or other consolidation, merger, sale, or conveyance as may be issued or payable with respect to or in exchange for the number of Shares of the Company theretofore purchasable upon the exercise of this Warrant had such recapitalization; capital reorganization; or other consolidation, merger, sale or conveyance not taken place. Any such provisions shall include provision for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Warrant. The foregoing provisions of this Section (i) shall similarly apply to successive reclassifications; capital reorganizations; and to successive consolidations, mergers, sales, or conveyances.

 

In the event that in any such capital reorganization or reclassification, consolidation, merger, sale or conveyance, additional shares shall be issued in exchange, conversion, substitution or payment, in whole or in part, for a security of the Company other than Stock, any such issue shall be treated as an issue of Stock covered by the provisions of subsection (f) hereof with the amount of the consideration received upon the issue thereof being determined by the Board of Directors of the Company, such determination to be final and binding on the Holder.

 

(j)     Transfer to Comply with the Securities Act of l933.

 

(i)     This Warrant or the Warrant Stock or any other security issued or issuable upon exercise of this Warrant may not be sold, transferred, or otherwise disposed of except to a person who, in the opinion of counsel for the Company, is a person to whom this Warrant or such Warrant Stock may legally be transferred pursuant to Section (d) hereof without registration and without the delivery of a current Prospectus under the Act with respect thereto and then only against receipt of an agreement of such person to comply with the provisions of this Section (k) with respect to any resale or other disposition of such securities.

 

(ii)     The Company may cause the following legend or one similar thereto to be set forth on each certificate representing Warrant Stock or any other security issued or issuable upon exercise of this Warrant not theretofore distributed to the public or sold to underwriters for distribution to the public pursuant to Section (j) hereof, unless counsel for the Company is of the opinion as to any such certificate that such legend is unnecessary:

 

 
 

 

 

The shares represented by this Certificate have not been registered under the Securities Act of l933 (the "Act") and are "restricted securities" as that term is defined in Rule 144 under the Act. The shares may not be offered for sale, sold, or otherwise transferred except pursuant to an effective registration statement under the Act or pursuant to an exemption from registration under the Act, the availability of which is to be established to the satisfaction of the Company.

 

(iii)      Notwithstanding the above, the Company has agreed to file a registration statement covering the Warrant Stock.

 

(k)     Applicable Law. This Warrant shall be governed by and construed in accordance with the laws of Delaware.

 

 

 

AMERICAN, INC.

 

 

 

 

 

 

 

 

 

 

By:

 

 

 

 

Timothy Keogh, Chief Executive Officer

 

 

 

 

 

 

 

   

 

AmeriCann Series I Warrant 10-27-16

 

 
 

 

 

PURCHASE FORM

 

                        Dated            .

 

The undersigned hereby irrevocable elects to exercise the within Warrant to the extent of purchasing         Shares of Warrant Stock and hereby makes payment of $____________ in payment of the actual exercise price thereof.

 

                                

 

 

INSTRUCTIONS FOR REGISTRATION OF STOCK

 

 

 

Name                                                                                      

                  (Please typewrite or print in block letters)

 

Address                                                                   

 

                                                                                  

 

Signature                                                                        

 

 

ASSIGNMENT FORM

 

FOR VALUE RECEIVED,                                                       

 

hereby sell, assigns, and transfers unto:

 

Name:                                                                                            

                     (Please typewrite or print in block letters)

 

Address:                                                                        

 

the right to purchase the Common Stock represented by this Warrant to the extent of              shares as to which such right is exercisable and does hereby irrevocably constitute and appoint                    attorney, to transfer the same on the books of the Company with full power of substitution in the premises.

 

Signature                                                 

 

Dated:                      .

 

AmeriCann Series I Warrant 11-15-16

 

EX-4.2 4 ex4-2.htm EXHIBIT 4.2 ex3-2.htm

 

 

 

 

 

 

EXHIBIT 4.2

 

 

 

 

 

 

 
 

 

 

AMERICANN, INC.

 

WARRANT TO PURCHASE COMMON STOCK

SERIES II

 

This is to certify that, FOR VALUE RECEIVED, _________________, or registered assigns (“Holder”) is entitled to purchase, subject to the provisions of this Warrant, from AmeriCann, Inc. (the “Company”), 25,000 shares of the common stock of the Company (“Common Stock”). This warrant may be exercised at a purchase price of $0.75 per share at any time prior to September 15, 2020. The number of shares of Common Stock to be received upon the exercise of this Warrant and the price to be paid for a share of Common Stock may be adjusted from time to time as hereinafter set forth. The shares of Common Stock deliverable upon such exercise, as may be adjusted from time to time, are hereinafter sometimes referred to as “Warrant Stock”; and the exercise price of a share of Common Stock in effect at any time, and as may be adjusted from time to time, is hereinafter sometimes referred to as the "Exercise Price."

 

(a) Exercise of Warrant. This Warrant may be exercised in whole or in part at any time or from time to time but not later than 5.00 P.M., Mountain time, September 15, 2020, if the Expiration Date is a day on which banking institutions are authorized by law to close, then this Warrant may be exercised on the next succeeding day which shall not be such a day, by presentation and surrender of this Warrant to the Company or at the office of its stock transfer agent, if any, with the Purchase Form annexed hereto duly executed and accompanied by payment of the Exercise Price for the number of Shares of Warrant Stock specified in such form, together with all Federal and state taxes applicable upon such exercise.

 

If this Warrant should be exercised in part only, the Company, upon surrender of this Warrant for cancellation, shall execute and shall deliver a new Warrant evidencing the right of the Holder to purchase the balance of the Shares of Warrant Stock purchaseable hereunder. Upon receipt by the Company of this Warrant at the office or the agency of the Company, in proper form for exercise, the Holder shall be deemed to be the Holder of record of the Shares of Warrant Stock issuable upon such exercise, notwithstanding that the stock transfer books of the Company shall then be closed or that certificates representing such Shares of Warrant Stock shall not then be actually delivered to the Holder.

 

(b) Reservation of Shares of Warrant Stock. The Company hereby agrees that, at all times, there shall be reserved for issuance and/or delivery upon exercise of this Warrant such number of shares of its Common Stock as shall be required for issuance or delivery upon exercise of this Warrant.

 

(c) Fractional Shares. No fractional Shares of Warrant Stock or scrip representing fractional Shares of Warrant Stock shall be issued upon the exercise of this Warrant. With respect to any fraction of a Share of Warrant Stock called for upon any exercise hereof, the Company shall pay to the Holder an amount in cash equal to such fraction multiplied by the current market value of such fractional share determined as follows:

 

 
1

 

 

(i)     If the Company's Common Stock is publicly traded, the average daily closing prices for 30 consecutive trading days immediately preceding the date of exercise of this Warrant. The closing price for each day shall be the last sale price regular-way or, in case no such sale takes place on such date, the average of the closing bid and asked prices regular-way, on the principal national securities exchange in which the Company's Common Stock is listed or admitted to trading, or if it is not listed or admitted to trading on any national securities exchange, the last sale price of such Common Stock on the consolidated transaction reporting system of the National Association of Securities Dealers ("NASD"), if such last sale information is reported on such system, or if not so reported, the average of the closing bid and asked prices of such Common Stock on the National Association of Securities Dealers Automatic Quotation system ("NASDAQ"), or any comparable system, or if the Common Stock is not listed on NASDAQ, or a comparable system, the average of the closing bid and asked prices as furnished by two members of the NASD selected from time to time by the Company for that purpose.

 

(ii)     If the Company's Common Stock is not publicly traded, the current value shall be an amount, not less than the book value, determined in such reasonable manner as may be prescribed by the Board of Directors of the Company, such determination to be final and binding on the Holder.

 

(d)     Exchange, Assignment or Loss of Warrant. This Warrant is exchangeable, without expense, at the option of the Holder, upon presentation and surrender hereof to the Company or at the office of its stock transfer agent, if any, for other Warrants of different denominations entitling the Holder thereof to purchase in the aggregate the same number of Shares of Warrant Stock purchasable hereunder. This Warrant may not be sold, hypothecated, assigned, or transferred prior to the date this Warrant is first exercisable. Any assignment shall be made subject to the provisions of Section (j) by surrender of this Warrant to the Company or at the office of its stock transfer agent, if any, with the Assignment Form annexed hereto duly executed and with funds sufficient to pay any transfer tax; whereupon, the Company, without charge, shall execute and shall deliver a new Warrant in the name of the assignee named in such instrument of assignment and this Warrant shall promptly be cancelled.

 

This Warrant may be divided or may be combined with other Warrants which carry the same rights upon presentation hereof at the office of the Company or at the office of its stock transfer agent, if any, together with a written notice specifying the names and the denominations in which new Warrants are to be issued and signed by the Holder hereof. The term "Warrant" as used herein includes any Warrants issued in substitution for or replacement of this Warrant or into which this Warrant may be divided or exchanged. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction, or mutilation of this Warrant, and (in the case of loss, theft, or destruction) of reasonably satisfactory indemnification, and upon surrender and cancellation of this Warrant, if mutilated, the Company will execute and will deliver a new Warrant of like tenor and date. Any such new Warrant executed and delivered shall constitute an additional contractual obligation on the part of the Company, whether or not this Warrant so lost, stolen, destroyed or mutilated shall be at any time enforceable by anyone.

 

 
2

 

 

(e)     Rights of the Holder. The Holder, by virtue hereof, shall not be entitled to any rights of a stockholder in the Company, either at law or in equity, and the rights of the Holder are limited to those expressed in the Warrant and are not enforceable against the Company except to the extent set forth herein.

 

(f)     Anti-Dilution Provisions.

 

(i) Adjustment of Price. Anything in this Section (f) to the contrary notwithstanding, if the Company shall issue, at any time, Common Stock or convertible securities by way of dividend, forward stock split or other distribution on any stock of the Company or subdivide or combine the outstanding shares of Stock, the Exercise Price shall be proportionately decreased in the case of such issuance, forward stock split, or distribution (on the day following the date fixed for determining shareholders entitled to receive such additional shares) or proportionately increased in the case of such combination (on the date that such combination shall become effective), provided, however, should the Company cancel or fail to make such dividend or other distribution or other issuance, the Exercise Price shall be forthwith adjusted to the price which would have prevailed prior to the Company setting such record date.

 

(ii) No Adjustment for Small Amounts. Anything in this Section to the contrary notwithstanding, the Company shall not be required to give effect to any adjustment in the Exercise Price unless and until the net effect of one or more adjustments, determined as above provided, shall have required a change of the Exercise Price by at least one cent, but when the cumulative net effect of more than one adjustment so determined shall be to change the actual Exercise Price by at least one cent, such change in the Exercise Price shall thereupon be given effect.

 

(iii) Number of Shares Adjusted. Upon any adjustment of the Exercise Price, the Holder of this Warrant shall thereafter (until another such adjustment) be entitled to purchase, at the new Exercise Price, the number of Units of Warrant Stock, calculated to the nearest full shares, obtained by multiplying the number of shares of Stock initially issuable upon exercise of this Warrant by the Exercise Price in effect on the date hereof and dividing the product so obtained by the new Exercise Price.

 

(g)     Officer's Certificate. Whenever the Exercise Price shall be adjusted as required by the provisions of Section (f) hereof, the Company shall forthwith file with its Secretary or an Assistant Secretary at its principal office, and with its stock transfer agent, if any, an Officer's Certificate showing the adjusted Exercise Price, determined as herein provided, and setting forth in reasonable detail the facts requiring such adjustment. Each such Officer's Certificate shall be made available at all reasonable times for inspection by the Holder; and the Company, after each such adjustment, shall forthwith deliver a copy of such certificate to the Holder. Such certificate shall be conclusive as to the correctness of such adjustment.

 

(h)     Notices to Warrant Holders. So long as this Warrant shall be outstanding and unexercised (i) if the Company shall pay any dividend or shall make any distribution upon the Common Stock or (ii) if the Company shall offer to the holders for subscription or purchase by them any shares of stock of any class or any other rights or (iii) if any capital reorganization of the Company; reclassification of the capital stock of the Company; consolidation or merger of the Company with or into another corporation; sale, lease or transfer of all or substantially all of the property and assets of the Company to another corporation; or voluntary or involuntary dissolution, liquidation, or winding up of the Company shall be effected, then, in any such case, the Company shall cause to be delivered to the Holder, at least ten (l0) days prior to the date specified in (x) or (y) below, as the case may be, a notice containing a brief description of the proposed action and stating the date on which (x) a record is to be taken for the purpose of such dividend, distribution, or rights, or (y) such reclassification, reorganization, consolidation, merger, conveyance, lease, dissolution, liquidation, or winding up is to take place and the date, if any, is to be fixed, as of which the holders of record shall be entitled to exchange their Shares for securities or other property deliverable upon such reclassification, reorganization, consolidation, merger, conveyance, dissolution, liquidation, or winding up.

 

 
3

 

 

(i)     Reclassification, Reorganization or Merger. In case of any reclassification, or capital reorganization (other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of an issuance of Common Stock by way of dividend or other distribution or of a subdivision or combination), or in case of any consolidation or merger of the Company with or into another corporation (other than a merger with a subsidiary, in which merger the Company is the continuing corporation and which does not result in any reclassification, or capital reorganization) or in case of any sale or conveyance to another corporation of the property of the Company as an entirety or substantially as an entirety, the Company shall cause effective provision to be made so that the Holder shall have the right thereafter, by exercising this Warrant, to purchase the kind and amount of shares of Stock and other securities and property receivable upon such reclassification; capital reorganization; or other consolidation, merger, sale, or conveyance as may be issued or payable with respect to or in exchange for the number of Shares of the Company theretofore purchasable upon the exercise of this Warrant had such recapitalization; capital reorganization; or other consolidation, merger, sale or conveyance not taken place. Any such provisions shall include provision for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Warrant. The foregoing provisions of this Section (i) shall similarly apply to successive reclassifications; capital reorganizations; and to successive consolidations, mergers, sales, or conveyances.

 

In the event that in any such capital reorganization or reclassification, consolidation, merger, sale or conveyance, additional shares shall be issued in exchange, conversion, substitution or payment, in whole or in part, for a security of the Company other than Stock, any such issue shall be treated as an issue of Stock covered by the provisions of subsection (f) hereof with the amount of the consideration received upon the issue thereof being determined by the Board of Directors of the Company, such determination to be final and binding on the Holder.

 

(j)     Transfer to Comply with the Securities Act of l933.

 

(i)     This Warrant or the Warrant Stock or any other security issued or issuable upon exercise of this Warrant may not be sold, transferred, or otherwise disposed of except to a person who, in the opinion of counsel for the Company, is a person to whom this Warrant or such Warrant Stock may legally be transferred pursuant to Section (d) hereof without registration and without the delivery of a current Prospectus under the Act with respect thereto and then only against receipt of an agreement of such person to comply with the provisions of this Section (k) with respect to any resale or other disposition of such securities.

 

 
4

 

 

(ii)     The Company may cause the following legend or one similar thereto to be set forth on each certificate representing Warrant Stock or any other security issued or issuable upon exercise of this Warrant not theretofore distributed to the public or sold to underwriters for distribution to the public pursuant to Section (j) hereof, unless counsel for the Company is of the opinion as to any such certificate that such legend is unnecessary:

 

The shares represented by this Certificate have not been registered under the Securities Act of l933 (the "Act") and are "restricted securities" as that term is defined in Rule 144 under the Act. The shares may not be offered for sale, sold, or otherwise transferred except pursuant to an effective registration statement under the Act or pursuant to an exemption from registration under the Act, the availability of which is to be established to the satisfaction of the Company.

 

(k)     Registration Rights.     The shares issuable upon the exercise of this Warrant will be registered in a registration statement that will be filed promptly with the Securities and Exchange Commission upon the completion of the Company’s October 27, 2016 private placement.

 

(l)     Applicable Law. This Warrant shall be governed by and construed in accordance with the laws of Delaware.

 

 

AMERICANN, INC.

 

 

 

 

 

 

 

 

 

 

By:

 

 

 

 

Timothy Keogh, Chief Executive Officer 

 

 

 

 

 

 

 

 

 

 

 

 

 

AmeriCann Warrant to Purch. Series II 2-1-17

 

 
5

 

 

PURCHASE FORM

 

                        Dated            .

 

The undersigned hereby irrevocable elects to exercise the within Warrant to the extent of purchasing         Shares of Warrant Stock and hereby makes payment of $                   in payment of the actual exercise price thereof.

 

                             

 

 

INSTRUCTIONS FOR REGISTRATION OF STOCK

 

 

Name                                                                                        

                  (Please typewrite or print in block letters)

 

Address                                                                   

 

                                                                                  

 

Signature                                                                            

 

                            

 

 

ASSIGNMENT FORM

 

 

FOR VALUE RECEIVED,                                                       

 

hereby sell, assigns, and transfers unto:

 

Name:                                                                                            

                     (Please typewrite or print in block letters)

 

Address:                                                                          

 

the right to purchase the Common Stock represented by this Warrant to the extent of              shares as to which such right is exercisable and does hereby irrevocably constitute and appoint                    attorney, to transfer the same on the books of the Company with full power of substitution in the premises.

 

Signature                                                 

 

Dated:                      .

 

 

AmeriCann Warrant to Purch. Series II 2-1-17

 

EX-4.3 5 ex4-3.htm EXHIBIT 4.3 ex3-2.htm

 

 

 

 

 

EXHIBIT 4.3

 

 

 

 

 

 

 
 

 

 

AMERICANN, INC.

 

WARRANT TO PURCHASE COMMON STOCK

SERIES III

 

This is to certify that, FOR VALUE RECEIVED, ________________, or registered assigns (“Holder”) is entitled to purchase, subject to the provisions of this Warrant, from AmeriCann, Inc. (the “Company”), 25,000 shares of the common stock of the Company (“Common Stock”). This warrant may be exercised at a purchase price of $1.25 per share at any time prior to September 15, 2020. The number of shares of Common Stock to be received upon the exercise of this Warrant and the price to be paid for a share of Common Stock may be adjusted from time to time as hereinafter set forth. The shares of Common Stock deliverable upon such exercise, as may be adjusted from time to time, are hereinafter sometimes referred to as “Warrant Stock”; and the exercise price of a share of Common Stock in effect at any time, and as may be adjusted from time to time, is hereinafter sometimes referred to as the "Exercise Price."

 

(a) Exercise of Warrant. This Warrant may be exercised in whole or in part at any time or from time to time but not later than 5.00 P.M., Mountain time, September 15, 2020, if the Expiration Date is a day on which banking institutions are authorized by law to close, then this Warrant may be exercised on the next succeeding day which shall not be such a day, by presentation and surrender of this Warrant to the Company or at the office of its stock transfer agent, if any, with the Purchase Form annexed hereto duly executed and accompanied by payment of the Exercise Price for the number of Shares of Warrant Stock specified in such form, together with all Federal and state taxes applicable upon such exercise.

 

Iif this Warrant should be exercised in part only, the Company, upon surrender of this Warrant for cancellation, shall execute and shall deliver a new Warrant evidencing the right of the Holder to purchase the balance of the Shares of Warrant Stock purchaseable hereunder. Upon receipt by the Company of this Warrant at the office or the agency of the Company, in proper form for exercise, the Holder shall be deemed to be the Holder of record of the Shares of Warrant Stock issuable upon such exercise, notwithstanding that the stock transfer books of the Company shall then be closed or that certificates representing such Shares of Warrant Stock shall not then be actually delivered to the Holder.

 

(b) Reservation of Shares of Warrant Stock. The Company hereby agrees that, at all times, there shall be reserved for issuance and/or delivery upon exercise of this Warrant such number of shares of its Common Stock as shall be required for issuance or delivery upon exercise of this Warrant.

 

(c) Fractional Shares. No fractional Shares of Warrant Stock or scrip representing fractional Shares of Warrant Stock shall be issued upon the exercise of this Warrant. With respect to any fraction of a Share of Warrant Stock called for upon any exercise hereof, the Company shall pay to the Holder an amount in cash equal to such fraction multiplied by the current market value of such fractional share determined as follows:

 

 
 

 

 

(i)     If the Company's Common Stock is publicly traded, the average daily closing prices for 30 consecutive trading days immediately preceding the date of exercise of this Warrant. The closing price for each day shall be the last sale price regular-way or, in case no such sale takes place on such date, the average of the closing bid and asked prices regular-way, on the principal national securities exchange in which the Company's Common Stock is listed or admitted to trading, or if it is not listed or admitted to trading on any national securities exchange, the last sale price of such Common Stock on the consolidated transaction reporting system of the National Association of Securities Dealers ("NASD"), if such last sale information is reported on such system, or if not so reported, the average of the closing bid and asked prices of such Common Stock on the National Association of Securities Dealers Automatic Quotation system ("NASDAQ"), or any comparable system, or if the Common Stock is not listed on NASDAQ, or a comparable system, the average of the closing bid and asked prices as furnished by two members of the NASD selected from time to time by the Company for that purpose.

 

(ii)     If the Company's Common Stock is not publicly traded, the current value shall be an amount, not less than the book value, determined in such reasonable manner as may be prescribed by the Board of Directors of the Company, such determination to be final and binding on the Holder.

 

(d)     Exchange, Assignment or Loss of Warrant. This Warrant is exchangeable, without expense, at the option of the Holder, upon presentation and surrender hereof to the Company or at the office of its stock transfer agent, if any, for other Warrants of different denominations entitling the Holder thereof to purchase in the aggregate the same number of Shares of Warrant Stock purchasable hereunder. This Warrant may not be sold, hypothecated, assigned, or transferred prior to the date this Warrant is first exercisable. Any assignment shall be made subject to the provisions of Section (j) by surrender of this Warrant to the Company or at the office of its stock transfer agent, if any, with the Assignment Form annexed hereto duly executed and with funds sufficient to pay any transfer tax; whereupon, the Company, without charge, shall execute and shall deliver a new Warrant in the name of the assignee named in such instrument of assignment and this Warrant shall promptly be cancelled.

 

This Warrant may be divided or may be combined with other Warrants which carry the same rights upon presentation hereof at the office of the Company or at the office of its stock transfer agent, if any, together with a written notice specifying the names and the denominations in which new Warrants are to be issued and signed by the Holder hereof. The term "Warrant" as used herein includes any Warrants issued in substitution for or replacement of this Warrant or into which this Warrant may be divided or exchanged. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction, or mutilation of this Warrant, and (in the case of loss, theft, or destruction) of reasonably satisfactory indemnification, and upon surrender and cancellation of this Warrant, if mutilated, the Company will execute and will deliver a new Warrant of like tenor and date. Any such new Warrant executed and delivered shall constitute an additional contractual obligation on the part of the Company, whether or not this Warrant so lost, stolen, destroyed or mutilated shall be at any time enforceable by anyone.

 

 
2

 

 

(e)     Rights of the Holder. The Holder, by virtue hereof, shall not be entitled to any rights of a stockholder in the Company, either at law or in equity, and the rights of the Holder are limited to those expressed in the Warrant and are not enforceable against the Company except to the extent set forth herein.

 

(f)     Anti-Dilution Provisions.

 

(i) Adjustment of Price. Anything in this Section (f) to the contrary notwithstanding, if the Company shall issue, at any time, Common Stock or convertible securities by way of dividend, forward stock split or other distribution on any stock of the Company or subdivide or combine the outstanding shares of Stock, the Exercise Price shall be proportionately decreased in the case of such issuance, forward stock split, or distribution (on the day following the date fixed for determining shareholders entitled to receive such additional shares) or proportionately increased in the case of such combination (on the date that such combination shall become effective), provided, however, should the Company cancel or fail to make such dividend or other distribution or other issuance, the Exercise Price shall be forthwith adjusted to the price which would have prevailed prior to the Company setting such record date.

 

(ii) No Adjustment for Small Amounts. Anything in this Section to the contrary notwithstanding, the Company shall not be required to give effect to any adjustment in the Exercise Price unless and until the net effect of one or more adjustments, determined as above provided, shall have required a change of the Exercise Price by at least one cent, but when the cumulative net effect of more than one adjustment so determined shall be to change the actual Exercise Price by at least one cent, such change in the Exercise Price shall thereupon be given effect.

 

(iii) Number of Shares Adjusted. Upon any adjustment of the Exercise Price, the Holder of this Warrant shall thereafter (until another such adjustment) be entitled to purchase, at the new Exercise Price, the number of Units of Warrant Stock, calculated to the nearest full shares, obtained by multiplying the number of shares of Stock initially issuable upon exercise of this Warrant by the Exercise Price in effect on the date hereof and dividing the product so obtained by the new Exercise Price.

 

(g)     Officer's Certificate. Whenever the Exercise Price shall be adjusted as required by the provisions of Section (f) hereof, the Company shall forthwith file with its Secretary or an Assistant Secretary at its principal office, and with its stock transfer agent, if any, an Officer's Certificate showing the adjusted Exercise Price, determined as herein provided, and setting forth in reasonable detail the facts requiring such adjustment. Each such Officer's Certificate shall be made available at all reasonable times for inspection by the Holder; and the Company, after each such adjustment, shall forthwith deliver a copy of such certificate to the Holder. Such certificate shall be conclusive as to the correctness of such adjustment.

 

(h)     Notices to Warrant Holders. So long as this Warrant shall be outstanding and unexercised (i) if the Company shall pay any dividend or shall make any distribution upon the Common Stock or (ii) if the Company shall offer to the holders for subscription or purchase by them any shares of stock of any class or any other rights or (iii) if any capital reorganization of the Company; reclassification of the capital stock of the Company; consolidation or merger of the Company with or into another corporation; sale, lease or transfer of all or substantially all of the property and assets of the Company to another corporation; or voluntary or involuntary dissolution, liquidation, or winding up of the Company shall be effected, then, in any such case, the Company shall cause to be delivered to the Holder, at least ten (l0) days prior to the date specified in (x) or (y) below, as the case may be, a notice containing a brief description of the proposed action and stating the date on which (x) a record is to be taken for the purpose of such dividend, distribution, or rights, or (y) such reclassification, reorganization, consolidation, merger, conveyance, lease, dissolution, liquidation, or winding up is to take place and the date, if any, is to be fixed, as of which the holders of record shall be entitled to exchange their Shares for securities or other property deliverable upon such reclassification, reorganization, consolidation, merger, conveyance, dissolution, liquidation, or winding up.

 

 
3

 

 

(i)     Reclassification, Reorganization or Merger. In case of any reclassification, or capital reorganization (other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of an issuance of Common Stock by way of dividend or other distribution or of a subdivision or combination), or in case of any consolidation or merger of the Company with or into another corporation (other than a merger with a subsidiary, in which merger the Company is the continuing corporation and which does not result in any reclassification, or capital reorganization) or in case of any sale or conveyance to another corporation of the property of the Company as an entirety or substantially as an entirety, the Company shall cause effective provision to be made so that the Holder shall have the right thereafter, by exercising this Warrant, to purchase the kind and amount of shares of Stock and other securities and property receivable upon such reclassification; capital reorganization; or other consolidation, merger, sale, or conveyance as may be issued or payable with respect to or in exchange for the number of Shares of the Company theretofore purchasable upon the exercise of this Warrant had such recapitalization; capital reorganization; or other consolidation, merger, sale or conveyance not taken place. Any such provisions shall include provision for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Warrant. The foregoing provisions of this Section (i) shall similarly apply to successive reclassifications; capital reorganizations; and to successive consolidations, mergers, sales, or conveyances.

 

In the event that in any such capital reorganization or reclassification, consolidation, merger, sale or conveyance, additional shares shall be issued in exchange, conversion, substitution or payment, in whole or in part, for a security of the Company other than Stock, any such issue shall be treated as an issue of Stock covered by the provisions of subsection (f) hereof with the amount of the consideration received upon the issue thereof being determined by the Board of Directors of the Company, such determination to be final and binding on the Holder.

 

(j)     Transfer to Comply with the Securities Act of l933.

 

(i)     This Warrant or the Warrant Stock or any other security issued or issuable upon exercise of this Warrant may not be sold, transferred, or otherwise disposed of except to a person who, in the opinion of counsel for the Company, is a person to whom this Warrant or such Warrant Stock may legally be transferred pursuant to Section (d) hereof without registration and without the delivery of a current Prospectus under the Act with respect thereto and then only against receipt of an agreement of such person to comply with the provisions of this Section (k) with respect to any resale or other disposition of such securities.

 

 
4

 

 

(ii)     The Company may cause the following legend or one similar thereto to be set forth on each certificate representing Warrant Stock or any other security issued or issuable upon exercise of this Warrant not theretofore distributed to the public or sold to underwriters for distribution to the public pursuant to Section (j) hereof, unless counsel for the Company is of the opinion as to any such certificate that such legend is unnecessary:

 

The shares represented by this Certificate have not been registered under the Securities Act of l933 (the "Act") and are "restricted securities" as that term is defined in Rule 144 under the Act. The shares may not be offered for sale, sold, or otherwise transferred except pursuant to an effective registration statement under the Act or pursuant to an exemption from registration under the Act, the availability of which is to be established to the satisfaction of the Company.

 

          (k)     Registration Rights.     The shares issuable upon the exercise of this Warrant will be registered in a registration statement that will be filed promptly with the Securities and Exchange Commission upon the completion of the Company’s October 27, 2016 private placement.

 

(l)     Applicable Law. This Warrant shall be governed by and construed in accordance with the laws of Delaware.

 

 

AMERICANN, INC.

 

 

 

 

 

 

 

 

 

 

By:

 

 

 

 

Timothy Keogh, Chief Executive Officer

 

 

 

 

 

 

 

 

 

AmeriCann Warrant to Purch. Series III 2-1-17

 

 
5

 

 

PURCHASE FORM

 

                        Dated            .

 

The undersigned hereby irrevocable elects to exercise the within Warrant to the extent of purchasing         Shares of Warrant Stock and hereby makes payment of $                   in payment of the actual exercise price thereof.

 

                               

 

 

INSTRUCTIONS FOR REGISTRATION OF STOCK

 

 

Name                                                                                          

                  (Please typewrite or print in block letters)

 

Address                                                                   

 

                                                                                 

 

Signature                                                                        

 

                               

 

 

ASSIGNMENT FORM

 

 

FOR VALUE RECEIVED,                                                      

 

hereby sell, assigns, and transfers unto:

 

Name:                                                                                            

                     (Please typewrite or print in block letters)

 

Address:                                                                     

 

the right to purchase the Common Stock represented by this Warrant to the extent of              shares as to which such right is exercisable and does hereby irrevocably constitute and appoint                    attorney, to transfer the same on the books of the Company with full power of substitution in the premises.

 

Signature                                                 

 

Dated:                      .

 

 

AmeriCann Warrant to Purch. Series III 2-1-17

 

EX-5 6 ex5.htm EXHIBIT 5 ex3-2.htm

 

 

 

 

 

 

 

EXHIBIT 5

 

 

 

 

 

 

 

 

 

 
 

 

 

HART & HART, LLC

ATTORNEYS AT LAW

1624 Washington Street

Denver, CO 80203

William T. Hart, P.C.

Will Hart

________

(303) 839-0061

harttrinen@aol.com

Fax: (303) 839-5414

     

 

February 23, 2017

 

AmeriCann, Inc.

3200 Brighton Blvd. Unit 144

Denver, CO 80216

 

This letter will constitute an opinion upon the legality of the sale by certain shareholders by AmeriCann, Inc., a Delaware corporation (the “Company”), of up to 4,150,000 shares of the Company’s common stock.

 

We have examined the Articles of Incorporation, the Bylaws, and the minutes of the Board of Directors of the Company, and the applicable laws of the State of Delaware and a copy of the Registration Statement. In our opinion:

 

(i)      for those shares which are presently outstanding, the Company was authorized to issue such shares and such shares are legally issued, fully paid and non-assessable shares of the Company’s common stock; and

 

(ii)     any shares issued upon the exercise of the warrants held by seling shareholders, if exercised in accordance with their terms, will be legally issued and will represent fully paid and non-assessable shares of the Company’s common stock.

 

Very truly yours,

 

HART & HART, LLC

 

/s/ William T. Hart

 

William T. Hart

 

EX-10.1 7 ex10-1.htm EXHIBIT 10.1 ex3-2.htm

 

 

 

 

EXHIBIT 10.1

 

 

 

 

 

 

 
 

 

  

EMPLOYMENT AGREEMENT

 

This Employment Agreement (“Agreement”) is entered into as of March 25, 2014, by and between Americann, Inc. (formerly named Nevada Health Scan, Inc.), a Delaware corporation (“NHS”), AmeriCann, Inc., a Colorado corporation (“AmeriCann,” and along with NHS, the “Companies”) and Timothy R. Keogh, (“Employee”).

 

In consideration of the mutual promises and conditions in this Agreement, it is hereby agreed as follows:

 

1.

EMPLOYMENT

 

The Companies employ Employee, and Employee accepts employment with Companies upon the terms and conditions of this Agreement. During the Term (as hereinafter defined) of this Agreement, Employee will be employed by the Companies to serve as their President and Chief Executive Officer. Employee will initially devote approximately 50% of his working time per month to the conduct of the business of the Companies. Employee will devote more than 50% of his time to the Company as the Company’s operations expand. Employee will perform those duties and have such authority and powers as are customarily associated with the offices of a President and Chief Executive Officer of a company engaged in a business that is similar to the business of the Companies. During the Term of this Agreement, Employee shall perform the services under this Agreement at such locations to be agreed between Employee and the Companies. Notwithstanding any provision to the contrary herein, Employee shall be entitled to a seat on the Company’s Board of Directors (the “Board”) during the Term of this Agreement.

 

2.

TERM

 

Subject to earlier termination as provided in this Agreement, Employee shall be employed for a term of three years commencing on March 31, 2014 (the “Start Date”) (the “Term”).

 

3.

SALARY, BENEFITS AND OTHER COMPENSATION

 

3.1     Base Salary. As payment for the services to be rendered by Employee, the Companies agree to pay to Employee a base salary, payable in installments consistent with the Companies' payroll policy, subject to applicable withholdings, of Twelve Thousand Dollars ($12,000.00) per month (the "Base Salary"). Employee will be entitled to regular salary reviews and potential raises during the Term of this Agreement in the sole discretion of the Board.

 

 
 

 

 

3.2     Stock Grant. NHS will cause Strategic Capital Partners, LLC (“Strategic Partners”) to sell and transfer to Employee, upon execution of this Agreement, 1,200,000 shares of NHS’ Common Stock (the “Shares”), at a purchase price of $0.001 per share. By its execution of this Agreement below, Strategic Partners so agrees. All of the Shares will be transferred to Employee as of the date of this Agreement, subject to the vesting provisions below, and will be held by Employee, including the unvested Shares. Of the 1,200,000 shares, 300,000 Shares will vest immediately upon execution of this Agreement. The remaining Shares shall vest as follows, provided that Employee is still employed by either of the Companies as of date of each such vesting: (i) 300,000 Shares will vest on the earlier of March 20, 2015 or the date the Company receives at least $15,000,000 from the sale of its debt or equity securities; (ii) 300,000 Shares will vest on the earlier of March 20, 2016 or the date the Company receives at least $30,000,000 from the sale of its debt or equity securities; and (iii) 300,000 Shares will vest on the earlier March 19, 2017 or the date the Company receives at least $45,000,000 from the sale of its debt or equity securities. For purposes of the foregoing, traditional financing from banks or similar financial institutions will not be given effect and the required amounts to be raised will be cumulative. Notwithstanding the foregoing, all remaining unvested Shares shall become fully vested immediately prior to the happening of any of the following: (i) the sale of more than fifty percent (50%) of the issued and outstanding voting stock of NHS (excluding new issuances of stock by NHS); (ii) the sale of all or substantially all of NHS’ assets; (iii) a merger, consolidation or other reorganization in which the issued and outstanding capital stock of NHS immediately prior to such merger, consolidation or reorganization represents less than fifty percent (50%) of the outstanding voting stock of the surviving entity (or, if the surviving entity is a wholly owned subsidiary, its parent) immediately after such merger, consolidation or reorganization; (iv) Termination Other than For Cause (as defined below); or (v) Termination for Good Reason (as defined below). All Shares that are not vested, pursuant to the terms of this Agreement at the time of termination of Employee’s employment with the Companies, if such termination is a Termination for Cause (as defined below) or a Voluntary Termination (as defined below), shall be repurchased by NHS or its designee for $0.001 per share, which shall be paid promptly upon termination. Employee may not sell, transfer or convey the Shares for a period of twelve (12) months from the date of this Agreement, except that Employee may freely sell, transfer or convey up to 300,000 Shares provided such Shares are registered under the Securities Act of 1933 or are exempt from registration.     

 

3.3     Stock Options. NHS will grant to Employee, (i) an option, which will vest on March 20, 2015, to purchase 400,000 shares of NHS’ Common Stock at a per share price of $8.00, and (ii) an option, which will vest on March 20, 2016, to purchase 400,000 shares of NHS’ Common Stock at a per share price of $12.00 (collectively, the “Options”). The Options will expire on March 20, 2018. The vesting conditions for the Shares as set forth in Section 3.2 of this Agreement will apply to the Options described above, except the vesting dates in this Section 3.3 will control and any invested Options will not be purchased by the Company.

 

3.4     Benefit Plans. During the Term of this Agreement, Employee shall be eligible to participate in all employee benefit plans to the extent maintained by the Companies, including (without limitation) any retirement plans, any life, disability, health, accident and other insurance programs, paid vacations, and similar plans or programs, subject in each case to the generally applicable terms and conditions of the plan or program in question and subject to the administration of such plan or program. Upon termination for any reason, Employee will retain all of Employee's rights to benefits that have vested under such plan or program, but Employee's rights to participate in those plans and programs will cease on the Employee's termination unless the termination is a Termination by the Companies Other Than for Cause, in which case the Companies will continue to pay premiums for Employee’s health insurance until the end of the Term, either under the Companies’ health insurance plan or through COBRA.

 

 
2

 

  

3.5     Life and Disability Insurance. During the term of this Agreement, the Companies will provide Employee with a life insurance policy, on behalf of beneficiaries designated in the sole discretion of Employee, in the amount of $1,000,000, and a disability insurance policy on commercially reasonable terms.

 

3.6     Vacation. Employee shall be entitled to two weeks paid vacation in calendar year 2014, and three weeks paid vacation in each calendar year thereafter.

 

3.7     Expenses. The Companies shall reimburse Employee for Employee’s out-of-pocket expenses incurred in connection with the Companies’ business, including travel expenses, food, entertainment, fees for airline lounges and lodging while away from home, and relocation expenses approved in advance by the directors of NHS.

 

3.8     Registration Rights. NHS will register 300,000 of the Shares for public sale, at NHS’ sole cost, as soon as reasonably possible. NHS will provide registration rights to Employee for the remainder of the Shares and all shares subject to the Options.

 

4.

TERMINATION

 

4.1     Definitions. For purposes of this Agreement, the following terms have the following meanings:

 

(a) "Termination for Cause" means termination by the Companies of Employee's employment due to (i) willful or gross neglect of Employee’s duties causing material harm to the Companies; (ii) willful or gross misconduct or insubordination; (iii) commission of fraud, misappropriation or embezzlement causing material harm to the Companies; (iv) any material breach of this Agreement by Employee; or (v) Employee’s conviction or plea of no contest to a felony involving moral turpitude; provided, however, that no such termination will be deemed to be a Termination for Cause unless the Companies have provided Employee with written notice of what they reasonably believe are the grounds for any Termination for Cause and Employee fails to take appropriate remedial actions during the ten (10) day period following receipt of such written notice.

 

(b) "Termination Other than For Cause" means termination by the Companies of Employee's employment by the Companies for reasons other than those which constitute Termination For Cause.

 

(c) "Voluntary Termination" means termination by the Employee of the Employee's employment with the Companies other than a Termination for Good Reason.

 

(d)     “Termination for Good Reason” means termination by the Employee of employment with the Companies due to: (i) the relocation by the Companies of Employee’s office or principal place for the performance of his employment duties out of the United States; (ii) a material reduction of Employee’s responsibilities and duties; (iii) the Companies’ breach of any material term of this Agreement; or (iv) a reduction in Employee’s salary; provided, however, that no such termination will be deemed to be a Termination for Good Reason unless the Employee has provided the Companies with written notice of what he reasonably believes are the grounds for any Termination for Good Reason and the Companies fail to take appropriate remedial actions during the ten (10) day period following receipt of such written notice.

 

 
3

 

 

4.2     Termination for Cause. Termination for Cause may be effected by the Companies at any time during the Term of this Agreement and may be effected by written notification to Employee provided, however, that no Termination for Cause will be effective unless Employee has been provided with the prior written notice and opportunity for remedial action described in Section 4.1(a), above. Upon Termination for Cause, Employee is to be immediately paid, as his sole and exclusive remedy, all accrued Base Salary and accrued vacation pay, all to the date of termination.

 

4.3     Termination Other Than for Cause. Notwithstanding anything else in this Agreement, the Companies may effect a Termination Other Than for Cause at any time upon giving notice to Employee of such Termination Other Than for Cause. Upon any Termination Other Than for Cause, Employee will immediately be paid, as his sole and exclusive remedy and in a single lump sum, all accrued Base Salary and accrued vacation pay, to the date of termination, and all Base Salary that would have been paid for the remainder of the Term had Employee not been terminated.

 

4.4     Voluntary Termination. Employee may effect a Voluntary Termination by giving written notice to the Companies of such Voluntary Termination. In the event of a Voluntary Termination, the Companies will pay to Employee on the date of termination, as his sole and exclusive remedy, all accrued Base Salary and accrued vacation pay, all to the date of termination.

 

4.5     Termination for Good Reason. Employee may effect a Termination for Good Reason at any time by written notification to the Companies, provided, however, that no Termination for Good Reason will be effective unless the Companies have been provided with the prior written notice and opportunity for remedial action described in Section 4.1(d), above. Upon any Termination for Good Reason, Employee will immediately be paid, as his sole and exclusive remedy and in a single lump sum, all accrued Base Salary and accrued vacation pay, to the date of termination, and all Base Salary that would have been paid for the remainder of the Term had Employee not been terminated.

 

4.6     Effect of Termination on Vested Shares and Option Agreement. Notwithstanding anything to the contrary contained in this Agreement, any termination of Employee's employment by the Companies will have no effect on Employee’s vested Shares and/or Options, except as otherwise provided in the Option Agreement.

 

5.

NONCOMPETE

 

During the Term of this Agreement, and for a period of one (1) year thereafter in the event of a Voluntary Termination by Employee, Employee shall not, directly or indirectly, whether alone or as a partner, employee, consultant, member, joint venturer, creditor, shareholder, owner, manager or otherwise, be employed by or be an owner of more than 5% of the stock of a company in the cannabis industry whose stock is publicly traded.

 

 
4

 

 

6.

ASSIGNMENT OF INVENTIONS/CONFIDENTIAL INFORMATION

 

All processes, inventions, patents, copyrights, trademarks, and other intangible rights (collectively the “Inventions”) that are conceived or developed by Employee, either alone or with others, during the Term of Employee’s employment and solely in the course of Employee’s duties to the Companies hereunder, will be the sole property of the Companies, and Employee hereby assigns to the Companies all of Employee's right, title and interest in and to such Inventions.

 

In view of the fact that the Employee's work for the Companies will bring him into close contact with many confidential affairs of the Companies not readily available to the public, the Employee agrees, during the Term and for a period of one (1) year thereafter:

 

 

To keep secret and retain in the strictest confidence, all confidential matters of the Companies, including, without limitation, all information concerning properties owned by the Companies or which are under consideration by the Companies, and all other confidential and proprietary information of the Companies and their affiliates (“Confidential Information”), and not to disclose such Confidential Information to anyone outside the Companies, or to ever use such Confidential Information for the personal gain or benefit of the Employee except in the course of performing his duties hereunder or with the Companies' express written consent. Notwithstanding the above, Confidential Information does not include information which (a) is known, or becomes known, to the Employee through means other than his employment with the Companies, or (b) becomes a matter of public knowledge through no fault of the Employee.

 

 

That all records of the Companies, are and shall remain the property of the Companies at all times and to furnish on demand, all books, records, letters, vouchers, maps, drawings, notes or any other information that is written, photographed, or stored in any manner containing data regarding properties in which the Companies have an interest or which are under consideration by the Companies and all other Company records whether in original, duplicated, copied, transcribed, or any other form.

If the Employee commits a breach, or threatens to commit a breach, of any of the provisions of the foregoing, the Companies shall have the following rights and remedies:

 

 

The right to have the provisions of this Agreement specifically enforced by any court of competent jurisdiction, it being acknowledged that any such breach or threatened breach shall cause irreparable injury to the Companies and that money damages shall not provide an adequate remedy to the Companies;

 

 

The right to recover from the Employee all money damages, direct, consequential, or incidental, suffered by the Companies as a result of any acts constituting a breach of any of the provisions of the foregoing.

 

Each of the rights and remedies enumerated above shall be independent of the other and shall be severally enforceable, and all of such rights and remedies shall be in addition to, and not in lieu of, any other rights and remedies available to the Companies under law or in equity.

 

 
5

 

 

7.

EMPLOYEE’S REPRESENTATIONS

 

Employee represents that Employee does not have any obligations that would conflict with or prohibit Employee from performing the duties of his position. Employee further represents that he is not bound by any prior agreement that prohibits him from accepting this position and that his employment with the Companies will not breach any agreement with any former employer not to compete or solicit or any obligation to keep in confidence information acquired by him prior to employment with the Companies. Employee further represents to the Companies that he will not bring with him or use in the performance of his duties and responsibilities for the Companies any materials or documents of the former employer or other owners that are generally not available to the public, unless he has obtained written authorization from the former employer or other owner for their permission and use and has provided the Companies with a copy thereof.

 

8.

MISCELLANEOUS

 

8.1     Arbitration. Any dispute arising out of or in connection with this Agreement shall be resolved by binding arbitration under the Rules of the American Arbitration Association (“AAA”). The arbitration proceedings shall be conducted in Denver, Colorado. The parties will negotiate in good faith for a period of thirty (30) days after the filing of the demand for arbitration, in an attempt to agree on a single arbitrator to hear the dispute. If the parties are unable to agree on a single arbitrator within such thirty (30) day period, an arbitrator will be appointed by the AAA. The parties may conduct reasonable pre-hearing discovery, including requests for production of documents and depositions. The arbitrator shall have the power to resolve any discovery disputes which arise between the parties. Nothing in this clause shall be construed to preclude any party from seeking injunctive relief in order to protect its rights pending arbitration, and any such request for injunctive relief shall not be deemed a waiver of the obligation to arbitrate. Judgment upon the award of the arbitrator may be entered and enforced by any court or tribunal having jurisdiction.

 

8.2     Entire Agreement; Modification. Except as otherwise provided in this Agreement and in the Option Agreement, this Agreement represents the entire understanding among the parties with respect to the subject matter of this Agreement, and this Agreement supersedes any and all prior understandings, agreements, plans, and negotiations, whether written or oral, with respect to the subject matter hereof, including without limitation, any understandings, agreements, or obligations respecting any past or future compensation, bonuses, reimbursements, or other payments to Employee from Companies. All modifications to the Agreement must be in writing and signed by both parties hereto.

 

8.3     Headings. The Section headings of this Agreement are intended for reference and may not by themselves determine the construction or interpretation of this Agreement.

 

 
6

 

 

8.4     Governing Law. This Agreement is to be governed by and construed in accordance with the laws of the State of Colorado.

 

8.5     Severability. If any provision of this Agreement is held invalid or unenforceable, the remainder of this Agreement shall nevertheless remain in full force and effect. If any provision is held invalid or unenforceable with respect to particular circumstances, it shall nevertheless remain in full force and effect in all other circumstances.

 

8.6     Prevailing Party Attorneys' Fees. In the event of any arbitration or other legal proceeding relating to this Agreement or the enforcement of any provision of this Agreement, the prevailing party shall be entitled to recover reasonable attorneys’ fees, costs and disbursements (in addition to any other relief to which the prevailing party may be entitled) as determined by and within the discretion of the court or arbitrator.

 

8.7     Reimbursement of Transaction Expenses. The Companies will promptly reimburse Employee for all attorneys’ fees and costs incurred by Employee in connection with the negotiation and drafting of this Agreement and any related agreements, including the Stock Option Agreements and the CA Purchase Documents.

 

8.8     Counterparts. This Agreement may be executed in one or more counterparts and by facsimile or electronic signatures, all of which taken together will constitute one and the same Agreement.

 

8.9     Withholdings. All sums payable to Employee under this Agreement will be reduced by all federal, state, local, and other withholdings and similar taxes and payments required by applicable law.

 

8.10     Indemnification. The Companies agree that they will indemnify and hold the Employee harmless to the fullest extent permitted by applicable law from and against any loss, cost, expense or liability resulting from or by reason of the fact of the Employee's employment hereunder, whether as an officer, employee, agent, fiduciary, director or other official of the Companies, except to the extent of any expenses, costs, judgments, fines or settlement amounts which result from a violation of Section 8 or conduct which is knowingly fraudulent or deliberately dishonest or to constitute some other type of willful misconduct. The Companies will carry directors and officers liability insurance with no less than $5 million coverage.

 

 
7

 

 

IN WITNESS WHEREOF, this Agreement has been executed by the parties as of the date first above written.

 

AMERICANN, INC. A DELAWARE CORPORATION

 

By: /s/ Timothy Keogh                         

Name: Timothy Keogh

Title: Chief Executive Officer

 

AMERICANN, INC. A COLORADO CORPORATION

 

By: /s/ Timothy Keogh                         

Name: Timothy Keogh 

Title: Chief Executive Officer

 

 

EMPLOYEE

 

 

/s/ Timothy Keogh                                

Timothy Keogh

 

 

FOR PURPOSES OF SECTION 3.2 ONLY:

 

STRATEGIC CAPITAL PARTNERS, LLC

 

By: /s/ Benjamin J. Barton                     

Name: Bemjamin J. Barton

Title: Manager

 

 

 

 

 

 

 

Americann Employ. Agree. Keogh 2-1-17

 

8

EX-10.2 8 ex10-2.htm EXHIBIT 10.2 ex3-2.htm

 

 

 

 

 

 

EXHIBIT 10.2 

 

 

 

 

 

 

 

 

 

  

LOAN AGREEMENT

 

 

This Loan Agreement (this “Agreement”), is made as of September 21, 2014 between:

 

 

1.

AmeriCann, Inc. (“AmeriCann”) and

 

 

2.

Wellness Group Pharms, LLC (“WGP”).

 

 

INTRODUCTION

 

WGP has requested that AmeriCann extend credit to WGP in the form of loan not to exceed $4,760,000 to be used to fund WGP’s acquisition, development and construction of property, plant, equipment, all necessary permits and start-up costs and expenses in accordance with those costs and operating income and expense projections shown on the attached Exhibit A. The Property on which the cultivation and growing facility will be constructed is described on Exhibit B.

 

AGREEMENT

 

The parties agree as follows:

 

 

1.

The Loan.

 

1.1      Subject to the terms and conditions in this Agreement, AmeriCann will make a loan (the “Loan”) to WGP in the principal amount requested by WGP up to $4,760,000 (the Commitment Limit). If less than the Commitment Limit is borrowed initially, and if no event of default has occurred and is continuing, and all other conditions have been satisfied, subject to the terms, conditions, obligations and rights of AmeriCann under this Agreement, WGP shall be entitled to request that additional advances be made to it, such that the total loan balance outstanding would not exceed the Commitment Limit. AmeriCann will deposit $50,000 in escrow upon the execution of this Agreement. If the deposit has not previously been returned to AmeriCann pursuant to the terms of this Agreement, the deposit will be released to WGP as the first Loan advance (or as part of the first loan advance).

 

 

1.2

The basic term of the loans will be as follows:

 

Loan amount:

$4,760,000

Term:

72 Months

Interest rate:

18% per year

     

After 12 months, prepayment can be made at 120% of the outstanding principal of the loan.

 

 

 

 

As a condition to making the Loan, WGP will pay AmeriCann a consulting fee of $47,600 per month for the first 24 months of the Loan. At the end of the 24 month period, the monthly consulting fee will be adjusted to an amount equal to $10,000 per month for every $1,000,000 financed (pro rata for fractional amounts of $1,000,000), based on the outstanding balance of the loan at the end of such 24 month period.

 

Principal and Interest (P & I) payments and the consulting fee will accrue during the first 12 months, but payment will be deferred and applied to the outstanding principal balance of the Loan which will be repaid over the remaining 60 months. However, WGP will have the right, but not obligation, to commence making P & I and/or consulting fee payments at any time during the first 12 months.

 

Development Fee equal to 30% of the final total loan amount will be applied to the outstanding balance of the loan and amortized over the term of the loan at the rate identified.

 

Loan drawdowns for the construction phase of the project will be subject to certifications by the architect and building contractor and will be based upon the percentage of the project’s completion. Loan drawdowns for start-up costs and expenses will be based upon WGP’s budget for such costs, subject to AmeriCann’s approval of the budget.

 

The Loan will be secured by a mortgage or first deed of trust against the Property. All other assets, including accounts receivable, equipment and assignment of leases and rents, if any, will also serve as collateral for the Loan.

 

WGP will be required to submit compiled financial statements, reviewed by an independent accountant, on a monthly basis during the first year of the loan, with quarterly submissions thereafter.

 

 

2.

License Application.

 

2.1      WGP will promptly make an application to the appropriate authorities in Illinois for a license to construct and operate a marijuana cultivation and growing facility. WGP will use its best efforts to have the license granted. WGP will promptly apprise AmeriCann of any communications it receives from applicable Illinois agencies or authorities, and will forward to AmeriCann, within two days of receipt, copies of any communication it receives from any person relative to the license application.

 

2.2      WGP will notify AmeriCann (via email), within two days of receiving notification that its license application has been accepted or rejected.

 

2.3     Within seven days of receiving notification that its license application has been accepted, WGP must notify AmeriCann of its election to proceed to close the Loan. If WGP does not notify AmeriCann of its election to proceed to close the Loan, WGP must pay AmeriCann a breakup fee of $150,000, which will be payable to AmeriCann via wire transfer upon the expiration of such seven day period, plus $47,600 per month for twenty-four months.

 

 
2

 

 

2.4     If WGP does not notify AmeriCann of its election to close the Loan, the deposit will be returned to AmeriCann.

 

2.5      If a license to construct and operate a marijuana cultivation and growing facility has not been granted to WGP by January 31, 2015, then AmeriCann, at any time thereafter, may at its sole option, terminate this Agreement by written notification to WGP. Upon such termination, the deposit will be returned to AmeriCann.

 

2.6      If WGP’s license is rejected, but WGP decides to reapply for a license, WGP will give AmeriCann notice of such fact, and the provisions of Sections 2.1 through 2.5 will apply to any new license application.

 

 

3.

Conditions to AmeriCann’s Obligation to Close.

 

The obligation of AmeriCann hereunder to fund the Loan is subject to the satisfaction, at or before the Closing, of each of the following conditions, provided that these conditions are for AmeriCann’s sole benefit and may be waived by AmeriCann at any time in its sole discretion by providing WGP with prior written notice thereof. WGP will use its best efforts to satisfy these conditions.

 

3.1     The promissory note evidencing the Loan, together with the mortgage, deed of trust, security agreements, account control agreements, assignments of receivables and rents, as well as any other collateral documents reasonably requested by AmeriCann (the “Security Documents”), will be on terms acceptable to AmeriCann.

 

3.2     The Security Documents shall have been executed and delivered to AmeriCann, and WGP will have taken such other actions, as in each case, as shall be necessary or, in the opinion of AmeriCann, to perfect a first priority lien in the Property and a first priority security lien on the other assets securing the Loan.

 

3.3     WGP shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for the construction and operation of a marijuana cultivation and growing facility on the Property.

 

3.4     WGP will have all necessary (i) certificates, licenses, and other approvals, governmental and otherwise, for the operation of the of a marijuana cultivation and growing facility on the Property and (ii) zoning, building code, land use, environmental and other similar permits or approvals, all of which will be currently in full force and effect and not subject to revocation, suspension, forfeiture, or modification, acceptable to AmeriCann at its sole and absolute discretion. The Property and its use and occupancy will be in full compliance with all applicable laws and WGP will have received no notice of any violation or potential violation of the applicable laws which have not been remedied or satisfied, and the zoning classification of the Property permits the use of the Property as intended.

 

3.5     The Property will be free from damage caused by fire or other casualty.

 

 
3

 

 

3.6     Within two business days prior to the Closing, WGP shall have delivered or caused to be delivered to AmeriCann (A) certified copies of UCC search results, listing all effective financing statements which name as debtor WGP filed in the prior five years, together with copies of such financing statements, none of which, except as otherwise agreed in writing by AmeriCann, shall cover any of WGP’s assets which will serve as security for the Loan, as well as the results of searches for any tax liens or judgment liens filed against WGP or its property, which results, except as otherwise agreed to in writing by AmeriCann shall not show any such liens; and (B) a UCC perfection certificate, duly completed and executed by WGP, in form and substance satisfactory to AmeriCann.

 

3.7     AmeriCann shall have been provided the following for its review and approval, and such approval shall be granted or withheld in AmeriCann’s sole discretion:

 

a)     A lender’s title insurance policy, to be issued at WGP’s sole cost and expense, made in favor of AmeriCann, committing to issue to AmeriCann, as lender, extended coverage title insurance policy for the Property, in an amount equal to the purchase price of the Property, subject only to those certain exceptions to title acceptable to an AmeriCann, in its sole and absolute discretion;

 

b)     A Phase I environmental inspection prepared by an environmental engineering company acceptable to AmeriCann, acquired at WGP’s sole cost and expense, of the Property and acceptable to AmeriCann in its sole and absolute discretion. In the event the Phase I inspection report recommends a Phase II environmental inspection, WGP shall promptly order such Phase II environmental inspection at its sole cost and expense, certified to AmeriCann, which shall be acceptable to AmeriCann at its sole and absolute discretion;

 

c)     Building elevations, drawings of interior partitions, electrical equipment, lighting and HVAC locations and specifications and other features of the facility reasonably requested by AmeriCann;

 

d)     Evidence satisfactory to AmeriCann that the Property can be acquired and a cultivation and growing facility can be constructed on the Property, in accordance with the specifications approved by AmeriCann, for an amount not exceeding the Commitment Limit;

 

e)     An insurance Policy insuring the Property against fire and casualty, and insuring AmeriCann against general liability, naming AmeriCann as “an additional insured”, in form and substance acceptable AmeriCann;

 

f)     Evidence that all costs and expenses for labor, materials, supplies, and equipment used in the construction of any improvements on the Property have been paid in full;

 

g)     Evidence that all taxes, fees and other charges relating to the Property, and in connection with the execution, delivery and recording of the Security Documents shall have been paid, and all delinquent taxes, assessments or other governmental charges or liens affecting the Property, if any, shall have been paid. WGP shall provide a treasurer's tax certificates disclosing that no general and special taxes or assessments encumbering the Property are delinquent and that the Property does not lie within any special or general assessment district except as approved by AmeriCann;

 

 
4

 

 

h)     A certificate evidencing WGP’s good standing issued by the Illinois Secretary of State (or comparable office), as of a date within ten (10) days of the Closing Date;

 

i)     An appraisal by a real estate appraiser reasonably acceptable to AmeriCann that shows an appraised value of the Property equal to or greater than the purchase price to be paid by WGP for the Property;

 

j)     At WGP’s sole cost and expense, a current ALTA improvement survey plat of the Property acceptable to AmeriCann and the title company issuing the title policy indicating, without limitation, that all foundations or other improvements currently constructed are located within the lot lines, without infringement on established easements or rights-of-way and not in violation of any ordinance including zoning ordinances which impose lot line setback requirements and parking requirements. The survey shall show the legal description of the Property as it will be insured by the title company, the courses and distances of the Property lot lines, all appurtenant service easements, setbacks, building lines and width of abutting streets, distance to nearest intersecting streets affording ingress and egress to and from the Property, and the location and dimensions of all encroachments, improvements, above or below ground easements and utilities, and designated parking spaces. The surveyor shall also certify whether or not any portion of the Property is located within a Federal Emergency Management Agency identified flood-prone area of a community and if located thereon, state the map number and whether or not the Property appears in the "Flood Hazard Area." The survey must be certified as accurate by a licensed surveyor in Illinois and contain a certificate imprinted thereon in the form approved by the ALTA stating that the survey is made for the benefit of AmeriCann and the title company issuing the title policy;

 

k)     Evidence that any and all other requirements which may be set forth in the Security Documents, as reasonably determined necessary by AmeriCann in its sole and absolute discretion, have been met; and

 

l)     Such other documents relating to the Loan as AmeriCann or its counsel may reasonably request.

 

 

4.

Closing.

 

4.1     The Closing of the Loan will take place at the offices of AmeriCann not less than 60 days after AmeriCann receives WGP’s notice pursuant to Section 2.4 that it has agreed to proceed with the Loan. Subject to the foregoing, the Closing will take place at a mutually agreeable time and date. However, if the closing has not taken place by July 15, 2015, due to no fault of AmeriCann or WGP, then either party may terminate this Agreement by written notice to the other, and neither party will have any liability to the other party.

 

 
5

 

 

 

5.

Termination.

 

5.1     In the event that the Closing shall not have occurred on or before July 15, 2015 due to AmeriCann’s or WGP’s failure to satisfy the conditions set forth in this Agreement (and the non-breaching party's failure to waive such unsatisfied condition(s)), the non-breaching party shall have the option to terminate this Agreement with respect to such breaching party after such date by delivering a written notice to that effect to the other, and may recover damages for such breach. Notwithstanding the above, if WGP does not use its best efforts to provide AmeriCann with the documentation/information specified in Section 3 within 5 days after AmeriCann receives WGP’s notice pursuant to Section 2.4 that it has agreed to proceed with the loan, WGP will pay AmeriCann, as liquidated damages and not as a penalty, an amount equal to the breakup fee, plus AmeriCann’s legal, accounting, consulting, travel, and other out-of-pocket expenses incurred in connection with the transaction contemplated by this Agreement. If AmeriCann is ready to close the Loan, but WGP refuses to execute the documents required to close the Loan, WGP will pay AmeriCann, as liquidated damages and not as a penalty, an amount equal to the breakup fee, plus AmeriCann’s legal, accounting, consulting, travel, and other out-of-pocket expenses incurred in connection with the transaction contemplated by this Agreement.

 

 

6.

Miscellaneous.

 

6.1     Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of Illinois, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Illinois or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than Illinois.

 

6.2     Arbitration. Any dispute or claim involving this Agreement will be settled through binding arbitration pursuant to the Commercial Arbitration Rules of the American Arbitration Association in Denver, Colorado

 

6.3     Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile signature shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile signature.

 

6.4     Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.

 

6.5     Severability. If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

 
6

 

 

6.6     Amendments. Provisions of this Agreement may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of AmeriCann and WGP. Without limiting the foregoing, WGP confirms that AmeriCann has not made any commitment or promises or has any other obligation to provide any financing to WGP or otherwise.

 

6.7     Notices. Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party) or by electronic mail; or (iii) one Business Day after deposit with an overnight courier service, in each case properly addressed to the party to receive the same. The addresses, facsimile numbers and e-mail addresses for such communications shall be:

 

If to AmeriCann:

AmeriCann, Inc.

3200 Brighton Blvd. Unit 114

Denver, CO 80211

Telephone: (303) 862-9000

Facsimile:
Attention: Timothy Keogh

E-mail:        tim@americann-inc.com

 

With a copy to:

 

Hart & Hart, LLC

1624 Washington Street

Denver, CO 80203

Telephone: (303) 839-0061

Facsimile: (303) 839-5414

Attention: William Hart, Esq.

E-mail:        harttrinen@aol.com

 

 
7

 

 

If to WGP:

 

p-1411 West Peterson Avenue

Suite 202

Park Ridge, IL 60068

Telephone:

Facsimile:

Attention:

E-mail:

 

6.8     Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and assigns. Neither party may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other party.

 

6.9     No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

6.10     Negotiations with Third Parties. Until this Agreement is terminated pursuant to its provisions, WGP will not, directly or indirectly, negotiate with any third party with respect to obtaining financing to acquire the Property or construct and equip a marijuana cultivation and growing facility. For purposes of the foregoing, financing includes any type of debt or equity financing, or financing obtained from a joint venture or other enterprise.

 

6.11     Additional Capital. AmeriCann will have the first right of refusal to provide any additional capital which WGP may require to acquire the Property, construct and equip a marijuana cultivation and growing facility, and/or for start-up costs and expenses.

 

6.12     Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

 

6.13     No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express their mutual intent, and no rules of strict construction will be applied against any party.

 

6.14     Remedies. Each party having any rights under any provision of this Agreement shall be entitled to enforce such rights specifically (without posting a bond or other security), to recover damages by reason of any breach of any provision of this Agreement and to exercise all other rights granted by law.

 

 
8

 

 

6.15     Usury Savings Clause. It is the intent of AmeriCann and WGP in the making to contract in strict compliance with applicable usury laws. In the furtherance thereof, AmeriCann and WGP stipulate and agree that none of the terms and provisions contained herein, or in any note or security agreement, or in any other instrument executed in connection herewith, shall ever be construed to create a contract to pay for the use, forbearance, or detention of money, interest at a rate in excess of the maximum interest rate permitted to be charged by applicable law; that neither WGP nor any guarantor, endorser, or other party now or hereafter becoming liable for payment of any obligations to AmeriCann shall ever be required to pay interest on the Loan or required by the Security Documents at a rate in excess of the maximum interest that may be lawfully charged under applicable law, and the provisions of this Section shall control over all other provisions of this Agreement, the Security Documents, and any other instruments now or hereafter executed in connection herewith which may be in apparent conflict herewith. AmeriCann expressly disavows any intention to charge or collect excessive or unearned interest or finance charges in the event that maturity of the Loan is accelerated. If the maturity of the Loan shall be accelerated for any reason or if the principal of the Loan obligations are paid prior to the end of the term, and as a result thereof the interest received for the actual period of existence of the Loan obligations exceeds the applicable maximum lawful rate, AmeriCann shall, at its option, either refund to WGP the amount of such excess or credit the amount of such excess against the principal balance of the Loan then outstanding (without prepayment premium or similar charge) and thereby shall render inapplicable any and all penalties of any kind provided by applicable law as a result of such excess interest. In the event that AmeriCann shall contract for, charge, or receive any amount or amounts which are deemed to constitute interest which would increase the effective interest rate on the obligations evidenced by the Notes to a rate in excess of that permitted to be charged by applicable law, all such amounts deemed to constitute interest in excess of the lawful rate shall, upon such determination, at the option of AmeriCann, be either immediately returned to WGP or credited against the principal balance of the amounts then outstanding (without prepayment premium or similar charge), in which event any and all penalties of any kind under applicable law as a result of such excess interest shall be inapplicable. By execution of this Agreement, WGP acknowledges that it believes the obligations to be non-usurious, and agrees that if, at any time, WGP should have reason to believe that the Loan obligations are in fact usurious, it will give AmeriCann notice of such condition, and WGP agrees that AmeriCann shall have ninety (90) days in which to make appropriate refund or other adjustment in order to correct such condition if in fact such exists. The term “applicable law” as used in this Section shall mean the laws of the State of Illinois or the laws of the United States, whichever laws allow the greater rate of interest, as such laws now exist or may be changed or amended or come into effect in the future.

 

 

 

[Signature Page Follows]

 

 
9

 

 

IN WITNESS WHEREOF, AmeriCann and WGP have caused their respective signature page to this loan to be duly executed as of the date first written above.

 

 

 

AMERICANN, INC.

 

 

 

 

 

 

 

 

 

 

By:

/s/ Timothy Keogh

 

 

 

Name: Timothy Keogh

 

 

 

Title: President

 

 

 

 

WELLNESS GROUP PHARMS, LLC

 

 

 

 

 

 

 

 

 

 

By:

/s/ Paul Montes

 

 

 

Name: Paul Montes

 

 

 

Title: Manager

 

 

 

 

 

 

 

AmeriCann Loan Agree. Wellness 1-31-17

 

 

 

 

Annex No. 1

to the Loan Agreement between

AmeriCann, Inc. and

Wellness Group Pharms, LLC

       

 

This Annex No. 1 (“Annex No. 1”) is made as of February 22, 2015 between:

 

 

1.

AmeriCann, Inc. (“AmeriCann”);

 

and

 

 

2.

Wellness Group Pharms, LLC (“WGP”).

 

Whereas, the parties entered into a loan agreement dated September 21, 2014, which is attached hereto as Exhibit No. 1 (“Loan Agreement”);

 

Whereas, WGP received notification from the Illinois Department of Agriculture on February 2, 2014, that WGP was selected to receive an operating permit to construct and operate a marijuana cultivation and growing facility (the “Facility”) in Illinois State Police District 22, which is attached hereto as Exhibit No. 2;

 

Whereas, WGP has contracted with Aspen American Insurance Company to put in place the bond described in and required by Exhibit No. 2. The contract with Aspen American Insurance Company, pursuant to which Aspen American Insurance Company will issue the bond, is attached hereto as Exhibit No. 3;

 

Whereas, WGP requires funds in an amount and on conditions different than stated in the Loan Agreement;

 

Whereas, due to the change in the relationship between the parties specified in the Loan Agreement, the parties agree to amend the Loan Agreement as follows:

 

1.

The New Loan (the “New Loan”)

 

1.1

New Loan amount:

$2,772,724, subject to clause 7.4

 

End of Term:

End of Pilot Program (currently December 31, 2017)

 

Interest rate: 

18% per annum

 

1.2     The New Loan shall be designated as working capital for WGP to undertake and carry out operations in the Facility.

 

1.3     WGP shall treat all amounts received from AmeriCann under the Loan Agreement, and under this Annex No. 1, as a debt obligation due to AmeriCann and shall be reflected as such on its balance sheet.

 

 
1

 

 

1.4     WGP shall not contract for any additional debt without first obtaining AmeriCann’s approval. If AmeriCann consents to WGP contracting for any additional debt, all and any such additional debt approved by AmeriCann shall be subordinate to AmeriCann’s senior position.

 

 

1.5     Any and all security instruments provided to AmeriCann to secure any and all amounts paid out by AmeriCann shall be first-ranking security positions.

 

1.6     Clauses 1.3, 1.4, and 1.5 above shall not apply in the event AmeriCann totally converts the New Loan into a share in gross revenue under clause 13.1 below.

 

1.7     Clause 1.4 shall not apply in the event clause 11.2 becomes applicable.

 

1.8     Interest on the New Loan shall initially accrue and be added to the New Loan as principal until the first calendar month in which WGP commences operations in the Facility (“Accrued Interest”). During this period, Accrued Interest becoming principal shall be paid along with the New Loan principal and the Accrued Consulting Fee in accordance with clauses 6.3 and 6.4 of this Annex No. 1.

 

1.9     The Parties agree to negotiate extension of the term of the loan, in good faith, if the term of the Pilot Program is extended by the State of Illinois.

 

2.

Drawdown No. 1 on the New Loan

 

2.1     Drawdown No. 1 shall be in the amount of $600,000.

 

2.2     AmeriCann shall undertake the necessary procedures to initiate a wire transfer for $400,000 to Aspen American Insurance Company before 12:00pm MT Monday, February 23, 2015, and shall deliver to WGP by the close of business on February 24, 2015, a certified check payable to the Department of Agriculture for $200,000. Failure of AmeriCann to comply with the terms of this clause 2.2 shall render this Annex No. 1, and the Loan Agreement, terminated, and neither party shall have any rights or obligations to the other party under this Annex No. 1 or the Loan Agreement.

 

3.

Designation of Drawdown No. 1

 

Drawdown No. 1 shall be designated as follows:

 

3.1     $400,000 shall be placed in escrow to the secure the bond contract constituting Exhibit No. 3.

 

3.2     $200,000 shall be paid to the Illinois Department of Agriculture for the license fee described in and required by Exhibit No. 2.

 

 
2

 

 

4.

Documentation Evidencing and Securing Drawdown No. 1

 

4.1     The parties shall enter into a Commercial Promissory Note for Drawdown No. 1 simultaneously with the signing of this Annex No. 1, and the executed Commercial Promissory Note shall constitute Exhibit No. 4 to this Annex No. 1.

 

4.2     The parties shall enter into a Security Agreement for Drawdown No. 1 simultaneously with the signing of this Annex No. 1 and the executed Security Agreement shall constitute Exhibit No. 5 to this Annex No. 1. The executed Security Agreement shall secure all amounts of the New Loan paid out.

 

5.

Additional Drawdowns on the New Loan

 

5.1     Additional drawdowns on the New Loan shall be in the amounts and paid out in accordance with the draw schedule and by the deadlines specified in Exhibit No. 6 to this Annex No. 1 (“Working Capital Draw Schedule and Construction Budget”).

 

5.2     The parties shall enter into a Commercial Promissory Note for any and all additional drawdowns on the New Loan on the day preceding the day AmeriCann is to undertake the necessary procedures to pay out any and all additional drawdowns. The executed Commercial Promissory Notes shall be attached to, and become a component part of, this Annex No. 1.

 

5.3     The executed Security Agreement constituting Exhibit No. 5 to this Annex No. 1 shall also secure any and all additional drawdowns of the New Loan.

 

6.

Repayment of the New Loan, and Payment of Accrued Interest and the Accrued Consulting Fee

 

6.1     Repayment of the New Loan by WGP to AmeriCann, and simultaneous payment of Accrued Interest and the Accrued Consulting Fee as defined in clause 7.4 below, shall be in monthly installments commencing with the calendar month in which WGP begins operations in the Facility based on the principles described in this Section 6.

 

6.2     The amount of the monthly payment shall be determined on the first business day of the month on the basis of the calculations described in this Section 6 and in particular on the basis of clauses 6.3 and 6.4 below.

 

6.3     WGP shall be allowed to maintain a total of $250,000 in cash on hand and in all of its bank accounts, as working reserve capital. If WGP has total balances of $250,000 or less as cash on hand and in all of its bank accounts on the first business day of a particular month, there shall be no repayment of the New Loan or payment of Accrued Interest and the Accrued Consulting Fee.

 

6.4     Subject to clause 12.7, if the cash on hand and the balances in all of WGP’s bank accounts exceed $250,000 on the first business day of a particular month, ninety percent (90%) of the balance exceeding $250,000 shall be paid to AmeriCann as a monthly installment for repayment of the New Loan and for payment of Accrued Interest and the Accrued Consulting Fee. WGP may distribute the remaining ten percent (10%) of the balance exceeding $250,000 in that particular month in its discretion.

 

 
3

 

  

6.5     If WGP is to make a monthly installment for repayment of the New Loan and for payment of Accrued Interest and the Accrued Consulting Fee to AmeriCann under clause 6.4 above, the payment shall be made to AmeriCann by the 10th day of that particular month.

 

6.6     WGP shall disclose any and all bank accounts to which it is the beneficiary to AmeriCann while this Section 6 is in force and applicable, and WGP shall disclose the relevant accounting records to account for any and all cash on hand. For the avoidance of doubt, cash on hand means any monies to which WGP comes into possession or to which WGP obtains legal title due to its operations in the Facility.

 

6.7     WGP shall disclose the amount of cash on hand and the balance of any and all bank accounts to which it is the beneficiary to AmeriCann as near to the first business day in a particular month as is reasonably possible, but no later than on the first business day of a particular month. This disclosure shall be made by presenting the accounting ledgers showing cash on hand and by presenting the bank statements for any and all bank accounts to which WGP is the beneficiary. WGP shall have a right to demand the accounting ledgers showing cash on hand and the bank statements showing the balance of any and all bank accounts on the first business day of a particular month if it suspects that a significant payment of cash or a deposit to an account was made between the date WGP disclosed all balances of its accounts and the first business day of the month.

 

6.8     WGP shall not pay any cash or transfer any funds from any and all of its bank accounts at any time other than in the ordinary course of its business. WGP shall not allow any funds or receivable due to it from the ordinary course of its business to be paid in cash to a third party or to be transferred to an account other than to an account to which it is the beneficiary. For the avoidance of doubt, this prohibition on paying cash and transferring funds is intended to prohibit WGP from making any distribution to any party that may be related to WGP or have an interest in WGP’s business in the Facility; for the avoidance of doubt, this prohibition on paying cash and transferring funds is intended to prohibit WGP from avoiding repayment of the New Loan and the Accrued Consulting Fee due to this Section 6 being in force.

 

6.9     This Section 6 shall lose force upon full repayment of the New Loan and the Accrued Consulting Fee and WGP may then distribute cash and funds from its bank accounts in its full discretion.

 

6.10     WGP will have the right, but not the obligation, to commence making repayment of the New Loan and payment of the Accrued Consulting Fee at any time without penalty.

 

6.11     On or before the fifth day of each month, AmeriCann shall provide a monthly statement to WGP reflecting the balance due on the New Loan, plus any Accrued Consulting Fee, and any Accrued Interest, net of any payments made by WGP.

 

 
4

 

 

7.

Consultancy Arrangement

 

7.1     The parties agree to prepare and enter into, with all reasonable haste, a consulting services contract (“Consultancy Contract”) that will take into account the principles specified in this Annex No. 1 and specified in particular in this Section 7. AmeriCann shall deliver a draft of the Consultancy Contract to WGP for review.

 

7.2     The term of the Consultancy Contract shall be for a minimum period of twelve (12) years commencing on March 1, 2015. The Consultancy Contract shall expire simultaneously with the Lease Contract described in Section 12 of this Annex No. 1.

 

7.3     The consulting fee payable by WGP to AmeriCann under the Consultancy Contract shall be a monthly fee of Twenty Thousand Dollars ($20,000) per month (the “Consulting Fee”).

 

7.4     The Consulting Fee shall initially accrue and be added to the New Loan as principal until the first calendar month in which WGP commences operations in the Facility (the “Accrued Consulting Fee”). WGP shall pay the Accrued Consulting Fee as specified in Section 6 of this Annex No. 1 and in particular clauses 6.3 and 6.4. WGP will have the right, but not the obligation, to commence making Consulting Fee payments at any time prior to the time required under Section 6 of this Annex No. 1.

 

7.5     In the calendar month immediately after the calendar month in which WGP commences operations in the Facility, WGP shall pay the Consulting Fee by the 10th day of the month for which the Consulting Fee shall be due. AmeriCann shall issue an invoice for the Consulting Fee by the first day of each month (or the first business day after the first day of the month if the first day of the month lands on a non-business day) for the month for which the Consulting Fee shall be due.

 

7.6     WGP shall not assign its rights and obligations under the Consultancy Contract to a party that assumes WGP’s obligations thereunder without the prior written consent of AmeriCann.

 

7.7     Any deviation in the Consultancy Contract from the principles in this Section 7 may only be through an instrument in writing signed by the parties hereto.

 

8.

Formation of an Executive Committee

 

8.1     The parties agree to the formation of an Executive Committee for purposes of performing management over construction of the Facility and over the subsequent operation of the Facility.

 

8.1.i.     AmeriCann acknowledges that management and administration decisions, specifically matters relating to personnel, marketing and other incurred day to day operating expenses, are to be controlled by WGP, and not by the Executive Committee.

 

 
5

 

 

8.2     The Executive Committee shall have decision-making authority over all significant decisions related to construction of the Facility and subsequent operation of the Facility. AmeriCann acknowledges that certain Construction Services Contract dated September 28, 2014, by and between WGP and Icon Construction Services, LLC (“Construction Contract”), which is attached hereto as Exhibit No. 8. AmeriCann and the Executive Committee shall honor and comply with the Construction Contract for the first phase of the project. AmeriCann intends to utilize Icon Construction for future phases of the project. AmeriCann will pay for the total construction costs, including all interior finishes and production equipment and systems necessary for the production of cannabis products as contemplated by WGP and AmeriCann and as described herein, but if the actual costs for the first phase of the project exceed the Construction Budget, the difference will be added to the Working Capital Loan to WGP. If necessary, this will be determined by an independent arbitrator.

 

8.2.i     In the event that AmeriCann has provided the full allotment of capital according to the Working Capital Draw Schedule and Construction Budget, and Icon Construction Services, LLC has failed to meet the construction schedule, except for good cause or reasons of force majeure, AmeriCann reserves the right to terminate the construction contract and replace Icon Construction with another qualified contractor to complete the project within the required timeframe.

 

8.3     The parties agree to prepare with all reasonable haste additional guidance concerning what will constitute a significant decision and what types of decisions will not be determined by the Executive Committee.

 

8.4     The Executive Committee shall consist of three persons. One representative shall be appointed by WGP, one representative shall be appointed by AmeriCann, and one independent representative with cannabis or horticultural industry experience shall be appointed. AmeriCann shall have the right to appoint this representative as well as to replace this independent representative at its sole discretion.

 

8.5     The Executive Committee shall be responsible for determining issues by a majority vote.

 

8.6     AmeriCann will pay any compensation that may be required to the independent representative for serving on the Executive Committee. None of these costs will be added to the project’s construction or operating costs.

 

9.

Meetings of the Executive Committee

    

 

9.1     The Executive Committee shall meet as frequently as deemed necessary by the Executive Committee. Any single member of the Executive Committee may call a meeting upon at least 48 hours’ notice. It is expected that during any phases of construction and design meetings for future phases that meetings would be more frequent.

 

9.2     Meetings of the Executive Committee may take place by phone or other electronic means.

 

 
6

 

 

9.3     Upon convening, the WGP representative shall act as a secretary, to take notes during the meeting and to record the voting on issues addressed during the meeting.

 

9.4     The secretary shall circulate the notes/a report to the other members of the Executive Committee by email within two (2) business days following the meeting.

 

10.

The Property Transaction

 

10.1     The land to be acquired for the Facility consists of 701,769 sq. ft. or approximately 16.1 acres located in Anna, Illinois at 690 Lick Creek Road (the “Property”). The contract to acquire the land under which WGP is the purchasing party is attached hereto as Exhibit No. 7, which also consists of a Second Amendment to the Agreement for Purchase.

 

10.2     AmeriCann shall become the purchasing party in the transaction to acquire ownership of the Property. WGP shall take the necessary legal steps to assign the right to acquire ownership of the Property to AmeriCann.

 

11.

Construction of the Facility

 

11.1     AmeriCann shall construct the Facility on the Property, based on the Construction Contract. The first phase of construction of the Facility, which shall be an approximate 27,000 square foot pre-engineered building, shall be completed so that WGP, in accordance with plans and specifications as presented in WGP’s application to the State of Illinois, may commence operations within six (6) months from the calendar month in which the Illinois Department of Agriculture issued the operating permit to construct and operate the Facility.

 

11.2     Subject to clause 11.3 below, in the event that AmeriCann fails to make capital disbursements required by the project in accordance with the amount and time requirements set forth in the Working Capital Draw Schedule and Construction Budget attached hereto as Exhibit No. 6, any provisions in this Annex No. 1 and any provisions in the Loan Agreement, that are not by their nature provisions for repayment of a loan in a loan contract shall become void (but the Lease Contract will continue in full force and effect, without Turnover Rent or Performance Fee). All loan disbursements made as of the date that the additional contract terms become void shall be repayable to AmeriCann under their same repayment terms and conditions. Any Accrued Consulting Fees shall be converted to loans payable under the same terms and conditions as other disbursements under this Annex No. 1 and the Loan Agreement. The Security Agreement shall stay in effect regarding existing disbursements, Accrued Consulting Fees, and any other accrued fees and costs. Should this clause 11.2 become applicable, WGP shall have the right to raise capital to complete the project in the event that AmeriCann fails to make required capital disbursements, and AmeriCann must subordinate its rights under the Security Agreement to any new source of financing by WGP.

 

 
7

 

 

11.3     The parties hereby jointly acknowledge that all time frames for payout of the capital disbursements required by the Working Capital Draw Schedule and Construction Budget in Exhibit No. 6 are approximate as of the date this Annex No. 1 is signed and the deadlines for payouts under the Working Capital Draw Schedule and Construction Budget being Exhibit No. 6 shall therefore be subject to a thirty (30) day grace period. Furthermore, it may occur that certain capital disbursements are paid out in amounts greater than required by the Working Capital Draw Schedule and Construction Budget being Exhibit No. 6 and in such case, the overpayment shall be credited to later amounts required to be paid out under the Working Capital Draw Schedule and Construction Budget in Exhibit No. 6. Overpayments shall therefore be cumulative so that the total amount of overpayments may be credited to any subsequent payout specified in the Working Capital Schedule and Construction Budget in Exhibit No. 6.

 

11.4     AmeriCann will deliver for WGP’s use as the tenant, a completed facility for the cultivation and processing of cannabis and cannabis-related products. AmeriCann will not provide any cannabis seeds, cuttings or any other cannabis material. AmeriCann does not cultivate, process, or distribute cannabis. WGP, as a licensed cannabis cultivator and processor in the State of Illinois shall be responsible for all cannabis related material. WGP shall be responsible for all operating expenses including staffing, utilities, maintenance, replace of fixtures, and other items.

 

12.

The Lease Contract Between the Parties

 

12.1     The parties agree to prepare and enter into, with all reasonable haste, a lease (“Lease Contract”) for the Facility, with AmeriCann as the landlord and WGP as the tenant, which will take into account the principles specified in this Annex No. 1 and specified in particular in this Section 12.

 

12.2     The term of the Lease Contract shall be for a period of twelve (12) years commencing from the month in which both a final and enforceable occupancy certificate is issued for the Facility, and WGP has been granted approval by the State of Illinois to commence production operations in the Facility. If the first month of the lease does not begin on the first day of the month, rent for that month shall be prorated for the number of days in the month the lease is in force.

 

12.3     The Lease Contract shall be a triple net lease, with base rent amounting to $6.00 per square foot of completed useable area of the Facility per month (“Base Rent”), plus a Performance Fee/Turnover Rent as defined in clause 12.4 below. AmeriCann hereby waives the collection of Base Rent in 2015; payment of Base Rent shall therefore commence on January 1, 2016. Starting with the month in which WGP commences operations in the Facility and for a period of up to three (3) months, WGP shall have the option at its own discretion to add the Base Rent to the working capital loan, and in such case the Base Rent shall become characterized as a Performance Fee.

 

12.4     Turnover rent (or the “Performance Fee” as defined below) shall be equal to 25% of gross monthly sales of all “usable cannabis” as defined by Section 10(w) of the Illinois Compassionate Use of Medical Cannabis Pilot Program Act [410 ILCS 130/10] (the “Act”) and 20% of gross monthly sales of all “medical cannabis infused product” as defined by Section 10(q) of the Act (“Turnover Rent”). Starting with the month in which WGP commences operations in the Facility and for a period of up to three (3) months, WGP shall have the option at its own discretion to add the Turnover Rent to the working capital loan, and in such case the Turnover Rent shall become characterized as a Performance Fee. The Turnover Rent and/or Performance Fee will not apply in the event the provisions of clause 11.2 become applicable as set forth therein.

 

 
8

 

 

12.5     The portion of the Turnover Rent paid on the sale of medical cannabis infused products described in clause 12.4 above shall be paid under an exclusive license within the State of Illinois granted by AmeriCann to WGP of AmeriCann’s Intellectual Property, Brand, Good Manufacturing Practices and Standard Operating Procedures for all extraction and infused products produced from the project. This fee may be adjusted down for individual product lines. WGP acknowledges all IP, Brands, GMPs and SOPs are the property of AmeriCann. AmeriCann is responsible, at AmeriCann’s sole cost and expense, for the design, acquisition and installation of all equipment necessary to engage in the described process as identified in the Working Capital Draw Schedule and Construction Budget.

 

12.6     Once Base Rent and Turnover Rent/Performance Fee become due and payable after the rent-free period granted under 12.3 expires, Base Rent and Turnover Rent may be subject to accrual if WGP’s cash on hand and the balances in all of WGP’s bank accounts do not exceed $250,000 as described in clause 6.3 above. In such case the Base Rent and Turnover Rent/Performance Fee that are subject to accrual shall become principal as part of the New Loan and shall be paid as principal on the New Loan in accordance with clauses 6.3 and 6.4 above.

 

12.7     If WGP is able to make a payment to AmeriCann because cash on hand and the balances in all of WGP’s bank accounts exceed $250,000, but the funds available to WGP to make a payment to AmeriCann do not exceed the amount of Base Rent and Turnover Rent/Performance Fee due for that particular month, the amount available to WGP shall be designated as Base Rent and Turnover Rent/Performance Fee. (Base Rent and Turnover Rent/Performance Fee shall have priority over repayment of the New Loan and payment of Accrued Interest and the Accrued Consulting Fee under clause 6.4.) If the full amount of Base Rent and Turnover Rent/Performance Fee due in any particular month is not paid due to WGP having insufficient funds exceeding $250,000, any amount of Base Rent and Turnover Rent/Performance Fee due but not paid in that particular month shall be subject to accrual as part of the New Loan in accordance with clause 12.6 above.

 

12.8     AmeriCann shall issue an invoice for the Base Rent and the Turnover Rent by the first day of each month (or the first business day after the first day of the month if the first day of the month lands on a non-business day) for the month for which the Base Rent and the Turnover Rent shall be due. Base Rent and any Turnover Rent/Performance Fee due shall be paid by the 10th day of the month for which the payment is due.

 

13.

New Relationship Between the Parties

 

13.1     AmeriCann shall have the right to convert the New Loan into a percentage of gross revenue received from operation of the Facility. The conversion rate shall be one- half of a percent (0.5%) for every five hundred thousand dollars ($500,000) converted into gross revenue. The conversion increments may be prorated for lesser amounts converted.

 

 
9

 

 

13.2     During the term of the Lease Contract, WGP and its members, and their directors, agents, officers, or board members, shall not undertake or be involved in any cannabis cultivation or processing (extraction or infused products) business in the State of Illinois, except in connection with WGP’s operation of the Facility, without the prior written consent of AmeriCann. WGP and AmeriCann may explore other opportunities within the cannabis industry in other states at their own discretion.

 

13.3     AmeriCann shall have the option to designate one or more people to become members in WGP. Collectively, these individuals will pay $110,000 to Cannabis Pharms, LLC, one of the current members of WGP, for a 7.5% stake to share in the               profits and losses in WGP. None of those who become new members in WGP will be members of management, officers, directors or employees of AmeriCann or related as family to anyone who serves in this capacity. New membership in WGP by any person is strictly subject to approval by the State of Illinois as required under the Act. This option must be exercised by written notice from AmeriCann to WGP within 12 months following execution of this Annex No. 1. If written notice is not so provided, or funding is not provided timely, the option lapses automatically. If the option is exercised, said person(s) must execute an appropriate subscription agreement, and a counterpart to the WGP operating agreement.

 

13.4     AmeriCann has granted an option to WGP to acquire stock in AmeriCann. A draft of the Stock Option Agreement constitutes Exhibit No. 9 to this Annex No. 1.

 

14.

Compliance with Law and Regulatory Approval

 

14.1     If any portion of the Loan Agreement, this Annex No. 1, the Promissory Note, or the Security Agreement are determined to be violative of the Act, Illinois law or are inconsistent with the requirements of any regulations issued by the State of Illinois, the parties agree to undertake good faith efforts amend the applicable document(s) to cure any regulatory or legal defects. Under no circumstances other than the express written consent of AmeriCann, however, will WGP be relieved of its obligation to make full and timely payments of all money that has been loaned and distributed to it by AmeriCann, and such monetary distributions shall remain subject to the Security Agreement.

 

14.2     WGP shall have a duty to make the necessary and timely notifications to the State of Illinois as required by Illinois law with respect to obtaining and retaining a license to conduct business in the legal marijuana industry in the State of Illinois. This includes making all timely disclosures and requests for permission as regulated by the Illinois Department of Agriculture and any other state or municipal agencies with regulatory jurisdiction over WGP.

 

15.

Final Provisions

 

15.1     Any provision of the Loan Agreement, not specifically amended by this Annex No. 1 shall remain in force. In case of any conflict or inconsistency between the Loan Agreement, and this Annex No. 1, the provisions of this Annex No. 1 shall prevail.

 

 
10

 

 

15.2     If any provision of this Annex No. 1 is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Annex No. 1 so long as this Annex No. 1 as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

IN WITNESS WHEREOF, AmeriCann and WGP have caused their respective signature page to this Annex No. 1 to be duly executed as of the date first written above.

 

 

AMERICANN, INC.

 

 

By: /s/ Timothy Keogh                           

Name: Timothy Keogh

Title:     President

 

 

 

WELLNESS GROUP PHARMS, LLC

 

 

By: /s/ Paul Montex                                 

Name: Paul Montes 

Title:    Manager

 

 

 

 

 

AmeriCann Annex to Wellness Loan Agree. 1-31-17

 

 
11

 

 

Exhibit 1

Loan Agreement

 

 

 

 

 
12

 

 

Exhibit 2

Operating Permit

 

 

 

 

 
13

 

 

Exhibit 3

Aspen American Insurance Company Bond Contract

 

 

 

 

 
14

 

 

Exhibit 4

Commercial Promissory Note For Drawdown No. 1

 

 

 

 

 
15

 

 

COMMERCIAL PROMISSORY NOTE

 

February 22, 2015

$600,000

 

1.     Amount; Obligation to Pay; Interest Rate. FOR VALUE RECEIVED, Wellness Group Pharms, LLC, an Illinois limited liability company (the "Maker") promises to pay to the order of AmeriCann, Inc. (the "Payee") the principal sum of SIX HUNDRED THOUSAND DOLLARS ($600,000) (the “Principal”), with “Interest” on the unpaid principal balance as set forth below. Maker warrants that the loan evidenced by this Note is for commercial, investment, or business purposes only.

 

2.     Loan Agreement. This Promissory Note (the “Note”) is drawn upon the Loan Agreement first entered into by Maker and Payee September 21, 2014 (the “Loan Agreement”) and its Annex No. 1 (the “Annex”). This Note incorporates by reference the terms of the Annex. If there are any conflicting terms in the Annex, the terms of this Note shall prevail.

 

3.     Maturity Date. Principal of this Promissory Note (the “Note”), any amounts of Interest, and any unpaid fees, charges or expenses are due no later than December 31, 2017 or the last day of the Illinois Medical Cannabis Pilot Program, whichever is later (the “Maturity Date”).

 

4.     Interest and Payment.    Interest will accrue on the unpaid Principal balance of this Note at the rate of EIGHTEEN PERCENT (18%). Interest shall accrue using an Actual/365 days counting method. No minimum payments shall be required until the Maker receives revenue from the operation of a cultivation center for medicinal cannabis located in Anna, IL. Once payment of Principal and Interest becomes due, the amount of the monthly installments shall be calculated by adding the Principal and accrued interest and dividing by the number of calendar months existing between the month in which WGP first received revenue from operation of the Facility, inclusive, and the Maturity Date, inclusive. Notwithstanding the foregoing, all amounts of the principal balance, plus any remaining accrued Interest and fees, charges and expenses will be paid in full at the Maturity Date. All obligations owing hereunder may be prepaid in whole or in part by Maker without penalty.

 

5.     Additional Payments. The payment provisions in this Note are specific to Drawdown No. 1, as that term is defined in the Annex. The minimum monthly payments defined in this Note are in addition to the monthly payments for Accrued Consulting Fees referenced in Sections 6 and 7 of the Annex and to any monthly payments for additional drawdowns of the loan amount defined in Section 1 of the Annex.

 

6.     Security. This Note is secured by a “Security Agreement” of even date by and between Maker and Payee covering business assets located in the State of Illinois as more particularly described therein (collectively, with any other document requested by Payee, the “Loan Documents”). The occurrence of any Event of Default under this Note will constitute an Event of Default under the Loan Documents.

 

 
1

 

 

7.     Default and Acceleration. Any one or more of the following events or conditions shall if not cured after five (5) days from receipt of written notice (30 days for non-payment events or conditions) constitute a default hereunder: (i) Maker's failure to timely pay any amount due hereunder; (ii) default or failure by Maker to perform any covenant, condition, or obligation of Maker under this Note; (iii) default or failure by Maker to perform any covenant, condition, or obligation of Maker under the terms of the Loan Documents; or (iv) the institution by Maker of proceedings to be adjudicated as bankrupt, insolvent, or in receivership, or the consent by it to institution of bankruptcy, insolvency, or receivership proceedings against it, or the filing by it of a petition or answer or consent seeking reorganization or release under the federal Bankruptcy Code or state receivership laws or any other applicable federal or state law, or the consent by it to the filing of any such petition or the appointment of a receiver, liquidator, assignee, trustee or other similar official for Maker. If any such default occurs, Payee may then or at any time thereafter, without further notice (except as may be required by law), and at its option, accelerate maturity and cause the entire unpaid principal balance of this Note, with interest, fees and charges accrued hereon, and all obligations in all instruments securing or collateral to it, to become immediately due and payable. If Payee waives Payee's right to accelerate maturity as a result of a default hereunder, either one or more times or repeatedly, Payee shall not be deemed to have waived the right to require strict compliance with the terms of this Note thereafter.

 

8.     Interest After Default, Acceleration or Maturity. Should default be made in payment of any of the indebtedness evidenced hereby after the entire principal amount hereof shall have become due and payable, whether by acceleration, at maturity or otherwise, the entire unpaid balance of said principal sum shall bear interest, while such default continues both before and after judgment, at twenty-five percent (25%) per annum on the unpaid principal balance until paid, calculated on a 365-day year; provided, however, that the interest payable under this section shall in no way exceed the maximum interest rate allowed by law.

 

9.     Application of Payments. All sums paid hereon shall be applied first to the payment of accrued interest due on the unpaid principal balance, then to unpaid principal and any remainder to unpaid fees, charges and expenses.

 

10.     Attorneys’ Fees and Expenses. In the event that Payee of this Note brings suit hereon, or employs an attorney or incurs expenses after an Event of Default to compel payment of this Note or any portion of the indebtedness evidenced hereby, or to cure any defaults under this Note, whether through suit, probate, insolvency, reorganization, receivership, bankruptcy or any other legal or informal proceeding, the Maker and all endorsers, guarantors and sureties agree additionally to pay all reasonable attorneys’ fees, court costs and other reasonable expenses thereby incurred by Payee or other Payee of this Note.

 

 
2

 

 

11.     Waiver; Offset Rights. Except as expressly set forth in this Note or as may be required by law, Maker and all endorsers, guarantors, sureties and accommodation parties of this Note, both before and after maturity, hereby expressly (i) waive all protest, notice of protest, demand for payment, presentment for payment, notice of intention to accelerate maturity, notice of acceleration of maturity, notice of dishonor, bringing of suit, and diligence in taking any action to collect any amounts called for hereunder and in the handling of property, rights or collateral at any time existing in connection herewith; (ii) consent to and waive notice of any one or more renewal, extension or modification of this Note by Payee, whether made to or in favor of the Maker or any other person or persons, regardless whether such renewal, extension or modification modifies the terms, interest rate or time for payment of the Note and regardless of the length of term of the renewal, extension or modification; (iii) consent to and waive notice of any substitution, exchange or release of any security by Payee now or hereafter given for this Note; (iv) consent to and waive notice of the release by Payee of any party primarily or secondarily liable hereon; (v) consent to and waive notice of any other indulgences by Payee, none of which shall otherwise affect the liability of any of said parties for the indebtedness evidenced by this Note; (vi) agree that it will not be necessary for Payee, to enforce payment of this Note, first to institute suit against or to exhaust Payee's remedies against Maker or any other party liable hereunder, or to proceed against any other security for this Note; and (vii) grant to Payee a security interest in any and all funds now or hereafter on deposit with Payee to the credit or account of Maker or any endorsers, guarantors, sureties and accommodation parties hereof, as additional security for the payment of this Note; in the event of default hereunder, Payee shall have the unconditional contractual right to retain such funds and apply or offset such funds to the payment of amounts owing hereunder, and shall also have a common law lien against such funds.

 

12.     Definitions; Applicable Law. The terms "Maker" and "Payee" and other nouns and pronouns include the singular and/or the plural, as appropriate. The terms "Maker" and "Payee" also include their respective heirs, personal representatives, successors and assigns. The term "Payee" includes subsequent Payees of this Note. This Note shall be governed by and construed in accordance with the laws of the State of Illinois.

THIS NOTE REPRESENTS THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. ORAL AGREEMENTS OR ORAL COMMITMENTS TO FORBEAR FROM ENFORCING PAYMENT OF A DEBT ARE NOT ENFORCEABLE UNDER ILLINOIS LAW.

IN WITNESS WHEREOF, Maker has executed this Note effective as of the date first set forth above.

 

 

MAKER:

WELLNESS GROUP PHARMS, LLC

 

 

 

 

 

 

 

 

 

 

By:

/s/ Paul Montes

 

 

 

Paul Montes, Manager

 

 

 

 

 

 

 

 

AmeriCann Commercial Prom Note $600K Wellness 2-2-17

 

 
3

 

 

Exhibit 5

Security Agreement

 

 

 

 

 

 

 

 

SECURITY AGREEMENT

 

 

This SECURITY AGREEMENT dated February 22, 2015 is made by and between Wellness Group Pharms, LLC ("Grantor") and AmeriCann, Inc. ("Secured Party").

 

For value received, and to secure both the payment of the Indebtedness and the performance of the obligations owed to Secured Party, Grantor grants to Secured Party a security interest in the Collateral, in accordance with the definitions and terms set forth below.

 

1.             Definitions.

 

a)     Indebtedness. "Indebtedness" means all amounts now or hereafter owed by Grantor to Secured Party pursuant to the Commercial Promissory Note of even date (the “Note”), the Loan Agreement of September 21, 2014, and its Annex No. 1 of even date (the “Loan Agreement”). Indebtedness shall include Accrued Consulting Fees, as that term is used in Sections 6 and 7 of Annex No. 1 to the Loan Agreement. Indebtedness shall also include any additional promissory notes issued pursuant to further drawdowns on the Loan Agreement.

 

b)     Collateral. The "Collateral" means:

 

i)     Personal Property. All of Grantor's right, title and interest, now owned or hereafter acquired, and all other owned or hereinafter personal property owned by Grantor, and all added, substituted or replacement personal property, and all equipment, furnishings, accessions, accessories, specifications, and improvements therefore or thereto.

 

ii)     General Intangibles, Accounts and Other Rights to Payment. All of Grantor's right, title and interest, now owned or hereafter acquired, of whatever nature and however evidenced, in and to the following: (i) all accounts; (ii) all rights arising under contracts (including, without limitation notes receivable); (iii) all chattel paper; (iv) all general intangibles evidencing or comprising a right to receive payment; (v) all documents of title, receipts, drafts, checks, acceptances, bonds, notes, or other negotiable and non-negotiable instruments, documents, bills of exchange, stocks, securities, deposits, certificates of deposit, or other writings evidencing or comprising a monetary obligation to Grantor or any of them; (vi) all federal, state, county or city tax refunds of whatever nature; and (vii) all rights to receive the payment of money or other consideration, including, but not limited to, all such right, title and interest that arises from the sale, lease, exchange or other disposition of inventory or the furnishing of services.

 

iii)     Real Property. All of Grantor's right, title and interest, now owned or hereafter acquired, of whatever nature and however evidenced, in and to any real property now or hereinafter owned by Grantor. Such a grant shall also include, without limitation, all of Grantor’s right as landlord or tenant in and to all existing or future leases and tenancies regarding such real property as set forth herein, whether written or oral or any duration, including all renewals and extensions thereof and all rents, deposits and other amounts received or receivable thereunder, as well as all facilities, fixtures, machinery, apparatus, installations, goods, equipment, inventory, and other properties of whatsoever nature, now or hereinafter located in or used or procured for use in connection with the real property as set forth herein, together with all contracts, agreements, licenses, permits, plans, specifications, drawings, surveys, entitlements, engineering reports and other work products related to the real property. To further Secured Party’s rights under this Section, Grantor and Secured Party agree to supplement this Section by executing an independent separate mortgage or first deed of trust against any real property hereafter acquired by Grantor until the Indebtedness has been satisfied.

 

 
1

 

 

iv)     Insurance. All insurances, including: (i) all insurances now or hereafter in effect to any Collateral including, without limitation, personal property, liability and all other insurances; (ii) all claims and all returns of premiums and assessments that are not immediately applied to premiums and assessments that accrue from time to time, and all other sums or claims for sums due or to become due under the foregoing insurances; (iii) all policies of life insurance; and (iv) all right, title, and interest in, to, or under the foregoing.

 

v)     Deposits and Documents. All of Grantor’s right, title, and interest in and to books, correspondence, credit files, records, invoices, and other documents, including without limitation all documents (electronic or otherwise) in the possession or control of Grantor; and all balances, credits, deposits, deposit accounts or monies of or in the name of Grantor.

 

vi)     Investment Property. All of Grantor’s right, title and interest in investment property, including without limitation, all stocks, bonds, debentures, notes, bills, certificates, options, rights, shares, or other securities now or hereafter owned or acquired, all dividends or distributions in respect thereof and all brokerage or commodities accounts.

 

vii)     Instruments and Letter of Credit Rights. All of Grantor’s right, title, and interest in and to (i) promissory notes, checks, drafts, bills of exchange, and other instruments; and (ii) letter of credit rights.

 

viii)     Proceeds and Products. All proceeds of any and all of the foregoing Collateral and, to the extent not otherwise included, all payments under insurance whether or not Secured Party is a loss payee thereof, or any indemnity, warranty or guaranty, payable by reason of loss, damage, or otherwise, with respect to any of the foregoing Collateral.

 

2.     Obligations of Grantor. Grantor represents and warrants as follows:

 

a)     Perfection of Security Interest. Grantor agrees to execute financing statements and to take whatever other action is requested by Secured Party to perfect and continue Secured Party's perfected security interest in the Collateral. Grantor hereby appoints Secured Party as Grantor's attorney-in-fact for the purpose of executing any documents necessary to perfect or continue the perfected security interest granted herein. Secured Party may at any time, and without further authorization from Grantor, file copies of this Security Agreement as a financing statement. Grantor will reimburse Secured Party for all expenses of perfecting or continuing this security interest.

 

 
2

 

 

b)     Removal of Collateral. Grantor warrants that the Collateral is located in locations that are approved by Secured Party in writing. Grantor will not remove any of the Collateral from their present locations without the prior written consent of Secured Party, except for allowable sales of inventory as set forth in Section 2(c), below.

 

c)     Transactions Involving Collateral. Grantor may sell or otherwise transfer the Collateral in its ordinary course of business. Grantor will not otherwise transfer or pledge, mortgage, encumber or otherwise permit the Collateral to be subject to any future lien, security interest, or charge, other than the security interest provided for herein, without the prior written consent of Secured Party, which consent Secured Party may withhold in its sole discretion.

 

d)     Title. Grantor warrants that it holds marketable title to the Collateral, subject to no other security interests other than that existing as of the date of this Agreement. Grantor will defend Secured Party's rights in the Collateral against claims and demands by any and all persons.

 

e)     Compliance with Laws. Grantor warrants that its use of the Collateral complies, and in the future will comply, with all existing Illinois laws, ordinances, and regulations of any governmental authorities.

 

f)     Use. Grantor will keep the Collateral in as good, working condition, except for ordinary wear and tear. Grantor will use commercially reasonable efforts to not permit damage to or destruction of the Collateral or to any part thereof.

 

g)     Transfer of Instruments, Etc. If Grantor shall become entitled to receive or shall receive, in connection with any of its securities, any: (i) stock certificate, including without limitation any certificate representing a stock dividend or in connection with any increase or reduction of capital, reclassification, merger, consolidation, sale of assets, combination of shares, stock split, spin-off, split-off or split-up; (ii) option, warrant, or right, whether as an addition to or in substitution or in exchange for any of its securities, or otherwise; (iii) dividend or distribution payable in property, including securities issued by any issuer other than the issuer of any of its securities; or (iv) dividends or distributions of any sort; then Grantor shall accept the same as Secured Party’s agent, in trust for Secured Party, and shall deliver them forthwith to Secured Party in the exact form received, with, as applicable, Grantor’s endorsement when necessary, or appropriate stock powers duly executed, to be held by Secured Party, subject to the terms hereof, as part of the Collateral. This Agreement does not grant Secured Party power to control the voting or disposition of the securities prior to the occurrence of an Event of Default.

 

 
3

 

 

h)     Taxes, Assessments and Liens. Grantor will pay when due all taxes, assessments, and liens upon the Collateral, its use or operation. Grantor may withhold any such payment or may elect to contest any lien if and so long as: (i) borrower is in good faith conducting appropriate proceedings to contest the obligation to pay; (ii) Grantor's use of and Secured Party's interest in the Collateral are not jeopardized; and (iii) Grantor deposits with Secured Party cash, a sufficient surety bond, or other security satisfactory to Secured Party in an amount adequate to provide for the discharge of the lien plus any interest, costs, attorneys' fees or other charges that could accrue as a result of foreclosure or sale. In any contest, Grantor must defend itself and Secured Party and must satisfy any final adverse judgment before enforcement of such judgment may be obtained against the Collateral. Grantor must cause Secured Party to be named as an additional obligee under any surety bond furnished in the contest proceedings.

 

i)     Compliance with Governmental Requirements. Grantor will comply promptly with all laws, ordinances and regulations of the State of Illinois applicable to the use of the Collateral.

 

j)     Maintenance of Insurance. Grantor will procure and maintain policies of insurance on the Collateral as Grantor deems reasonably necessary and prudent.

 

k)     Application of Insurance Proceeds. Grantor must promptly notify Secured Party of any loss or damage to the Collateral or any portion thereof having a fair market value in excess of the applicable insurance deductible. Secured Party may make proof of loss if Grantor fails to do so within fifteen (15) days of the casualty. All proceeds of any insurance on the Collateral will be applied in the same manner as the payment of principal due and owing under the terms of the Note.

 

3.     Grantor's Right to Possession. Until an Event of Default occurs and continues beyond the time permitted for cure under the Note or the Loan Agreement, Grantor may have possession of the tangible personal property, any real property, and beneficial use of all of the Collateral and may use it in any lawful manner not inconsistent with this Security Agreement, the Loan Agreement, or the Note.

 

4.     Expenditures by Secured Party. If not discharged or paid by Grantor when due, or if not provided for in a good faith contest as required by Section 2(h), above, Secured Party may discharge taxes, liens, security interests, or other encumbrances at any time levied or placed on the Collateral, may pay for insurance on the Collateral, and may pay for maintenance and preservation of the Collateral. All such payments will become a part of the Indebtedness secured hereby, payable on demand, with interest from date of expenditure until repaid at the Default Rate under the notes then outstanding as set forth in the Note. Such right will be in addition to any other rights or remedies to which Secured Party may be entitled on account of default.

 

 
4

 

 

5.     Events of Default. If any of the following events occur ("Events of Default"), Grantor will be in default under this Agreement, and Secured Party will be entitled to exercise any remedies described in Section 6 below:

 

a)     Any of the Indebtedness is not paid when due, and failure to pay is not cured within 5 days after receipt of written notice from Secured Party to Grantor; or

 

b)     Grantor fails to comply with any term, obligation, covenant or condition contained herein or in the Loan Agreement or Note, the Secured Party has notified Grantor in writing of the failure to comply, and Grantor has failed to cure the failure to comply within the applicable cure period set forth in the Note or the Loan Agreement; or

 

c)     Any warranty, representation, or statement made or furnished to Secured Party by or on behalf of Grantor proves to have been false in any material respect when made or furnished or becomes false during the term hereof.

 

6.     Rights of Secured Party.

 

a)     Rights Prior to Default or Thereafter. Secured Party and its designated representatives or agents may at all times examine and inspect the Collateral, wherever located. Prior to the occurrence of an Event of Default, Grantor will have a license to collect all rents and profits from the use or operation of the Collateral.

 

b)     Rights Upon Default or Thereafter. Upon the occurrence of an Event of Default, Secured Party may exercise any one or more of the following rights and remedies in addition to any other rights or remedies that may be available at law, in equity, or otherwise:

 

i)     Secured Party may declare the entire Indebtedness immediately due and payable.

 

ii)     Secured Party may require Grantor to deliver to Secured Party all or any portion of the Collateral and any and all certificates of title and other documents relating thereto. Secured Party may require Grantor to assemble the Collateral and make it available to Secured Party at a place to be designated by Secured Party. Secured Party also will have full power to enter upon the property of Grantor to take possession of and remove the Collateral.

 

iii)     Secured Party will have full power to sell, lease, transfer, or otherwise deal with the Collateral or proceeds thereof in its own name or that of Grantor. Secured Party may sell the Collateral at public auction. Unless the Collateral threatens to decline rapidly in value or is of the type customarily sold on a recognized market, Secured Party will give Grantor reasonable notice of the time and place of any public sale or reasonable notice of the time after which any private sale or any other intended disposition thereof is to be made. The requirements of reasonable notice of any sale will be conclusively met if such notice is mailed by registered or certified mail, postage prepaid, to the address of Grantor stated in this Agreement at least ten (10) days before the time of the sale or intended disposition. Grantor will be liable for expenses of retaking, holding, preparing for sale, selling, and all other expenses of Security Party in preserving, maintaining or enforcing its rights hereunder, and the same will be secured hereby.

 

 
5

 

 

iv)     Secured Party may have a receiver appointed as a matter of right. The receiver may be an employee of Secured Party and may serve without bond. All reasonable fees of the receiver and his or her attorney must be paid by Grantor on demand and secured hereby.

 

v)     Secured Party may revoke Grantor's right to collect the rents and revenues from the Collateral, and may, either itself or through a receiver, collect the same. To facilitate collection, Secured Party may notify any third-party account holder of Grantor to pay directly to Secured Party, and Grantor will not take any action to adversely affect direct payment from third-party account holder to Secured Party.

 

vi)     Secured Party may seek to obtain a judgment for any deficiency remaining in the Indebtedness due to Secured Party after application of all amounts received from the exercise of the rights provided in this Section. Grantor will be liable for a deficiency even if the underlying transaction is a sale of accounts or chattel paper.

 

vii)     In addition to the foregoing, Secured Party will have and may exercise any or all of the rights and remedies as set forth in the Loan Documents or of a secured creditor under the provisions of the Uniform Commercial Code, at law, in equity, or otherwise.

 

7.     Waiver. Secured Party will not be deemed to have waived any rights hereunder or under the Note or the Loan Agreement unless such waiver is in writing and signed by Secured Party. No delay or omission on the part of Secured Party in exercising any right will operate as a waiver of such right or any other right. No consent or waiver, express or implied, by any party to or of any breach or default by the other in the performance by the other of its obligations hereunder will be deemed or construed to be consent to or waiver of any other breach or default in the performance by such other party of the same or any other obligations hereunder.

 

8.     Remedies Cumulative. All of Secured Party's rights and remedies, whether evidenced hereby, by any other document, or by law, will be cumulative and may be exercised singularly or concurrently. Election by Secured Party to pursue any remedy will not exclude pursuit of any other remedy, and an election to make expenditures or take action to perform an obligation of Grantor under this Agreement after Grantor's failure to perform will not affect Secured Party's right to declare a default and exercise its remedies under Section 6 hereof or under any term set forth in the Note or the Loan Agreement.

 

9.     Successors and Assigns. This Security Agreement will be binding upon and inure to the benefit of the parties, their heirs, successors, and assigns.

 

10.     Notices and Correspondence. All notices, requests, demands or other communications to or upon the respective parties hereto must be in writing and will be deemed to have been given or made three (3) days after the same is placed in the United States mail to their respective addresses given below, or, in the case of email, when receipt is confirmed by the receiving party.

 

 
6

 

 

TO SECURED PARTY:

 

AmeriCann, Inc.

3200 Brighton Boulevard, Unit 114

Denver, CO 80211

Attention: Timothy Keogh

E-mail: tim@americann-inc.com

 

TO GRANTOR:

 

Wellness Group Pharms, LLC

1411 West Peterson Avenue

Suite 102

Park Ridge, IL 60068

Attention: Paul Montes, Manager

E-mail: montespaul@comcast.net

 

 

11.     Litigation Expenses. In any controversy, claim or dispute arising out of, or relating to, this Agreement, the prevailing party will be entitled to and awarded, in addition to any other relief, attorneys’ fees and litigation costs.

 

12.     Choice of Law. This Agreement will be governed by and construed in accordance with the laws of the State of Illinois.

 

13.     Arbitration.     Any controversy or claim arising out of or relating to this contract, or the breach thereof, shall be settled by arbitration in Chicago, Illinois administered by the American Arbitration Association in accordance with its Commercial Arbitration Rules, and judgment on the award rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof.

 

14.     Savings Provision. Invalidity, unenforceability, or invalidation of any one or more of the provisions of this Agreement for any reason will in no way affect any other provisions hereof, which other provisions will remain in full force and effect.

 

ORAL AGREEMENTS OR ORAL COMMITMENTS TO LOAN MONEY, EXTEND CREDIT OR TO FORBEAR FROM ENFORCING REPAYMENT OF A DEBT ARE NOT ENFORCEABLE UNDER ILLINOIS LAW.

 

 

Signatures on Following Page

 

 
7

 

 

IN WITNESS WHEREOF, Grantor has executed this instrument as of the day and year first above written.

 

 

 

GRANTOR:

 

WELLNESS GROUP PHARMS, LLC

  SECURED PARTY:

 

AMERICANN, INC.

 
           
           
 

 

 

 

 

 

By:

/s/ Paul Montes

 

By:

/s/ Timothy Keogh

 

 

Paul Montes, Manager

 

 

Timothy Keogh, President

 

     

 

 

 

AmeriCann Security Agree. Wellness 2-2-17

 

 
8

 

 

Exhibit 6

Working Capital Draw Schedule for the New Loan and Construction Budget

 

 

 

 

 

 

 

 

Exhibit 7

Land Acquisition Contract

 

 

 

 

 

 
 

 

 

Exhibit 8

Construction Contract

 

 

 

 

 
 

 

 

Exhibit No. 9

Stock Option Agreement

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

AmeriCann Annex to Wellness Loan Agree. 1-31-17

 

EX-10.3 9 ex10-3.htm EXHIBIT 10.3 ex3-2.htm

 

 

 

 

 

 

EXHIBIT 10.3

 

 

 

 

 

 

 
 

 

  

AMERICANN, INC.

 

LOAN MODIFICATION AGREEMENT

 

The parties agree as follows:

 

1.     As of July 14, 2016 AmeriCann, Inc. owed Strategic Capital Partners, LLC (“SCP”) $2,431,646.

 

2.     SCP agrees to convert $500,000 of the amount owed into 400,000 shares of the restricted common stock of AmeriCann.

 

3.     In connection with the conversion, AmeriCann will issue SCP warrants to purchase 800,000 shares of AmeriCann’s common stock, exercisable at a price of $1.50 per share, and warrants to purchase an additional 800,000 shares of AmeriCann’s common stock, exercisable at a price of $3.00 per share. The warrants will be in the forms attached to this Agreement.

 

4.     The remaining $1,931,646 will be converted into two notes in the forms attached to this Agreement.

 

DATED THIS 14th day of July, 2016.

 

 

 

AMERICANN, INC.

 

 

 

 

 

 

 

 

 

 

By:

/s/ Timothy Keogh

 

 

 

Timothy Keogh, Chief Executive Officer

 

 

 

 

 

 

 

 

 

STRATEGIC CAPITAL PARTNERS, LLC

 

 

 

 

 

 

 

 

 

 

By:

/s/ Benjamin J. Barton

 

 

 

Benjamin J. Barton, Managing Member

 

 

 

 

 

 

AmeriCann Loan Modification Agree. With Strategic 7-14-16

 

 
 

 

 

AMERICANN, INC.

 

WARRANT

 

 

This is to certify that, FOR VALUE RECEIVED, Strategic Capital Partners, LLC, or registered assigns (“Holder”) is the holder of 800,000 Warrants of AmeriCann, Inc. (the “Company”). Each Warrant allows the holder to purchase one share of the Company’s Common Stock at a price of $1.50 per share at any time on or before June 30, 2020. The number of shares of Common Stock to be received upon the exercise of this Warrant, and the price to be paid for a share of Common Stock, may be adjusted from time to time as hereinafter set forth. The shares of Common Stock deliverable upon such exercise, as may be adjusted from time to time, are hereinafter sometimes referred to as “Warrant Stock”, and the exercise price of a share of Common Stock in effect at any time, and as may be adjusted from time to time, is hereinafter sometimes referred to as the "Exercise Price."

 

Nothwithstanding the above, this Warrant will expire 45 days after written notice to the holder that the average closing price of the Company’s common stock was at least $3.00 for twenty consecutive trading days and the average daily volume of trades of the Company’s common stock during the twenty trading days was at least 100,000 shares, provided a registration statement is in effect with respect to the shares issuable upn the exercise of this Warrant.

 

(a) Exercise of Warrant. This Warrant may be exercised in whole or in part at any time or from time to time but not later than 5.00 P.M., Mountain time, June 30, 2020 (the “Expiration Date”). If June 30, 2020 is a day on which banking institutions are authorized by law to close, then this Warrant may be exercised on the next succeeding day which shall not be such a day, by presentation and surrender of this Warrant to the Company or at the office of its stock transfer agent, if any, with the Purchase Form annexed hereto duly executed and accompanied by payment of the Exercise Price for the number of Shares of Warrant Stock specified in such form, together with all Federal and state taxes applicable upon such exercise.

 

If this Warrant should be exercised in part only, the Company, upon surrender of this Warrant for cancellation, shall execute and shall deliver a new Warrant evidencing the right of the Holder to purchase the balance of the Shares of Warrant Stock purchaseable hereunder. Upon receipt by the Company of this Warrant at the office or the agency of the Company, in proper form for exercise, the Holder shall be deemed to be the Holder of record of the Shares of Warrant Stock issuable upon such exercise, notwithstanding that the stock transfer books of the Company shall then be closed or that certificates representing such Shares of Warrant Stock shall not then be actually delivered to the Holder.

 

(b) Reservation of Shares of Warrant Stock. The Company hereby agrees that, at all times, there shall be reserved for issuance and/or delivery upon exercise of this Warrant such number of shares of its Common Stock as shall be required for issuance or delivery upon exercise of this Warrant.

 

 
1

 

 

(c) Fractional Shares. No fractional Shares of Warrant Stock or scrip representing fractional Shares of Warrant Stock shall be issued upon the exercise of this Warrant. With respect to any fraction of a Share of Warrant Stock called for upon any exercise hereof, the Company shall pay to the Holder an amount in cash equal to such fraction multiplied by the current market value of such fractional share determined as follows:

 

(i)     If the Company's Common Stock is publicly traded, the average daily closing prices for 30 consecutive trading days immediately preceding the date of exercise of this Warrant. The closing price for each day shall be the last sale price regular-way or, in case no such sale takes place on such date, the average of the closing bid and asked prices regular-way, on the principal national securities exchange in which the Company's Common Stock is listed or admitted to trading, or if it is not listed or admitted to trading on any national securities exchange, the last sale price of such Common Stock on the consolidated transaction reporting system of the Financial Institution Regulatory Authority (“FINRA”), if such last sale information is reported on such system, or if not so reported, the average of the closing bid and asked prices of such Common Stock on the National Association of Securities Dealers Automatic Quotation system ("NASDAQ"), or any comparable system, or if the Common Stock is not listed on NASDAQ, or a comparable system, the average of the closing bid and asked prices as furnished by two members of the NASD selected from time to time by the Company for that purpose.

 

(ii)     If the Company's Common Stock is not publicly traded, the current value shall be an amount, not less than the book value, determined in such reasonable manner as may be prescribed by the Board of Directors of the Company, such determination to be final and binding on the Holder.

 

(d)     Exchange, Assignment or Loss of Warrant. This Warrant is exchangeable, without expense, at the option of the Holder, upon presentation and surrender hereof to the Company or at the office of its stock transfer agent, if any, for other Warrants of different denominations entitling the Holder thereof to purchase in the aggregate the same number of Shares of Warrant Stock purchasable hereunder. This Warrant may not be sold, hypothecated, assigned, or transferred prior to the date this Warrant is first exercisable. Any assignment shall be made subject to the provisions of Section (j) by surrender of this Warrant to the Company or at the office of its stock transfer agent, if any, with the Assignment Form annexed hereto duly executed and with funds sufficient to pay any transfer tax; whereupon, the Company, without charge, shall execute and shall deliver a new Warrant in the name of the assignee named in such instrument of assignment and this Warrant shall promptly be cancelled.

 

This Warrant may be divided or may be combined with other Warrants which carry the same rights upon presentation hereof at the office of the Company or at the office of its stock transfer agent, if any, together with a written notice specifying the names and the denominations in which new Warrants are to be issued and signed by the Holder hereof. The term "Warrant" as used herein includes any Warrants issued in substitution for or replacement of this Warrant or into which this Warrant may be divided or exchanged. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction, or mutilation of this Warrant, and (in the case of loss, theft, or destruction) of reasonably satisfactory indemnification, and upon surrender and cancellation of this Warrant, if mutilated, the Company will execute and will deliver a new Warrant of like tenor and date. Any such new Warrant executed and delivered shall constitute an additional contractual obligation on the part of the Company, whether or not this Warrant so lost, stolen, destroyed or mutilated shall be at any time enforceable by anyone.

 

 
2

 

 

(e)     Rights of the Holder. The Holder, by virtue hereof, shall not be entitled to any rights of a stockholder in the Company, either at law or in equity, and the rights of the Holder are limited to those expressed in the Warrant and are not enforceable against the Company except to the extent set forth herein.

 

(f)     Anti-Dilution Provisions.

 

(i) Adjustment of Price. Anything in this Section (f) to the contrary notwithstanding, if the Company shall issue, at any time, Common Stock or convertible securities by way of dividend, forward stock split or other distribution on any stock of the Company or subdivide or combine the outstanding shares of Stock, the Exercise Price shall be proportionately decreased in the case of such issuance, forward stock split, or distribution (on the day following the date fixed for determining shareholders entitled to receive such additional shares) or proportionately increased in the case of such combination (on the date that such combination shall become effective), provided, however, should the Company cancel or fail to make such dividend or other distribution or other issuance, the Exercise Price shall be forthwith adjusted to the price which would have prevailed prior to the Company setting such record date.

 

(ii) No Adjustment for Small Amounts. Anything in this Section to the contrary notwithstanding, the Company shall not be required to give effect to any adjustment in the Exercise Price unless and until the net effect of one or more adjustments, determined as above provided, shall have required a change of the Exercise Price by at least one cent, but when the cumulative net effect of more than one adjustment so determined shall be to change the actual Exercise Price by at least one cent, such change in the Exercise Price shall thereupon be given effect.

 

(iii) Number of Shares Adjusted. Upon any adjustment of the Exercise Price, the Holder of this Warrant shall thereafter (until another such adjustment) be entitled to purchase, at the new Exercise Price, the number of Warrant Stock, calculated to the nearest full shares, obtained by multiplying the number of shares of Stock initially issuable upon exercise of this Warrant by the Exercise Price in effect on the date hereof and dividing the product so obtained by the new Exercise Price.

 

(g)          Officer's Certificate. Whenever the Exercise Price shall be adjusted as required by the provisions of Section (f) hereof, the Company shall forthwith file with its Secretary or an Assistant Secretary at its principal office, and with its stock transfer agent, if any, an Officer's Certificate showing the adjusted Exercise Price, determined as herein provided, and setting forth in reasonable detail the facts requiring such adjustment. Each such Officer's Certificate shall be made available at all reasonable times for inspection by the Holder; and the Company, after each such adjustment, shall forthwith deliver a copy of such certificate to the Holder. Such certificate shall be conclusive as to the correctness of such adjustment.

 

(h)     Notices to Warrant Holders. So long as this Warrant shall be outstanding and unexercised (i) if the Company shall pay any dividend or shall make any distribution upon the Common Stock or (ii) if the Company shall offer to the holders for subscription or purchase by them any shares of stock of any class or any other rights or (iii) if any capital reorganization of the Company; reclassification of the capital stock of the Company; consolidation or merger of the Company with or into another corporation; sale, lease or transfer of all or substantially all of the property and assets of the Company to another corporation; or voluntary or involuntary dissolution, liquidation, or winding up of the Company shall be effected, then, in any such case, the Company shall cause to be delivered to the Holder, at least ten (l0) days prior to the date specified in (x) or (y) below, as the case may be, a notice containing a brief description of the proposed action and stating the date on which (x) a record is to be taken for the purpose of such dividend, distribution, or rights, or (y) such reclassification, reorganization, consolidation, merger, conveyance, lease, dissolution, liquidation, or winding up is to take place and the date, if any, is to be fixed, as of which the holders of record shall be entitled to exchange their Shares for securities or other property deliverable upon such reclassification, reorganization, consolidation, merger, conveyance, dissolution, liquidation, or winding up.

 

 
3

 

 

(i)     Reclassification, Reorganization or Merger. In case of any reclassification, or capital reorganization (other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of an issuance of Common Stock by way of dividend or other distribution or of a subdivision or combination), or in case of any consolidation or merger of the Company with or into another corporation (other than a merger with a subsidiary, in which merger the Company is the continuing corporation and which does not result in any reclassification, or capital reorganization) or in case of any sale or conveyance to another corporation of the property of the Company as an entirety or substantially as an entirety, the Company shall cause effective provision to be made so that the Holder shall have the right thereafter, by exercising this Warrant, to purchase the kind and amount of shares of Stock and other securities and property receivable upon such reclassification; capital reorganization; or other consolidation, merger, sale, or conveyance as may be issued or payable with respect to or in exchange for the number of Shares of the Company theretofore purchasable upon the exercise of this Warrant had such recapitalization; capital reorganization; or other consolidation, merger, sale or conveyance not taken place. Any such provisions shall include provision for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Warrant. The foregoing provisions of this Section (i) shall similarly apply to successive reclassifications; capital reorganizations; and to successive consolidations, mergers, sales, or conveyances.

 

In the event that in any such capital reorganization or reclassification, consolidation, merger, sale or conveyance, additional shares shall be issued in exchange, conversion, substitution or payment, in whole or in part, for a security of the Company other than Stock, any such issue shall be treated as an issue of Stock covered by the provisions of subsection (f) hereof with the amount of the consideration received upon the issue thereof being determined by the Board of Directors of the Company, such determination to be final and binding on the Holder.

 

(j)     Transfer to Comply with the Securities Act of l933.

 

(i)     This Warrant or the Warrant Stock or any other security issued or issuable upon exercise of this Warrant may not be sold, transferred, or otherwise disposed of except to a person who, in the opinion of counsel for the Company, is a person to whom this Warrant or such Warrant Stock may legally be transferred pursuant to Section (d) hereof without registration and without the delivery of a current Prospectus under the Act with respect thereto and then only against receipt of an agreement of such person to comply with the provisions of this Section (k) with respect to any resale or other disposition of such securities.

 

 
4

 

  

(ii)     The Company may cause the following legend or one similar thereto to be set forth on each certificate representing Warrant Stock or any other security issued or issuable upon exercise of this Warrant not theretofore distributed to the public or sold to underwriters for distribution to the public pursuant to Section (j) hereof, unless counsel for the Company is of the opinion as to any such certificate that such legend is unnecessary:

 

The shares represented by this Certificate have not been registered under the Securities Act of l933 (the "Act") and are "restricted securities" as that term is defined in Rule 144 under the Act. The shares may not be offered for sale, sold, or otherwise transferred except pursuant to an effective registration statement under the Act or pursuant to an exemption from registration under the Act, the availability of which is to be established to the satisfaction of the Company.

 

(iii)     Notwithstanding the above, the Company has agreed to file a registration statement covering the Warrant Stock.

 

(k)     Applicable Law. This Warrant shall be governed by and construed in accordance with the laws of Delaware.

 

 

 

AMERICAN, INC.

 

 

 

 

 

 

 

 

 

 

By:

/s/ Timothy Keogh

 

 

 

Timothy Keogh, Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

AmeriCann Warrant Strategic $1.50 7-14-16

 

 
5

 

 

 

PURCHASE FORM

 

                        Dated            .

 

The undersigned hereby irrevocable elects to exercise the within Warrant to the extent of purchasing         Shares of Warrant Stock and hereby makes payment of $____________ in payment of the actual exercise price thereof.

 

                             

 

 

INSTRUCTIONS FOR REGISTRATION OF STOCK

 

 

 

 

Name                                                                                       

                  (Please typewrite or print in block letters)

 

Address                                                                   

 

                                                                                  

 

Signature                                                                            

 

 

ASSIGNMENT FORM

 

 

FOR VALUE RECEIVED,                                                     

 

hereby sell, assigns, and transfers unto:

 

Name:                                                                                              

                     (Please typewrite or print in block letters)

 

Address:                                                                               

 

the right to purchase the Common Stock represented by this Warrant to the extent of              shares as to which such right is exercisable and does hereby irrevocably constitute and appoint                    attorney, to transfer the same on the books of the Company with full power of substitution in the premises.

 

Signature                                                 

 

Dated:                      .

 

AmeriCann Warrant Strategic $1.50 7-14-16

 

 
6

 

 

AMERICANN, INC.

 

WARRANT

 

 

This is to certify that, FOR VALUE RECEIVED, Strategic Capital Partners, LLC, or registered assigns (“Holder”) is the holder of 800,000 Warrants of AmeriCann, Inc. (the “Company”). Each Warrant allows the holder to purchase one share of the Company’s Common Stock at a price of $3.00 per share at any time on or before June 30, 2020. The number of shares of Common Stock to be received upon the exercise of this Warrant, and the price to be paid for a share of Common Stock, may be adjusted from time to time as hereinafter set forth. The shares of Common Stock deliverable upon such exercise, as may be adjusted from time to time, are hereinafter sometimes referred to as “Warrant Stock”, and the exercise price of a share of Common Stock in effect at any time, and as may be adjusted from time to time, is hereinafter sometimes referred to as the "Exercise Price."

 

Nothwithstanding the above, this Warrant will expire 45 days after written notice to the holder that the average closing price of the Company’s common stock was at least $4.80 for twenty consecutive trading days and the average daily volume of trades of the Company’s common stock during the twenty trading days was at least 100,000 shares, provided a registration statement is in effect with respect to the shares issuable upn the exercise of this Warrant.

 

(a) Exercise of Warrant. This Warrant may be exercised in whole or in part at any time or from time to time but not later than 5.00 P.M., Mountain time, June 30, 2020 (the “Expiration Date”). If June 30, 2020 is a day on which banking institutions are authorized by law to close, then this Warrant may be exercised on the next succeeding day which shall not be such a day, by presentation and surrender of this Warrant to the Company or at the office of its stock transfer agent, if any, with the Purchase Form annexed hereto duly executed and accompanied by payment of the Exercise Price for the number of Shares of Warrant Stock specified in such form, together with all Federal and state taxes applicable upon such exercise.

 

If this Warrant should be exercised in part only, the Company, upon surrender of this Warrant for cancellation, shall execute and shall deliver a new Warrant evidencing the right of the Holder to purchase the balance of the Shares of Warrant Stock purchaseable hereunder. Upon receipt by the Company of this Warrant at the office or the agency of the Company, in proper form for exercise, the Holder shall be deemed to be the Holder of record of the Shares of Warrant Stock issuable upon such exercise, notwithstanding that the stock transfer books of the Company shall then be closed or that certificates representing such Shares of Warrant Stock shall not then be actually delivered to the Holder.

 

(b) Reservation of Shares of Warrant Stock. The Company hereby agrees that, at all times, there shall be reserved for issuance and/or delivery upon exercise of this Warrant such number of shares of its Common Stock as shall be required for issuance or delivery upon exercise of this Warrant.

 

 
1

 

 

(c) Fractional Shares. No fractional Shares of Warrant Stock or scrip representing fractional Shares of Warrant Stock shall be issued upon the exercise of this Warrant. With respect to any fraction of a Share of Warrant Stock called for upon any exercise hereof, the Company shall pay to the Holder an amount in cash equal to such fraction multiplied by the current market value of such fractional share determined as follows:

 

(i)     If the Company's Common Stock is publicly traded, the average daily closing prices for 30 consecutive trading days immediately preceding the date of exercise of this Warrant. The closing price for each day shall be the last sale price regular-way or, in case no such sale takes place on such date, the average of the closing bid and asked prices regular-way, on the principal national securities exchange in which the Company's Common Stock is listed or admitted to trading, or if it is not listed or admitted to trading on any national securities exchange, the last sale price of such Common Stock on the consolidated transaction reporting system of the Financial Institution Regulatory Authority (“FINRA”), if such last sale information is reported on such system, or if not so reported, the average of the closing bid and asked prices of such Common Stock on the National Association of Securities Dealers Automatic Quotation system ("NASDAQ"), or any comparable system, or if the Common Stock is not listed on NASDAQ, or a comparable system, the average of the closing bid and asked prices as furnished by two members of the NASD selected from time to time by the Company for that purpose.

 

(ii)     If the Company's Common Stock is not publicly traded, the current value shall be an amount, not less than the book value, determined in such reasonable manner as may be prescribed by the Board of Directors of the Company, such determination to be final and binding on the Holder.

 

(d)     Exchange, Assignment or Loss of Warrant. This Warrant is exchangeable, without expense, at the option of the Holder, upon presentation and surrender hereof to the Company or at the office of its stock transfer agent, if any, for other Warrants of different denominations entitling the Holder thereof to purchase in the aggregate the same number of Shares of Warrant Stock purchasable hereunder. This Warrant may not be sold, hypothecated, assigned, or transferred prior to the date this Warrant is first exercisable. Any assignment shall be made subject to the provisions of Section (j) by surrender of this Warrant to the Company or at the office of its stock transfer agent, if any, with the Assignment Form annexed hereto duly executed and with funds sufficient to pay any transfer tax; whereupon, the Company, without charge, shall execute and shall deliver a new Warrant in the name of the assignee named in such instrument of assignment and this Warrant shall promptly be cancelled.

 

This Warrant may be divided or may be combined with other Warrants which carry the same rights upon presentation hereof at the office of the Company or at the office of its stock transfer agent, if any, together with a written notice specifying the names and the denominations in which new Warrants are to be issued and signed by the Holder hereof. The term "Warrant" as used herein includes any Warrants issued in substitution for or replacement of this Warrant or into which this Warrant may be divided or exchanged. Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction, or mutilation of this Warrant, and (in the case of loss, theft, or destruction) of reasonably satisfactory indemnification, and upon surrender and cancellation of this Warrant, if mutilated, the Company will execute and will deliver a new Warrant of like tenor and date. Any such new Warrant executed and delivered shall constitute an additional contractual obligation on the part of the Company, whether or not this Warrant so lost, stolen, destroyed or mutilated shall be at any time enforceable by anyone.

 

 
2

 

 

(e)     Rights of the Holder. The Holder, by virtue hereof, shall not be entitled to any rights of a stockholder in the Company, either at law or in equity, and the rights of the Holder are limited to those expressed in the Warrant and are not enforceable against the Company except to the extent set forth herein.

 

(f)     Anti-Dilution Provisions.

 

(i)      Adjustment of Price. Anything in this Section (f) to the contrary notwithstanding, if the Company shall issue, at any time, Common Stock or convertible securities by way of dividend, forward stock split or other distribution on any stock of the Company or subdivide or combine the outstanding shares of Stock, the Exercise Price shall be proportionately decreased in the case of such issuance, forward stock split, or distribution (on the day following the date fixed for determining shareholders entitled to receive such additional shares) or proportionately increased in the case of such combination (on the date that such combination shall become effective), provided, however, should the Company cancel or fail to make such dividend or other distribution or other issuance, the Exercise Price shall be forthwith adjusted to the price which would have prevailed prior to the Company setting such record date.

 

(ii)      No Adjustment for Small Amounts. Anything in this Section to the contrary notwithstanding, the Company shall not be required to give effect to any adjustment in the Exercise Price unless and until the net effect of one or more adjustments, determined as above provided, shall have required a change of the Exercise Price by at least one cent, but when the cumulative net effect of more than one adjustment so determined shall be to change the actual Exercise Price by at least one cent, such change in the Exercise Price shall thereupon be given effect.

 

(iii)      Number of Shares Adjusted. Upon any adjustment of the Exercise Price, the Holder of this Warrant shall thereafter (until another such adjustment) be entitled to purchase, at the new Exercise Price, the number of Warrant Stock, calculated to the nearest full shares, obtained by multiplying the number of shares of Stock initially issuable upon exercise of this Warrant by the Exercise Price in effect on the date hereof and dividing the product so obtained by the new Exercise Price.

 

(g)     Officer's Certificate. Whenever the Exercise Price shall be adjusted as required by the provisions of Section (f) hereof, the Company shall forthwith file with its Secretary or an Assistant Secretary at its principal office, and with its stock transfer agent, if any, an Officer's Certificate showing the adjusted Exercise Price, determined as herein provided, and setting forth in reasonable detail the facts requiring such adjustment. Each such Officer's Certificate shall be made available at all reasonable times for inspection by the Holder; and the Company, after each such adjustment, shall forthwith deliver a copy of such certificate to the Holder. Such certificate shall be conclusive as to the correctness of such adjustment.

 

(h)     Notices to Warrant Holders. So long as this Warrant shall be outstanding and unexercised (i) if the Company shall pay any dividend or shall make any distribution upon the Common Stock or (ii) if the Company shall offer to the holders for subscription or purchase by them any shares of stock of any class or any other rights or (iii) if any capital reorganization of the Company; reclassification of the capital stock of the Company; consolidation or merger of the Company with or into another corporation; sale, lease or transfer of all or substantially all of the property and assets of the Company to another corporation; or voluntary or involuntary dissolution, liquidation, or winding up of the Company shall be effected, then, in any such case, the Company shall cause to be delivered to the Holder, at least ten (l0) days prior to the date specified in (x) or (y) below, as the case may be, a notice containing a brief description of the proposed action and stating the date on which (x) a record is to be taken for the purpose of such dividend, distribution, or rights, or (y) such reclassification, reorganization, consolidation, merger, conveyance, lease, dissolution, liquidation, or winding up is to take place and the date, if any, is to be fixed, as of which the holders of record shall be entitled to exchange their Shares for securities or other property deliverable upon such reclassification, reorganization, consolidation, merger, conveyance, dissolution, liquidation, or winding up.

 

 
3

 

 

(i)     Reclassification, Reorganization or Merger. In case of any reclassification, or capital reorganization (other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of an issuance of Common Stock by way of dividend or other distribution or of a subdivision or combination), or in case of any consolidation or merger of the Company with or into another corporation (other than a merger with a subsidiary, in which merger the Company is the continuing corporation and which does not result in any reclassification, or capital reorganization) or in case of any sale or conveyance to another corporation of the property of the Company as an entirety or substantially as an entirety, the Company shall cause effective provision to be made so that the Holder shall have the right thereafter, by exercising this Warrant, to purchase the kind and amount of shares of Stock and other securities and property receivable upon such reclassification; capital reorganization; or other consolidation, merger, sale, or conveyance as may be issued or payable with respect to or in exchange for the number of Shares of the Company theretofore purchasable upon the exercise of this Warrant had such recapitalization; capital reorganization; or other consolidation, merger, sale or conveyance not taken place. Any such provisions shall include provision for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Warrant. The foregoing provisions of this Section (i) shall similarly apply to successive reclassifications; capital reorganizations; and to successive consolidations, mergers, sales, or conveyances.

 

In the event that in any such capital reorganization or reclassification, consolidation, merger, sale or conveyance, additional shares shall be issued in exchange, conversion, substitution or payment, in whole or in part, for a security of the Company other than Stock, any such issue shall be treated as an issue of Stock covered by the provisions of subsection (f) hereof with the amount of the consideration received upon the issue thereof being determined by the Board of Directors of the Company, such determination to be final and binding on the Holder.

 

(j)     Transfer to Comply with the Securities Act of l933.

 

(i)     This Warrant or the Warrant Stock or any other security issued or issuable upon exercise of this Warrant may not be sold, transferred, or otherwise disposed of except to a person who, in the opinion of counsel for the Company, is a person to whom this Warrant or such Warrant Stock may legally be transferred pursuant to Section (d) hereof without registration and without the delivery of a current Prospectus under the Act with respect thereto and then only against receipt of an agreement of such person to comply with the provisions of this Section (k) with respect to any resale or other disposition of such securities.

 

 
4

 

  

(ii)     The Company may cause the following legend or one similar thereto to be set forth on each certificate representing Warrant Stock or any other security issued or issuable upon exercise of this Warrant not theretofore distributed to the public or sold to underwriters for distribution to the public pursuant to Section (j) hereof, unless counsel for the Company is of the opinion as to any such certificate that such legend is unnecessary:

 

The shares represented by this Certificate have not been registered under the Securities Act of l933 (the "Act") and are "restricted securities" as that term is defined in Rule 144 under the Act. The shares may not be offered for sale, sold, or otherwise transferred except pursuant to an effective registration statement under the Act or pursuant to an exemption from registration under the Act, the availability of which is to be established to the satisfaction of the Company.

 

(iii)      Notwithstanding the above, the Company has agreed to file a registration statement covering the Warrant Stock.

 

(k)     Applicable Law. This Warrant shall be governed by and construed in accordance with the laws of Delaware.

 

 

 

AMERICAN, INC.

 

 

 

 

 

 

 

 

 

 

By:

/s/ Timothy Keogh

 

 

 

Timothy Keogh, Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

AmeriCann Warrant Strategic $3.00 7-14-16

 

 
5

 

 

PURCHASE FORM

 

                        Dated            .

 

The undersigned hereby irrevocable elects to exercise the within Warrant to the extent of purchasing         Shares of Warrant Stock and hereby makes payment of $____________ in payment of the actual exercise price thereof.

 

                              

 

INSTRUCTIONS FOR REGISTRATION OF STOCK

 

 

 

Name                                                                                       

                  (Please typewrite or print in block letters)

 

Address                                                                   

 

                                                                                   

 

Signature                                                                            

 

 

ASSIGNMENT FORM

 

FOR VALUE RECEIVED,                                                        

 

hereby sell, assigns, and transfers unto:

 

Name:                                                                                                 

                     (Please typewrite or print in block letters)

 

Address:                                                                     

 

the right to purchase the Common Stock represented by this Warrant to the extent of              shares as to which such right is exercisable and does hereby irrevocably constitute and appoint                    attorney, to transfer the same on the books of the Company with full power of substitution in the premises.

 

Signature                                                 

 

Dated:                      .

 

 

AmeriCann Warrant Strategic $3.00 7-14-16

 

 
6

 

 

AMERICANN, INC.

CONVERTIBLE PROMISSORY NOTE

$1,000,000

 

 

FOR VALUE RECEIVED, AmeriCann, Inc., a Delaware corporation, and its successors and assigns, (the "Company") promises to pay to the order of Strategic Capital Partners, LLC, (the "Holder"), the principal sum of $1,000,000 in lawful money of the United States of America, together with interest on so much of the principal balance thereof as is from time to time outstanding at the rate hereinafter provided, and payable as hereinafter provided.

 

1.     Interest Rate. The unpaid balance of this Note shall bear interest at the rate of 9.5% per annum, simple interest. Interest shall be calculated on a 365-day year and the actual number of days in each month.

 

2.     Payment/Maturity Date. Interest will be payable quarterly, with the first interest payment due on September 30, 2016. Interest payable on September 30, 2016 will accrue from the date the Company accepts the Holder’s subscription. Interest will only be payable on Notes which are outstanding on an interest payment date. The total outstanding principal balance hereof, together with all accrued and unpaid interest, will be due on December 31, 2019.

 

3.     Conversion.

 

(a)     The Holder shall have the option to convert all or any part of the principal amount of this Note, together with all accrued interest thereon in accordance with the provisions of and upon satisfaction of the conditions contained in this Note, into fully paid and non-assessable shares of the Company’s common stock as is determined by dividing that portion of the outstanding principal balance and accrued interest under this Note as of such date that the Holder elects to convert by the Conversion Price. The initial Conversion Price will be $1.25.

 

(b)     No fractional shares of common stock shall be issued upon conversion of this Note, and in lieu thereof the number of shares of common stock to be issued upon each conversion shall be rounded up to the nearest whole number of shares of common stock.

 

(c)     The Holder’s conversion right set forth in this Section may be exercised at any time and from time to time but prior to payment in full of the principal and accrued interest on this Note.

 

(d)     The Holder may exercise the right to convert all or any portion of this Note only by delivery of a properly completed conversion notice on a Business Day to the Company’s principal executive offices. Such conversion shall be deemed to have been made immediately prior to the close of business on the Business Day of such delivery of the conversion notice (the “Conversion Date”), and the Holder shall be treated for all purposes as the record holder of the shares of common stock into which this Note is converted as of such date. For purposes of this Note, a Business Day is any day the Federal Reserve Bank is open.

 

 
1

 

  

(e)     As promptly as practicable after the Conversion Date, the Company at its expense shall issue and deliver to the Holder of this Note a stock certificate or certificates representing the number of shares of common stock into which this Note has been converted.

 

(f)     Upon the full conversion of this Note the Company shall be forever released from all of its obligations and liabilities under this Note.

 

(g)     Holder acknowledges that the shares of common stock issuable upon conversion of this note are “restricted securities,” as such term is defined under the Securities Act. Holder agrees that Holder will not attempt to pledge, transfer, convey or otherwise dispose of such shares except in a transaction that is the subject of either: (i) an effective registration statement under the Securities Act and any applicable state securities laws; or (ii) an opinion of counsel rendered by legal counsel satisfactory to the Company, which opinion of counsel shall be satisfactory to the Company, to the effect that such registration is not required. The Company may rely on such an opinion of Holder's counsel in making such determination. Holder consents to the placement of a legend on the shares of common stock issuable upon the exercise of this Note stating that the shares represented by the certificate have not been registered under the Securities Act and setting forth or referring to the restrictions on transferability and sale thereof.

 

(h)     If at any time there shall be a stock split of this Company’s common stock, the Conversion Price will be proportionately adjusted.

 

(i)     If the common stock to be issued on conversion of this Note shall be changed into any other class or classes of stock, whether by capital reorganization, reclassification, or otherwise, the holder of this Note shall, upon its conversion be entitled to receive, in lieu of the common stock which the Holder would have become entitled to receive but for such change, a number of shares of such other class or classes of stock that would have been subject to receipt by the Holder if it had exercised its rights of conversion immediately before such changes.

 

(j)     If at any time there shall be a capital reorganization of the Company’s common stock (other than of shares as provided for elsewhere in this Section 3) or merger of the Company into another corporation, or the sale of the Company’s properties and assets as, or substantially as, an entirety to any other person, then, as a part of such reorganization, merger or sale, lawful provision shall be made so that the Holder of this Note will be entitled to receive the number of shares of stock or other securities or property from the successor corporation resulting from such merger to which the Holder would have been entitled as a result of such capital reorganization, merger or sale if this Note had been converted immediately before such capital reorganization, merger or sale.

 

 
2

 

 

(k)     The Company will not, by amendment of its Articles of Incorporation or through any reorganization, recapitalization, transfer of assets, merger, dissolution, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all the provisions of this Section and in the taking of all such action as may be necessary or appropriate in order to protect the conversion rights of the holder of this Note against impairment.

 

(l)     Upon the occurrence of each adjustment or readjustment pursuant to any provision hereof, the Company at its expense shall promptly compute such adjustment or readjustment in accordance with the terms hereof and prepare and furnish to the Holder of this Note a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment is based.

 

(m)     Notwithstanding the above, if the average closing price of the Company’s common stock is at least $2.50 for twenty consecutive trading days, and the average daily volume of trades of the Company’s common stock during the twenty trading days is at least 100,000 shares, the Company may, within 10 days of the end of such twenty day period, notify the Holder that the right to convert this Note into shares of the Company’s common stock will end 45 days after the date of the notice.

 

4.     Reservation of Shares. At all times while this Note shall be convertible into shares of common stock, the Company shall reserve and keep available out of its authorized but unissued shares of common stock solely for the purpose of effecting the conversion of this Note such number of its shares of such common stock as shall from time to time be sufficient to effect the conversion of this Note in full. In the event that the number of authorized but unissued shares of such common stock shall not be sufficient to effect the conversion of the entire outstanding principal amount of this Note, then in addition to such other remedies as shall be available to the Holder, the Company shall take such corporate action as may be necessary to increase its authorized but unissued shares of such common stock to such number of shares as shall be sufficient for such purpose.

 

5.     Prepayment. The Company may repay this Note at any time prior to maturity without the consent of the Holder.

 

6.     Security. This Note is unsecured.

 

7.     Default. At the option of Holder, the unpaid principal balance of this Note and all accrued interest thereon shall become immediately due, payable, and collectible, without notice or demand, upon the occurrence at any time of any of the following events, each of which shall be deemed to be an event of default hereunder.

 

(a)     The Company fails to make any payment of interest or principal on the date on which such payment becomes due and payable under this Note, the Notes, or the notes referred to in Section 6(b) and the failure to pay continues uncured for a period of ten business days after the date on which notice of the failure to pay is first given to the Company

 

 
3

 

 

(b)     The Company breaches any representation, warranty or covenant or defaults in the timely performance of any other obligation in its agreements with the Note holders and the breach or default continues uncured for a period of ten trading days after the date on which notice of the breach or default is first given to the Company, or ten trading days after the Company becomes, or should have become aware of such breach or default;

 

(c)     The Company files for protection from its creditors under the federal bankruptcy code or a third party files an involuntary bankruptcy petition against the Company and the involuntary petition is not dismissed within 30 days.

 

8.     Default, Interest and Attorney Fees. Upon declaration of a default hereunder, the balance of the principal remaining unpaid, interest accrued thereon, and all other costs, and fees shall be immediately due and payable and the balance of the principal remaining unpaid will bear interest at 15% per year. In the event of default, the Company agrees to pay all costs of collection including reasonable attorney’s fees.

 

9.     Representations, Warranties and Covenants of the Company. The Company represents, warrants and covenants with the Holder as follows:

 

(a)     Authorization; Enforceability. All action on the part of the Company, necessary for the authorization, execution and delivery of this Note and the performance of all obligations of the Company hereunder has been taken, and this Note constitutes a valid and legally binding obligation of the Company, enforceable in accordance with its terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, and (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies.

 

(b)     Governmental Consents. No consent, approval, qualification, order or authorization of, or filing with, any local, state or federal governmental authority is required on the part of the Company in connection with the Company’s valid execution, delivery or performance of this Note.

 

(c)     No Violation. The execution, delivery and performance by the Company of this Note and the consummation of the obligations contemplated hereby will not result in a violation in any material respect of its Articles of Incorporation or By-Laws, or of any provision of any mortgage, agreement, instrument or contract to which it is a party or by which it is bound or, to the best of its knowledge, of any federal or state judgment, order, writ, decree, statute, rule or regulation applicable to the Company or be in material conflict with or constitute, with or without the passage of time or giving of notice, either a material default under any such provision or an event that results in the creation of any material lien, charge or encumbrance upon any assets of the Company or the suspension, revocation, impairment, forfeiture or nonrenewal of any material permit, license, authorization or approval applicable to the Company, its business or operations, or any of its assets.

 

 
4

 

 

(d)     Covenants. So long as any Note is outstanding the Company will not pay any dividends or other distributions to the holders of any shares of its preferred stock or common stock unless all payments have been made to the Holders on a current basis.

 

10.     Assignment of Note. This Note may not be assigned by the Company. The Note may be assigned by Holder with the express written consent of the Company.

 

11.     Loss of Note. Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Note, and in case of loss, theft or destruction of indemnification in form and substance acceptable to the Company in its reasonable discretion, and upon surrender and cancellation of this Note, if mutilated, the Company shall execute and deliver a new Note of like tenor and date.

 

12.     Non-Waiver. No delay or omission on the part of Holder in exercising any rights or remedy hereunder shall operate as a waiver of such right or remedy or of any other right or remedy under this Note. A waiver on any one or more occasion shall not be construed as a bar to or waiver of any such right and/or remedy on any future occasion.

 

13.     Maximum Interest. In no event whatsoever shall the amount paid, or agreed to be paid, to Holder for the use, forbearance, or retention of the money to be loaned hereunder ("Interest") exceed the maximum amount permissible under applicable law. If the performance or fulfillment of any provision hereof, or any agreement between Company and Holder shall result in Interest exceeding the limit for Interest prescribed by law, then the amount of such Interest shall be reduced to such limit. If, from any circumstance whatsoever, Holder should receive as Interest an amount which would exceed the highest lawful rate, the amount which would be excessive Interest shall be applied to the reduction of the principal balance owing hereunder (or, at the option of Holder, be paid over to Company) and not to the payment of Interest.

 

14.     Purpose of Loan. Company certifies that the loan evidenced by this Note is obtained for business or commercial purposes and that the proceeds thereof will not be used primarily for personal, family, household or agricultural purposes.

 

15.     Waiver of Presentment. Company and the endorsers, sureties, guarantors and all persons who may become liable for all or any part of this obligation shall be jointly and severally liable for such obligation and hereby jointly and severally waive presentment and demand for payment, notice of dishonor, protest and notice of protest, and any and all lack of diligence or delays in collection or enforcement hereof. Said parties consent to any modification or extension of time (whether one or more) of payment hereof, the release of all or any part of the security for the payment hereof, and the release of any party liable for payment of this obligation. Any modification, extension, or release may be without notice to any such party and shall not discharge said party's liability hereunder.

 

 
5

 

 

16.     Governing Law. As an additional consideration for the extension of credit, Company and each endorser, surety, guarantor, and any other person who may become liable for all or any part of this obligation understand and agree that the loan evidenced by this Note will be construed in accordance with the laws of the State of Colorado.

 

17.     Arbitration. Any controversy or claim arising out of, or relating to this Note, or the making, performance, or interpretation thereof, shall be settled by arbitration in Denver, Colorado in accordance with the Commercial Rules of the American Arbitration Association then existing, and judgment on the arbitration award may be entered in any court having jurisdiction over the subject matter of the controversy.

 

18.     Binding Effect. The term "Company" as used herein shall include the original Company of this Note and any party who may subsequently become liable for the payment hereof as an assumer with the consent of the Holder, provided that Holder may, at its option, consider the original Company of this Note alone as Company unless Holder has consented in writing to the substitution of another party as Company.

 

19.     Relationship of Parties. Nothing herein contained shall create or be deemed or construed to create a joint venture or partnership between Company and Holder, Holder is acting hereunder as a lender only.

 

20.     Severability. Invalidation of any of the provisions of this Note or of any paragraph, sentence, clause, phrase, or word herein, or the application thereof in any given circumstance, shall not affect the validity of the remainder of this Note.

 

21.     Amendment. This Note may not be amended, modified, or changed, except only by an instrument in writing signed by both of the parties.

 

22.     Time of the Essence. Time is of the essence for the performance of each and every obligation of Company hereunder.

 

23.     Notices. All notices, consents, approvals, requests, demands and other communications which are required or may be given hereunder shall be in writing and shall be duly given if personally delivered, sent by overnight courier or posted by U.S. registered or certified mail, return receipt requested, postage prepaid and addressed to the other parties at the addresses set forth below.

 

If to the Company:

 

AmeriCann, Inc.

3200 Brighton Blvd., Unit 144

Denver, CO 80216

Attn: President     

 

If to the Holder, at the address as shown on the register maintained by the Company for such purpose.

 

 
6

 

 

The Company or the Holder may change their address for purposes of this Section by giving to the other addressee notice of such new address in conformance with this Section. If the Company receives any notice pursuant to this Note or any other Note of this series, it must, not later than five business days thereafter, dispatch a copy of such notice to the Holder of this Note and to each other Holder of any Note as reflected in the current Note Register.

 

 

IN WITNESS WHEREOF, the undersigned has executed this Note as of the 14th day of July, 2016.

 

 

AMERICANN, INC.

 

 

 

 

 

 

 

 

 

 

By:

/s/ Timothy Keogh

 

 

 

Timothy Keogh, President

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

AmeriCann Conv. Prom. Note Strategic $1,000,000 7-14-16

 

 

 
7

 

 

NOTICE OF CONVERSION

 

 

The undersigned hereby elects to convert the Convertible Note of AmeriCann, Inc., (the “Company”) into shares of the Company’s common stock according to the terms of the Note, as of the date written below.

 

Conversion calculations:

 

Date of Conversion:  

 

 

 

 

Principal Amount of Note to be Converted:  

 

 

 

 

Payment of Interest in Common Stock __Yes _No  

 

 

 

 

                   If yes, $ of Accrued Interest to be converted.  

 

 

 

 

 

 

 

Signature:

 

 

 

 

 

Name (Print):

 

 

 

 

 

Address:

 

 

 

 

     
     

               

 

 

 

 

 

 

 

 

 

 

 

 

 

 

AmeriCann Conv. Prom. Note Strategic $1,000,000 7-14-16

 

 
8

 

  

AMERICANN, INC.

 

ASSIGNMENT OF CONVERTIBLE NOTE

 

(Form of Assignment to be Executed if Note Holder

Desires to Transfer all or part of Convertible Note)

 

 

 

     FOR VALUE RECEIVED,                                                            hereby sells, assigns and transfers to                                                                                                      .

                                                                                                                                     (Please print name and address including zip code)

 

 

 

Please insert social security, federal tax ID number or other identifying number:

 

 

 

 

 

 

Check one:

 

 

the attached Note, or

 

$______ of the principal represented by the attached Note

 

 

 

 

Dated:

 

 

 

 

 

 

Signature

 

 

 

(Signature must conform in all respects
to name of holder as shown on the
face of the Note).

 

 

 

Note:

Any transfer or assignment of the Note is subject to compliance with the restrictions on transfer imposed by the terms of the Note.

 

 

 

 

AmeriCann Conv. Prom. Note Strategic $1,000,000 7-14-16

 

 
9

 

 

AMERICANN, INC.

SECURED CONVERTIBLE PROMISSORY NOTE

$931,640

 

 

FOR VALUE RECEIVED, AmeriCann, Inc., a Delaware corporation, and its successors and assigns, (the "Company") promises to pay to the order of Strategic Capital Partners, LLC, (the "Holder"), the principal sum of $931,640 in lawful money of the United States of America, together with interest on so much of the principal balance thereof as is from time to time outstanding at the rate hereinafter provided, and payable as hereinafter provided.

 

1.     Interest Rate. The unpaid balance of this Note shall bear interest at the rate of 8% per annum, simple interest. Interest shall be calculated on a 365-day year and the actual number of days in each month.

 

2.     Payment/Maturity Date. Interest will be payable quarterly, with the first interest payment due on September 30, 2016. Interest payable on September 30, 2016 will accrue from the date the Company accepts the Holder’s subscription. Interest will only be payable on Notes which are outstanding on an interest payment date. The total outstanding principal balance hereof, together with all accrued and unpaid interest, will be due on December 31, 2019.

 

In addition to the foregoing, any amounts received from Wellness Group Pharms will be applied to the principal amount of the Note.

 

3.     Prepayment. The Company may repay this Note at any time prior to maturity without consent of the Holder.

 

4.     Security.

 

This Note will be secured by

 

 

a second lien on the Company’s property in Denver, Colorado, as well as any improvements constructed and any trade fixtures located on the property, and

 

 

the Company’s claims against Wellness Group Pharms.

 

5.     Default. At the option of Holder, the unpaid principal balance of this Note and all accrued interest thereon shall become immediately due, payable, and collectible, without notice or demand, upon the occurrence at any time of any of the following events, each of which shall be deemed to be an event of default hereunder.

 

(a)     The Company fails to make any payment of interest or principal on the date on which such payment becomes due and payable under this Note, the Notes, or the notes referred to in Section 6(b) and the failure to pay continues uncured for a period of ten business days after the date on which notice of the failure to pay is first given to the Company.

 

 
1

 

 

(b)     The Company breaches any representation, warranty or covenant or defaults in the timely performance of any other obligation in its agreements with the Note holders and the breach or default continues uncured for a period of ten trading days after the date on which notice of the breach or default is first given to the Company, or ten trading days after the Company becomes, or should have become aware of such breach or default;

 

(c)     The Company files for protection from its creditors under the federal bankruptcy code or a third party files an involuntary bankruptcy petition against the Company and the involuntary petition is not dismissed within 30 days.

 

6.     Default, Interest and Attorney Fees. Upon declaration of a default hereunder, the balance of the principal remaining unpaid, interest accrued thereon, and all other costs, and fees shall be immediately due and payable and the balance of the principal remaining unpaid will bear interest at 15% per year. In the event of default, the Company agrees to pay all costs of collection including reasonable attorney’s fees.

 

7.     Representations, Warranties and Covenants of the Company. The Company represents, warrants and covenants with the Holder as follows:

 

(a)     Authorization; Enforceability. All action on the part of the Company, necessary for the authorization, execution and delivery of this Note and the performance of all obligations of the Company hereunder has been taken, and this Note constitutes a valid and legally binding obligation of the Company, enforceable in accordance with its terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, and (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies.

 

(b)     Governmental Consents. No consent, approval, qualification, order or authorization of, or filing with, any local, state or federal governmental authority is required on the part of the Company in connection with the Company’s valid execution, delivery or performance of this Note.

 

(c)     No Violation. The execution, delivery and performance by the Company of this Note and the consummation of the obligations contemplated hereby will not result in a violation in any material respect of its Articles of Incorporation or By-Laws, or of any provision of any mortgage, agreement, instrument or contract to which it is a party or by which it is bound or, to the best of its knowledge, of any federal or state judgment, order, writ, decree, statute, rule or regulation applicable to the Company or be in material conflict with or constitute, with or without the passage of time or giving of notice, either a material default under any such provision or an event that results in the creation of any material lien, charge or encumbrance upon any assets of the Company or the suspension, revocation, impairment, forfeiture or nonrenewal of any material permit, license, authorization or approval applicable to the Company, its business or operations, or any of its assets.

 

 
2

 

 

(d)     Covenants. So long as any Note is outstanding the Company will not pay any dividends or other distributions to the holders of any shares of its preferred stock or common stock unless all payments have been made to the Holders on a current basis.

 

8.     Assignment of Note. This Note may not be assigned by the Company. The Note may be assigned by Holder with the express written consent of the Company.

 

9.     Loss of Note. Upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Note, and in case of loss, theft or destruction of indemnification in form and substance acceptable to the Company in its reasonable discretion, and upon surrender and cancellation of this Note, if mutilated, the Company shall execute and deliver a new Note of like tenor and date.

 

10.     Non-Waiver. No delay or omission on the part of Holder in exercising any rights or remedy hereunder shall operate as a waiver of such right or remedy or of any other right or remedy under this Note. A waiver on any one or more occasion shall not be construed as a bar to or waiver of any such right and/or remedy on any future occasion.

 

11.     Maximum Interest. In no event whatsoever shall the amount paid, or agreed to be paid, to Holder for the use, forbearance, or retention of the money to be loaned hereunder ("Interest") exceed the maximum amount permissible under applicable law. If the performance or fulfillment of any provision hereof, or any agreement between Company and Holder shall result in Interest exceeding the limit for Interest prescribed by law, then the amount of such Interest shall be reduced to such limit. If, from any circumstance whatsoever, Holder should receive as Interest an amount which would exceed the highest lawful rate, the amount which would be excessive Interest shall be applied to the reduction of the principal balance owing hereunder (or, at the option of Holder, be paid over to Company) and not to the payment of Interest.

 

12.     Purpose of Loan. Company certifies that the loan evidenced by this Note is obtained for business or commercial purposes and that the proceeds thereof will not be used primarily for personal, family, household or agricultural purposes.

 

13.     Waiver of Presentment. Company and the endorsers, sureties, guarantors and all persons who may become liable for all or any part of this obligation shall be jointly and severally liable for such obligation and hereby jointly and severally waive presentment and demand for payment, notice of dishonor, protest and notice of protest, and any and all lack of diligence or delays in collection or enforcement hereof. Said parties consent to any modification or extension of time (whether one or more) of payment hereof, the release of all or any part of the security for the payment hereof, and the release of any party liable for payment of this obligation. Any modification, extension, or release may be without notice to any such party and shall not discharge said party's liability hereunder.

 

14.     Governing Law. As an additional consideration for the extension of credit, Company and each endorser, surety, guarantor, and any other person who may become liable for all or any part of this obligation understand and agree that the loan evidenced by this Note will be construed in accordance with the laws of the State of Colorado.

 

 
3

 

 

15.     Arbitration. Any controversy or claim arising out of, or relating to this Note, or the making, performance, or interpretation thereof, shall be settled by arbitration in Denver, Colorado in accordance with the Commercial Rules of the American Arbitration Association then existing, and judgment on the arbitration award may be entered in any court having jurisdiction over the subject matter of the controversy.

 

16.     Binding Effect. The term "Company" as used herein shall include the original Company of this Note and any party who may subsequently become liable for the payment hereof as an assumer with the consent of the Holder, provided that Holder may, at its option, consider the original Company of this Note alone as Company unless Holder has consented in writing to the substitution of another party as Company.

 

17.     Relationship of Parties. Nothing herein contained shall create or be deemed or construed to create a joint venture or partnership between Company and Holder, Holder is acting hereunder as a lender only.

 

18.     Severability. Invalidation of any of the provisions of this Note or of any paragraph, sentence, clause, phrase, or word herein, or the application thereof in any given circumstance, shall not affect the validity of the remainder of this Note.

 

19.     Amendment. This Note may not be amended, modified, or changed, except only by an instrument in writing signed by both of the parties.

 

20.     Time of the Essence. Time is of the essence for the performance of each and every obligation of Company hereunder.

 

21.     Notices. All notices, consents, approvals, requests, demands and other communications which are required or may be given hereunder shall be in writing and shall be duly given if personally delivered, sent by overnight courier or posted by U.S. registered or certified mail, return receipt requested, postage prepaid and addressed to the other parties at the addresses set forth below.

 

If to the Company:

 

AmeriCann, Inc.

3200 Brighton Blvd., Unit 144

Denver, CO 80216

Attn: President     

 

If to the Holder, at the address as shown on the register maintained by the Company for such purpose.

 

 
4

 

 

The Company or the Holder may change their address for purposes of this Section by giving to the other addressee notice of such new address in conformance with this Section. If the Company receives any notice pursuant to this Note or any other Note of this series, it must, not later than five business days thereafter, dispatch a copy of such notice to the Holder of this Note and to each other Holder of any Note as reflected in the current Note Register.

 

 

IN WITNESS WHEREOF, the undersigned has executed this Note as of the 14th day of July, 2016.

 

 

AMERICANN, INC.

 

 

 

 

 

 

 

 

 

 

By:

/s/ Timothy Keogh

 

 

 

Timothy Keogh, President

 

 

 

 

 

 

 

 

 

 

 

 

AmeriCann Secured Conv. Prom. Note Strategic $931,640 7-14-16

 

 
5

 

 

NOTICE OF CONVERSION

 

 

The undersigned hereby elects to convert the Convertible Note of AmeriCann, Inc., (the “Company”) into shares of the Company’s common stock according to the terms of the Note, as of the date written below.

 

Conversion calculations:  

 

Date of Conversion:  

 

 

 

 

Principal Amount of Note to be Converted:  

 

 

 

 

Payment of Interest in Common Stock __Yes _No        

 

 

 

 

                    If yes, $ of Accrued Interest to be converted.  

 

 

 

 

 

 

 

Signature:

 

 

 

 

 

Name (Print): 

 

 

 

 

 

Address:

 

 

 

 

     

             

 

 

 

 

 

 

 

AmeriCann Secured Conv. Prom. Note Strategic $931,640 7-14-16

 

 
6

 

  

AMERICANN, INC.

 

ASSIGNMENT OF CONVERTIBLE NOTE

 

(Form of Assignment to be Executed if Note Holder

Desires to Transfer all or part of Convertible Note)

 

 

 

     FOR VALUE RECEIVED,                                                            hereby sells, assigns and transfers to                                                                                                      .

                                                                                                                                     (Please print name and address including zip code)

 

 

 

 

Please insert social security, federal tax ID number or other identifying number:

 

 

 

 

 

 

Check one:

 

 

the attached Note, or

 

$______ of the principal represented by the attached Note

 

 

 

 

Dated: 

 

 

 

 

 

 

Signature

 

 

 

(Signature must conform in all respects
to name of holder as shown on the
face of the Note).

 

 

 

Note:

Any transfer or assignment of the Note is subject to compliance with the restrictions on transfer imposed by the terms of the Note.

 

 

 

 

 

AmeriCann Secured Conv. Prom. Note Strategic $931,640 7-14-16

 

7 

EX-10.4 10 ex10-4.htm EXHIBIT 10.4 ex3-2.htm

 

 

 

 

EXHIBIT 10.4

 

 

 

 

 

 

 

 
 

 

  

THIRD AMENDMENT TO CONSULTING AGREEMENT

 

THIS THIRD AMENDMENT TO CONSULTING AGREEMENT is entered into effective as of May 1, 2015, by and between Nature’s Own Wellness Center, a Colorado limited liability company, having its usual place of business at 4900 Jackson Street, Denver, Colorado 80216 and 4900 Jackson, LLC a Colorado limited liability company, having its usual place of business at 4900 Jackson Street, Denver, Colorado 80216 (hereinafter collectively referred to as the “Company") and AmeriCann, Inc., a Colorado corporation, with its principal place of business located at 3200 Brighton Blvd., Unit #114, Denver, CO 80216 (hereinafter referred to as the "Consultant") (collectively the “Parties”).

 

WHEREAS the Parties entered into that certain Consulting Agreement effective July 1, 2014, for Consultant to provide services to Company in accordance with the terms and conditions of the Consulting Agreement; and

 

WHEREAS the Parties entered into that certain First Amendment to Consulting Agreement effective August 13, 2014, amending the Consulting Agreement; and

 

WHEREAS the Parties entered into that certain Second Amendment to Consulting Agreement effective January 1, 2015, amending the Consulting Agreement; and

 

WHEREAS, the Parties desire to further amend the Consulting Agreement, as amended, in the manner and to the extent set forth in this Third Amendment to Consulting Agreement.

 

NOW THEREFORE, in consideration of the covenants and obligations contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby amend the Consulting Agreement as follows:

 

1.     Paragraph 3(a) of the Consulting Agreement is amended to reduce the Consulting Fee the Company shall pay Consultant from Ten Thousand Dollars ($10,000.00) monthly to Five Thousand Dollars ($5,000.00) monthly in advance commencing May 1, 2015, and on the first day of each and every month thereafter with the last monthly payment due May 1, 2017 for Services to be performed in the month of May 2017.

 

2.     The Parties consent to the release of Nature’s Own Wellness Center from the Consulting Agreement, as amended, and from all obligations thereunder.

 

3.     In all other respects, the Consulting Agreement, as amended, shall remain unchanged and is hereby ratified and affirmed and in full force and effect.

 

4.     To the extent this Amendment and the Consulting Agreement, as amended, are inconsistent, this Third Amendment shall control.

 

 
 

 

 

IN WITNESS WHEREOF, the Parties have executed this Agreement by their signatures below.

 

COMPANY:

 

NATURE’S OWN WELLNESS CENTER

 

 

By: /s/ Justin Anderson                                 

      Justin Anderson, Manager

 

4900 JACKSON, LLC

 

By: /s/ John Ray                                              

      John Ray, Manager

 

 

CONSULTANT:

AMERICANN, INC.

 

 

By: /s/ Timothy Keogh                                  

       Timothy Keogh, Its President

 

 

 

 

 

AmeriCann 3rd Amend. To Consult Agree Natures Own 2-2-17

 

 
 

 

 

SECOND PROMISSORY NOTE MODIFICATION

AND EXTENSION AGREEMENT

 

May 1, 2015 

 

This Second Promissory Note Modification and Extension Agreement, hereinafter referred to as “Second Extension Agreement,” is entered into as of the date above written, by and between AmeriCann, Inc., a Colorado corporation, 3200 Brighton Blvd., Unit #114, Denver, CO 80216, (“Lender”), and Nature’s Own Wellness Center, a Colorado limited liability company, whose address is 4900 Jackson Street, Denver, Colorado 80216, and 4900 Jackson, LLC, a Colorado limited liability company, whose address is 4900 Jackson Street, Denver, Colorado 80216 (collectively referred to herein as “Borrower”).

 

WHEREAS, Lender and Borrower entered into a Promissory Note dated June 20, 2014, in the original principal amount of One Million Dollars ($1,000,000.00), hereinafter referred to as the “Note” secured by Security Agreements and guaranteed by a personal Guaranty;

 

WHEREAS, Lender and Borrower entered into a Promissory Note Modification and Extension Agreement dated January 1, 2015, to modify and extend the payment and due dates of the Note in accordance with the “NOWC Amortization Schedule” attached thereto as Appendix A;

 

WHEREAS, simultaneously with the execution of this Second Extension Agreement, the parties are executing and have entered into an Agreement to Modify Guaranty substituting Richard Abbott and Anna Lipacheva as “Substitute Guarantors” for Justin Pius Anderson, the original Guarantor, and to release Nature’s Own Wellness Center from its obligations as Borrower and maker of the Note;

 

WHEREAS, simultaneously with the execution of this Second Extension Agreement, Richard Abbott and Anna Lipacheva as “Substitute Guarantors” are executing and have entered into a “Substitute Guaranty” guarantying the obligations under the Note in accordance with the terms of the Substitute Guaranty;

 

WHEREAS, the principal balance of the Note immediately prior to this Second Extension Agreement is $965,000.00 with interest paid current through the date of this Second Extension Agreement; and

 

WHEREAS, Lender and the remaining Borrower 4900 Jackson, LLC, desire to enter into this Modification and Extension Agreement to reduce the interest rate under the Note, to modify the payment schedule and extend the above due dates of the Note, to approve release of Nature’s Own Wellness Center as a Borrower, and to reaffirm the Loan Documents as set forth below.

 

NOW, THEREFORE, in consideration of $10.00 and other good and valuable consideration, the sufficiency of which is hereby acknowledged by the parties, Lender and Borrower hereby agree as follows:

 

 
 

 

 

1.     The interest rate in paragraph one of the Note shall be reduced from 18% per annum to 12% annum effective May 1, 2015.     

 

2.     Lender and Borrower 4900 Jackson, LLC, hereby modify and extend the above referenced payment and due dates of the Note in accordance with the “Amortization Schedule” dated May 1, 2015, attached hereto as Appendix A. Borrower shall timely make the principal and interest payments on the dates and in the amounts set forth in the “Interest” and “Principal” columns on Appendix A. If not sooner paid, the entire unpaid principal balance, together with all accrued interest thereon, shall be due on May 1, 2017.

 

3.     4900 Jackson, LLC, consents to the release of Justin Anderson from his obligations under the Guaranty and of Nature’s Own Wellness Center from its obligations as a maker/Borrower of the Note, and the parties hereto agree that the same are hereby so released.

 

4.     All references in the Security Agreements and Substituted Guaranty to the Note and the indebtedness secured thereby are hereby amended to include without separate description this Second Promissory Note Modification and Extension Agreement.

 

5.     As modified herein, the Note, Security Agreements and Substituted Guaranty shall continue in full force and effect, and Borrower 4900 Jackson, LCC, hereby reaffirms the same, and all other terms and conditions of same shall remain unchanged and in effect.

 

6.     To the extent this Second Promissory Note Modification and Extension Agreement, the Promissory Note Modification and Extension Agreement and the Note are inconsistent, this Second Promissory Note Modification and Extension Agreement shall control.

 

IN WITNESS WHEREOF, the parties have executed and agreed to this Second Promissory Note Modification and Extension Agreement as of the date first set forth above.

 

BORROWER:

 

NATURE’S OWN WELLNESS CENTER

a Colorado limited liability company          

 

 

By: /s/ Justin Anderson                                  

Print Name: Justin Anderson    

Its Manager or Authorized Signatory

 

4900 JACKSON, LLC

a Colorado limited liability company          

 

 

By: /s/ John Ray                                             

Print Name: John Ray    

Its Manager or Authorized Signatory

 

 
 

 

 

GUARANTOR:

 

/s/ Justin P. Anderson                                   

Justin Pius Anderson

 

 

SUBSTITUTE GUARANTORS:

 

/s/ Richard Abbott                                         

Richard Abbott

 

/s/ Anna Lipacheva

Anna Lipacheva

 

 

LENDER:

 

AMERICANN, INC.

 

 

By: /s/ Timothy Keogh                                  

       Timothy Keogh, President

 

 

 

 

 

 

 

 

 

AmeriCann 2nd Prom Note Modification & Exten. Agree 2-2-17

 

 
 

 

  

AGREEMENT TO MODIFY GUARANTY

 

May 1, 2015

 

 

THIS AGREEMENT, is entered into as of the date above written, by and between AmeriCann, Inc., a Colorado corporation, 3200 Brighton Blvd., Unit #114, Denver, Colorado, 80216 (“Lender”), Justin Pius Anderson (“Guarantor”), Nature’s Own Wellness Center, a Colorado limited liability company (“Nature’s Own”), 4900 Jackson, LLC, a Colorado limited liability company (“4900 Jackson”), and Richard Abbott and Anna Lipacheva (the “Substitute Guarantors”).

 

WHEREAS, Guarantor entered into a Guaranty in favor of Lender dated June 20, 2014 (the “Guaranty”), pertaining to a Promissory Note in the original principal amount of One Million Dollars ($1,000,000.00) dated June 20, 2014 (the “Note”); and

 

WHEREAS, Nature’s Own and 4900 Jackson are Borrowers/makers of the Note; and

 

WHEREAS, Substitute Guarantors are willing to extend their personal guaranties of the Note in favor of Lender on the same terms and conditions as are set forth in the Guaranty (the “Substitute Guaranty”); and

 

WHEREAS, Lender is willing to accept the Substitute Guarantors in the place of Guarantor under the terms of the Substitute Guaranty, a copy of which is attached hereto, and will release Guarantor from his obligations under the Guaranty;

 

NOW, THEREFORE, in consideration of $10.00, the mutual promises set forth herein, and other good and valuable consideration, the sufficiency of which is hereby acknowledged by the parties, Lender, Guarantor, Nature’s Own, 4900 Jackson and Substitute Guarantors hereby agree as follows:

 

1.     Lender has reviewed and approved the credit of the Substitute Guarantors. The Substitute Guarantors agree that they will execute the Substitute Guaranty in the form attached hereto simultaneously with the execution of this Agreement to Modify Guaranty.

 

2.     When the Substitute Guarantors have executed the Substitute Guaranty, then Lender agrees that Guarantor is released from his obligations under the Guaranty, and Nature’s Own is released from its obligations as a maker of the Note and from its obligations under that certain Consulting Agreement effective July 1, 2014, as amended, between the parties.

 

3.     The Note continues in full force and effect, and, except as to removing Nature’s Own as a maker, is not modified in any respect by any of the terms of this Agreement.

 

4.     By its signature below, 4900 Jackson consents to the release of Justin Anderson from his obligations under the Guaranty and of Nature’s Own from its obligations as a maker of the Note and its obligations under the Consulting Agreement. 4900 Jackson expressly agrees that it is not being released from any of its obligations to Lender whatsoever and hereby reaffirms its obligations and legal commitments under the Note, under any other related loan documents including the Security Agreements and under the Consulting Agreement.

 

 
 

 

 

IN WITNESS WHEREOF, the parties have executed and agreed to this Agreement as of the date first set forth above.

 

GUARANTOR:

 

/s/ Justin P. Anderson                                   

Justin Pius Anderson

 

NATURE’S OWN:

 

NATURE’S OWN WELLNESS CENTER:

 

By: /s/ Justin Anderson                                

Its Manager                         

 

4900 JACKSON

 

4900 JACKSON, LLC

a Colorado limited liability company          

 

By: /s/ John Ray                                             

Print Name: John Ray

 

SUBSTITUTE GUARANTORS:

 

 

/s/ Richard Abbott                                         

Richard Abbott

 

 

/s/ Anna Lipacheva                                        

Anna Lipacheva

 

 

LENDER:

 

AMERICANN, INC.

 

By: /s/ Timothy Keogh                                                       

      Timothy Keogh, President

 

 

AmeriCann Agree to Modify Guaranty Natures Own 2-2-17

 

 
 

 

 

SUBSTITUTE GUARANTY

 

THIS GUARANTY, made this 1st day of May, 2015, by Richard Abbott and Anna Lipacheva (hereinafter referred to as the "Substitute Guarantor"), to and for the benefit of AmeriCann, Inc., a Colorado corporation, and any successor holder of the Note more particularly referred to below (hereinafter collectively referred to as the "Lender").

 

1.00 RECITALS

 

1.01 Loan. Nature’s Own Wellness Center, a Colorado limited liability company, whose address is 4900 Jackson Street, Denver, Colorado 80216, and 4900 Jackson, LLC, a Colorado limited liability company, whose address is 4900 Jackson Street, Denver, Colorado 80216 (hereinafter collectively referred to as the "Borrower") applied for, and received, a loan from Lender in the principal amount of One Million Dollars ($1,000,000.00) (hereinafter referred to as the "Loan") evidenced by Borrower's Note (hereinafter referred to as the "Note"), dated June 20, 2014, as amended January 1 and May 1, 2015, secured by a two Security Agreements (hereinafter referred to as the "Security Agreement"), dated June 20, 2014 therewith, granting a security interest in Borrower’s licenses, receivables, general intangibles, inventories including all products cultivated, manufactured, prepared or sold, growing plants, any other crops, farm products, furnishings, fixtures, equipment and machinery including lighting, improvements made to the leased premises, and proceeds and products of any of the Borrower’s business.

 

1.02 Inducement for Guaranty. Lender was unwilling to make the Loan unless Justin Pius Anderson guaranteed payment and performance of the Note and Security Agreement. Justin Pius Anderson has now requested that he be released from his obligations under his Guaranty and that Nature’s Own Wellness Center be released from its obligations as a maker of the Note. Lender has agreed to such releases in consideration of Substitute Guarantor simultaneously executing this Substitute Guaranty replacing Mr. Anderson as Guarantor. (From this point forward, the term “Borrower” in this Substituted Guaranty shall mean only 4900 Jackson, LLC).

 

Substitute Guarantor hereby expressly guarantees payment of the Note, as amended, and performance by Borrower of each and every term, covenant, condition and agreement contained therein, and in any amendments thereto, and in the Security Agreements and under any and all other agreements that have been executed or that will be executed by the Borrower to or for the benefit of the Lender in connection with the Loan on the part of Borrower to be kept, observed or performed, including the Consulting Agreement dated effective July 1, 2014, as amended. The Note, Security Agreements and such other agreements are hereinafter collectively referred to as the "Loan Documents." Substituted Guarantor desires to give such guaranty in order to induce Lender to make and maintain the Loan.

 

2.00 GUARANTY, WAIVER AND CONSENTS

 

2.01 Guaranty. Substituted Guarantor unconditionally and absolutely guarantees the due and punctual payment of the principal of the Note, as amended, the interest thereon and any other money due or which may become due under the Loan Documents, and the due and punctual performance and observance by Borrower of any other terms, covenants and conditions of the Loan Documents and of the Consulting Agreement dated effective July 1, 2014, as amended, on the part of the Borrower to be kept, observed or performed, whether according to the present terms thereof, at any earlier or accelerated date or dates as provided therein, or pursuant to any extension of time or to any change or changes in the terms, covenants and conditions thereof (other than an increase in the principal of, or interest on, the Note), now or at any time hereafter made or granted.

 

 
 

 

 

2.02 Waiver and Consents. Substituted Guarantor waives diligence, presentment, protest, notice of dishonor, demand for payment, extension of time for payment, notice of acceptance of this Guaranty, nonpayment at maturity and indulgences and notice of every kind, and consents to any and all forbearances and extensions of the time for payment of the Note or performance under the Loan Documents, and to any and all changes in the terms, covenants and conditions of the Loan Documents hereafter made or granted, and to any and all substitutions, exchanges or releases of all or any part of the collateral therefor. It is the intention hereof that Substituted Guarantor shall remain liable hereunder until the full amount of the principal of the Note, with interest, and any other sums due or to become due under the Loan Documents, shall have been fully paid, and the terms, covenants and conditions of the Loan Documents shall have been fully kept, observed and performed by Borrower notwithstanding any act, omission or thing which might otherwise operate as a legal or equitable discharge of Guarantor.

 

3.00 AGREEMENTS AND COVENANTS OF GUARANTOR

 

3.01 No Subrogation. Substituted Guarantor agrees that it shall have no right of subrogation whatsoever with respect to the Loan Documents, or to original moneys due and unpaid thereon, or any collateral securing the same, unless and until Lender shall have received payment in full of all sums due under the Loan Documents.

 

3.02 Enforcement. This Substituted Guaranty may be enforced by Lender without first resorting to or exhausting any other security or collateral and without first having recourse to the Note or any of the remedies provided by the Loan Documents through foreclosure proceedings or otherwise. Nothing herein contained, however, shall prevent Lender from suing on the Note, or foreclosing the Security Agreements, or from exercising any other rights under the Loan Documents. If such foreclosure or other remedy is availed of, only the net proceeds therefrom, after deduction of all charges and expenses of every kind and nature whatsoever, shall be applied in reduction of the amount due on the Note and/or the other Loan Documents. Lender shall not be required to institute or prosecute proceedings to recover any deficiency as a condition of payment hereunder or enforcement hereof. At any sale of the security or collateral for the indebtedness or any part thereof, whether by foreclosure or otherwise, Lender may at its discretion purchase all or any part of such collateral so sold or offered for sale for its own account and may apply the amount bid therefor against the balance due it pursuant to the terms of the Note and/or the other Loan Documents.

 

3.03 Expenses of Enforcement. In the event this Substituted Guaranty is placed in the hands of an attorney for enforcement, Substituted Guarantor will reimburse Lender for all expenses incurred in connection therewith, including reasonable attorney's fees.

 

 
 

 

 

4.00 MISCELLANEOUS

 

4.01 Successors and Assigns. This Substituted Guaranty shall inure to the benefit and may be enforced by Lender, and any subsequent holder of the Note and/or beneficiary under the Security Agreements and shall be binding upon and enforceable against the legal representatives, heirs and assigns of Substituted Guarantor.

 

4.02 No Alteration of Other Documents. No provision of this Substituted Guaranty shall be construed to alter or amend the Loan Documents, or to relieve Borrower of any duties or obligations under the Loan Documents.

 

4.03 Word Meanings. As used herein the singular shall include the plural, the plural the singular and the use of any gender shall be applicable to all genders.

 

4.04 Joint Obligation. In the event that more than one person or party shall execute this Substituted Guaranty as the Substituted Guarantor herein, this agreement shall bind all persons and parties jointly and severally.

 

4.05 Colorado Law; Venue. This Substituted Guaranty and the terms and provisions hereof shall be governed by and construed according to the laws of the State of Colorado, without regard to principles of conflict of laws. Any suit hereon may be brought and prosecuted in the courts of the City and County of Denver, Colorado.

 

4.06 Remedies Cumulative. Substituted Guarantor hereby agrees with Lender that all rights, remedies and recourses afforded to Lender by reason of this Substituted Guaranty, or otherwise, are separate and cumulative and may be pursued separately, successively or concurrently, as occasion therefor shall occur, and are nonexclusive and shall in no way limit or prejudice any other legal or equitable right, remedy or recourse which Lender may have.

 

4.07 Captions. The captions herein are for reference purposes only.

 

 

WITNESS the execution hereof by the Guarantor.

 

 

SUBSTITUTED GUARANTORS:

 

 

/s/ Richard Abbott                                          

Richard Abbott

 

 

/s/ Anna Lipacheva                                        

Anna Lipacheva

 

AmeriCann Substitute Guaranty 2-2-17

 

EX-10.5 11 ex10-5.htm EXHIBIT 10.5 ex3-2.htm

 

 

 

 

 

 

EXHIBIT 10.5

 

 

 

 

 

 

 
 

 

  

CONSULTING AGREEMENT

 

 

THIS CONSULTING AGREEMENT (the "Agreement") is made and entered into the 7th day of April, 2016 (the "Effective Date") by and between Coastal Compassion, Inc., a Massachusetts non-profit organization with an address at 36 N. Water Street, Unit 2, New Bedford, MA 02740 (hereinafter “Company"), and AmeriCann, Inc., a Delaware corporation with an address at 3200 Brighton Blvd., Unit 114, Denver, CO 80216 (hereinafter "Consultant") (each a “party” and collectively the “parties”).

 

RECITALS

 

WHEREAS, Company and Consultant entered into a Development Agreement dated __________________, 2015, to finance (the “Loan”) and support the construction and operation of a marijuana cultivation, processing, and dispensary facility in Fairhaven, MA (the “Fairhaven Facility”); the Development Agreement is hereby incorporated into this Agreement by reference where relevant and any capitalized terms appearing herein shall have the same meaning of the same terms in the Development Agreement; and,

 

WHEREAS, Company wishes to engage Consultant to provide the services described herein and Consultant agrees to provide the services for the compensation and otherwise in accordance with the terms and conditions contained in this Agreement.

 

NOW THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, accepted and agreed to, Company and Consultant, intending to be legally bound, agree to the terms set forth below.

 

1.     THE SERVICES.

 

Consultant shall provide consulting and support services to Company during preconstruction, construction, preopening, operations and throughout the term of the agreement.

 

(a)     Consultant will make regularly-scheduled visits to the Fairhaven Facility to meet with Company and consultants, assist with implementation of programs and provide relevant support and access to Consultant’s staff, contractors, consultants, advisors and experts.

 

(b)     Company will have access to Consultant’s staff, contractors, consultants, advisors and experts throughout the term of the Agreement by phone, email, and video conference to supplement the regularly-scheduled visits. Company and Consultant agree to identify a mutually acceptable day and time for a weekly or by-weekly conference call.

 

(c)     Company shall have access to Consultant’s facilities throughout the country, where permissible, for training, education and research.

 

(d)     The initial areas of focus for the consulting services (the “Services”) include the following areas which may be expanded and adjusted to meet the needs of the Company during the Term of the Agreement:

 

 
 

 

 

1)     Construction Loan Administration – Consultant will assist Company with reviewing and approving construction budgets, estimates, and systems for monitoring construction costs to streamline construction progress and the administration of the Construction Loan.

 

2)     Working Capital Loan Administration – Consultant will review Company’s operating budgets and forecasts; make recommendations of improved efficiencies in all areas of expenses; provide strategic start-up consultation prior to the commencement of operations and administer the Working Capital Loan.

 

3)     Compliance – During the term of the agreement the Consultant will conduct compliance audits, reviews, and help address deficiencies to protect the license and the Consultant’s investment.

 

4)     Lean Manufacturing – Consultant will conduct audits and inspections of work-flow of the operation and implement lean manufacturing practices to eliminate waste (time, process, labor) within the operation.

 

5)     Marketing Support – Consultant will assist Company with designing and developing a marketing plan that complies with DPH regulations to raise the profile of the Company, educate patients on benefits of medical cannabis, and promote community outreach efforts.

 

6)     Remote Monitoring – Consultant will review the designed and selected environmental controls and security systems to determine remote monitoring capabilities. Consultant will present options to Company for systems to remotely monitor the facility.

 

7)     Infused Product Manufacturing – Consultant will assist Company in designing and developing the infused product offerings designed to treat specific medical conditions outlined by DPH. The infused product offerings will be tailored to the size of production and manufacturing space within the current facility.

 

 

A)

Consultant will assist Company with creation of Good Manufacturing Practices (GMPs) for products within the line.

 

 

B)

Consultant will assist Company with the selection and installation of infused product manufacturing equipment and provide training and Standard Operating Procedures for selected equipment.

 

 

C)

Consultant will assist Company with training and Standard Operation Procedures for selected C02 extraction equipment.

 

 

D)

Consultant may provide Company with the “Cannabis Consumer Advisor Program (C-CAP).” C-CAP is being designed, developed and financed by Consultant to solicit objective feedback from medical cannabis patients to empower Company to improve product offerings and educate patients. An outline of C-CAP is attached to this Agreement as Exhibit 1.

 

 
 

 

 

(e)     Company has budgeted up to forty (40) hours of consulting per month during the Term of the Agreement.

 

(f)     Consultant represents and warrants to Company that it is under no contractual or other restrictions or obligations which are inconsistent with the execution of this Agreement, or which will interfere with the rendering of the Services. Consultant represents and warrants that the execution and performance of this Agreement will not violate any policies or procedures of any other person or entity for which it performs services concurrently with those performed herein. Consultant’s work is not restricted or exclusive to Company and Consultant is not prohibited from providing the same or similar services to competitors of Company.

 

(g)     When rendering the Services, Consultant shall comply, to the best of its knowledge, with all business conduct, regulatory, and health and safety guidelines established by Company and by any governmental authority with respect to Company’s business, including but not limited Massachusetts’ 105 CMR 725.000 et seq.

 

(h)     Consultant agrees that all Services will be rendered by it as an independent contractor and that this Agreement does not create an employer-employee relationship between Company and Consultant or any of Consultant’s employees or agents. Neither Consultant nor any of Consultant’s employees or agents shall have the right to receive any employee benefits from Company including, but not limited to, health and accident insurance, life insurance, sick leave and/or vacation. Consultant agrees to pay all taxes due in respect of the Consulting Fee (as defined in Section 2 herein) and to indemnify Company in the event Company is required to pay any such taxes on behalf of Consultant.

 

(i)     Consultant does not cultivate, harvest, distribute or sell cannabis.

 

2.     CONSULTING FEE.

 

(a)     Beginning on the first (1st) day of the first (1st) Calendar month after Consultant provides any portion of the Loan amount as described in the Development Agreement (“Commencement Date”) and subject to the provisions hereof, Company shall pay Consultant a consulting fee of Ten Thousand Dollars ($10,000.00) per month for the Services provided to Company (the "Consulting Fee").

 

(b)     The Consulting Fee shall initially accrue and be added to the Loan as principal until the first day of the sixth (6th) calendar month after which Company begins sales in the Fairhaven Facility (the “Accrued Consulting Fee”).

 

(c)     The Accrued Consulting Fee shall be paid along with the Loan as specified in Section 3 of Development Agreement and in particular as specified in Sections 3.1 and 3.2 of the Development Agreement.

 

(d)     Company shall have the right, but not the obligation, to commence repayment of the Accrued Consulting Fee at any time.

 

(e)     Beginning with the fifth (5th) calendar month after which Company begins sales at the Fairhaven Facility, Company shall pay the Consulting Fee by the tenth (10th) day of the month for which the Consulting Fee shall be due. Consultant shall issue an invoice for the Consulting Fee by the first (1st) business day of each month for the month for which the Consulting Fee shall be due.

 

 
 

 

 

(f)     Consultant shall be entitled to prompt reimbursement for all pre-approved expenses incurred when rendering the Services, upon submission and approval of written statements and receipts. Company shall make reimbursements to Consultant within fifteen (15) days after Consultant submits its statements and receipts.

 

(g)     Once the Consulting Fee becomes payable on a monthly basis, if the Consulting Fee is not paid by the tenth (10th) day of any month, a late fee of two point five percent (2.5%) shall be added to the Consulting Fee for each such month the payment is late and Consultant may commence collection of the amount due under this Agreement.

 

3.     SECURITY INTEREST.

 

(a)     To secure the payment of the Consulting Fee and the reimbursements under Section 2(f) during the Term, to the extent allowed for under Massachusetts law, Company grants to Consultant a security interest in all of the same collateral described in Section 1(b) of the Security Agreement(s) (“Collateral”) that secures repayment of, among other things, the Commercial Promissory Note(s). The Security Agreement(s) and Commercial Promissory Note(s) are hereby incorporated into this Agreement by reference.

 

(b)     Consultant shall be entitled to file a separate financing statement or any other documents deemed necessary as provided for in the Security Agreement(s) to perfect the security interest herein granted.

 

(c)     Company’s obligations to pay the Consulting Fee for each month and reimbursements under Section 2(f) of this Agreement are separate, distinct and independent obligations of Company from the Commercial Promissory Note(s), and payment of the Commercial Promissory Note(s) does not in any way affect the validity and enforceability of this Agreement nor of the rights of Consultant under the Security Agreement(s) as a secured creditor, which shall continue in full force and effect notwithstanding the Commercial Promissory Note(s) obligations.

 

(d)     Notwithstanding any provision of this Agreement, the Consultant hereby agrees that Consultant’s security interest shall not include the seizure of assets protected by the Humanitarian Medical Use of Marijuana Act, Ch. 369 of the Acts of 2012, i.e. any product containing any amount of marijuana. The Consultant shall not be entitled to a security interest that provides to Consultant inventory of Company that contains any amount of marijuana, in any form, whether flower or infused product. The Consultant hereby forfeits any such remedy. In addition, Consultant hereby understands and agrees that a Certificate of Registration, whether provisional or final, is non-transferrable, and may not be assigned or transferred without prior Department of Public Health approval. Consultant agrees that Company’s Certificate of Registration is not an asset that may be seized by Consultant and is not available as a remedy for Consultant’s default under this or any other Agreement, and hereby expressly waives any such remedy or security interest.

 

 
 

 

 

4.     TERM AND TERMINATION.

 

(a)     This Agreement shall commence on the Effective Date and shall continue for a period of three (3) years or until such time as Company makes the final payment under the Commercial Promissory Note(s), whichever is later (the “Term”).

 

(b)     If Consultant voluntarily ceases rendering the Services, or is unable to render the Services, the Company shall no longer be obligated to pay the Consulting Fee as of such date.

 

(c)     This Agreement may be terminated without cause by Consultant upon not less than thirty (30) days prior written notice by Consultant to Company.

 

(d)     Company shall not have a right to terminate this Agreement except under the following three circumstances:

 

1)     If Consultant has failed to perform the duties and services outlined in Section 1 of this Agreement and failed to cure within thirty (30) days following written notice from Company.

 

2)     If Consultant has failed to fund more than 50% of the Loan through no fault of Company. “Through no fault of Company” shall mean that Company has timely complied with each of the following conditions:

 

 

A)

Provided Consultant copies of all invoices, payments, checks, receipts for expenses and the like for all activities and transactions related to the startup and operations of the business in the Fairhaven Facility;

 

 

B)

Provided Consultant with a Balance Sheet, General Ledger and a Profit and Loss Statement, all current as of the date of submittal;

 

 

C)

Has and continues to diligently complete startup of the business and operates the business in a businesslike manner; and

 

 

D)

Following individual members of Consultant’s teams’ approval as may be required by the Massachusetts’ Department of Public Health, provided Consultant access to the Fairhaven Facility at any time during business hours to inspect the build-out, construction and operations of the business in the Fairhaven Facility.

 

If Company has not timely complied with each of the foregoing conditions A through D, and Consultant does not fund at least 50% of the Loan as described in the “Development Agreement”, the lack of such funding shall be deemed to be through the fault of Company, and Company shall have no right to terminate this Agreement. In that event, this Agreement shall remain in full force and effect and Consultant shall have no obligation to advance additional funds on the Loan.

 

 
 

 

 

3)     If the provisions of this Section 4(b) above apply.

 

(e)     Upon termination under Sections 4(b), 4(c) or 4(d), neither party shall have any further obligations under this Agreement, except for the obligations which by their terms survive this termination as noted in Section 14 herein.

 

(f)     Notwithstanding anything to the contrary contained herein, the termination of this Agreement under any part of this Section 4, or for any other reason, shall have no effect on the independent obligations of Company to Consultant under the Development Agreement, the Commercial Promissory Note(s), and/or the Security Agreement(s)

 

5.     RESTRICTED ACTIVITIES. During the Term and for a period of one (1) year thereafter, Company will not, directly or indirectly:

 

(i)     solicit or request any employee of or consultant to Consultant to leave the employ of or cease consulting for Consultant;

 

(ii)     solicit or request any employee of or consultant to Consultant to join the employ of, or begin consulting for, any individual or entity that researches, develops, markets or sells products that compete with those of Consultant;

 

(iii)     solicit or request any individual or entity that researches, develops, markets or sells products that compete with those of Consultant, to employ or retain as a consultant any employee or consultant of Consultant; or

 

(iv)     Induce or attempt to induce any supplier or vendor of Consultant to terminate or breach any written or oral agreement or understanding with Consultant.

 

6.     WAIVER. Any waiver by Consultant of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any subsequent breach of the same or any other provision hereof. All waivers by Consultant shall be in writing.

 

7.     SEVERABILITY; REFORMATION. In case any one or more of the provisions or parts of a provision contained in this Agreement shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall have no effect on any other provision or part of a provision of this Agreement; and this Agreement shall, to the fullest extent lawful, be reformed and construed as if such invalid or illegal or unenforceable provision, or part of a provision, had never been contained herein, and such provision or part reformed so that it would be valid, legal and enforceable to the maximum extent possible. Without limiting the foregoing, if any provision (or part of provision) contained in this Agreement shall for any reason be held to be excessively broad as to duration, activity or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the fullest extent compatible with then existing applicable law.

 

 
 

 

 

8.     NON-ASSIGNMENT. Company shall not have the right to assign its rights or obligations under this Agreement to a party which assumes Company's obligations hereunder without the prior written consent of Consultant.

 

9.     HEADINGS. Headings and subheadings are for convenience only and shall not be deemed to be a part of this Agreement.

 

10.   AMENDMENTS. This Agreement may be amended or modified, in whole or in part, only by an instrument in writing signed by all parties hereto. Any amendment, consent, decision, waiver or other action to be made, taken or given by Company with respect to the Agreement shall be made, taken or given on behalf of Company only by authority of the Board of Directors.

 

11.   NOTICES. Any notice, consent, request, instruction, approval or other communication required or permitted under this Agreement, or any other document or instrument in connection herewith, shall be in writing and shall be deemed to have been validly given, made or served on the date when personally delivered, or mailed by certified United States mail, return receipt requested, postage prepaid and properly addressed, to the respective party to whom such notice, consent, request, instruction, approval or other communication relates, at the addresses for Consultant and Company stated on the first page hereof, or to such other address as shall be furnished in writing by either party to the other.

 

12.   COUNTERPARTS. This Agreement may be executed in two or more counterparts, each of which shall constitute an original and all of which shall be deemed a single agreement.

 

13.   GOVERNING LAW, MEDIATION and ARBITRATION. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the laws of the State of Colorado, without giving effect to any choice of law or conflict of law provision or rule.

 

For any dispute, claim or controversy arising out of or relating to this Agreement or the breach, termination, enforcement, interpretation or validity thereof, including the determination of the scope or applicability of this agreement to arbitrate, the parties will attempt in good faith to resolve any dispute or claim arising out of or in relation to this Agreement through negotiations between a Director of each of the parties with authority to settle the relevant dispute. If the dispute cannot be settled amicably within fourteen (14) days from the date on which either party has served written notice on the other of the dispute then the remaining provisions of this Paragraph shall apply. Following good faith attempts to resolve the dispute, the parties agree to participate in at least four hours of mediation. The parties agree to share equally in the costs of the mediation. Mediation involves each side of a dispute sitting down with an impartial person, the mediator, to attempt to reach a voluntary settlement. Mediation involves no formal court procedures or rules of evidence, and the mediator does not have the power to render a binding decision or force an agreement on the parties. Mediation shall be conducted at a mutually-agreeable site in Boston, Massachusetts.

 

In the event that good faith attempts of resolution and mediation fail to provide a resolution to the dispute, resolution of the dispute shall be determined by arbitration at a mutually-agreeable site Denver, Colorado before one arbitrator. The arbitration shall be administered by the American Arbitration Association or JAMS. Judgment on the award may be entered in any court having jurisdiction. The losing party shall pay for all arbitrator’s fees and costs, and shall reimburse the prevailing party for its attorneys’ fees and costs.

 

 
 

 

 

14.   SURVIVAL. The provisions of Sections 1(d), 2(f), 3, 5, 13 and 14 of this Agreement shall survive the expiration or termination of this Agreement. This Agreement shall prevail over any conflicting provisions in the Development Agreement with respect to the subject matter hereof; and other than observing the relevant provisions of the Development Agreement, this Agreement supersedes all prior agreements, written or oral, between Company and Consultant relating to the subject matter of this Agreement.

 

 

 

 

 

 

 

 

<signature page to follow>

 

 
 

 

 

IN WITNESS WHEREOF, Consultant and Company have caused this Agreement to be executed by their duly authorized representatives as of the Effective Date written above.

 

 

AMERICANN, INC.

 

 

By: /s/ Benjamin J. Barton                             

Name: Benjamin J. Barton

Title: Director, CFO

 

 

COASTAL COMPASSION, INC.

 

 

By: /s/ Joanne Leppanen                               

Name: Joanne Leppanen

Title: Director, Executive Director

 

 

 

 

 

 

 

AmeriCann Consult. Agree Coastal 2-2-17

 

 
 

 

 

COASTAL COMPASSION, INC | AMERICANN, INC

PROMISSORY NOTE & AGREEMENT

 

 

 

1.

DEFINED TERMS. As used in this Promissory Note (this “Note”), the following terms shall have the following meanings:

 

a.

 

Borrower:

Coastal Compassion, Inc.

36 N. Water Street, Unit 2

New Bedford, MA 02739

 

 

 

 

b.

 

Lender:

AMERICANN, INC

3200 Brighton Blvd, Unit 114

Denver, CO 80216

 

 

 

 

c.

 

Loan Amount:

Two Million Five-Hundred Thousand Dollars ($2,500,000)

       
d.   Loan: The obligations of the Borrower under this Note.
       
e.   Payment Date The 1st day of each calendar quarter, with the first payment commencing on the first (1st) day of the sixth (6th) calendar month the Borrower begins providing medicine to qualifying patients and their personal caregivers through the related Registered Marijuana Dispensary (“RMD”), as defined in105 CMR 725.000 et seq.

 

 

 

 

f.   Maturity Date: Sixty (60) months after the first Payment Date.

      

 

2.

DEBT: For value received, the Borrower hereby promises to pay to the order of the Lender the Loan Amount, or so much of the Loan Amount as has been advanced by the Lender, together with interest on the unpaid balance under this Note at the applicable interest rate set forth in Section 3 below and with all other amounts due hereunder. All amounts due from Borrower to Lender under this Note shall be made without benefit of any setoff, counterclaim, or other defense.

 

 

3.

INTEREST: From the date the loan is made, interest shall accrue on the unpaid principal balance at a fixed rate of interest equal to eighteen (18) percent, compounded quarterly (the “Fixed Rate”). Interest shall at all times be calculated on a 90-day quarter of three 30-day months, but shall accrue and be payable on the actual number of days elapsed.

 

 

4.

PAYMENTS: Commencing on the first Payment Date and thereafter on each subsequent Payment Date until the Maturity Date, the Borrower shall make equal monthly payments of principal and interest sufficient to fully amortize the outstanding principal balance of the Loan at the Fixed Rate over a five (5) year period of time. If not otherwise paid, all outstanding principal and accrued but unpaid interest shall otherwise be paid on or before the Maturity Date. If interest is due and accrued for a period of more or less than one (1) quarter on the First Payment Date, the amount of the first payment shall be increased or decreased to the extent that the amount of interest then due exceeds or is less than one (1) quarter’s interest.

 

 
 

 

 

All principal, accrued interest, and any other amounts due hereunder, shall be due and payable on the Maturity Date or on such earlier date as may be required under the terms of this Note. Any payments on this Note, whether such payment is of a regular installment or represents a prepayment (if permitted hereunder), shall be made in coin and currency of the United States of America which is legal tender for the payment of public and private debts, in immediately available funds, to the Lender at Lender’s address set forth or at such other address as Lender may from time to time designate in writing.

 

 

5.

DELINQUENCY CHARGES: If the Borrower fails to pay any amount due under this Note for thirty (30) days after such payment becomes due, the Lender may, at its option, whether immediately or at the time of final payment of the amounts evidenced by this Note, impose a delinquency or “late” charge equal to five (5) percent of the amount of such past due payment, notwithstanding the date on which such payment is actually paid in full. To the extent permissible by law, the Borrower and Lender agree that any such delinquency charges shall not be deemed to be additional interest or penalty, but shall be deemed to be liquidated damages because of the difficulty in computing the actual amount of damages in advance.

 

 

6.

DEFAULT: “Event(s) of Default” shall mean the occurrence of any of the following events:

 

 

a.

The Borrower fails to make any payment of principal or interest on the Note when due thereunder or any other payment obligation in respect of this Note within thirty (30) days of the date when due, unless excused in writing by the Lender; or

 

 

b.

The Borrower defaults in the performance of any other term, covenant or agreement contained in this Note and such default shall continue uncured for thirty (30) days; or

 

 

c.

The Borrower is dissolved, becomes insolvent or bankrupt or ceases paying its debts as they mature for a period of thirty (30) days after such maturity or Borrower makes an assignment for the benefit of creditors; or a trustee, receiver or liquidator is appointed for the Borrower or for a substantial part of the property of the Borrower; or bankruptcy, reorganization, arrangement, insolvency or similar proceedings are instituted by or against the Borrower under the laws of any jurisdiction (provided that, if involuntary, such proceedings shall not be an Event of Default unless they are not stayed or dismissed within forty-five (45) days); or

 

 

d.

Entry of any court order against the Borrower which enjoins, restrains or in any way prevents the Borrower from conducting a substantial part of their business activities or materially interferes with the ownership, use or occupation of any if their assets which court order is not rescinded or dismissed within ninety (90) days of its issuance; or

 

 

e.

The criminal conviction or indictment of the Borrower or any director, officer or manager of the Borrower, or the entry of any judgment against the Borrower or any director, officer or manager of the Borrower for any act involving moral turpitude, dishonesty, theft, unethical business conduct or any conduct which, in the reasonable discretion of the Lender, substantially and materially impairs or injures the reputation of the Borrower or any senior officer or manager of the Borrower or substantially and materially harms the Borrower in any way; or

 

 
 

 

 

 

f.

Borrower’s breach of any representations or warranties made or agreed to be made in this Agreement or otherwise in connection with the Note by any party to this Agreement or the in any respect or if such representations and warranties shall prove to be false or misleading in any respect when made; or

 

 

g.

A levy be made on any property of the Borrower under any process, or any lien creditor commences suit to enforce a judgment lien against any property of the Borrower or any assets of the Borrower and such levy or action shall not be bonded against by sureties deemed by Lender to be sufficient in its sole opinion and judgment; or

 

 

h.

Borrower’s failure to obtain a final registration to operate a RMD in the Commonwealth of Massachusetts, or such registration has been revoked or suspended for a period of sixty (60) days or longer.

 

 

7.

ACCELERATION AND OTHER REMEDIES: If an Event of Default, as such term is defined in Section 6 of this Note occurs, then, and in any such event, the Lender may, at its option, declare the entire unpaid balance of this Note, together with interest accrued thereon, to be immediately due and payable and may proceed to exercise any rights or remedies that it may have under this Note, or such other rights and remedies which the Lender may have at law, equity or otherwise, and Lender shall be released from any and all obligations to the Borrower under the terms of this Agreement. In addition to the rights and remedies set forth in this Agreement, Lender shall have all the other rights and remedies accorded in equity and under all other applicable laws, and under any other instrument or agreement now or in the future entered into between Lender and the Borrower, and all of such rights and remedies are cumulative and none is exclusive. Exercise or partial exercise by Lender of one or more of its rights or remedies shall not be deemed an election, nor bar the Lender from subsequent exercise or partial exercise of any other rights or remedies. The failure or delay of the Lender to exercise any rights or remedies shall not operate as a waiver thereof, but all rights and remedies shall continue in full force and effect until all of the obligations of Borrower have been indefeasibly paid and performed.

 

 

8.

LIMITATION OF REMEDIES: Notwithstanding any provision of this Note, the Lender hereby agrees that Lender’s rights and remedies following a default shall not include the seizure of assets protected by the Humanitarian Medical Use of Marijuana Act, Ch. 369 of the Acts of 2012, i.e. any product containing any amount of marijuana. The Lender shall not be entitled to a repayment or remedy that provides to Lender inventory of Borrower that contains any amount of marijuana, in any form, whether flower or infused product. The Lender hereby forfeits any such remedy. In addition, Lender hereby understands and agrees that a Certificate of Registration, whether provisional or final, is non-transferrable, and may not be assigned or transferred without prior Department of Public Health approval. Lender agrees that Borrower’s Certificate of Registration is not an asset that may be seized by Lender or available as a remedy for Borrower’s default under this Agreement, and hereby expressly waives any such remedy.

 

 
 

 

 

 

9.

COSTS AND EXPENSES UPON DEFAULT: In addition to principal, interest and delinquency charges, the Lender shall be entitled to collect all costs of collection, including, but not limited to, reasonable attorneys’ fees and expenses incurred in connection with Lender’s collection efforts, whether or not suit on this Note is filed, and all such costs and expenses shall be payable on demand.

 

 

10.

APPLICATION OF PAYMENTS: All payments hereunder shall be applied first to delinquency charges, costs of collection and enforcement and other similar amounts due, if any, under this Note, then to interest which is due and payable under this Note, and the remainder, if any, to principal due and payable under this Note. Notwithstanding anything herein to the contrary, if an Event of Default has occurred which has not been waived in writing by the Lender, such payments may be applied to sums due under this Note in any order and combination that Lender may, in its sole and absolute discretion, determine.

 

 

11.

PERMITTED PREPAYMENT: The Borrower shall have the right to prepay the Loan in whole, or in part, together with all delinquency charges and any other amounts which may be due hereunder at any time, without premium or penalty. The Borrower must give Lender no less than five (5) days’ prior written notice of the Borrower’s intention to prepay. The date fixed for prepayment in such notice shall become the maturity date with respect to such portion of the outstanding balance being repaid.

 

 

12.

INDEMNIFICATION: To the extent permitted by applicable Law, the Borrower hereby indemnifies and agrees to hold Lender and its directors, officers, agents, and employees (individually and collectively, the “Indemnitee(s)”) harmless from and against:

 

 

a.

Any and all claims, demands, actions, or causes of action (including, without limitation, any such matters that relate to Lender’s direct or indirect involvement in the funding or construction of the RMD) that are asserted against any Indemnitee by any person, if the claim, demand, action or cause of action, directly or indirectly, relates to a claim, demand, action, or cause of action that the person has or asserts against the Borrower; and

 

 

b.

Any and all liabilities, losses, costs, or expenses (including court costs and attorneys’ fees) that any Indemnitee suffers or incurs as a result of the assertion of any claim, demand, action, or cause of action specified in this Section 11.

 

The Borrower agrees to indemnify and hold the Lender harmless from and against all loss, cost or expense which Lender may sustain or incur as a consequence of default by the Borrower in prepayment of any portion of the Loan and accrued interest thereon, after having given notice that prepayment will occur, or payment by acceleration or otherwise, including, but not limited to, any such loss or expense arising from interest or fees payable by the Lender to lenders of funds obtained by the Lender in order to make or maintain the Loan. This indemnification shall survive the payment of the outstanding principal balance of the Loan. A certificate of the Lender as to any additional amounts payable pursuant to this grammatical paragraph shall, absent manifest error, be final, conclusive and binding upon the Borrower.

 

 
 

 

 

 

13.

COSTS; ILLEGALITY OF LOAN: The Borrower shall pay to the Lender on demand:

 

 

a.

All costs and reasonable expenses of the Lender in connection with, and any stamp or other taxes or charges (including filing fees) payable with respect to, this Note and the enforcement hereof;

 

 

b.

Any amount necessary to compensate the Lender for any losses or costs (including funding costs) sustained by it as a consequence of any Event of Default by the Borrower hereunder; and

 

 

c.

Any increased costs the Lender may sustain in maintaining the borrowing evidenced hereby due to the introduction of, or any change in, law or applicable regulations (including the interpretation thereof) or due to the compliance by the Lender with any guideline or request from any central bank or governmental authority. In addition, if it shall become unlawful, or any central bank or other governmental authority shall assert it to be unlawful, for the Lender (or any bank which is directly or indirectly funding the Lender with respect to the Loan) to maintain the borrowing evidenced hereby, the Borrower agrees to prepay this Note in full together with accrued interest and other amounts payable hereunder on demand. It is understood that the marijuana is currently illegal under the laws of the United States of America and such illegality shall have no effect upon this loan.

 

 

14.

WAIVERS: THE BORROWER IRREVOCABLY WAIVES ITS RIGHTS TO NOTICE AND HEARING TO THE EXTENT PERMITTED BY STATE OR FEDERAL LAW WITH RESPECT TO ANY PREJUDGMENT REMEDY WHICH THE LENDER MAY DESIRE TO USE, and, further, irrevocably waives presentment for payment, demand, notice of nonpayment, diligence in collection, commencement of suit against any obligor, notice of protest, and protest of this Note and all other notices in connection with the delivery, acceptance, performance, default or enforcement of the payment of this Note, before or after the maturity of this Note, with or without notice to the Borrower, and agrees that its liability shall not be in any manner affected by any indulgence, extension of time, renewal, waiver or modification granted or consented to by Lender. The Borrower consents to any and all extensions of time, renewals, waivers or modifications that may be granted by Lender with respect to the payment or other provisions of this Note, and to any substitution, exchange or release of the collateral for this Note, or any part thereof, with or without substitution of said collateral, and agrees to the addition or release of any guarantor, all whether primarily or secondarily liable, before or after maturity of this Note, with or without notice to the Borrower, and without affecting its liability under this Note. Any delay on the part of Lender in exercising any right under this Note shall not operate as a waiver of any such right, and any waiver granted or consented to on one occasion shall not operate as a waiver in the event of any subsequent default.

 

 
 

 

 

 

15.

NO USURY: The Lender and the Borrower intend to comply at all times with applicable usury laws. If at any time such laws would ever render usurious any amounts called for under this Note, then it is the Borrower’s and the Lender’s express intention that the Borrower shall not be required to pay interest on this Note at a rate in excess of the maximum lawful rate, that the provisions of this Section 12 shall control over all other provisions of this Note which may be in apparent conflict herewith, that such excess amount shall be credited to the principal balance of this Note (or, if this Note has been fully paid, refunded by the Lender to the Borrower), and the provisions hereof shall be reformed and the amounts thereafter collectible under this Note reduced, without the necessity of the execution of any further documents, so as to comply with the then applicable law, but so as to permit the recovery by the Lender of the fullest amount otherwise called for under this Note. Any such crediting or refund shall not cure or waive any default by the Borrower under this Note. If, at any time following any reduction in the interest rate payable by the Borrower there remains unpaid any principal amount under this Note and the maximum interest rate allowed by applicable law is increased or eliminated, then the interest rate payable under this Note shall be readjusted, to the extent not prohibited by applicable law, so that the dollar amount of interest payable hereunder shall be equal to the dollar amount of interest which would have been paid by the Borrower without giving effect to the reduction in interest resulting from compliance with applicable usury laws. The Borrower agrees that in determining whether or not any interest payable under this Note exceeds the highest rate allowed by law, any non-principal payment (except payments specifically stated in this Note to be “interest”), including, without limitation, if any are applicable as provided herein, prepayment fees and delinquency charges, shall, to the maximum extent allowed by law, be an expense, fee or premium rather than interest. The term “Applicable Law”, as used in this Note shall mean the laws of The Commonwealth of Massachusetts or the laws of the United States, whichever laws allow the greater rate of interest, as such laws now exist or may be changed or amended or come into effect in the future.

 

 

16.

JOINT AND SEVERAL LIABILITY: The liabilities of the Borrower are joint and several; provided, however, the release by Lender of any other person liable hereunder shall not release any other person obligated on account of this Note. Each reference herein to “Borrower” or “Borrowers” is to such party individually and also to all such parties jointly. No party obligated on account of this Note may seek contribution from any other party also obligated unless and until all liabilities to Lender from the party from whom contribution is sought have been satisfied in full.

 

 

17.

SUCCESSORS AND ASSIGNS: This Note shall be binding upon the Borrower and upon its successors and assigns, and shall inure to the benefit of the Lender and its successors, endorsees, and assigns.

 

 

18.

SECURITY: The Borrower hereby grants to the Lender a continuing security interest in all personal property, furnishings, fixtures, equipment, leases, tangible property, intangible property not subject to an encumbrance by a lessor, contractual agreements with third parties, and any and all deposits or other sums at any time credited by or due from the Lender to the Borrower and any cash, securities, instruments, or other property of the Borrower which now or hereafter are at any time in the possession or control of the Lender, and such sums shall constitute additional security to the Lender for the liabilities of the Borrower to the Lender, including, without limitation, the liability evidenced hereby, and may be applied or set off by the Lender against such liabilities at any time from and after an Event of Default hereunder or after demand for payment is made by the Lender, whether or not available to Lender. Borrower agrees that Lender may file any financing statement, lien entry form or other document Lender requires in order to perfect, amend or continue Lender’s security interest and Borrower agrees to cooperate with Lender as may be necessary to accomplish said filing and to do whatever Lender deems necessary to protect Lender’s security interest. Borrower agrees and warrants that all records shall be located at Borrower's address as set forth in Section 1. In the event of Default, the security interest described herein shall be disbursed to all Lenders on a pro rata basis based on their loan amount as compared to the entire loan amount. Lender hereby agrees that filing a UCC-1 statement or bringing an action in the trial court shall not make their interest superior or provide priority above any other Lender’s interest, but instead agrees to the pro rata disbursement of the security interest as defined herein.

 

 
 

 

 

 

19.

COLLECTION: Any check, draft, money order or other instrument given in payment of all or any portion hereof may be accepted by the Lender and handled by collection in the customary manner, but the same shall not constitute payment hereunder or diminish any rights of the Lender except to the extent that actual cash proceeds of such instrument are unconditionally received by the Lender and applied to this indebtedness in the manner elsewhere herein provided.

 

 

20.

AMENDMENTS: This Note may be changed or amended only by an agreement in writing signed by the party against whom enforcement is sought.

 

 

21.

GOVERNING LAW; SUBMISSION TO JURISDICTION: This Note is given to evidence debt for business or commercial purposes, is being delivered to Lender at one of its offices in The Commonwealth of Massachusetts and shall be governed by and construed under the laws of said Commonwealth. The Borrower and each officer, director, and employee of the Borrower hereby submit to personal jurisdiction in said Commonwealth for the enforcement of the Borrower’ obligations hereunder, and waive any and all personal rights under the law of any other state to object to jurisdiction within such Commonwealth for the purposes of litigation to enforce such obligations of the Borrower. In the event such litigation is commenced, the Borrower agrees that service of process may be made, and personal jurisdiction over the Borrower obtained, by service of a copy of the summons, complaint and other pleadings required to commence such litigation upon the Borrower at the address set forth in Section 1 of this Note or at another address provided in writing by the Borrower to the Lender. The terms of this Agreement shall be subject to approval by the Massachusetts Department of Public Health, and in the event that the Department of Public Health requires amendments, this Agreement shall be amended as required by the Department of Public Health and to reflect the intent of the parties.

 

 
 

 

 

 

22.

CAPTIONS: All paragraph and subparagraph captions are for convenience of reference only and shall not affect the construction of any provision herein.

 

 

23.

SEVERABILITY: The invalidity of any provision of this Note shall in no way affect the validity of any other provision.

 

 

24.

NON-LIABILITY OF LENDER: The Borrower acknowledges and agrees that by accepting or approving anything required to be observed, performed, fulfilled, or given to Lender pursuant to this Agreement, including any certificate, financial statement, appraisal, statement of profit and loss, or other financial statement, survey, appraisal or insurance policy, Lender shall not be deemed to have warranted or represented the sufficiency, legality, effectiveness or legal effect of the same, or of any term, provision, or condition thereof, and such acceptance or approval thereof shall not be or constitute any warranty or representation to anyone with respect thereto by Lender.

 

 

25.

BORROWER’S REPRESENTATIONS AND WARRANTIES: Borrower represents and warrants that:

 

 

a.

Borrower will comply with all laws, statutes, regulations and ordinances pertaining to the conduct of Borrower’s business and promises to hold Lender harmless from any damages, liabilities, costs, expenses (including attorneys’ fees) or other harm arising out of any violation thereof;

 

 

b.

Borrower is duly organized, licensed, validly existing and in good standing under the laws of its state of formation and shall hereafter remain in good standing in that state, and is duly qualified, licensed and in good standing in every other state in which it is doing business, and shall hereafter remain duly qualified, licensed and in good standing in every other state in which it is doing business, and shall hereafter remain duly qualified, licensed and in good standing in every other state in which the failure to qualify or become licensed could have a material adverse effect on the financial condition, business or operations of Borrower. Notwithstanding the foregoing, at the time of this Note, Borrower has a provisional registration for the operation of a RMD and is seeking a Final Certificate of Registration;

 

 

c.

the execution, delivery and performance of this Agreement and any other document executed in connection herewith, are within Borrower’s powers, have been duly authorized, are not in contravention of law or the terms of Borrower’s charter, by-laws or other organization papers, or of any indenture, agreement or undertaking to which Borrower is a party;

 

 

d.

Borrower is in compliance with its organization documents and by-laws, all contractual requirements by which it may be bound and all applicable laws, rules and regulations other than laws, rules or regulations the validity or applicability of which it is contesting in good faith or provisions of any of the foregoing the failure to comply with which cannot reasonably be expected to materially adversely affect its financial condition, business or prospects or the value of the Collateral; and

 

 
 

 

 

 

e.

There is no action, suit, proceeding or investigation pending or, to Borrower’s knowledge, threatened against or affecting it or any of its assets before or by any court or other governmental authority which, if determined adversely to it, would have a material adverse effect on its financial condition, business or prospects.

 

 

26.

SURVIVAL OF COVENANTS, REPRESENTATIONS AND WARRANTIES: All representations and warranties of the Borrower contained herein shall survive the making of the Note and the execution and delivery of the Note, and are material and have been or will be relied upon by Lender, notwithstanding any investigation made by Lender or on behalf of Lender. For the purpose of this Agreement, all statements contained in any certificate, agreement, financial statement, or other writing delivered by or on behalf of the Borrower pursuant or in connection with the transactions contemplated hereby or thereby shall be deemed to be representations and warranties of the Borrower contained herein or in the other loan documents, as the case may be.

 

 

27.

NO PRESUMPTION AGAINST ANY PARTY: Neither this Agreement, any of the other Loan Documents, any other documents, agreement, or instrument entered into in connection herewith, nor any uncertainty or ambiguity herein or therein shall be construed or resolved using any presumption against any party hereto, whether under any rule of construction or otherwise. On the contrary, this Agreement, and all other documents, instruments, and agreements entered into in connection herewith have been reviewed by each of the parties and by their respective counsel and shall be construed and interpreted according to the ordinary meanings of the words used so as to accomplish fairly the purposes and intentions of all parties hereto.

 

 

28.

USE OF LOAN AMOUNT/RETURN OF FUNDS: The Lender shall disburse the Loan Amount to Borrower after Borrower signs this Agreement. The amount loaned under this Agreement shall be used for the operating and capital expenses of the build out and opening of Coastal Compassion, Inc.

 

 

29.

EQUALITY OF TERMS AMONG LENDERS: All Lenders who contribute prior to December 1st, 2015 shall be offered substantially similar terms by Borrower.

 

 

30.

DISPUTE RESOLUTION. For any dispute, claim or controversy arising out of or relating to this Agreement or the breach, termination, enforcement, interpretation or validity thereof, including the determination of the scope or applicability of this agreement to arbitrate, the parties will attempt in good faith to resolve any dispute or claim arising out of or in relation to this Agreement through negotiations between a Director of each of the parties with authority to settle the relevant dispute. If the dispute cannot be settled amicably within fourteen (14) days from the date on which either party has served written notice on the other of the dispute then the remaining provisions of this Paragraph shall apply. Following good faith attempts to resolve the dispute, the parties agree to participate in at least four hours of mediation. The parties agree to share equally in the costs of the mediation. Mediation involves each side of a dispute sitting down with an impartial person, the mediator, to attempt to reach a voluntary settlement. Mediation involves no formal court procedures or rules of evidence, and the mediator does not have the power to render a binding decision or force an agreement on the parties. Mediation shall be conducted at a mutually-agreeable site in Boston, Massachusetts.

 

 
 

 

  

In the event that good faith attempts of resolution and mediation fail to provide a resolution to the dispute, resolution of the dispute shall be determined by arbitration at a mutually-agreeable site Denver, Colorado before one arbitrator. The arbitration shall be administered by the American Arbitration Association or JAMS. Judgment on the award may be entered in any court having jurisdiction. The losing party shall pay for all arbitrator’s fees and costs, and shall reimburse the prevailing party for its attorneys’ fees and costs.

  

 

IN WITNESS WHEREOF, this Note has been executed and delivered under seal this 4th of April, 2016.

 

 

BORROWER:

 

 

Coastal Compassion, Inc.

A Massachusetts non-profit corporation

 

 

 

 

 

 

 

 

 

 

By:

/s/ JoAnne Leppanen

 

 

 

Name: JoAnne Leppanen

 

 

 

Title: Executive Director, Director

 

 

 

 

LENDER:

 

AmeriCann, Inc.

 

 

 

 

 

 

 

 

 

 

By:

/s/ Benjamin J. Barton

 

 

 

Name: Benjamin J. Barton

 

 

 

Title: Director, CFO

 

 

 

 

 

 

AmeriCann Prom. Note Coastal $2.5M 2-2-17

 

 

EX-10.6 12 ex10-6.htm EXHIBIT 10.6 ex10-6.htm

 

 

EXHIBIT 10.6

 

 

 

 

 

 

SHARE PURCHASE AGREEMENT

 

This Share Purchase Agreement, dated as of October 17, 2016 (this “Agreement”), is entered into by and between AmeriCann, Inc., a Delaware corporation (the “Company”), and Massachusetts Medical Properties, LLC, a Delaware limited liability company (the “Purchaser”).

 

WHEREAS, the Company is party to that certain Purchase and Sale Agreement , dated as of January 9, 2015 (as amended, the “Freetown PSA”), with Freetown Acquisition Company, LLC (“Freetown LLC”) pursuant to which the Company has agreed to acquire from Freetown LLC certain properties (the “Freetown Properties”) as more particularly described in the Freetown PSA;

 

WHEREAS, in connection with the closing of the acquisition of the Freetown Properties, (i) the Company desires to issue and sell to the Purchaser, and the Purchaser desires to purchase from the Company, 100,000 shares (the “Shares”) of common stock, par value $0.0001 (“Common Stock”), of the Company, in accordance with the provisions of this Agreement; (ii) the Company will execute and issue in favor of the Purchaser a warrant, in the form attached hereto as Exhibit C (the “Warrant”), to purchase 3,640,000 shares of Common Stock (the “Warrant Shares” and, together with the Shares, the “New Shares”); (iii) Freetown LLC will execute and deliver a deed, in the form attached hereto as Exhibit D (the “Deed to Company”), pursuant to which the Company will become the fee simple owner of the Freetown Properties; (iv) the Company will execute and deliver a deed, in the form attached hereto as Exhibit E (the “Deed to Purchaser”), pursuant to which the Purchaser will become the fee simple owner of the Freetown Properties; and (v) the parties desire to enter into a ground lease agreement, in the form attached hereto as Exhibit B (the “Lease Agreement”), pursuant to which the Purchaser will lease the Freetown Properties to the Company.

 

NOW THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows:

 

ARTICLE I
DEFINITIONS

 

Section 1.01     Definitions. As used in this Agreement, the following terms have the meanings indicated:

 

Affiliate” means, with respect to any Person, any other Person that directly or indirectly through one or more intermediaries controls, is controlled by or is under common control with, the Person in question. As used herein, the term “control” means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through ownership of voting securities, by contract or otherwise. For the avoidance of doubt, for purposes of this Agreement, the Company and its subsidiaries, on the one hand, and the Purchaser or any of its members, on the other, shall not be considered Affiliates.

 

Agreement” has the meaning set forth in the introductory paragraph of this Agreement.

 

Anti-Corruption Laws” has the meaning specified in Section 3.22(b).

 

 
1

 

 

Business Day” means any day other than a Saturday, Sunday, any federal legal holiday or day on which banking institutions in the State of Colorado are authorized or required by Law or other governmental action to close.

 

Closing” has the meaning specified in Section 2.01.

 

Commission” means the United States Securities and Exchange Commission.

 

Common Stock” has the meaning set forth in the recitals.

 

Company” has the meaning set forth in the introductory paragraph of this Agreement.

 

Company Related Parties” has the meaning specified in Section 5.02.

 

Contract” means any contract, agreement, indenture, note, bond, mortgage, deed of trust, loan, instrument, lease, license, commitment or other arrangement, understanding, undertaking, commitment or obligation, whether written or oral.

 

Deed to Company” has the meaning set forth in the recitals.

 

Deed to Purchaser” has the meaning set forth in the recitals.

 

Environmental Law” means any Laws pertaining to protection of the environment (including natural resources), the prevention of pollution, the remediation of contamination, the restoration of environmental quality, or occupational health and workplace safety, including all Laws addressing any release into the environment of, any exposure to, or any remediation of Hazardous Substance.

 

Environmental Permits” means all approvals, authorizations, consents, licenses, permits, variances, waivers, exemptions, registrations of a Governmental Authority required under any Environmental Laws for the operation of the business of the Company or its subsidiaries.

 

Exchange Act” means the Securities Exchange Act of 1934, as amended from time to time, and the rules and regulations of the Commission promulgated thereunder.

 

FCPA” has the meaning specified in Section 3.22(b).

 

Freetown LLC” has the meaning set forth in the recitals.

 

Freetown Properties” has the meaning set forth in the recitals.

 

Freetown PSA” has the meaning set forth in the recitals.

 

GAAP” means generally accepted accounting principles in the United States of America as of the date hereof; provided that for the financial statements of the Company prepared as of a certain date, GAAP referenced therein shall be GAAP as of the date of such financial statements.

 

 
2

 

 

Governmental Authority” means, with respect to a particular Person, any country, state, county, city and political subdivision in which such Person or such Person’s Property is located or which exercises valid jurisdiction over any such Person or such Person’s Property, and any court, agency, department, commission, board, bureau or instrumentality of any of them and any monetary authority which exercises valid jurisdiction over any such Person or such Person’s Property. Unless otherwise specified, all references to Governmental Authority herein with respect to the Company means a Governmental Authority having jurisdiction over the Company or its subsidiaries or any of their respective Properties.

 

Hazardous Substances” means (a) any “hazardous substance” as defined in the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended, (b) any “hazardous waste” as defined in the Resource Conservation and Recovery Act, as amended, (c) any petroleum, petroleum products, natural gas, oil and gas waste, and oil and any components or derivatives thereof, (d) any polychlorinated biphenyl, and (e) any pollutant, contaminant or hazardous or toxic, material, waste or substance regulated under any other Environmental Law.

 

Indemnified Party” has the meaning specified in Section 5.03(b).

 

Indemnifying Party” has the meaning specified in Section 5.03(b).

 

Law” means any federal, state, local or foreign order, writ, injunction, judgment, settlement, award, decree, statute, law (including common law), rule or regulation.

 

Lease Agreement” has the meaning set forth in the recitals.

 

Lien” means any mortgage, claim, encumbrance, pledge, lien (statutory or otherwise), security agreement, conditional sale or trust receipt or a lease, consignment or bailment, preference or priority, assessment, deed of trust, charge, easement, servitude or other encumbrance upon or with respect to any property of any kind.

 

Material Adverse Effect” means any change, event or effect that, individually or together with any other changes, events or effects, has or would reasonably be expected to have a material adverse effect on (a) the condition (financial or otherwise), business, prospects, properties, assets, net worth or results of operations of the Company and its subsidiaries, taken as a whole, or (b) the ability of the Company to perform its obligations under the Transaction Documents.

 

New Shares” has the meaning set forth in the recitals.

 

Organizational Documents” means, as applicable, an entity’s agreement or certificate of limited partnership, limited liability company agreement, certificate of formation, certificate or articles of incorporation, bylaws or other similar organizational documents.

 

Permits” means any approvals, authorizations, consents, licenses, permits, variances, waivers, grants, franchises, concessions, exemptions, orders, registrations or certificates of a Governmental Authority.

 

 
3

 

 

Person” means any individual, corporation, company, voluntary association, partnership, joint venture, trust, limited liability company, unincorporated organization, government or any agency, instrumentality or political subdivision thereof or any other form of entity.

 

Property” means any interest in any kind of property or asset, whether real, personal or mixed, or tangible or intangible (including intellectual property rights).

 

Purchaser Related Parties” has the meaning specified in Section 5.01.

 

Purchaser” has the meaning set forth in the introductory paragraph of this Agreement.

 

Representatives” means, with respect to a specified Person, the investors, officers, directors, managers, employees, agents, advisors, counsel, accountants, investment bankers and other representatives of such Person.

 

SEC Documents” has the meaning specified in Section 3.04.

 

Securities Act” means the Securities Act of 1933, as amended from time to time, and the rules and regulations of the Commission promulgated thereunder.

 

Shares” has the meaning set forth in the recitals.

 

Tax Return” has the meaning specified in Section 3.18(b).

 

Taxes” has the meaning specified in Section 3.18(b).

 

Third-Party Claim” has the meaning specified in Section 5.03(b).

 

Transaction Documents” means, collectively, this Agreement, the Deed to Company, the Deed to Purchaser, the Lease Agreement, the Warrant and any and all other agreements or instruments executed and delivered to the Purchaser by the Company hereunder or thereunder, as applicable.

 

Warrant” has the meaning set forth in the recitals.

 

Warrant Shares” has the meaning set forth in the recitals.

 

Section 1.02     Accounting Procedures and Interpretation. Unless otherwise specified herein, all accounting terms used herein shall be interpreted, all determinations with respect to accounting matters hereunder shall be made, and all financial statements of the Company and certificates and reports as to financial matters required to be furnished to the Purchaser hereunder shall be prepared, in accordance with GAAP applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto or, in the case of unaudited statements, as permitted by Form 10-Q promulgated by the Commission) and in compliance as to form in all material respects with applicable accounting requirements and with the published rules and regulations of the Commission with respect thereto.

 

 
4

 

 

ARTICLE II
AGREEMENT TO SELL AND PURCHASE

 

Section 2.01     Closing. At the Closing, subject to the terms and conditions hereof, the Company hereby agrees to issue to the Purchaser the Shares and the Warrant. The consummation of the issuance of the Shares and the Warrant hereunder (the “Closing”) shall take place on date hereof at the offices of Baker Botts L.L.P., 910 Louisiana St., Houston, Texas 77002.

 

Section 2.02     Deliveries at the Closing.

 

(a)     Deliveries of the Company at the Closing. At the Closing, the Company shall deliver or cause to be delivered to the Purchaser:

 

(i)     An opinion from Hart & Hart, LLC, counsel for the Company, in the form attached hereto as Exhibit A, which shall be addressed to the Purchaser and dated the date hereof;

 

(ii)     Evidence of issuance of the Shares credited to book-entry accounts maintained by the Company, free and clear of any Liens, other than transfer restrictions under applicable federal and state securities laws;

 

(iii)     A certificate of the Chief Executive Officer of the Company, on behalf of the Company, dated the date hereof, certifying as to and attaching (A) the certificate of incorporation and bylaws of the Company and (B) board resolutions authorizing the execution and delivery of the Transaction Documents and the consummation of the transactions contemplated thereby, including the issuance of the Shares;

 

(iv)     The Lease Agreement, which shall have been duly executed by the Company;

 

(v)     The Deed to Company, which shall have been duly executed by Freetown LLC;

 

(vi)     The Deed to Purchaser, which shall have been duly executed by the Company;

 

(vii)     The Warrant, which shall have been duly executed by the Company; and

 

(viii)     Such other documents relating to the transactions contemplated by this Agreement as the Purchaser or its counsel may reasonably request.

 

(b)     Deliveries of the Purchaser at the Closing. At the Closing, the Purchaser shall deliver or cause to be delivered to the Company:

 

(i)     The Lease Agreement, which shall have been duly executed by the Purchaser;

 

 
5

 

 

(ii)     The Warrant, which shall have been duly executed by the Purchaser;

 

(iii)     Evidence of payment by the Purchaser to Freetown LLC of the purchase price payable under the Freetown PSA; and

 

(iv)     Such other documents relating to the transactions contemplated by this Agreement as the Company or its counsel may reasonably request.

 

Section 2.03     Further Assurances. Each of the Company and the Purchaser shall use its respective commercially reasonable efforts to obtain all approvals and consents required by or necessary to consummate the transactions contemplated by this Agreement and the other Transaction Documents. Each of the Company and the Purchaser agrees to execute and deliver all such documents or instruments, to take all appropriate action and to do all other things it determines to be necessary, proper or advisable under applicable Laws and regulations or as otherwise reasonably requested by the other to consummate the transactions contemplated by this Agreement or the other Transaction Documents.

 

ARTICLE III
REPRESENTATIONS AND WARRANTIES AND
COVENANTS RELATED TO THE COMPANY

 

As of the date hereof, the Company represents and warrants to and covenants with the Purchaser as follows:

 

Section 3.01     Existence. Each of the Company and its subsidiaries has been duly incorporated or formed, as the case may be, and is validly existing as a limited liability company, limited partnership or corporation, as the case may be, in good standing under the Laws of its jurisdiction of incorporation or formation, as the case may be, and has the full limited liability company, limited partnership or corporate, as the case may be, power and authority to own or lease its Properties and assets and to conduct the businesses in all material respects which it is engaged, and is duly registered or qualified as a foreign limited liability company, limited partnership or corporation, as the case may be, for the transaction of business under the laws of each jurisdiction in which the character of the business conducted by it or the nature or location of the properties owned or leased by it makes such registration or qualification necessary, except where the failure to so register or qualify would not (a) reasonably be expected to have a Material Adverse Effect or (b) subject the shareholders of the Company to any material liability or disability. None of the Company or any of its subsidiaries is in violation of its Organizational Documents.

 

Section 3.02     Capitalization and Valid Issuance of New Shares.

 

(a)     As of the date hereof, and prior to the issuance and sale of the Shares, the authorized capital stock of the Company consists of 100,000,000 shares of Common Stock and 20,000,000 shares of preferred stock, par value $0.0001 per share, and the issued and outstanding capital stock of the Company consist of 17,031,000 shares of Common Stock. All outstanding shares of Common Stock have been duly authorized and validly issued and are fully paid and nonassessable.

 

 
6

 

 

(b)     The New Shares are duly authorized and, when issued and delivered to the Purchaser in accordance with the terms of this Agreement or the Warrant, will be validly issued, fully paid and nonassessable and will be free of any and all Liens and restrictions on transfer, other than (i) restrictions on transfer under applicable state and federal securities laws and (ii) such Liens as are created by the Purchaser.

 

(c)     There are no persons entitled to statutory, preemptive or other similar contractual rights to subscribe for the New Shares; and, except (i) for the New Shares to be issued pursuant to this Agreement and the Warrant, (ii) for awards issued pursuant to the Company’s long-term incentive plans or (iii) as disclosed in the SEC Documents, no options, warrants or other rights to purchase, agreements or other obligations to issue, or rights to convert any obligations into or exchange any securities for, Company securities or ownership interests in the Company are outstanding.

 

Section 3.03     Ownership of Subsidiaries. All of the outstanding shares of capital stock or other equity interests of each subsidiary of the Company (a) have been duly authorized and validly issued (in accordance with the Organizational Documents of such subsidiary), are fully paid (in the case of an interest in a limited partnership or limited liability company, to the extent required under the Organizational Documents of such subsidiary) and nonassessable (except (i) in the case of an interest in a Delaware limited partnership or Delaware limited liability company, as such nonassessability may be affected by Sections 17-607 and 17-804 of the Delaware LP Act or Sections 18-607 and 18-804 of the Delaware LLC Act, as applicable, (ii) in the case of an interest in a limited partnership or limited liability company formed under the laws of another domestic state, as such nonassessability may be affected by similar provisions of such state’s limited partnership or limited liability company statute, as applicable, and (iii) in the case of an interest in an entity formed under the laws of a foreign jurisdiction, as such nonassessability may be affected by similar provisions of such jurisdiction’s corporate, partnership, limited partnership or limited liability company statute, if any, as applicable) and (b) are owned, directly or indirectly, by the Company, free and clear of all Liens.

 

Section 3.04     SEC Documents. Except as disclosed in the SEC Documents, since January 1, 2016, the Company’s forms, registration statements, reports, schedules and statements required to be filed by it under the Exchange Act or the Securities Act (all such documents filed prior to the date hereof, collectively the “SEC Documents”) have been filed with the Commission on a timely basis. The SEC Documents, at the time filed (or in the case of registration statements, solely on the dates of effectiveness) (except to the extent corrected by a subsequent SEC Document) (a) did not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made in the case of any such documents other than a registration statement, not misleading, (b) complied as to form in all material respects with the applicable requirements of the Exchange Act and the Securities Act, as the case may be, and (c) complied as to form in all material respects with applicable accounting requirements and with the published rules and regulations of the Commission with respect thereto. The financial statements of the Company and other financial information included in the SEC Documents were prepared in accordance with GAAP applied on a consistent basis during the periods involved (except as may be indicated in the notes thereto or, in the case of unaudited statements, as permitted by Form 10-Q of the Commission), and fairly present (subject in the case of unaudited statements to normal and recurring and year-end audit adjustments) in all material respects the consolidated financial position of the Company and its consolidated subsidiaries as of the dates thereof and the consolidated results of its operations and cash flows of the Company and its consolidated subsidiaries for the periods then ended. The independent auditor of the Company as of the date of the most recent audited balance sheet of the Company is an independent registered public accounting firm with respect to the Company and has not resigned or been dismissed as independent registered public accountants of the Company as a result of or in connection with any disagreement with the Company on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures. Since the date of the most recent balance sheet of the Company audited by such auditor, (i) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the SEC Documents fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto and (ii) except as disclosed in the SEC Documents, the Company is not aware of (x) any significant deficiency or material weakness in the design or operation of internal controls over financial reporting that are likely to adversely affect its ability to record, process, summarize and report financial data or (y) any fraud, whether or not material, that involves management or other employees who have a significant role in the internal controls over financial reporting of the Company.

 

 
7

 

 

Section 3.05     No Material Adverse Change. Except as expressly set forth in or contemplated by the SEC Documents, since June 30, 2016 through the date hereof no Material Adverse Effect has occurred.

 

Section 3.06     No Registration Required. Assuming the accuracy of the representations and warranties of the Purchaser contained in Article IV, the issuance and sale of the New Shares pursuant to this Agreement and the Warrant is exempt from registration requirements of the Securities Act, and neither the Company nor, to the knowledge of the Company, any authorized Representative acting on its behalf has taken or will take any action hereafter that would cause the loss of such exemption.

 

Section 3.07     Litigation. Except as set forth in the SEC Documents, there are (a) no legal or governmental proceedings pending or, to the knowledge of the Company, threatened, against the Company or any of its subsidiaries or to which any Property or asset of any such entity is subject and (b) no injunctions, restraining orders or orders of any nature issued by a federal or state court or foreign court of competent jurisdiction to which any of the Company or its subsidiaries is or may be subject, that would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect or which challenges the validity of any of the Transaction Documents or the right of the Company to enter into any of the Transaction Documents or to consummate the transactions contemplated hereby and thereby and, to the knowledge of the Company, no such proceedings are threatened by Governmental Authorities or others.

 

Section 3.08     No Default. (a) None of the Company or its subsidiaries is in violation of any law, statute, ordinance, administrative or governmental rule or regulation applicable to it or of any decree of any Governmental Authority having jurisdiction over it and (b) none of the Company or its subsidiaries is in breach, default (or an event that, with notice or lapse of time or both, would constitute such an event) or violation in the performance of any obligation, covenant or condition contained in any bond, debenture, note or any other evidence of indebtedness or in any agreement, indenture, lease or other instrument to which it is a party or by which it or any of its properties may be bound, which breach, default or violation would, if continued, reasonably be expected to have a Material Adverse Effect or materially impair the ability of the Company to perform its obligations under the Transaction Documents.

 

 
8

 

 

Section 3.09     No Conflicts. None of (a) the offering, issuance and sale by the Company of the New Shares, (b) the execution, delivery and performance of the Transaction Documents, or (c) the consummation of the transactions contemplated hereby and thereby (i) constitutes or will constitute a violation of the Organizational Documents of any of the Company or its subsidiaries, (ii) constitutes or will constitute a breach or violation of, or a default (or an event which, with notice or lapse of time or both, would constitute such a default) under, any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which any of the Company or its subsidiaries is a party or by which any of them or any of their respective properties may be bound, (iii) violates or will violate any statute, Law, Permit or regulation or any order, judgment, decree or injunction of any court or Governmental Authority or body having jurisdiction over of the Company or its subsidiaries or any of their properties in a proceeding to which any of them or their property is or was a party, or (iv) results or will result in the creation or imposition of any Lien upon any property or asset of any of the Company or its subsidiaries, which conflicts, breaches, violations, defaults or liens, in the case of clauses (ii), (iii) or (iv), would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect or materially impair the ability of the Company to consummate the transactions contemplated by this Agreement.

 

Section 3.10     Authority; Enforceability. The Company has all requisite power and authority to issue, sell and deliver the New Shares, in accordance with and upon the terms and conditions set forth in this Agreement and the Warrant. All corporate action to be taken by the Company for the authorization, issuance, sale and delivery of the New Shares, the execution and delivery of the Transaction Documents and the consummation of the transactions contemplated hereby and thereby has been validly taken. No approval from the holders of outstanding Common Stock is required under the Organizational Documents of the Company or any applicable Law. Each of the Transaction Documents has been duly and validly authorized and has been or, with respect to the Transaction Documents to be delivered at the Closing, will be, validly executed and delivered by the Company, and constitutes, or will constitute, the legal, valid and binding obligations of the Company, enforceable in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization and other laws of general applicability relating to or affecting creditors’ rights and by general principles of equity.

 

Section 3.11     Approvals. No authorization, consent, approval, waiver, license, qualification or written exemption from, nor any filing, declaration, qualification or registration with, any Governmental Authority or any other Person is required in connection with the execution, delivery or performance by the Company of any of the Transaction Documents or the Company’s issuance and sale of the New Shares, except as may be required under the state securities or “Blue Sky” Laws.

 

 
9

 

 

Section 3.12     Distribution Restrictions. No subsidiary of the Company is currently prohibited, directly or indirectly, from making any distributions to the Company or another subsidiary of the Company, from making any other distribution on such subsidiary’s equity interests, from repaying to the Company or its affiliates any loans or advances to such subsidiary from the Company or its affiliates or from transferring any of such subsidiary’s property or assets to the Company or any other subsidiary, except (i) as described in or contemplated by the SEC Documents and (ii) such prohibitions mandated by the laws of each such subsidiary’s state of formation.

 

Section 3.13     Investment Company Status. The Company is not now, and immediately after the issuance of the New Shares and the consummation of the transactions hereunder and under the Transaction Documents will not be, an “investment company” or a company controlled by an “investment company” within the meaning of the Investment Company Act of 1940, as amended.

 

Section 3.14     Certain Fees. No fees or commissions are or will be payable by the Company to brokers, finders or investment bankers with respect to the issuance of the New Shares or the Warrant or the consummation of the transactions contemplated by this Agreement or the Transaction Documents. The Company agrees that it will indemnify and hold harmless the Purchaser from and against any and all claims, demands, or liabilities for broker’s, finder’s, placement, or other similar fees or commissions incurred by the Company or alleged to have been incurred by the Company in connection with the issuance of the New Shares or the consummation of the transactions contemplated by this Agreement or the Transactions Documents.

 

Section 3.15     No Labor Disputes. No labor dispute with the employees of any of the Company exists or, to the knowledge of the Company, is imminent.

 

Section 3.16     Insurance. The Company maintains or is entitled to the benefits of insurance from reputable insurers covering its properties, operations, personnel and businesses against such losses and risks as are reasonably adequate to protect it and its businesses in a commercially reasonable manner. All such insurance is outstanding and duly in force on the date hereof.

 

Section 3.17     Books and Records; Sarbanes-Oxley Compliance.

 

(a)     The Company maintains systems of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of the Company consolidated financial statements in conformity with GAAP and to maintain accountability for its assets, (iii) access to the assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

 

(b)     The Company has established and maintains disclosure controls and procedures (to the extent required by and as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), which are designed to provide reasonable assurance that material information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate, to allow for timely decisions regarding required disclosure. The Company has carried out evaluations of the effectiveness of its disclosure controls and procedures as of the end of the most recently completed fiscal quarter covered by the Company’s periodic reports filed with the Commission, and, except as disclosed in the SEC Documents, such disclosure controls and procedures are effective in all material respects to perform the functions for which they were established.

 

 
10

 

 

(c)     The Company and, to the Company’s knowledge, its directors or officers, in their capacities as such, are in compliance in all material respects with all applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith.

 

Section 3.18     Taxes.

 

(a)     Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, (i) the Company has prepared and timely filed (taking into account any extension of time within which to file) all Tax Returns required to be filed and all such filed Tax Returns are complete and accurate, (ii) the Company has timely paid all Taxes that are required to be paid by it, (iii) there are no audits, examinations, investigations, actions, suits, claims or other proceedings in respect of Taxes pending or threatened in writing nor has any deficiency for any Tax been assessed by any Governmental Authority in writing against the Company, and (iv) all Taxes required to be withheld by the Company have been withheld and paid over to the appropriate Tax authority (except, in the case of this clause (iv) or clause (i) or (ii) above, with respect to matters contested in good faith and for which adequate reserves have been established on the Company’s financial statements in accordance with GAAP).

 

(b)     As used in this Agreement, (i) “Taxes” means any and all domestic or foreign, federal, state, local or other taxes of any kind (together with any and all interest, penalties, additions to tax and additional amounts imposed with respect thereto) imposed by any Governmental Authority, including taxes on or with respect to income, franchises, windfall or other profits, gross receipts, property, sales, use, capital stock, payroll, employment, unemployment, social security, workers’ compensation or net worth, and taxes in the nature of excise, withholding, ad valorem or value added, and including any liability in respect of any items described above as a transferee or successor, pursuant to Section 1.1502-6 of the regulations promulgated by the U.S. Treasury Department pursuant to and in respect of provisions of the Internal Revenue Code of 1986, as amended (or any similar provision of state, local or foreign Law), or as an indemnitor, guarantor, surety or in a similar capacity under any Contract and (ii) “Tax Return” means any return, report or similar filing (including the attached schedules) filed or required to be filed with respect to Taxes (and any amendments thereto), including any information return, claim for refund or declaration of estimated Taxes.

 

 
11

 

 

Section 3.19     Compliance with Laws; Environmental Laws.

 

(a)     The Company is not in violation of any Law applicable to the Company, except as would not, individually or in the aggregate, have a Material Adverse Effect. The Company possesses all Permits issued by the appropriate regulatory authorities necessary to own its properties and to conduct its business, except where the failure to possess such Permits would not, individually or in the aggregate, have a Material Adverse Effect, and the Company has not received any written notice of proceedings relating to the revocation or modification of any such Permit, except where such potential revocation or modification would not, individually or in the aggregate, have a Material Adverse Effect.

 

(b)     The Company has timely applied for or obtained and is in compliance with all such obtained material Environmental Permits required for its operations as currently conducted, except as (i) would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect or (ii) have been disclosed in SEC Documents. The Company has not received written notice of any pending action or proceeding and, to the knowledge of the Company, no action or proceeding is threatened, to suspend, revoke, modify or terminate any Environmental Permit held by it that would have a Material Adverse Effect. The operations of the Company are in compliance with all applicable Environmental Laws and, to the knowledge of the Company, no occurrences or conditions currently exist that would reasonably be expected to adversely affect the Company’s continued compliance with such Environmental Laws and any Environmental Permits issued thereunder, except as (A) would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect or (B) have been disclosed in SEC Documents. There are no present claims asserted against the Company under applicable Environmental Laws, including claims relating to the release, spill or disposal of any Hazardous Substances resulting from the operations of the Company, except as such claims (1) would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect or (2) have been disclosed in SEC Documents. Notwithstanding any other provision of this Agreement, the representations and warranties set forth in this Section 3.19(b) are the only representations and warranties relating to Environmental Laws or Environmental Permits.

 

Section 3.20     Required Disclosures and Descriptions. There are no legal or governmental proceedings pending or, to the knowledge of the Company, threatened, against the Company or its subsidiaries, or to which any of the Company or its subsidiaries is a party, or to which any of their respective properties is subject, that are required to be described in the SEC Documents but are not described as required, and there are no agreements, contracts, indentures, leases or other instruments that are required to be described in the SEC Documents or to be filed as an exhibit to the SEC Documents that are not described or filed as required by the Securities Act or the Exchange Act.

 

Section 3.21     Title to Property. Each of the Company and its subsidiaries has good and indefeasible title to all real property and good title to all personal property described in the SEC Documents as owned by such entities, free and clear of all Liens except such (a) as are described in the SEC Documents, or (b) as would not, in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

 
12

 

 

Section 3.22     FCPA; OFAC; Anti-Corruption.

 

(a)     The Company has not, no Affiliate or agent of the Company has, and no other Person acting on behalf of or associated with the Company, acting alone or together, has: (i) received, directly or indirectly, any rebates, payments, commissions, promotional allowances, or any other economic benefits, regardless of their nature or type, from any customer, supplier, or employee or agent of any customer or supplier; or (ii) directly or indirectly given or agreed to give any money, gift or similar benefit to any customer, supplier, or employee or agent of any customer or supplier, any official or employee of any Governmental Authority (domestic or foreign), or any political party or candidate for office, or other Person who was, is or may be in a position to help or hinder the business of the Company (or assist the Company in connection with any actual or proposed transaction), in each case which: (A) may subject the Company to any damage or penalty in any civil, criminal, or governmental legal proceeding; (B) if given in the past, may have had an adverse effect on the assets, business, or operations of the Company; or (C) if continued in the future, may adversely affect the assets, business, or operations of the Company.

 

(b)     The Company is not aware of or has, nor to the Company’s knowledge has any of its employees, agents, advisors, consultants, representatives, or others for whom any of them may have responsibility, taken any action, directly or indirectly, that constitutes: (i) a breach or an alleged breach by such Persons of the Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”), including making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay, or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA; or (ii) a breach or alleged breach by such Persons of any other applicable Laws relating to bribery or corruption (the “Anti-Corruption Laws”).

 

(c)     None of the Company or any director or officer of the Company, and to the knowledge of the Company, no agent, employee or affiliate of the Company, is the subject of any sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department, the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority.

 

(d)     The Company has conducted its business in compliance with the FCPA and the Anti-Corruption Laws and has retained, and will continue to retain, accurate books and records and has instituted and maintained policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.

 

 
13

 

 

ARTICLE IV
REPRESENTATIONS AND WARRANTIES AND
COVENANTS OF THE PURCHASER

 

The Purchaser represents and warrants and covenants to the Company as follows:

 

Section 4.01     Existence. The Purchaser is duly organized and validly existing and in good standing under the laws of its state of formation, with all necessary limited liability company power and authority to own properties and to conduct its business as currently conducted.

 

Section 4.02     Authorization, Enforceability. The Purchaser has all necessary limited liability company power and authority to enter into, deliver and perform its obligations under the Transaction Documents. The execution, delivery and performance of the Transaction Documents by the Purchaser and the consummation by it of the transactions contemplated thereby have been duly and validly authorized by all necessary limited liability company action, and no further consent or authorization of the Purchaser is required. Each of the Transaction Documents has been duly executed and delivered by the Purchaser, and constitutes the legal, valid and binding obligations of the Purchaser; provided, that, with respect to each such agreement, the enforceability thereof may be limited by applicable bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium or similar laws from time to time in effect affecting creditors’ rights and remedies generally and by general principles of equity (regardless of whether such principles are considered in a proceeding in equity or at law).

 

Section 4.03     No Breach. The execution, delivery and performance of the Transaction Documents by the Purchaser and the consummation by the Purchaser of the transactions contemplated thereby will not (a) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, any material agreement to which the Purchaser is a party or by which the Purchaser is bound or to which any of the property or assets of the Purchaser is subject, (b) conflict with or result in any violation of the provisions of the Organizational Documents of the Purchaser, or (c) violate any statute, order, rule or regulation of any court or governmental agency or body having jurisdiction over the Purchaser or the property or assets of the Purchaser, except in the case of clauses (a) and (c) for such conflicts, breaches, violations or defaults as would not prevent the consummation of the transactions contemplated by the Transaction Documents.

 

Section 4.04     Certain Fees. No fees or commissions are or will be payable by the Purchaser to brokers, finders or investment bankers with respect to the purchase of the New Shares or the Warrant or the consummation of the transactions contemplated by this Agreement, except for fees or commissions for which the Company is not responsible. The Purchaser agrees that it will indemnify and hold harmless the Company from and against any and all claims, demands, or liabilities for broker’s, finder’s, placement, or other similar fees or commissions incurred by the Purchaser or alleged to have been incurred by the Purchaser in connection with the purchase of the New Shares or the consummation of the transactions contemplated by this Agreement.

 

 
14

 

 

Section 4.05     Unregistered Securities.

 

(a)     Accredited Investor Status; Sophisticated Purchaser. The Purchaser is an “accredited investor” within the meaning of Rule 501 under the Securities Act and is able to bear the risk of its investment in the New Shares. The Purchaser has such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the purchase of the New Shares. The Purchaser understands that its purchase of the New Shares involves a high degree of risk. The Purchaser has sought such accounting, legal and tax advice as it has considered necessary to make an informed investment decision with respect to its acquisition of the New Shares.

 

(b)     Legends. The Purchaser understands that, until such time as the New Shares have been registered pursuant to the provisions of the Securities Act, or the New Shares are eligible for resale pursuant to Rule 144 promulgated under the Securities Act without any restriction as to the number of securities as of a particular date that can then be immediately sold, the New Shares will bear a restrictive legend:

 

THIS SECURITY HAS NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (the “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED OR SOLD UNLESS (I) REGISTERED AND QUALIFIED PURSUANT TO THE APPLICABLE PROVISIONS OF FEDERAL AND STATE SECURITIES LAWS, (II) PURSUANT TO RULE 144 OF THE SECURITIES ACT OR (III) AN EXEMPTION FROM SUCH REGISTRATION OR QUALIFICATION APPLIES. THEREFORE, NO SALE OR TRANSFER OF THIS SECURITY SHALL BE MADE, NO ATTEMPTED SALE OR TRANSFER SHALL BE VALID, AND THE ISSUER SHALL NOT BE REQUIRED TO GIVE ANY EFFECT TO ANY SUCH TRANSACTION UNLESS (A) SUCH TRANSACTION HAS BEEN DULY REGISTERED UNDER THE SECURITIES ACT AND QUALIFIED OR APPROVED UNDER APPROPRIATE STATE SECURITIES LAWS OR (B) THIS SECURITY MAY BE SOLD PURSUANT TO RULE 144 OF THE SECURITIES ACT.

 

The Purchaser understands that, until such time as the New Shares have been registered pursuant to the provisions of the Securities Act, or the New Shares are eligible for resale pursuant to Rule 144 promulgated under the Securities Act without any restriction as to the number of securities as of a particular date that can then be immediately sold, the New Shares will bear the restrictive legend set forth above.

 

(c)     Purchase Representation. The Purchaser is purchasing the Shares for its own account and not with a view to distribution in violation of any securities laws. The Purchaser has been advised and understands the New Shares have not been registered under the Securities Act or under the “blue sky” laws of any jurisdiction and may be resold only if registered pursuant to the provisions of the Securities Act (or if eligible, pursuant to the provisions of Rule 144 promulgated under the Securities Act or pursuant to another available exemption from the registration requirements of the Securities Act). The Purchaser has been advised and understands that the Company, in issuing the Shares, is relying upon, among other things, the representations and warranties of the Purchaser contained in this Article IV in concluding that such issuance is a “private offering” and is exempt from the registration provisions of the Securities Act.

 

 
15

 

 

(d)     Rule 144. The Purchaser understands that there may not exist or develop a public market for the New Shares and that the New Shares must be held indefinitely unless and until the New Shares are registered under the Securities Act or an exemption from registration is available. The Purchaser has been advised of and is aware of the provisions of Rule 144 promulgated under the Securities Act.

 

ARTICLE V
INDEMNIFICATION, COSTS AND EXPENSES

 

Section 5.01     Indemnification by the Company. The Company agrees to indemnify the Purchaser and its Representatives (collectively, the “Purchaser Related Parties”) from costs, losses, liabilities, damages, or expenses of any kind or nature whatsoever, and hold each of them harmless against, any and all actions, suits, proceedings (including any investigations, litigation or inquiries), demands, and causes of action, and, in connection therewith, and promptly upon demand, pay or reimburse each of them for all costs, losses, liabilities, damages, or expenses of any kind or nature whatsoever (including the reasonable fees and disbursements of counsel and all other reasonable expenses incurred in connection with investigating, defending or preparing to defend any such matter that may be incurred by them or asserted against or involve any of them), whether or not involving a Third-Party Claim, as a result of, arising out of, or in any way related to (a) the failure of any of the representations or warranties made by the Company contained herein to be true and correct in all material respects as of the date made (except to the extent any representation or warranty includes the word “material,” Material Adverse Effect or words of similar import, with respect to which such representation or warranty, or applicable portions thereof, must have been true and correct) or (b) the breach of any covenants of the Company contained herein, provided that, in the case of the immediately preceding clause (a), such claim for indemnification is made prior to the expiration of the survival period of such representation or warranty; provided, however, that for purposes of determining when an indemnification claim has been made, the date upon which a Purchaser Related Party shall have given notice (stating in reasonable detail the basis of the claim for indemnification) to the Company shall constitute the date upon which such claim has been made. No Purchaser Related Party shall be entitled to recover special, indirect, exemplary, incidental, lost profits, speculative or punitive damages under this Section 5.01; provided, however, that such limitation shall not prevent any Purchaser Related Party from recovering under this Section 5.01 for any such damages to the extent that such damages are direct damages in the form of diminution in value or are payable to a third party in connection with any Third-Party Claims.

 

Section 5.02     Indemnification by the Purchaser. The Purchaser agrees to indemnify the Company and its Representatives (collectively, the “Company Related Parties”) from, costs, losses, liabilities, damages, or expenses of any kind or nature whatsoever, and hold each of them harmless against, any and all actions, suits, proceedings (including any investigations, litigation or inquiries), demands, and causes of action, and, in connection therewith, and promptly upon demand, pay or reimburse each of them for all costs, losses, liabilities, damages, or expenses of any kind or nature whatsoever (including the reasonable fees and disbursements of counsel and all other reasonable expenses incurred in connection with investigating, defending or preparing to defend any such matter that may be incurred by them or asserted against or involve any of them), whether or not involving a Third-Party Claim, as a result of, arising out of, or in any way related to (a) the failure of any of the representations or warranties made by the Purchaser contained herein to be true and correct in all material respects as of the date made or (b) the breach of any of the covenants of the Purchaser contained herein, provided that, in the case of the immediately preceding clause (a), such claim for indemnification relating to a breach of any representation or warranty is made prior to the expiration of the survival period of such representation or warranty; provided, however, that for purposes of determining when an indemnification claim has been made, the date upon which a Company Related Party shall have given notice (stating in reasonable detail the basis of the claim for indemnification) to the Purchaser shall constitute the date upon which such claim has been made. No Company Related Party shall be entitled to recover special, indirect, exemplary, incidental, lost profits, speculative or punitive damages under this Section 5.02; provided, however, that such limitation shall not prevent any Company Related Party from recovering under this Section 5.02 for any such damages to the extent that such damages are direct damages in the form of diminution in value or payable to a third party in connection with any Third-Party Claims.

 

 
16

 

 

Section 5.03     Indemnification Procedure.

 

(a)     A claim for indemnification for any matter not involving a Third-Party Claim may be asserted by notice to the party from whom indemnification is sought; provided, however, that failure to so notify the indemnifying party shall not preclude the indemnified party from any indemnification which it may claim in accordance with this Article V, except as otherwise provided in Section 5.01 and Section 5.02.

 

(b)     Promptly after any Company Related Party or Purchaser Related Party (hereinafter, the “Indemnified Party”) has received notice of any indemnifiable claim hereunder, or the commencement of any action, suit or proceeding by a third person, which the Indemnified Party believes in good faith is an indemnifiable claim under this Agreement (each a “Third-Party Claim”), the Indemnified Party shall give the indemnitor hereunder (the “Indemnifying Party”) written notice of such Third-Party Claim, but failure to so notify the Indemnifying Party will not relieve the Indemnifying Party from any liability it may have to such Indemnified Party hereunder except to the extent that the Indemnifying Party is materially prejudiced by such failure. Such notice shall state the nature and the basis of such Third-Party Claim to the extent then known. The Indemnifying Party shall have the right to defend and settle, at its own expense and by its own counsel who shall be reasonably acceptable to the Indemnified Party, any such matter. If the Indemnifying Party undertakes to defend or settle, it shall promptly, and in no event later than ten (10) days, notify the Indemnified Party of its intention to do so, and the Indemnified Party shall cooperate with the Indemnifying Party and its counsel in all commercially reasonable respects in the defense thereof and the settlement thereof. Such cooperation shall include, but shall not be limited to, furnishing the Indemnifying Party with any books, records and other information reasonably requested by the Indemnifying Party and in the Indemnified Party’s possession or control. Such cooperation of the Indemnified Party shall be at the cost of the Indemnifying Party. After the Indemnifying Party has notified the Indemnified Party of its intention to undertake to defend or settle any such asserted liability, and for so long as the Indemnifying Party diligently pursues such defense, the Indemnifying Party shall not be liable for any additional legal expenses incurred by the Indemnified Party in connection with any defense or settlement of such asserted liability; provided, however, that the Indemnified Party shall be entitled (i) at its expense, to participate in the defense of such asserted liability and the negotiations of the settlement thereof and (ii) if (A) the Indemnifying Party has, within ten (10) Business Days of when the Indemnified Party provides written notice of a Third-Party Claim, failed (1) to assume the defense or employ counsel reasonably acceptable to the Indemnified Party and (2) notify the Indemnified Party of such assumption or (B) if the defendants in any such action include both the Indemnified Party and the Indemnifying Party and counsel to the Indemnified Party shall have concluded that there may be reasonable defenses available to the Indemnified Party that are different from or in addition to those available to the Indemnifying Party or if the interests of the Indemnified Party reasonably may be deemed to conflict with the interests of the Indemnifying Party, then the Indemnified Party shall have the right to select a separate counsel and to assume such legal defense and otherwise to participate in the defense of such action, with the expenses and fees of such separate counsel and other expenses related to such participation to be reimbursed by the Indemnifying Party as incurred. The Indemnifying Party shall not, in connection with any Third-Party Claim, be liable for the fees and expenses of more than one separate counsel (in addition to local counsel) for all Indemnified Parties in connection with such Third-Party Claim, except to the extent the use of one counsel to represent all Indemnified Parties in respect of such Third-Party Claim would present such counsel with an actual or potential conflict of interest. Notwithstanding any other provision of this Agreement, the Indemnifying Party shall not settle any indemnified claim without the consent of the Indemnified Party, unless the settlement thereof imposes no liability or obligation on, and includes a complete release from liability of, and does not include any admission of wrongdoing or malfeasance by, the Indemnified Party. The remedies provided for in this Section 5.03 are cumulative and are not exclusive of any remedies that may be available to a party at law or in equity or otherwise.

 

 
17

 

 

ARTICLE VI
MISCELLANEOUS

 

Section 6.01     Expenses. Except as otherwise provided in the Transaction Documents, all costs and expenses, including fees and disbursements of counsel, financial advisors and accountants, incurred in connection with the Transaction Documents and the transactions contemplated thereby shall be paid by the party incurring such costs and expenses.

 

Section 6.02     Interpretation. Article, Section, Schedule and Exhibit references in this Agreement are references to the corresponding Article, Section, Schedule or Exhibit to this Agreement, unless otherwise specified. All Exhibits and Schedules to this Agreement are hereby incorporated and made a part hereof as if set forth in full herein and are an integral part of this Agreement. All references to instruments, documents, Contracts and agreements are references to such instruments, documents, Contracts and agreements as the same may be amended, supplemented and otherwise modified from time to time, unless otherwise specified. The word “including” shall mean “including but not limited to” and shall not be construed to limit any general statement that it follows to the specific or similar items or matters immediately following it. Whenever the Company has an obligation under the Transaction Documents, the expense of complying with that obligation shall be an expense of the Company unless otherwise specified. Any reference in this Agreement to “$” shall mean U.S. dollars. Whenever any determination, consent or approval is to be made or given by the Purchaser, such action shall be in the Purchaser’s sole discretion, unless otherwise specified in this Agreement. If any provision in the Transaction Documents is held to be illegal, invalid, not binding or unenforceable, (a) such provision shall be fully severable and the Transaction Documents shall be construed and enforced as if such illegal, invalid, not binding or unenforceable provision had never comprised a part of the Transaction Documents, and the remaining provisions shall remain in full force and effect, and (b) the parties hereto shall negotiate in good faith to modify the Transaction Documents so as to effect the original intent of the parties as closely as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated to the greatest extent possible. When calculating the period of time before which, within which or following which any act is to be done or step taken pursuant to the Transaction Documents, the date that is the reference date in calculating such period shall be excluded. If the last day of such period is a non-Business Day, the period in question shall end on the next succeeding Business Day. Any words imparting the singular number only shall include the plural and vice versa. The words such as “herein,” “hereinafter,” “hereof” and “hereunder” refer to this Agreement as a whole and not merely to a subdivision in which such words appear unless the context otherwise requires. The provision of a Table of Contents, the division of this Agreement into Articles, Sections and other subdivisions and the insertion of headings are for convenience of reference only and shall not affect or be utilized in construing or interpreting this Agreement.

 

 
18

 

 

Section 6.03     Survival of Provisions. The representations and warranties set forth in Section 3.01, Section 3.02, Section 3.10, Section 3.14, Section 4.01, Section 4.02, Section 4.04, and Section 4.05 hereunder shall survive the execution and delivery of this Agreement indefinitely and the other representations and warranties set forth herein shall survive for a period of twenty-four (24) months following the date hereof, regardless of any investigation made by or on behalf of the Company or the Purchaser. The covenants made in this Agreement or any other Transaction Document shall survive the Closing and remain operative and in full force and effect regardless of acceptance of the Shares and the Warrant. Regardless of any purported general termination of this Agreement, the provisions of Article V and all indemnification rights and obligations of the Company and the Purchaser thereunder, and this Article VI shall remain operative and in full force and effect as between the Company and the Purchaser, unless the Company and the Purchaser execute a writing that expressly (with specific references to the applicable Section or subsection of this Agreement) terminates such rights and obligations as between the Company and the Purchaser.

 

Section 6.04     No Waiver; Modifications in Writing.

 

(a)     Delay. No failure or delay on the part of any party in exercising any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, power or remedy preclude any other or further exercise thereof or the exercise of any other right, power or remedy. The remedies provided for herein are cumulative and are not exclusive of any remedies that may be available to a party at law or in equity or otherwise.

 

(b)     Specific Waiver. Except as otherwise provided herein, no amendment, waiver, consent, modification or termination of any provision of any Transaction Document shall be effective unless signed by each of the parties thereto affected by such amendment, waiver, consent, modification or termination. Any amendment, supplement or modification of or to any provision of any Transaction Document, any waiver of any provision of any Transaction Document and any consent to any departure by the Company from the terms of any provision of any Transaction Document shall be effective only in the specific instance and for the specific purpose for which made or given. Except where notice is specifically required by this Agreement, no notice to or demand on the Company in any case shall entitle the Company to any other or further notice or demand in similar or other circumstances. Any investigation by or on behalf of any party shall not be deemed to constitute a waiver by the party taking such action of compliance with any representation, warranty, covenant or agreement contained herein.

 

 
19

 

 

Section 6.05     Binding Effect. This Agreement shall be binding upon the Company, the Purchaser and their respective successors and permitted assigns. Except as expressly provided in this Agreement, this Agreement shall not be construed so as to confer any right or benefit upon any Person other than the parties to this Agreement and their respective successors and permitted assigns.

 

Section 6.06     Communications. All notices and demands provided for hereunder shall be in writing and shall be given by registered or certified mail, return receipt requested, telecopy, air courier guaranteeing overnight delivery or personal delivery to the following addresses

 

(a)     If to the Purchaser:

 

Baker Botts L.L.P.

910 Louisiana St.

Houston, Texas 77002
Attention: Hillary Holmes
Facsimile: (713) 229-7708
Email: hillary.holmes@bakerbotts.com

 

(b)     If to the Company:

 

AmeriCann, Inc.

3200 Brighton Blvd., Unit 144

Denver, Colorado 80216
Attention: Tim Keogh
Email: timk@americann.co

 

with a copy to (which shall not constitute notice):

 

Hart & Hart, LLC

1624 Washington St.

Denver, Colorado 80203

Attention: Bill Hart

Email: harttrinen@aol.com

 

or to such other address as the Company or the Purchaser may designate in writing. All notices and communications shall be deemed to have been duly given: at the time delivered by hand, if personally delivered; upon actual receipt if sent by certified or registered mail, return receipt requested, or regular mail, if mailed; upon actual receipt of the overnight courier copy, if sent via facsimile; and upon actual receipt when delivered to an air courier guaranteeing overnight delivery.

 

 
20

 

 

Section 6.07     Removal of Legend. In connection with a sale of the New Shares by the Purchaser in reliance on Rule 144 promulgated under the Securities Act, the Purchaser or its broker shall deliver to the Company a broker representation letter providing to the Company any information the Company deems necessary to determine that the sale of such New Shares is made in compliance with Rule 144 promulgated under the Securities Act, including, as may be appropriate, a certification that the Purchaser is not an affiliate of the Company (as defined in Rule 144 promulgated under the Securities Act) and a certification as to the length of time the such New Shares have been held. Upon receipt of such representation letter, the Company shall promptly remove the notation of a restrictive legend in the Purchaser’s or the book-entry account maintained by the Company, including the legend referred to in Section 4.05, and the Company shall bear all costs associated therewith. At such time as the New Shares have been held by the Purchaser for more than one year where the Purchaser is not, and has not been in the preceding three months, an affiliate of the Company (as defined in Rule 144 promulgated under the Securities Act), if the book-entry account of such New Shares still bears the notation of the restrictive legend referred to in Section 4.05, the Company agrees, upon request of the Purchaser or its permitted assignee, to take all steps necessary to promptly effect the removal of the legend described in Section 4.05 from such New Shares, and the Company shall bear all costs associated therewith, regardless of whether the request is made in connection with a sale or otherwise, so long as the Purchaser or its permitted assigns provide to the Company any information the Company deems reasonably necessary to determine that the legend is no longer required under the Securities Act or applicable state laws, including (if there is no such registration statement) a certification that the holder is not an affiliate of the Company (as defined in Rule 144 promulgated under the Securities Act), as well as a covenant to inform the Company if it should thereafter become an affiliate (as defined in Rule 144 promulgated under the Securities Act) and to consent to the notation of an appropriate restriction, and a certification as to the length of time such New Shares have been held. The Company shall cooperate with the Purchaser to effect the removal of the legend referred to in Section 4.05 at any time such legend is no longer appropriate.

 

Section 6.08     Entire Agreement. This Agreement, the other Transaction Documents and the other agreements and documents referred to herein are intended by the parties as a final expression of their agreement and intended to be a complete and exclusive statement of the agreement and understanding of the parties hereto in respect of the subject matter contained herein and therein. There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to in this Agreement, the other Transaction Documents or the other agreements and documents referred to herein or therein with respect to the rights granted by the Company or any of its Affiliates or the Purchaser or any of its Affiliates set forth herein or therein. This Agreement, the other Transaction Documents and the other agreements and documents referred to herein or therein supersede all prior agreements and understandings between the parties with respect to such subject matter.

 

 
21

 

 

Section 6.09     Governing Law; Submission to Jurisdiction. This Agreement, and all claims or causes of action (whether in contract or tort) that may be based upon, arise out of or relate to this Agreement or the negotiation, execution or performance of this Agreement (including any claim or cause of action based upon, arising out of or related to any representation or warranty made in or in connection with this Agreement), will be construed in accordance with and governed by the laws of the State of New York without regard to principles of conflicts of laws. Any action against any party relating to the foregoing shall be brought in any federal or state court of competent jurisdiction located within the State of New York, and the parties hereto hereby irrevocably submit to the non-exclusive jurisdiction of any federal or state court located within the State of New York over any such action. The parties hereby irrevocably waive, to the fullest extent permitted by applicable Law, any objection which they may now or hereafter have to the laying of venue of any such dispute brought in such court or any defense of inconvenient forum for the maintenance of such dispute. Each of the parties hereto agrees that a judgment in any such dispute may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law.

 

Section 6.10     Waiver of Jury Trial. THE PARTIES TO THIS AGREEMENT EACH HEREBY WAIVES, AND AGREES TO CAUSE ITS AFFILIATES TO WAIVE, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION (A) ARISING UNDER THIS AGREEMENT OR (B) IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS AGREEMENT OR ANY OF THE TRANSACTIONS RELATED HERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY OR OTHERWISE. THE PARTIES TO THIS AGREEMENT EACH HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES TO THIS AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.

 

Section 6.11     Exclusive Remedy.

 

(a)     Each party hereto hereby acknowledges and agrees that the rights of each party to consummate the transactions contemplated hereby are special, unique and of extraordinary character and that, if any party violates or fails or refuses to perform any covenant or agreement made by it herein, the non-breaching party may be without an adequate remedy at law. If any party violates or fails or refuses to perform any covenant or agreement made by such party herein, the non-breaching party subject to the terms hereof and in addition to any remedy at law for damages or other relief, may institute and prosecute an action in any court of competent jurisdiction to enforce specific performance of such covenant or agreement or seek any other equitable relief.

 

(b)     The sole and exclusive remedy for any and all claims arising under, out of, or related to this Agreement or the transactions contemplated hereby, shall be the rights of indemnification set forth in Article V only, and no Person will have any other entitlement, remedy or recourse, whether in contract, tort or otherwise, it being agreed that all of such other remedies, entitlements and recourse are expressly waived and released by the parties hereto to the fullest extent permitted by Law. Notwithstanding anything in the foregoing to the contrary, nothing in this Agreement shall limit or otherwise restrict a fraud claim brought by any party hereto or the right to seek specific performance pursuant to Section 6.11(a).

 

 
22

 

 

Section 6.12     No Recourse Against Others.

 

(a)     All claims, obligations, liabilities or causes of action (whether in contract or in tort, in law or in equity, or granted by statute) that may be based upon, in respect of, arise under, out or by reason of, be connected with or relate in any manner to this Agreement, or the negotiation, execution or performance of this Agreement (including any representation or warranty made in, in connection with, or as an inducement to, this Agreement), may be made only against (and are expressly limited to) the Company and the Purchaser. No Person other than the Company or the Purchaser, including no member, partner, stockholder, Affiliate or Representative thereof, nor any member, partner, stockholder, Affiliate or Representative of any of the foregoing, shall have any liability (whether in contract or in tort, in law or in equity, or granted by statute) for any claims, causes of action, obligations or liabilities arising under, out of, in connection with or related in any manner to this Agreement or based on, in respect of or by reason of this Agreement or its negotiation, execution, performance or breach; and, to the maximum extent permitted by Law, each of the Company and the Purchaser hereby waives and releases all such liabilities, claims, causes of action and obligations against any such third Person.

 

(b)     Without limiting the foregoing, to the maximum extent permitted by Law, (i) each of the Company and the Purchaser hereby waives and releases any and all rights, claims, demands or causes of action that may otherwise be available at law or in equity, or granted by statute, to avoid or disregard the entity form of the other or otherwise impose liability of the other on any third Person, whether granted by statute or based on theories of equity, agency, control, instrumentality, alter ego, domination, sham, single business enterprise, piercing the veil, unfairness, undercapitalization or otherwise; and (ii) each of the Company and the Purchaser disclaims any reliance upon any third Person with respect to the performance of this Agreement or any representation or warranty made in, in connection with or as an inducement to this Agreement.

 

Section 6.13     No Third-Party Beneficiaries. Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement, other than (a) the Company, (b) the Purchaser, (c) solely for purposes of Section 6.12, any member, partner, stockholder, Affiliate or Representative of the Company or the Purchaser, or any member, partner, stockholder, Affiliate or Representative of any of the foregoing; and (d) solely for purposes of Article V, any Company Related Party or Purchaser Related Party.

 

 
23

 

 

Section 6.14     Execution in Counterparts. This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which counterparts, when so executed and delivered, shall be deemed to be an original and all of which counterparts, taken together, shall constitute but one and the same agreement.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[Signature page follows.]

 

 
24

 

 

IN WITNESS WHEREOF, the parties hereto execute this Agreement, effective as of the date first above written.

 

 

AMERICANN, INC.

 

 

 

 

 

 

 

 

 

 

By:

/s/ Timothy Keogh

 

 

Name:

Timothy Keogh

 

 

Title:

Chief Executive Officer

 

 

 

 

 

MASSACHUSETTS MEDICAL PROPERTIES, LLC

 

 

 

 

 

 

 

 

 

 

By:

/s/ J.F. Barton

 

 

Name:

J.F. Barton

 

 

Title:

Authorized Person

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

AmeriCann Exh. 10.6 Share Purch Agree Mass. Med. 2-1-17

 

 
Exhibit A

 

 

Exhibit A

 

FORM OF OPINION OF HART & HART, LLC

 

Capitalized terms used but not defined herein have the meanings assigned to such terms in the Share Purchase Agreement (the “Purchase Agreement”). The Company shall furnish to the Purchaser at the Closing an opinion of Hart & Hart, LLC, counsel for the Company, addressed to the Purchaser and dated the date hereof in form satisfactory to the Purchaser, stating that:

 

(i)      Each of the Company and its subsidiaries is validly existing and in good standing under the laws of its jurisdiction of formation. Each of the Company and its subsidiaries has all requisite power and authority under the laws of its jurisdiction of formation necessary to own or lease its properties and to conduct its business, in each case in all material respects as described in the SEC Documents.

 

(ii)      Except as have been waived or satisfied, there are no preemptive rights or other rights to subscribe for or to purchase, nor any restriction upon the voting or transfer of, any interests in the Company.

 

(iii)      The New Shares to be issued and sold to the Purchaser by the Company pursuant to the Purchase Agreement and the Warrant, as applicable, have been duly authorized in accordance with the Organizational Documents of the Company and, when issued and delivered to the Purchaser against payment therefor in accordance with the terms of the Purchase Agreement or Warrant, as applicable, will be validly issued, fully paid and nonassessable.

 

(iv)      No consent, approval, authorization, filing with or order of any federal or Delaware court, Governmental Authority or body having jurisdiction over the Company is required for the issuance and sale by the Company of the New Shares, the execution, delivery and performance by the Company of the Transaction Documents, or the consummation of the transactions contemplated by the Transaction Documents, except those that have been obtained.

 

(v)      Assuming the accuracy of the representations and warranties of the Purchaser and the Company contained in the Purchase Agreement and the Warrant, the offer, issuance and sale of the New Shares by the Company to the Purchaser solely in the manner contemplated by the Purchase Agreement or the Warrant are exempt from the registration requirements of the Securities Act; provided, however, that no opinion is expressed as to any subsequent sale or resale of the New Shares.

 

(vi)      The Company is not an “investment company” as such term is defined in the Investment Company Act of 1940, as amended.

 

(vii)      None of the offering, issuance or sale by the Company of the New Shares or the execution, delivery and performance of the Transaction Documents by the Company, or the consummation of the transactions contemplated thereby will result in a breach or violation of (A) the Organizational Documents of the Company or any of its subsidiaries, (B) any bond, debenture, note or any other evidence of indebtedness or in any agreement, indenture, lease or other instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries or properties may be bound, or (C) any applicable Law, which in the case of clauses (B) or (C) would be reasonably expected to have a Material Adverse Effect.

 

(viii)      Each of Transaction Documents has been duly authorized and validly executed and delivered by the Company, and constitutes a valid and binding obligation of the Company, enforceable against it in accordance with its terms, except insofar as the enforceability thereof may be limited by (A) applicable bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium or similar laws from time to time in effect affecting creditors’ rights and remedies generally and by general principles of equity (regardless of whether such principles are considered in a proceeding in equity or at law) and (B) public policy, applicable law relating to fiduciary duties and indemnification and an implied covenant of good faith and fair dealing.

 

 

Exhibit A

 
 

 

 

Exhibit B

 

FORM OF Lease Agreement

 

(See attached.)

 

 

 

 

 Exhibit B

 
 

 

 

GROUND LEASE

 

 

DATED as of October 17, 2016

 

 

between

 

 

Massachusetts Medical Properties LLC, as Landlord

 

 

and

 

 

AmeriCann, Inc., as Tenant

 

 

 

 

 

 

 
 

 

 

GROUND LEASE

 

This Ground Lease is entered into as of October 17, 2016, by and between Massachusetts Medical Properties LLC, a Delaware limited liability company having a principal place of business at P. O. Box 558, Wood River, IL 62095 (“Landlord”) and AmeriCann, Inc., a Colorado corporation having a principal place of business at 3200 Brighton Blvd., Suite 114, Denver, CO 80216 (“Tenant”).

 


In consideration of the covenants and agreements set forth herein, the parties to this Ground Lease (“Lease”) hereby agree to the following:

 

 

 

1.     DEFINITIONS

 

The following terms whenever initially capitalized and used herein shall have the following meanings:

 

Additional Rent” shall have the meaning set forth in Section 4.3 of this Lease.

 

Alteration” shall have the meaning set forth in Section 8.4 of this Lease.

 

Award” shall mean all compensation, sums or anything of value awarded, paid or received in a total or a partial Condemnation.

 

Base Rent” shall mean the greatest of (i) Thirty Thousand Dollars ($30,000.00) per month ($360,000.00 per Year), (ii) Thirty-Eight Cents ($0.38) per month ($4.50 per Year) multiplied by the total square footage of all Completed Buildings (as such term is defined in Section 9.3 hereof) at the Premises, or (iii) Turnover Rent (as such term is defined in Section 4.1 hereof).

 

Buildings” shall mean any and all structures and improvements constructed on the Premises (including, but not limited to, any greenhouse facilities), any additional construction thereof, and any restoration or replacement thereof, and any alterations, additions or improvements made thereto pursuant to the provisions hereof, and any new structures placed thereon, including, without limitation, the improvements to be constructed pursuant to Article 9 of this Lease.

 

Building Equipment” shall mean all equipment, including without limitation, machinery, apparatus, fittings, plumbing equipment and fixtures, heating and air conditioning equipment and fixtures, lighting fixtures, now or hereafter attached to the Premises and the property of Tenant, but not including equipment used solely for construction of Building.

 

Commencement Date” shall be the date of execution of this Lease.

 

 
 

 

 

Condemnation” shall mean (i) the taking by a Condemnor of the title to or the possession or use of all or part of the Premises by virtue of condemnation, eminent domain or for any public or quasi-public use and (ii) a voluntary sale or transfer by Landlord to any Condemnor, either under threat of condemnation or while legal proceedings for condemnation are pending.

 

Condemnor” shall mean any public or quasi-public authority, or private corporation or individual having the power of Condemnation.

 

Contested Imposition” shall have the meaning set forth in Section 4.7 of this Lease.

 

Event of Default” shall have the meaning set forth in Section 16.1 of this Lease.

 

Force Majeure” or “Unavoidable Delays” shall mean acts of God, strikes, lockouts, material or labor restrictions by any governmental authority, war, civil riot, fire, floods, and any other unavoidable casualties not reasonably within the control of the Landlord or Tenant and which Landlord or Tenant is unable, wholly or in part, to prevent or overcome upon the exercise of due diligence.

 

Governmental Authority” shall mean the United States of America, the Commonwealth of Massachusetts, the Town of Freetown, the County of Bristol, and any political subdivision thereof and any agency, department, commission, board, bureau or instrumentality of any of them.

 

Impositions” shall have the meaning set forth in Section 4.4 of this Lease.

 

Land” shall have the meaning set forth in Section 2.1 of this Lease.

 

Legal Requirements” shall mean any and all present and future laws, acts, rules, requirements, orders, directions, ordinances, regulations, judgments, decrees or injunctions of or by any Governmental Authority, ordinary or extraordinary, foreseen or unforeseen which may at any time be applicable to the Premises or any part thereof or to any condition or use thereof and all licenses, permits and other governmental consents which are or may be required for the use and occupancy of the Premises for the Permitted Uses.

 

Mortgage” shall mean any mortgage, deed of trust or other indenture constituting a lien on the Land and/or this Lease or any interest therein, together with the note or obligations which it secures.

 

Mortgagee” shall mean the holder, trustee or beneficiary of any Mortgage.

 

Permitted Mortgage” shall mean any mortgage which constitutes, or any security interest given in connection therewith which together constitute, a lien upon the leasehold estate hereby created and Tenant's interest in the Buildings (including Tenant's interest as sublessor in any present or future subleases and any other interest of Tenant in the Building Equipment), which mortgage complies with the requirements of Section 15.3.

 

 
2

 

 

Permitted Uses” shall mean the operation of a cannabis cultivation facility, registered marijuana distribution center, and any other uses permitted by Legal Requirements.

 

Premises” shall mean the Land, the Buildings and the Building Equipment located at certain property known and numbered as Lot 1A and Lot 3A, Ridge Hill Road, Freetown, MA and more particularly described in the Bristol County Registry of Deeds in Book 6740, Page 36.

 

Rent Commencement Date” shall mean the date that is six (6) months following the Commencement Date.

 

Sublease” shall mean any agreement, written or oral, entered into by Tenant by which any entity is given any rights of use or occupancy of or any benefit flowing from the Premises or any portion thereof, including a permit, license or concession.

 

Substantial Alteration” shall have the meaning set forth in Section 8.4 of this Lease.

 

Term” shall mean the period of fifty (50) Years beginning on the Commencement Date and ending on the Termination Date as provided herein, subject to Tenant’s right to extend as set forth in Section 3.3 of this Lease.

 

Termination Date” shall mean the date fifty (50) Years from the Commencement Date, or such earlier date of termination of this Lease in accordance herewith, subject to Tenant’s right to extend as set forth in Section 3.3 of this Lease.

 

Year” shall mean, unless otherwise specified, a 12 month period beginning on the Commencement Date, and each successive Year thereafter shall commence on the anniversary of the Commencement Date.

 

2.     LEASE OF LAND

 

2.1.     Land. Landlord, for and in consideration of the rents, covenants and agreements herein contained on the part of Tenant to be paid, kept and performed, has leased, rented, let and demised, and by these presents does lease, rent, let and demise, unto Tenant, and Tenant does hereby take, accept and hire, upon and subject to the conditions hereinafter expressed, all those certain plots and parcels of land, more particularly described in Exhibit A annexed hereto and made a part hereof, together with all rights, privileges and easements appurtenant thereto or which are hereinafter provided in this Lease, (hereinafter collectively called the “Land”).

 

3.     TERM

 

3.1.     Term. The Term of this Lease will commence on the Commencement Date. Tenant shall accept possession of the Premises on the Commencement Date, and by such acceptance shall be deemed to have accepted the Premises in their condition as of the Commencement Date. For so long as Tenant timely pays the Rent, complies with and performs all obligations and covenants required by it under this Lease, and no Event of Default (as hereinafter defined) exists or continues beyond any applicable cure period, then Tenant shall have the right to hold and occupy the Premises for the Term.

 

 
3

 

 

3.2.     Termination Date. This Lease shall terminate on the Termination Date, subject to Tenant’s right to extend as set forth below. It is intended that at no time during the Term will the Landlord have title to any improvements that may be constructed upon the Premises, including, without limitation, the Buildings, and that such title shall continue to be in the name of Tenant until the expiration or earlier termination of this Lease.

 

3.3.     Option to Extend. Subject to the further provisions of this Section 3.3, Tenant shall have the right and option to extend the Term for four (4) additional periods of ten (10) Years each (each, an “Extension Term”). The first Extension Term shall commence immediately upon expiration of the initial Term and each successive Extension Term shall commence upon the expiration of the preceding Extension Term, provided that Tenant shall give Landlord notice of Tenant’s exercise of such option no later than twelve (12) months prior to the then scheduled expiration of the Term. Notwithstanding anything to the contrary contained herein, it shall be a condition to Tenant’s exercise of its option to extend that no default, or event which with the giving of notice or the passage of time, or both, would constitute a default exist (unless the same is cured within the applicable cure period) at the time of Tenant giving such notice to extend or at the commencement of the applicable Extension Term. The expression “Term” shall mean the initial Term and any Extension Term. All the terms, covenants, conditions, provisions and agreements in the Lease contained herein shall be applicable to any Extension Term. If Tenant shall give notice of its exercise of said option to extend in the manner, within the time period provided aforesaid and with all conditions to such exercise satisfied, the Term shall be extended upon the giving of such notice without the requirement of any further action on the part of either Landlord or Tenant.

 

4.     RENT

 

4.1     Base Rent. (a) Tenant shall pay to Landlord in United States dollars at the address for Landlord specified in the first paragraph of this Lease, during the Term of this Lease the Base Rent as set forth in Section 1, except as otherwise set forth below. The Base Rent shall commence to accrue on the Commencement Date; however, no Base Rent shall be payable until the Rent Commencement Date. On the Rent Commencement Date, Tenant shall pay all Base Rent that has accrued from the Commencement Date (i.e. six (6) months of Base Rent payments). Thereafter, Tenant shall pay Base Rent monthly in accordance with this Article 4. All payments of Base Rent shall be made without notice in equal monthly installments in advance on the first day of each and every month of the Term hereof, commencing on the Rent Commencement Date. If the Rent Commencement Date falls on a date other than the first calendar day of a month, or the Termination Date falls on a date other than the last calendar day of a month, then the Base Rent due for such partial month shall be prorated based upon the actual number of days falling within said month.

 

(b)     Commencing as of the first day of the month of the fifth anniversary of the Commencement Date and on the first day of the month of each successive five (5) year period thereafter, there will be an adjustment (hereinafter referred to as the “Base Rent Adjustment”) in each component of Base Rent other than Turnover Rent calculated by adding to such component of Base Rent in effect during the immediately preceding Year the product of: (i) such component of Base Rent multiplied by (ii) the positive percentage increase in the Consumer Price Index between Year 1 of such immediately preceding 5 Year period and Year 5 of such immediately preceding 5 Year period, provided that such Base Rent shall never be less than the Base Rent for the immediately preceding Year. The following example is included for illustration purposes regarding the calculation of the Base Rent Adjustment: if the Base Rent in effect prior to the Base Rent Adjustment is $30,000 per month and the positive percentage increase in the Consumer Price Index between Year 1 and Year 5 of the preceding 5 Year period is 5%, the Base Rent shall be adjusted as follows: $30,000 plus ($30,000 multiplied by 5% which equals $1500), such that the adjusted Base Rent shall be $31,500 for the next 5 Year period.

 

 
4

 

 

(c)     The “Consumer Price Index” shall be the Index for All Urban Consumers, U. S. Cities Average published by the Bureau of Labor Statistics of the U.S. Department of Labor. If the Consumer Price Index shall cease to be published, there shall be substituted therefor a price index published by the Bureau of Labor Statistics, or its successor government agency, which is intended to be representative of substantially similar changes in the cost of living as mutually agreed upon by Landlord and Tenant.

 

(d)     As used herein, “Turnover Rent” shall mean one and one half percent (1.5%) of all gross monthly sales defined as all sales of cannabis, cannabis-infused products and non-cannabis products sold by Tenant, any assignee of Tenant or any subtenants of the Premises. All sales as referenced in the preceding sentence shall include, without limitation, sales tracked through state approved tracking software and include sales to patients via the dispensary or delivery or, via wholesale transactions with a licensed Registered Marijuana Dispensary or other legal transactions permitted under Massachusetts law. Tenant hereby represents and warrants to Landlord that Tenant shall include provisions requiring subtenants of the Premises to pay Turnover Rent in all subleases entered into by Tenant with respect to the Premises. Landlord shall have the right to request confirmation of such representation from time to time. If Turnover Rent is payable as Base Rent, Tenant shall pay such Turnover Rent one month in arrears not later than ten (10) days following the end of the month for which Turnover Rent is payable. Tenant shall require monthly accounting of gross sales from all subtenants so that Tenant can determine the amount of Turnover Rent that shall be owed each month, and Tenant shall provide copies of such monthly accounting records to Landlord when Tenant pays Turnover Rent. Landlord shall have the right to audit Tenant’s records with respect to the monthly gross sales of its subtenants for the purpose of confirming the Turnover Rent paid not more than once per year.

 

4.2.     Base Rent Absolutely Net. It is the purpose and intent of Landlord and Tenant that Base Rent payable hereunder shall be absolutely net to Landlord so that this Lease shall yield to Landlord the Base Rent herein specified, in each Year during the Term, free of any charges, assessments, Impositions or deductions of any kind charged, assessed, or imposed on or against the Land and the Premises, and without abatement, deduction or set-off by the Tenant, except as hereinafter specifically otherwise provided, and Landlord shall not be expected or required to pay any such charge, assessment or Imposition, or be under any obligation or liability hereunder except as herein expressly set forth, and that all costs, expenses and obligations of any kind relating to the maintenance and operation of the Land, including all alterations, repairs, reconstruction and replacements as provided in this Lease, which may arise or become due during the Term hereof shall be paid by Tenant, and Landlord shall be indemnified and saved harmless by Tenant from and against such costs, expenses and obligations.

 

 
5

 

 

4.3.     Additional Rent. Tenant shall also pay without notice (except as specifically provided) and without abatement, deduction or set-off as additional rent (“Additional Rent”), all sums, Impositions, costs, expenses and other payments which Tenant in any of the provisions of this Lease assumes or agrees to pay and in the event of any non-payment of Additional Rent, Landlord shall have (in addition to all other rights and remedies) all the rights and remedies provided for herein or by law in the case of non-payment of Base Rent. On the Rent Commencement Date, Tenant shall pay to Landlord as Additional Rent (i) the amount of $21,322.58 and any additional amount actually paid by Landlord at closing to reimburse Landlord for costs paid by Landlord at the closing of the acquisition of the Land and (ii) for all legal fees incurred by Landlord in connection with the transaction. Such amounts may be paid from the Construction Escrow if such amount is reflected on the construction budget.

 

4.4.     “Additional Rental” Defined. Tenant shall pay as Additional Rent during the Term, before any fine, penalty, interest or cost may be added thereto, imposed for the non-payment thereof, all taxes (including personal property taxes and taxes on rents, leases or occupancy, if any), assessments, special assessments, water and sewer rents, rates and charges, charges for public utilities, excises, levies, license and permit fees and other governmental or quasi-governmental charges, general and special, ordinary and extraordinary, foreseen and unforeseen, of any kind and nature whatsoever which at any time prior to or during the Term was or may be assessed against, or become due and payable out of or in respect of, or become a lien on, the Premises, any use or occupation of the Premises, or such franchises as may be appurtenant to the use of the Premises (all of which are sometimes herein referred to collectively as “Impositions” and individually as “Imposition”) provided, however, as follows:

 

4.4.1.     Payment in Installments. If, by law, any Imposition may at the option of the taxpayer be paid in installments (whether or not interest shall accrue on the unpaid balance of such Imposition), Tenant may exercise the option to pay the same in installments and in such event, shall pay such installments as may become due during the Term as the same respectively become due and before any fine, penalty, further interest or cost may be added thereto

 

4.4.2.     Apportionment of Imposition. Any Imposition, (excluding Impositions which have been converted into installment payments by Tenant, as referred to in Section 4.4.1) relating to a fiscal period of the taxing authority, a part of which period is included within the Term and a part of which is included in a period of time before or after the expiration of the Term shall (whether or not such Imposition shall be assessed, imposed upon or in respect of or become a lien upon the Premises, or shall be payable, during the Term) be adjusted between Landlord and Tenant as of the commencement and expiration of the Term, so that Tenant shall pay that portion of such Imposition which that part of such fiscal periods included in the Term bears to such fiscal period, and Landlord shall pay the remainder thereof.

 

4.5.     Additional Rent Exclusions. Nothing herein contained in this Lease shall require Tenant to pay municipal, state, or federal income taxes assessed against Landlord, municipal, state or federal capital levy, excess profits, gift, estate, succession, inheritance or transfer taxes of Landlord, or corporation franchise or income taxes imposed upon Landlord.

 

 
6

 

 

4.6.     Payments. Tenant shall pay all such Impositions directly to the appropriate governmental authority, and shall deliver to Landlord, upon request, photostatic copies of the receipted bills or other evidence satisfactory to Landlord showing such payment. In the event that the Tenant does not receive a separate invoice from the Town of Freetown, or appropriate billing authority, Tenant shall make such payments to the Landlord (or as the Landlord may direct) within ten (10) business days of receipt of invoice from the Landlord.

 

4.7.     Contests. Tenant, if it shall so desire, may contest the validity or amount of any Imposition, in which event, Tenant may defer the payment of such Imposition (the “Contested Imposition”) during the pendency of such contest. Notwithstanding the foregoing, no Contested Imposition shall remain unpaid for such length of time as shall permit a lien to be created against the Premises, or any portion thereof. In the event that Landlord pays the Contested Imposition, Tenant shall reimburse Landlord for such payment within thirty (30) days after the making of such payment, and, if not so paid, shall be payable as Additional Rent with interest at the rate of five percent (5%) per annum within thirty (30) days of demand.

 

4.8.     Assessment Reduction. Tenant may, if it shall so desire, endeavor at any time or times to obtain a lowering of the assessed value of the Premises for the purpose of reducing taxes thereon and, in such event, Landlord will offer no objection and, at the request of Tenant, will cooperate with Tenant, but without expense to Landlord, in effecting such a reduction. Tenant may institute abatement proceedings for that purpose and any such tax refund shall be paid to the Tenant.

 

4.9.     Landlord Credit. Landlord acknowledges that Tenant has made a prepayment in the amount of $925,000.00 in connection with the acquisition of the Premises. The Landlord shall provide a credit to Tenant for said prepayment. The credit shall be applied to the Base Rent due hereunder at the rate of $18,500.00 per Year. The amount of $1,541.67 shall be deducted from each monthly payment of Base Rent due until the full credit of $925,000.00 has been received by Tenant.. In the event this Lease terminates prior to the full credit being received by Tenant, Landlord shall have no obligation to reimburse Tenant for any remaining portion of such amount upon any such termination. Landlord shall in no event have any obligation to provide a credit against rent for any other costs incurred by Tenant in connection with the acquisition of the Premises other than as set forth in this Section 4.9.

 

5.     INSURANCE

 

5.1     Tenant Requirements. At all times during the Term, and at Tenant’s sole cost and expense, Tenant shall provide and keep in effect the following insurance insuring Tenant, any Permitted Mortgagees, Landlord, and any other person or entity designated by Landlord as having an interest in the Premises (as their interests may appear):

 

(a)     Commercial general liability insurance in a good and solvent insurance company or companies licensed to do business in the Commonwealth of Massachusetts, selected by Tenant, and reasonably acceptable to Landlord in an amount of at least two million ($2,000,000.00) dollars with respect to injury or death to any one person and five million ($5,000,000.00) dollars with respect to injury or death to more than one person in any one accident or other occurrence;

 

 
7

 

 

(b)     Property insurance, with a replacement cost endorsement, on all improvements (including, without limitation, all Buildings as and when constructed), personal property and trade fixtures maintained in the Premises, including but not limited to carpeting, furnishings, equipment, furniture, inventory, and stock, and including sprinkler damage, vandalism and malicious mischief perils; and

 

(c)     Workers’ compensation insurance for all Tenant’s employees working at the Premises in an amount sufficient to comply with applicable laws or regulations, including employer’s liability coverage with limits not less than Five Hundred Thousand Dollars ($500,000.00).

 

All policies of insurance maintained by Tenant shall require at least thirty (30) days written notice to Landlord of termination or material alteration. Prior to the Commencement Date, Tenant shall provide to Landlord copies of all required insurance policies and insurance certificates evidencing the same. Thereafter, and prior to the expiration of each such insurance policy, Tenant shall provide to Landlord written evidence of renewal, including but not limited to replacement insurance certificates which evidence the same. If Tenant shall fail to procure or maintain any insurance policy required of Tenant by this Lease, then Landlord shall have the right, but not the obligation, to acquire such insurance policies and to pay such insurance premiums on behalf of and for the benefit of Tenant; all such amounts so paid by Landlord shall be deemed part of the Rent under this Lease, which amounts shall be paid by Tenant to Landlord within thirty (30) days of demand.

 

Tenant agrees that, in the event of loss due to any of the perils for which it has agreed to provide insurance, Tenant shall look solely to its insurance for recovery, and Tenant fully and completely waives any rights of subrogation it may have against Landlord or any other party who may be named as an additional insured under any of Tenant’s insurance policies.

 

5.2     Contractor Requirements. Tenant shall require any contractor of Tenant permitted to perform work in, on, or about the Premises to obtain and maintain the following insurance coverage: commercial general liability insurance, including the traditional broad form general liability coverages; workers’ compensation insurance for all contractor’s employees working in the Premises in an amount sufficient to comply with applicable laws or regulations; employers’ liability insurance; and any other insurance as Tenant may require from time to time. No work shall be commenced at the Premises until any contractor to perform such work has provided evidence of such insurance acceptable to Tenant and payment therefor. Such policies shall name Tenant, Landlord and any Permitted Mortgagee as insured and loss payee.

 

6.     SURRENDER ON TERMINATION

 

6.1     Surrender; Removable Property. On the Termination Date, Tenant shall peaceably and quietly leave, surrender and yield up unto the Landlord all and singular the Premises broom-clean and free of occupants, and shall repair all damage to the Premises caused by or resulting from the removal of any removable property of Tenant or of the subtenants. Any removable property of Tenant or of any subtenant which shall remain in the Building after the Termination Date and the removal of Tenant from the Premises may, at the option of Landlord, be deemed to have been abandoned, and either may be retained by Landlord as its property or may be disposed of in such manner as Landlord may see fit. If such personal property or any part thereof shall be sold, Landlord may receive and retain the proceeds of such sale and apply the same, at its option, against the expenses of the sale, the cost of moving storage, any arrears of Base Rent or Additional Rent payable hereunder and any damages to which the Landlord may be entitled to hereunder or pursuant to law.

 

 
8

 

 

6.2      Title. On the Termination Date, title to the Buildings and Building Equipment, and any other improvements created by the Tenant, shall automatically vest in Landlord without requirement of any deed, conveyance or bill of sale with respect thereto. However, if Landlord should require any such document in confirmation of such transfer, Tenant shall execute, acknowledge and deliver the same and shall pay any charge, tax and fee asserted or imposed by any and all governmental units in connection therewith.

 

7.     LANDLORD'S PERFORMANCE OF TENANT'S OBLIGATIONS.

 

7.1      Cures - Rights, Costs and Damages. If Tenant shall fail to pay any Imposition or make any other payment required to be made under this Lease or shall default in the performance of any other covenant, agreement, term, provision, limitation or condition herein contained, Landlord, without being under any obligation to do so and without thereby waiving such default, may make such payment and/or remedy such other default for the account and at the expense of Tenant, upon notice to Tenant except in the case of emergency, or in any other case, if Tenant shall fail to make such payment or remedy such default with all reasonable dispatch after Landlord shall have notified Tenant in writing of such default. Bills for any expense required by Landlord in connection therewith, and bills for all such expenses and disbursements of every kind and nature whatsoever, including reasonable counsel fees, involved in the collection of the Base Rent or Additional Rent or any part thereof, or the enforcement of any right against Tenant or fulfilling any obligations of Tenant, under or in connection with this Lease (together with interest at the rate of five percent (5%) per annum from the respective dates of the Landlord's making of each such payment or incurring of each such cost or expense), may be sent by Landlord to Tenant monthly, or immediately, at Landlord's option, and shall be due and payable in accordance with the terms of said bills and if not paid when due the amount thereof shall immediately become due and payable as Additional Rent.

 

8.     USE; TENANT'S DUTY TO MAINTAIN.

 

8.1     “AS IS” Condition. Tenant has leased the Land after a full and complete examination thereof, and accepts the Land in its “AS IS” condition. Tenant acknowledges and agrees that the Landlord makes no representation or warranty with respect to the status or condition of the Premises.

 

8.2     Use and Occupancy. Tenant shall use and occupy the Premises as and for the Permitted Uses and for no other purposes without the prior written approval of the Landlord which shall not be unreasonably withheld, conditioned or delayed. Tenant shall not use or occupy or permit the Premises to be used or occupied, not do or permit anything to be done in or on the Premises, in whole or in part, in a manner which would in any way violate any certificate of occupancy affecting the Premises, or make void or voidable any insurance then in force with respect thereto, or which may make it impossible to obtain fire or other insurance thereon required to be furnished by Tenant hereunder, or which will cause or be apt to cause structural injury to the Building or any part thereof, or which will constitute a public or private nuisance, or which will violate Legal Requirements. Tenant acknowledges and agrees that Landlord is not familiar with, and Landlord has no responsibility for, Tenant’s operations or the Permitted Uses for which Tenant intends to use the Premises, and Landlord makes no representation or warranty with respect to whether the Permitted Uses are in compliance with Legal Requirements.

 

 
9

 

 

8.3     Maintenance and Repairs. Tenant shall, at its sole cost and expense, keep the Premises (including sidewalks, parking areas and curbs) in good order, repair and condition. Tenant shall undertake all required maintenance, repairs, and replacements required to keep the Premises in good condition and repair and for the proper operation of Tenant’s business within the Premises. In the event Tenant fails to make any such repairs in and to the Premises as required by this Lease, then Landlord shall have the right, but not the obligation, to enter the Premises and to make such repairs for and on behalf of Tenant, and all sums expended by Landlord for such repairs shall be deemed part of the Rent and shall be payable by Tenant to Landlord upon demand.

 

8.4     Alterations. Tenant shall have the right from time to time after the completion of the Building(s) and at its sole cost and expense to make additions, alterations and changes, structural or otherwise (any addition, alteration or change involving an estimated cost up to but not exceeding $750,000, reasonably adjusted for inflation every 5 Years in the same manner as the Base Rent is adjusted pursuant to Section 4.1 hereof, being called an “Alteration” and any addition, alteration, or change involving an estimated cost of more than $750,000 being hereinafter called a “Substantial Alteration”) in or to the Premises, provided no Event of Default shall be continuing, subject, however, in all cases to the following:

 

(a)     No Substantial Alteration shall be commenced except after twenty (20) days prior written notice to Landlord.

 

(b)     No Alteration or Substantial Alteration shall be undertaken until Tenant shall have procured and paid for, so far as the same may be required from time to time, all permits and authorizations from all municipal departments and governmental sub-divisions having jurisdiction. Landlord shall join, but without expense to Landlord, in the application for such permits or authorizations whenever such action is necessary.

 

(c)     Any Substantial Alteration (other than alterations affecting the plumbing, heating, electrical and other Building utilities) shall be conducted under the supervision of an architect or engineer selected by Tenant, and no such Substantial Alteration shall be made, except in accordance with detailed plans and specifications and cost estimates prepared and approved in writing by such architect or engineer and reasonably approved in writing by Landlord, such approval not to be unreasonably withheld, conditioned or delayed. In addition to the items mentioned in the preceding sentence, Tenant shall also provide to Landlord evidence reasonably satisfactory to Landlord as to the funds available to Tenant to complete such Substantial Alteration.

 

(d)     Any Alterations or Substantial Alterations shall be made with reasonable dispatch (Unavoidable Delays excepted) and in a good and workmanlike manner and in compliance in all material respects with all applicable permits and authorizations and buildings and zoning laws and with all other Legal Requirements of any Governmental Authority.

 

 
10

 

 

8.5     Subtenant Alterations. Tenant, in the exercise of its reasonable judgment and subject to compliance with Section 8.4 with respect to Substantial Alterations, may grant permission to each of the subtenants to make, during and after construction of the Buildings, such alterations, additions, substitutions and improvements to the space subleased to each of them, respectively, as such subtenant may reasonably deem necessary or desirable, from time to time, to adapt said space for its purpose, provided the outside appearance, strength and integrity of the applicable Building, and the applicable Building’s systems are not affected, and provided, further, that in each case the sublease shall obligate Tenant or subtenant to pay the cost thereof.

 

8.6     Contest Rights. Tenant may, in good faith (and wherever necessary, in the name of, Landlord) contest the validity of any Legal Requirements and, pending the determination of such contest, may postpone compliance therewith. In the event of any such contest, Tenant shall prevent any lien related to such contest from attaching to the Premises, and Landlord shall have the right to require Tenant to post a bond or other security in connection with such contest.

 

9.     CONSTRUCTION OF BUILDING

 

9.1     Construction Documents. After the Commencement Date and upon receipt of the required capital funding, Tenant shall proceed in good faith to commence the construction of the initial Buildings in accordance with plans and specifications submitted to Landlord for review. Prior to the commencement of such construction, Tenant shall provide to Landlord (i) a budget for such construction, (ii) a certification from the architect of record that the funds placed in the Construction Escrow are sufficient for construction of such Building, (iii) a copy of the building permit and any other documentation required by the Town of Freetown, along with (iv) the insurance binder required of the contractor. Tenant will also procure the approval of the final plans and specifications by any and all Governmental Authority having jurisdiction in the matter and will provide Landlord with copies of the same. Landlord, without expense to Landlord, will cooperate with Tenant in procuring such approvals.

 

9.2      Financing of Project. Tenant shall have a period of six (6) months from the Commencement Date to obtain capital funding for the construction of the initial Buildings in the amount of $2.6 million dollars. The funds shall be held in an escrow account (“Construction Escrow”) by a third party escrow agent to be mutually agreed upon by Landlord and Tenant (the “Escrow Agent”) on or prior to the date which is sixty (60) days following the Commencement Date. In the event that Tenant is unable to raise such funds within said six (6) month period, Tenant shall have an additional six (6) month period to do so, provided that Tenant has paid Base Rent in accordance with Section 4.1. If Tenant is then unable to raise such funds on or before twelve (12) months from the Commencement Date, this Lease shall terminate and all obligations of the parties shall cease without recourse of either party to the other except for any obligations which accrued prior to such termination date and remain unsatisfied. On or prior to the date which is sixty (60) days following the Commencement Date, Landlord and Tenant shall enter into a mutually acceptable Construction Escrow Agreement with the Escrow Agent, which shall govern the release of funds from the Construction Escrow for construction costs. If Tenant desires to construct additional Buildings on the Premises after construction of the initial Buildings, Tenant shall submit all items required by Section 9.1 above, except that in lieu of a Construction Escrow, Tenant shall provide Landlord evidence reasonably satisfactory to Landlord that Tenant has sufficient funds available to meet the budget for such additional Buildings. Landlord shall have the right to disapprove the construction of additional Buildings if Landlord reasonably determines that sufficient funds are not available to complete construction of additional Buildings.

 

 
11

 

 

9.3     Completion Requirements. Tenant will erect the Buildings, in a good and workmanlike manner in accordance in all respects with the approved plans and specifications with normal on-site changes, and in compliance with all Legal Requirements. Upon completion of the Building, Tenant will obtain and deliver to Landlord (i) a certificate of substantial completion from the architect of record confirming that the applicable Buildings have been constructed in accordance with the approved plans and specifications, (ii) a photocopy of each temporary certificate of occupancy and of the final certificate of occupancy (if required before the Building may be occupied by Tenant) (a Building for which delivery of the items described in clauses (i) and (ii) has occurred shall be referred to as a “Completed Building”). If a temporary certificate of occupancy shall be issued, Tenant may occupy the Premises to the extent authorized under the provisions of such certificate and, further, if a certificate of occupancy for any part of a Building shall be issued, Tenant may occupy the part so certified under the provisions of such certificate. Tenant shall have all permits closed by the Town of Freetown.

 

9.4     Easements. Landlord agrees to execute, at no cost to Landlord, any and all easements, covenants and other matters of record which are determined by Tenant to be reasonably necessary to the construction and development of the Building and the Premises, including, without limitation, access, utility and drainage easements, provided the same does not affect existing easements or covenants of Landlord at the Premises.

 

10.     MECHANIC'S LIENS

 

10.1     No Liens. Tenant shall not create, or suffer to be created or to remain, and shall discharge, any mechanic's, laborer's or materialman's lien upon the Premises or any part thereof or the income therefrom and Tenant will not suffer any other matter or thing arising out of Tenant's use and occupancy of Premises whereby the estate, rights and interests of Landlord in the Premises or any part thereof might be impaired.

 

10.2     Discharge. If any mechanic's, laborer's or materialman's lien shall at any time be filed against the Premises or any part thereof, Tenant, within thirty (30) days after notice of the filing thereof, shall cause such lien to be discharged of record by payment, deposit, bond, order of court of competent jurisdiction or otherwise. If Tenant shall fail to cause such lien to be discharged within the period aforesaid, then, in addition to any other right or remedy, Landlord may, but shall not be obligated to, discharge the same either by paying the amount claimed to be due or by procuring the discharge of such lien by deposit or by bonding. Any amount so paid by Landlord and costs and expenses incurred by Landlord in connection therewith, together with interest thereon at the rate of eight percent (8%) per annum from the respective dates of Landlord's making of the payment or incurring of the cost and expenses, shall constitute Additional Rent payable by Tenant and shall be paid by Tenant to Landlord on demand.

 

 
12

 

 

11.     LANDLORD'S RIGHT TO INSPECT AND ENTER

 

11.1     Inspection and Entry. During the course of construction and completion of the Building, Landlord may enter upon the Premises, or any part thereof, for the purpose of ascertaining their condition or whether Tenant is observing and performing its obligations under this Lease, all without hindrance or molestation from Tenant. During the Term of the Lease, Landlord shall also have the right to enter upon the Premises for the purpose of making any necessary repairs and performing any work that may be necessary by reason of Tenant's failure to make any such repairs or perform any such work upon ten (10) days prior written notice to the Tenant, except in case of emergency. The above-mentioned rights of entry shall be exercisable at reasonable times, at reasonable hours and, subject to the provisions of the preceding sentence, on reasonable notice. Nothing contained herein, however, shall impose or imply any duty on the part of the Landlord to make any such repairs or perform any such work.

 

12.     INDEMNIFICATION.

 

12.1     Indemnification of Landlord. Tenant shall indemnify and save harmless Landlord against and from all liabilities, damages, penalties, costs, and expenses, including reasonable attorneys' fees, which may be imposed upon or incurred by or asserted against Landlord by reason of any of the following occurrences during the Term:

 

(a)     any work or thing done in, on or about the Premises or any part thereof by Tenant, subtenant or any agent, employee, invitee, representative of Tenant or any subtenant (collectively, “Tenant Parties”);

 

(b)     any use, non-use, possession, occupation, condition, operation, maintenance or management of the Premises or any part thereof or space adjacent thereto by any Tenant Party;

 

(c)     any negligence on the part of any Tenant Party;

 

(d)     any accident, injury or damage to any person or property occurring in, on or about the Premises or any part thereof, and not caused by any Landlord Party;

 

(e)     any failure on the part of Tenant to perform or comply with any of the covenants and agreements contained in this Lease on its part to be performed or complied with; or

 

(f)     any release of hazardous materials caused by a Tenant Party.

 

In case any action or proceeding is brought against Landlord by reason of any such claim, Tenant upon written notice from Landlord shall at Tenant's expense resist or defend such action or proceeding by counsel reasonably approved by Landlord in writing.

 

 
13

 

 

12.2     Indemnification of Tenant. Landlord shall indemnify and save harmless Tenant against and from all liabilities, damages, penalties, costs, and expenses, including reasonable attorneys' fees, which may be imposed upon or incurred by or asserted against Tenant by reason of any of the following occurrences during the Term:

 

(a)     any work or thing done in, on or about the Premises or any part thereof by Landlord, or any agent, employee, invitee, representative of Landlord (collectively, “Landlord Parties”)

 

(b)     any use, non-use, possession, occupation, condition, operation, maintenance or management of the Premises or any part thereof by any Landlord Party;

 

(c)     any negligence on the part of any Landlord Party;

 

(d)     any accident, injury or damage to any person or property occurring in, on or about the Premises or any part thereof, or space adjacent thereto caused by the negligence or willful misconduct of the Landlord;

 

(e)     any failure on the part of Landlord to perform or comply with any of the covenants and agreements contained in this Lease on its part to be performed or complied with; or

 

(f)     any release of hazardous materials caused by a Landlord Party.

 

In case any action or proceeding is brought against Tenant by reason of any such claim, Landlord upon written notice from Tenant shall at Landlord's expense resist or defend such action or proceeding by counsel approved by Tenant in writing.

 

13.     DAMAGE OR DESTRUCTION.

 

13.1     Tenant Repair and Restoration. If, at any time during the Term, the Premises or any part thereof shall be damaged or destroyed by fire or other occurrence (including any occurrence for which insurance coverage was not obtained or obtainable) of any kind or nature, ordinary or extraordinary, foreseen or unforeseen, Tenant, at its sole cost and expense, shall proceed with due diligence (subject to a reasonable time allowance for the purpose of adjusting the insurance loss and for Unavoidable Delays) to repair or replace the same as nearly as possible to its value, condition and character immediately prior to such damage or destruction (including temporary repairs and work necessary to protect the Premises from further damage), subject to such changes or alterations as the Tenant may elect to make in conformity with the provisions of Section 8.4. Such repair or replacement, including such changes and alterations as aforementioned and including temporary repairs, are referred to in this Section as the “Work.” Notwithstanding the foregoing, if insurance proceeds are unavailable to Tenant for such reconstruction for any reason (including, without limitation, due to application by a Permitted Mortgage of such insurance proceeds to amounts secured by a Permitted Mortgage), then Tenant shall not be required to so reconstruct the Premises and Tenant may terminate this Lease by written notice to Landlord within thirty (30) days after Tenant is notified of the unavailability of such insurance proceeds. If Tenant terminates this Lease in accordance with this Section 13.1, Tenant shall be required to raze any Buildings on the Premises that have been damaged by such fire or other occurrence and remove any and all debris from the Premises at Tenant’s sole cost and expense.

 

 
14

 

 

13.2     Conditions of Work. Except as otherwise provided in this Section 13, the conditions under which any Work is to be performed and the method of proceeding with and performing the same shall be governed by all of the provisions of Section 8.4.

 

13.3     Damage at End of Term. If the Premises shall be substantially damaged or destroyed in whole or in part by fire or other casualty at any time during the last five (5) years of the Term hereof:

 

13.3.1     Option to Terminate. Tenant may, at its option, terminate this Lease within sixty (60) days after such damage or destruction by serving upon the Landlord at any time within said sixty (60) day period, a written notice of Tenant's election so to terminate. Such notice of election and consent shall specify the date of termination and Tenant shall pay to Landlord, an amount equal to all Base Rent and the then ascertainable Additional Rent accrued through the effective date of termination.

 

13.3.2     Effect of Termination. On the Termination Date specified in such notice, this Lease shall terminate with the same force and effect as if such date were the date originally fixed for the termination hereof.

 

14.     CONDEMNATION.

 

14.1     Total; Partial Taking; Termination of Lease. If, during the Term there is any taking of all or any part of the Premises or any interest in this Lease by Condemnation, the rights and obligations of Landlord and Tenant shall be as follows:

 

14.1.1     Total Taking. If title to the whole or substantially all of the Premises shall be taken by Condemnation, this Lease shall terminate and expire on the date of such taking and the Base Rent and Additional Rent reserved shall be apportioned and paid to the date of such Condemnation.

 

14.1.2     Partial Taking. If title to less than the whole or substantially all of the Premises shall be taken in condemnation and either (i) fifty (50%) of the area of the Land shall be taken, or (ii) the portion of the Premises so taken cannot be so repaired or reconstructed so as to constitute a complete architectural unit of substantially the same usefulness as immediately before Condemnation, Tenant may, at its option, terminate this Lease within sixty (60) days after such taking by serving upon Landlord at any time within said sixty (60) day period, a written notice of Tenant’s election to so terminate.     

 

14.2     Award upon Termination. In the event of a Condemnation and the termination of this Lease:

 

(a)     the Tenant shall first be entitled to receive a sum equal to the value of the Improvements at the Premises;

 

(b)     the Landlord shall then be entitled to receive such portion of the Award as shall represent compensation for the value of the Land, or the part thereof so taken, considered as vacant and unimproved and unencumbered by this Lease; and

 

 
15

 

 

 

(c)

Landlord and Tenant shall share equally the remainder of the Award.

 

14.3     Tenant Defaults. If Tenant shall be in default in any of the terms, covenants and conditions of this Lease on the Termination Date, the amount of any payments to be made to Tenant under the provisions of this Section 14 shall be reduced by such amount as may be required to remedy any such default.

 

14.4     Partial Taking - Lease Continues. In the event of a Condemnation which does not result in a termination of this Lease pursuant to Section 14.1, the Term of this Lease shall not be reduced or affected in any way.

 

14.5     Restoration of Premises. Tenant shall not be required to proceed with the repair and/or restoration of the Premises unless the Award is sufficient so as to allow the Tenant to bring the Premises back to substantially its former condition, provided that Tenant shall be required to raze any Buildings on the Premises that have been damaged by such taking and remove any and all debris from the Premises at Tenant’s sole cost and expense.   

 

14.6     Conditions of Work. The conditions under which the work is to be performed and the method of proceeding with and performing the same shall be governed by all of the provisions of Section 8.4, except, to the extent compliance therewith is not reasonably possible.

 

14.7     Abatement of Rent. A just portion of the Base Rent and Additional Rent shall be abated, effective from the date of Condemnation, according to the nature and extent of the permanent injuries to the Premises. If the Landlord and Tenant cannot agree upon what is a just portion of the Base Rent to be abated, the amount shall be determined by arbitration in the manner provided in Section 17 of this Lease.

 

14.8     Temporary Taking. If the whole or any part of the Premises or of Tenant’s interest in this Lease shall be taken by Condemnation for a temporary use or occupancy and so long as the Tenant’s use of the Premise is not affected, the Term shall not be reduced or affected in any way and Tenant shall continue to pay in full the Base Rent and Additional Rent, without reduction or abatement, in the manner and at the times herein specified and, except only to the extent that Tenant is prevented from so doing pursuant to the terms of the order of the Condemnation, Tenant shall continue to perform and observe all of the other covenants and agreements, hereof as though such Condemnation had not occurred. In the event of any such Condemnation, Tenant shall be entitled to receive the entire amount of any Award whether such Award is paid by way of damages, rent or otherwise, unless such period of temporary use or occupancy shall extend beyond the Termination Date of the Term in which case such Award, after payment to Landlord therefrom of the estimated cost of restoration of the Premises to the extent that the Award is intended to compensate for damages to the Premises, shall be apportioned by Landlord and Tenant as of the Termination Date in the same ratio that the part of the entire period for which such compensation is made falling before the Termination Date and that part falling after, bear to such entire period.

 

14.9     Award. If the order or decree in any Condemnation shall fail separately to state the amount to be awarded to the Landlord and the amount to be awarded to the Tenant, and if the Landlord and the Tenant cannot agree thereon within thirty (30) days after the final Award shall have been fixed and determined, such dispute shall be determined by arbitration in the manner provided in Section 17, but the arbitrators shall be bound by the provisions of this Section 14 in the division of said Award.

 

 
16

 

 

14.10     Condemnation Proceedings. Each party shall have the right, at its own expense, to appear in a Condemnation proceeding and to participate in any and all hearings and trials.

 

14.11     Condemnation Notices. In the event Landlord or Tenant shall receive notice of any proposed or pending Condemnation affecting the Premises, the party receiving such notice shall promptly notify the other party of the receipt and contents thereof.

 

15.     ASSIGNMENT, SUBLETTING, MORTGAGE

 

15.1     Assignability; Sublease Requirements. Tenant may assign, mortgage, pledge, encumber or in any manner transfer this Lease or any part thereof, or the interest of Tenant in any sublease or the rentals thereunder, with the prior written consent of Landlord in each instance, such consent not to be unreasonably withheld, conditioned or delayed. Each sublease of space within the Building, shall be subject to the following requirements:

 

(a)     each sublease shall be subject and subordinate to this Lease and the rights of Landlord hereunder, and the rights of any Permitted Mortgagee as provided for in this Lease, provided that in the event of a termination of this Lease by Landlord, Landlord will not disturb the possession of such subtenant, and such sublease shall automatically be deemed to be a direct lease between Landlord and such subtenant in accordance with the terms and conditions of this Lease (and not such sublease) unless Landlord otherwise agrees in Landlord’s sole discretion; and

 

(b)     each such sublease shall provide that in the event this Lease (or any new lease made as set forth herein) is terminated, the subtenant will attorn to Landlord if Landlord shall accept such attornment upon such termination.

 

15.2     Assignee Bound. Every assignee, whether as assignee or as successor in interest of any assignee of Tenant herein named or as assignee of the holder of any Permitted Mortgage, or as successor in interest of any assignee, including any purchaser of the Lease under a foreclosure of any Permitted Mortgage, shall immediately be and become and remain liable for the payment of Base Rent and Additional Rent, and for the full and prompt performance of all the covenants and agreements hereof on Tenant’s part to be performed to the end of the Term, except as hereinafter provided in this Section 15. No such assignment shall release Tenant from any obligations hereunder.

 

15.3     Permitted Mortgages. With respect to any Permitted Mortgage made in accordance with the provisions of Section 15, the following provisions shall apply:

 

(a)     Definition of Permitted Mortgagee. For the purposes of this Article, the term “Permitted Mortgagee” shall mean the holder of record of a Permitted Mortgage.

 

 
17

 

 

(b)     Permitted Mortgages not Assignment, etc. For the purpose of this Section 15.3, the making of a Permitted Mortgage shall not be deemed to constitute an assignment or transfer of this Lease, nor shall any Permitted Mortgagee be deemed an assignee or transferee of this Lease or of the leasehold estate hereby created so as to require such Permitted Mortgagee, as such, to assume the performance of any of the terms, covenants or conditions on the part of Tenant to be performed hereunder; but the purchaser at any sale of this Lease in any proceedings for the foreclosure of any Permitted Mortgage, or the assignee or transferee of this Lease under any instrument of assignment or transfer in lieu of the foreclosure of any Permitted Mortgage, shall be deemed to be an assignee or transferee within the meaning of this Section 15.3(b) and shall be deemed to have assumed the performance of all of the terms, covenants and conditions on the part of Tenant to be performed hereunder from and after the date of such purchase and assignment.

 

15.4     Notice to Mortgagees. So long as any Permitted Mortgage shall remain a lien on Tenant’s leasehold estate hereunder, Landlord agrees, simultaneously with the giving of any written notice to Tenant (i) of default, or (ii) of a termination hereof, or (iii) of a matter on which a default may be predicated or claimed, or (iv) of a condition which if continued may lead to a termination hereof, to give duplicate copies thereof, or of any process in any action or proceeding brought to terminate this Lease, to each Permitted Mortgagee for which Tenant has provided Landlord the name and address of such Permitted Mortgagee.

 

15.5     Mortgagee Cures. Each Permitted Mortgagee will have the same period after receipt of the notice as provided in Section 15.4 to it for remedying the default or causing the same to be remedied as is given Tenant after notice to it plus thirty (30) days thereafter and Landlord agrees to accept such performance on the part of a Permitted Mortgagee as though the same had been done or performed by Tenant. At the expiration of the period provided in such notice plus thirty (30) days, Landlord will take no action to effect a termination of this Lease by reason of any default (except a default in the payment of Base Rent or Additional Rent or a default under any other provision of this Lease which requires Tenant to pay money) without first giving to each Permitted Mortgagee reasonable time within which either (i) to obtain possession of the Premises (including possession by a receiver) and thereafter to cure such default, or (ii) to institute foreclosure proceedings and to complete such foreclosure, or otherwise to acquire Tenant’s interest under this Lease with diligence and without unreasonable delay. In either such case, the default of which notice shall have been given shall be deemed cured. The Permitted Mortgagee shall not be required to continue such foreclosure proceedings if the default shall be cured by Tenant; provided, further, that nothing herein shall preclude Landlord from exercising any rights or remedies under this Lease with respect to any other default by Tenant during any period of such forbearance. The provisions of this Section 15.5 are conditioned on the following provisions:

 

(a)     Acquisition of Possession. The Permitted Mortgagee shall, within twenty (20) days after notice of such default notify Landlord of its election to proceed with due diligence promptly to acquire possession of the Premises or to foreclose the Permitted Mortgage or otherwise to extinguish Tenant’s interest in this Lease.

 

 
18

 

 

(b)     Agreement of Permitted Mortgagee. Such notice from the Permitted Mortgagee shall be accompanied by an instrument in writing wherein such Permitted Mortgagee agrees that:

 

(i)     during the period that such Permitted Mortgagee shall be in possession of the Premises and so long as it remains in possession and/or during the pendency of any such foreclosure or other proceedings and until the interest of Tenant in this Lease shall terminate or such proceeding shall be discontinued, it will pay or cause to be paid to Landlord all sums from time to time becoming due hereunder for Base Rent or Additional Rent; and

 

(ii)     if delivery of possession of the Premises shall be made to such Permitted Mortgagee, whether voluntarily or pursuant to any foreclosure or other proceedings or otherwise, such Permitted Mortgagee shall, promptly following such delivery of possession, perform all the covenants and agreements herein contained on Tenant’s part to be performed (including, but not limited to payment of Base Rent and Additional Rent) to the extent that Tenant shall have failed to perform the same to the date of delivery of possession, as aforesaid, except such covenants and agreements which cannot with the exercise of due diligence be performed by such Permitted Mortgagee. Nothing in this subclause (b) shall be construed to require such Permitted Mortgagee to perform any of the Tenant’s obligations hereunder accruing after such Permitted Mortgagee ceases to be in possession.

 

15.6     New Lease with Mortgagee. In the event of the termination of this Lease prior to its stated expiration date, Landlord agrees that it will give all Permitted Mortgagees notice of such termination and will enter into a new lease of the Premises with such Permitted Mortgagee or, at the request of such Permitted Mortgagee, with its assignee, designee or nominee for the remainder of the term effective as of the date of such termination, upon the same terms as contained in this Lease except for requirements which are no longer applicable or have already been performed, provided (i) such Permitted Mortgagee makes written request upon Landlord for such new lease within thirty (30) days after the giving of such notice of termination and such written request is accompanied by payment to Landlord of all amounts then due to landlord of which Landlord shall have given the Permitted Mortgagee notice, (ii) such Permitted Mortgagee pays or causes to be paid to Landlord at the time of the execution and delivery of such new lease any and all additional sums which would at the time of the execution and delivery thereof be due under this Lease but for such termination, and (iii) such Permitted Mortgagee pays or causes to be paid any and all expenses including reasonable counsel fees incurred by Landlord in connection with any such termination and in connection with the execution and delivery of such new lease, less the net income from the Premises collected by Landlord subsequent to the Termination Date and prior to the execution and delivery of such new lease. If Landlord receives more than one written request in accordance with the provisions of this Section 15.6 Landlord shall only be required to deliver the new lease to the Permitted Mortgagee whose Permitted Mortgage is prior in lien to any and all other Permitted Mortgages whose holders have made such request, and the written request, and its rights hereunder, of any Permitted Mortgagee which is subordinate in lien shall be null and void and of no force or effect. The provisions of this Section 15.6 shall survive the termination of this Lease and shall continue if full force and effect thereafter to the same extent as if this Section 15.6 were a separate and independent contract among Landlord, Tenant and Permitted Mortgagees. Landlord shall have no obligations, however, to deliver possession of the Premises as against anyone but Landlord, but shall assign to the new lease Tenant all subleases remaining in the Building which have not been terminated by Landlord or otherwise.

 

 
19

 

 

15.7     Cancellation by Tenant. This Lease shall not be modified or surrendered to Landlord or cancelled by Tenant, nor shall Landlord accept a surrender of this Lease without the prior written consent of all Permitted Mortgagees nor shall any merger result from the acquisition by any one entity of the fee and leasehold estates in the Premises.     

 

15.8     Cooperation with Lenders. Landlord agrees to cooperate reasonably, at no cost to Landlord, with any Permitted Mortgagee and with Tenant in Tenant’s negotiations with prospective lenders for the Premises.

 

15.9     Fee Mortgages. Landlord shall have the right to mortgage its fee interest in the Premises during the Term hereof, provided that a foreclosure of any such mortgage shall not affect this Lease or the rights of Tenant, any subtenant or any other party deriving its interest through Tenant.

 

16.     EVENTS OF DEFAULT; remedies.

 

16.1     Event of Default. Each of the following occurrences shall constitute an “Event of Default”:

 

(a) Tenant’s failure to pay rent, or any other sums due from Tenant to Landlord under the Lease within ten (10) days of their due dates;

 

(b) Tenant’s failure to perform, comply with, or observe any other agreement or obligation of Tenant under this Lease and the continuance of such failure for a period of thirty (30) days after the date Landlord delivers to Tenant written notice thereof, provided, that if Tenant proceeds with due diligence during such thirty (30) day period to cure such default and is unable, by reason of the nature of the work involved, to cure the same within the said thirty (30) days its time to do so shall be extended by the time reasonably necessary to cure the same;

 

(c) The filing of a petition by or against Tenant (i) in any bankruptcy or other insolvency proceeding; (ii) seeking any relief under any state or federal debtor relief law; (iii) for the appointment of a liquidator or receiver for all or substantially all of Tenant’s property or for Tenant’s interest in this Lease; or (iv) for the reorganization or modification of Tenant’s capital structure; however, if such a petition is filed against Tenant by non-affiliated third parties, then such filing shall not be an Event of Default unless Tenant fails to have the proceedings initiated by such petition dismissed within sixty (60) days after filing thereof; and

 

(d) The admission by Tenant that it cannot meet its obligations as they become due or the making by Tenant of an assignment for the benefit of its creditors.

 

 
20

 

 

16.2     Rights and Remedies. Upon any Event of Default, Landlord may, in addition to all other rights and remedies afforded Landlord hereunder or by law or equity, terminate this Lease.

 

16.3     Surrender and Re-Entry. Upon a termination of this Lease resulting from an Event of Default, Tenant shall quit and peacefully surrender the Premises to Landlord. At any time on or after any such termination, Landlord may without notice enter upon and re-enter the Premises and possess and repossess itself thereof, by summary proceedings, ejectment or otherwise, and may dispossess Tenant and remove Tenant and may have, hold and enjoy the Premises and the right to receive all income of and from the same.

 

16.4     Right to Relet. Following an Event of Default, Landlord agrees to use commercially reasonable efforts to relet the Premises or any part thereof, in the name of Landlord or otherwise, for such term or terms (which may be greater or less than the period which would otherwise have constituted the balance of the Term) and on such conditions as Landlord, in its reasonable discretion, may determine and may collect and receive the rents therefor.

 

16.5     Liquidated Damages. If this Lease shall be terminated as provided in Section 16.1, then at any time after such termination, Landlord shall be entitled to recover from Tenant, and Tenant shall pay to Landlord, within thirty (30) days of demand, as and for liquidated and agreed final damages for Tenant’s default, an amount equal to the difference between the Base Rent and Additional Rent payable hereunder for the unexpired portion of the Term and the then fair and reasonable rental value of the Land for the same period discounted to the Termination Date (as determined if there had not been a termination under Section 16.1) at the rate of eight percent (8%) per annum. If the Premises or any part thereof be relet by Landlord for more or less than the unexpired Term before presentation of proof of such liquidated damages to any court, commission or tribunal, the amount of rent reserved upon such reletting shall be deemed prima facie to be the fair and reasonable rental value for the part or the whole of the Premises so relet during the term of the reletting.

 

16.6     Payment by Tenant. Upon any Event of Default, Tenant shall pay to Landlord any and all reasonable costs and expenses incurred by Landlord (including court costs and reasonable attorneys’ fees and expenses) in enforcing its rights, remedies, and recourses arising out of the Event of Default.

 

16.7     Landlord’s Self Help. If Tenant defaults under any term or condition contained herein, Landlord may, at its option, and without obligation to do so, and without waiving its right to terminate this Lease or its claim for damages, cure such default, and Tenant shall reimburse Landlord for any amount paid or contractual liability incurred by Landlord in doing so; provided Landlord may immediately cure any default or failure by Tenant to perform any Lease obligation if the cure or performance is reasonably necessary to protect the Premises or Landlord’s interests, or to prevent injury or damage to persons or property. If Tenant fails to reimburse Landlord within thirty (30) days of demand, such amount with interest thereon as stated herein shall be added to the next payment of Rent due without further notice.

 

 
21

 

 

17.     ARBITRATION

 

17.1     Notice and Arbitrators. Whenever it is herein provided in this Lease that a dispute shall be determined by arbitration, the arbitration shall be conducted as provided in this Section 17.1. The party desiring such arbitration shall give written notice to that effect to the other, specifying the dispute to be arbitrated and the name and address of the person designated to act as the arbitrator in its behalf. Within ten (10) days after said notice is given, the other party shall give written notice to the first party, specifying the name and address of the person designated to act as arbitrator on its behalf. If the second party fails to notify the first party of the appointment of its arbitrator as aforesaid by the time above specified, then the appointment of the second arbitrator shall be made in the same manner as hereinafter provided for the appointment of a third arbitrator. The arbitrators so chosen shall meet within ten days (10) after the second arbitrator is appointed and within thirty days (30) thereafter shall decide the dispute. If within said period they cannot agree upon their decision, they shall appoint a third arbitrator and if they cannot agree upon said appointment, the third arbitrator shall be appointed upon their application or upon the application of either party by the American Arbitration Association in Boston. The three arbitrators shall meet and decide the dispute. A decision in which two of the arbitrators concur shall be binding and conclusive upon the parties. In designating arbitrators and in deciding the dispute, the arbitrators shall act in accordance with the rules then in force of the American Arbitration Association, subject, however, to such limitations as may be placed upon them by the provisions hereof. The obligation of Landlord and Tenant to submit a dispute to arbitration is limited to disputes arising under those Sections of this Lease which specifically provide for arbitration.

 

18.     ESTOPPEL AND CONSENTS

 

18.1     Estoppel Certificates. Landlord and Tenant shall execute and deliver to each other, at such time or times as either Landlord or Tenant may request, a certificate evidencing whether or not (i) the Lease is in full force and effect; (ii) the Lease has been modified or amended in any respect and describing such modifications or amendments, if any; and (iii) there are any existing defaults thereunder to the knowledge of the party executing the certificate, and specifying the nature of such defaults, if any. If either party shall fail to deliver said certificate within fifteen (15) days from receipt of request therefor it shall be concluded that the Lease is in full force and effect, unmodified and without default.

 

18.2     Parties and Notice. Whenever the consent or approval of a party to this Lease is required under this Lease, if such party fails to respond to the requesting party within fifteen (15) days (except where a shorter or longer period is otherwise specified herein for the giving of such consent or approval) after the mailing of a written request thereof, it shall be concluded that such consent or approval has been given.

 

18.3     No Unreasonable Withholding. Wherever in this Lease the consent or approval of either party is required, such consent or approval shall not be unreasonably withheld, conditioned nor delayed, except where otherwise specifically provided. The remedy of the party requesting such consent or approval, in the event such party should claim or establish that the other party has unreasonably withheld or delayed such consent or approval, shall be limited to injunction, declaratory judgment or arbitration, and in no event shall such other party be liable for a money judgment.

 

 
22

 

 

19.     NO WAIVERS

 

19.1     No Implied Waivers-Remedies Cumulative. No covenant or agreement of this Lease shall be deemed to have been waived by Landlord unless such waiver be in writing, signed by Landlord or Landlord's agent duly authorized in writing. Consent or approval of Landlord to any act or matter must be in writing (except for “deemed” consents in accordance with Section 19.1) and shall apply only with respect to the particular act or matter in which such consent or approval is given and shall not relieve Tenant from the obligation wherever required under this Lease to obtain the consent or approval of Landlord to any other act or matter. Landlord may restrain any breach or threatened breach of any covenant or agreement herein contained, but the mention herein of any particular remedy shall not preclude the Landlord from any other remedy it might have, either in law or in equity. The failure of Landlord to insist upon the strict performance of any one of the covenants or agreements of this Lease or to exercise any right, remedy or election herein contained or permitted by law shall not constitute or be construed as a waiver or relinquishment for the future of such covenant or agreement, right, remedy or election, but the same shall continue and remain in full force and effect. Any right or remedy of Landlord herein specified or any other right or remedy that Landlord may have at law, in equity or otherwise upon breach of any covenant or agreement herein contained upon the part of Tenant to be performed shall be distinct, separate and cumulative rights or remedies and no one of them, whether exercise by Landlord or not, shall be deemed to be in exclusion of any other.

 

19.2     Acceptance of Rent. Receipt or acceptance of rent by Landlord shall not be deemed to be a waiver of any default under the covenants or agreements, of this Lease, or of any right which Landlord may be entitled to exercise hereunder. In the event that Tenant is in arrears in the payment of Base Rent or Additional Rent, Tenant waives Tenant's right, if any, to designate the items against which any payments made by Tenant are to be credited and Tenant agrees that Landlord may apply any payments made by Tenant to any items Landlord see fits irrespective of and notwithstanding any designation or request by Tenant as to the items against which any such payments shall be credited nor shall any endorsement or statement on any check or any letter accompanying any check or payment as rent be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to Landlord's right to recover the balance of such rent or pursue any other remedy in this Lease provided.

 

20.     TENANT REPRESENTATIONS

 

20.1     Authority to do Business. Tenant is in good standing in the State of its incorporation and is authorized to do business in the Commonwealth of Massachusetts.

 

20.2     Legal Requirements. Tenant hereby represents and warrants to Landlord that the Permitted Uses are permitted by Legal Requirements as of the date hereof.

 

21.     MISCELLANEOUS

 

21.1     Limitation of Landlord's Liability. The term “Landlord,” as used herein, so far as Landlord's covenants and agreements hereunder are concerned, shall be limited to mean and include only the owner or owners at the time in question of the fee title to the Premises. Landlord’s maximum exposure and liability with respect to any claims of Tenant as a result of any default or breach of any of the terms, covenants. agreements, provisions, conditions and limitations of this Lease on Landlord’s part to be kept, observed or performed, is limited to the interest and/or title of Landlord in this Lease and the Land and the uncollected rents and income therefrom, and no other assets of Landlord shall be subject to any judgment, decree, execution, attachment, sequestration or other legal remedy.

 

 
23

 

 

21.2     Notices from One Party to the Other. All notices, approvals, consents, requests, and elections required or permitted under this Lease shall be in writing and shall be deemed duly given if and when mailed by registered or certified mail, postage prepaid, addressed, if to Tenant, at the address of Tenant set forth at the beginning of this Lease or such other address as Tenant shall have last designated by notice in writing to Landlord; if to Landlord, at the address of Landlord set forth at the beginning of this Lease or such other address as Landlord shall have last designated by notice in writing to Tenant; and if to a Permitted Mortgagee, at the Permitted Mortgagee's address set forth in Section 1 of this Lease or such other address as Lender shall have last designated by notice in writing to Landlord and Tenant. If either party at any time designates some other person to receive payments or notices under this Lease, all such payments or notices thereafter by the other party shall be paid or given to the agent designated until notice to the contrary is received from the designating party.

 

21.3     Quiet Enjoyment. Subject to all of the conditions, terms and provisions contained in this Lease, Landlord covenants that Tenant, upon paying the Base Rent and Additional Rent, and observing and keeping all terms, covenants, agreements, limitations and conditions hereof on its part to be kept, shall quietly have and enjoy the Premises during the term hereof, without hindrance or molestation by Landlord.

 

21.4     Provisions Severable. If any term or provisions of this Lease or the application thereof to any person or circumstances shall, to any extent, be invalid or unenforceable, the remainder of this Lease, or the application of such term or provision to persons or circumstances other than those as to which it is held invalid or unenforceable, shall not be affected thereby, and each term and provision of this Lease shall be valid and enforceable to the fullest extent permitted by law.

 

21.5     Choice of Law. This Lease shall be construed and enforced in accordance with the laws of the Commonwealth of Massachusetts.

 

21.6     Memorandum. Landlord and Tenant agree that, concurrently with the execution of this Lease, each will execute a short form memorandum of this Lease in form satisfactory for recording in the Bristol County Registry of Deeds. Tenant shall bear the expense for the recordation of such memorandum in the Bristol County Registry of Deeds.

 

21.7     Entire Agreement. This Lease with its schedules and annexes contains the entire agreement between Landlord and Tenant and may be amended only by a written instrument signed by the party to be charged.

 

 
24

 

 

21.8     Captions. The captions of Sections in this Lease and its Table of Contents are inserted only as a convenience and for reference and they in no way define, limit or describe the scope of this Lease or the intent of any provision thereof. References to Sections are to those in this Lease unless otherwise noted.

 

21.9     Singular and Plural, Gender. If two or more persons, firms, corporations or other entities constitute either the Landlord or the Tenant, the word “Landlord” or the word “Tenant” shall be construed as if it reads “Landlords” or “Tenants” and the pronouns “it,” “he” and “him” appearing herein shall be construed to be the singular or plural, masculine, feminine or neuter gender as the context in which it is used shall require.

 

21.10     Broker's Commission. Landlord and Tenant each represent and warrant to the other that it has not dealt with any broker or agent in connection with the negotiation or execution of this Lease. Tenant and Landlord shall each indemnify the other against all costs, expenses, attorneys fees, and other liability for commissions or other compensation claimed by any broker or agent claiming the same by, through, or under the indemnifying party.

 

21.11     Covenants Bind and Inure. The covenants and agreements herein contained shall bind and inure to the benefit of Landlord and Tenant and their respective heirs, legal representatives, successors and assigns, except as otherwise provided herein.

 

21.12     Tenant’s Right to Terminate. In the event that the Permitted Uses of a cannabis cultivation facility and/or a registered marijuana distribution center are no longer deemed to be in compliance with local, state or federal laws, then Tenant may terminate this Lease without recourse of either party to the other, except such obligations that are due and owing to the date of such termination.

 

 
25

 

 

IN WITNESS WHEREOF, the parties have hereunto set their hand and seals as of the date first above written.

 

 

LANDLORD:

 

MASSACHUSETTS MEDICAL PROPERTIES LLC

 

By: /s/ J.F. Barton                                           

 

Name:  J.F. Barton                                          

 

Title:  Manager                                               

   
   

 

TENANT:

 

AMERICANN, INC.

 

 

By: /s/ Timothy Keogh                              

Name: Timothy Keogh

Title: Chief Executive Officer

 

 
 

 

 

EXHIBIT A

 

LAND

 

 

 

Lot 1A and New Lot 3A on a plan entitled “Campanelli Freetown Land LLC, Campanelli Drive, Freetown, Massachusetts, Approval Not Required Plan”, prepared by Kelly Engineering Group, Inc., dated September 11, 2006, recorded with the Bristol County Registry of Deeds in Plan Book 144, Page 12 on August 16, 2007.

 

 

 

 

 

 

 

Exhibit A

 
 

 

 

Exhibit C

 

FORM OF Warrant

 

(See attached.)

 

 

 

 

 

 

 

 

 

 

 

Exhibit C

 
 

 

 

 

Execution Version

 

 

 

 

 

 

 

 

 

 

WARRANT

 

To Purchase Common Stock of

AMERICANN,
INC.






Dated October
17, 2016

 

 

 

 

 

 

 

 
 

 

 

TABLE OF CONTENTS

 

Page

 

SECTION 1.

Term; Exercise of Warrant

1

 

1.1

Time of Exercise

1

1.2

Manner of Exercise

1

1.3

Exchange of Warrant

2

 

SECTION 2.

Adjustment of Exercise Price and Number of Warrant Shares Purchasable upon Exercise

3

 

2.1

Stock Dividends, Subdivisions and Combinations

3

2.2

Recapitalization or Reclassification

3

2.3

Distributions

4

2.4

Notice

4

 

SECTION 3.

Representations, Warranties and Covenants of the Company

5

 

 

3.1

Representations and Warranties

5

3.2

Covenants of the Company

6

 

SECTION 4.

Representations and Warranties of the Holder

7

 

4.1

Acquisition of Warrant for Personal Account

7

4.2

Rule 144

7

4.3

Accredited Investor

7

4.4

Opportunity to Discuss; Information

7

 

SECTION 5.

Other Matters

8

 

5.1

Withholding

8

5.2

Binding Effect

8

5.3

Notices

8

5.4

Governing Law; Consent to Jurisdiction; Waiver of Jury Trial

8

5.5

Parties Bound and Benefited

9

5.6

Confidentiality

9

5.7

Identity of Transfer Agent

9

5.8

Amendment; Waiver

9

5.9

Assignment

9

5.10

Holder as Owner

9

5.11

Rights of Holder

9

5.12

Indemnification

10

5.13

Remedies

10

5.14

Lost Certificates

10

5.15

Severability

10

5.16

Nonwaiver and Expenses

10

5.17

Office of the Company; Maintenance of Books

11

5.18

Section Headings

11

 

Appendix A     -     Assignment of Warrant

Appendix B     -      Warrant Exercise Form

 

 

 

 

THIS SECURITY HAS NOT BEEN REGISTERED OR QUALIFIED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED OR SOLD UNLESS (I) REGISTERED AND QUALIFIED PURSUANT TO THE APPLICABLE PROVISIONS OF FEDERAL AND STATE SECURITIES LAWS, (II) PURSUANT TO RULE 144 OF THE ACT OR (III) AN EXEMPTION FROM SUCH REGISTRATION OR QUALIFICATION APPLIES.  THEREFORE, NO SALE OR TRANSFER OF THIS SECURITY SHALL BE MADE, NO ATTEMPTED SALE OR TRANSFER SHALL BE VALID, AND THE ISSUER SHALL NOT BE REQUIRED TO GIVE ANY EFFECT TO ANY SUCH TRANSACTION UNLESS (A) SUCH TRANSACTION HAS BEEN DULY REGISTERED UNDER THE ACT AND QUALIFIED OR APPROVED UNDER APPROPRIATE STATE SECURITIES LAWS OR (B) THIS SECURITY MAY BE SOLD PURSUANT TO RULE 144 OF THE ACT.

 

No. of Shares of Common Stock, par value $0.0001 per share: 3,640,000

 

WARRANT

 

To Purchase Common Stock of

 

AMERICANN, INC.

 

THIS IS TO CERTIFY, that, for value received, Massachusetts Medical Properties, LLC, a Delaware limited liability company, or its successors or registered assigns (the “Holder”), is entitled, subject to the terms and conditions hereinafter set forth, to purchase 3,640,000 shares (the “Warrant Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of AmeriCann, Inc., a Delaware corporation (the “Company”), from the Company (the “Warrant”) at an exercise price per share equal to $1.00 per share at the Issue Date (the exercise price in effect being herein called the “Exercise Price”).  The number of Warrant Shares purchasable upon exercise of this Warrant and the Exercise Price shall be subject to adjustment from time to time as described herein.

 

SECTION 1.     Term; Exercise of Warrant.

 

1.1     Time of Exercise.  This Warrant may be exercised at any time and from time to time during the period commencing as of 9:00 a.m., Central Time, on October 17, 2018 (the “Issue Date”) and ending as of 5:00 p.m., Central Time, on October 17, 2020, at which time this Warrant shall become void and all rights hereunder shall cease, unless extended by the parties.

 

1.2     Manner of Exercise.

 

1.2.1     The Holder may exercise this Warrant, in whole or in part, upon surrender of this Warrant, with the duly executed exercise notice, in the form attached hereto as Appendix B, to the Company at its corporate office in Denver, Colorado, and upon payment to the Company of the Exercise Price for each Warrant Share to be purchased in lawful money of the United States, or by certified or cashier’s check, or wired funds.

 

1.2.2     Upon receipt of this Warrant with the duly executed exercise notice and accompanied by payment of the aggregate Exercise Price for the Warrant Shares for which this Warrant is then being exercised, the Company shall cause to be issued and delivered to the Holder, within a reasonable time, not exceeding three (3) trading days after this Warrant shall have been so exercised, including the delivery of the duly executed exercise notice and payment of the aggregate Exercise Price, by (a) causing the Company’s transfer agent to credit the Warrant Shares in book-entry form to an account to be designated by the Holder or (b) if electronic delivery is unavailable, delivering at the address designated by the Holder certificates representing the total number of whole Warrant Shares for which this Warrant is being exercised.  

 

 
 

 

 

1.2.3     In case the Holder shall exercise this Warrant with respect to less than all of the Warrant Shares that may be purchased under this Warrant, the Company shall execute a new Warrant in substantially identical form (other than the number of Warrant Shares) for the balance of the Warrant Shares that may be purchased upon exercise of this Warrant and deliver such new Warrant to the Holder.

 

1.2.4     The Company covenants and agrees that it will pay when due and payable any and all taxes and governmental charges (other than any income tax due under federal, state or other law as a result of owning this Warrant or any Warrant Shares issued upon the exercise of this Warrant) which may be payable in respect of the issue of this Warrant, or the issue of any Warrant Shares upon the exercise of this Warrant.  The Company shall not, however, be required to pay any stamp, transfer or similar tax which may be payable in respect of any transfer involved in the issuance of this Warrant or of the Warrant Shares in a name other than that of the Holder at the time of surrender or an affiliate thereof; in the event any such transfer is involved and any such tax is payable, the Company shall not be required to issue such Warrant Shares until the payment of such tax (or the payment to the Company of an amount sufficient to reimburse it for the payment of any such tax).

 

1.3     Exchange of Warrant.  Upon the request of the Holder, this Warrant may be divided into, combined with or exchanged for another warrant or warrants of like tenor (collectively, the “Warrants”) to purchase a like aggregate number of Warrant Shares.  If the Holder desires to divide, combine or exchange this Warrant, the Holder shall make such request in writing delivered to the Company at its corporate office and shall surrender this Warrant and any other Warrants to be so divided, combined or exchanged.  The Company shall execute and deliver to the person or persons entitled thereto a Warrant or Warrants, as the case may be, as so requested.  The Company shall not be required to effect any division, combination or exchange which will result in the issuance of a Warrant entitling the Holder to purchase upon exercise a fraction of a Warrant Share. As to any fraction of a share which a Holder of one or more Warrants, the rights under which are exercised in the same transaction, would otherwise be entitled to purchase upon such exercise, the Company shall pay a cash adjustment in respect of such final fraction in an amount equal to the same fraction of the Market Price per share of Common Stock on the date of exercise, computed to the nearest whole U.S. cent. The Company shall prepare, issue and deliver at its own expense the new Warrant or Warrants under this Section 0.

 

Market Price” on any date means the VWAP of one share of Common Stock for the 10 consecutive trading days ending on the trading day immediately preceding the specified date. If the Common Stock is not listed on The Nasdaq Stock Market LLC, the New York Stock Exchange or another national securities exchange, “Market Price” of the Common Stock on any date means the fair value per share of Common Stock as of a date not earlier than 10 business days preceding the specified date as agreed upon by the Company and the Holder or, if the parties cannot agree within five (5) business days of the date on which the Holder delivers notice pursuant to 0, by a third party independent appraiser having experience in such matters who is selected by the Holder.

 

 
2

 

 

VWAP” means, for any trading day, the price for shares of Common Stock determined by the daily volume weighted average price per share for such trading day on the trading market on which such shares are then listed or quoted, in each case, for the regular trading session (including any extensions thereof, without regard to pre-open or after hours trading outside of such regular trading session) as reported on The Nasdaq Stock Market LLC or the New York Stock Exchange, or the principal national securities exchange on which such shares are then listed or quoted, whichever is applicable, as published by Bloomberg L.P. at 4:15 P.M., New York City time, on such trading day.

 

SECTION 2     Adjustment of Exercise Price and Number of Warrant Shares Purchasable upon Exercise.

 

Subject and pursuant to the provisions of this Section 0, the Exercise Price and the number of Warrant Shares subject to this Warrant shall be subject to adjustment from time to time as set forth hereinafter.

 

2.1     Stock Dividends, Subdivisions and Combinations.  If the Company shall, at any time or from time to time while this Warrant is outstanding, pay a dividend or make a distribution on its Common Stock in shares of Common Stock, subdivide its outstanding shares of Common Stock into a greater number of shares or combine its outstanding shares of Common Stock into a smaller number of shares or issue by reclassification of its outstanding shares of Common Stock any shares of its capital stock (including any such reclassification in connection with a consolidation or merger in which the Company is the continuing entity), then (A) the Exercise Price in effect immediately prior to the date on which such change shall become effective shall be adjusted by multiplying such Exercise Price by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately prior to such change and the denominator of which shall be the number of shares of Common Stock outstanding immediately after giving effect to such change and (B) the number of Warrant Shares purchasable upon exercise of this Warrant shall be adjusted by multiplying the number of Warrant Shares purchasable upon exercise of this Warrant immediately prior to the date on which such change shall become effective by a fraction, the numerator of which shall be the Exercise Price in effect immediately prior to the date on which such change shall become effective and the denominator of which shall be the Exercise Price in effect immediately after giving effect to such change, calculated in accordance with clause (A) above.  Such adjustments shall be made successively whenever any event listed above shall occur.

 

2.2     Recapitalization or Reclassification.  If any capital reorganization, reclassification of the capital stock of the Company, consolidation or merger of the Company with another entity in which the Company is not the survivor, or sale, transfer or other disposition of all or substantially all of the Company’s assets to another entity shall be effected, then, as a condition of such reorganization, reclassification, consolidation, merger, sale, transfer or other disposition, lawful and adequate provision shall be made whereby each Holder shall thereafter have the right to purchase and receive upon the basis and upon the terms and conditions herein specified and in lieu of the Warrant Shares immediately theretofore issuable upon exercise of the Warrant, such shares of stock, securities or assets as would have been issuable or payable with respect to or in exchange for a number of Warrant Shares equal to the number of Warrant Shares immediately theretofore issuable upon exercise of the Warrant, had such reorganization, reclassification, consolidation, merger, sale, transfer or other disposition not taken place, and in any such case appropriate provision shall be made with respect to the rights and interests of the Holder to the end that the provisions hereof (including, without limitation, provision for adjustment of the Exercise Price) shall thereafter be applicable, as nearly equivalent as may be practicable in relation to any shares of stock, securities or assets thereafter deliverable upon the exercise hereof.  

 

 
3

 

 

2.3     Distributions.  In case the Company shall fix a payment date for the making of a distribution to all holders of Common Stock (including any such distribution made in connection with a consolidation or merger in which the Company is the continuing entity) of evidences of indebtedness or assets (other than dividends or distributions referred to in Section 0), or subscription rights or warrants, the Exercise Price to be in effect after such payment date shall be determined by multiplying the Exercise Price in effect immediately prior to such payment date by a fraction, the numerator of which shall be the total number of shares of Common Stock outstanding multiplied by the Market Price per share of Common Stock immediately prior to such payment date, less the fair market value (as determined by the Company and the Holder or, if the parties cannot agree within five (5) business days, a third party independent appraiser having experience in such matters as agreed upon by the Holder) of said assets or evidences of indebtedness so distributed, or of such subscription rights or warrants, and the denominator of which shall be the total number of shares of Common Stock outstanding multiplied by such Market Price per share of Common Stock immediately prior to such payment date.

 

2.4     Notice.

 

2.4.1     If at any time (A) the Company shall take a record of the holders of its Common Stock for the purpose of entitling them to receive a dividend (other than a cash dividend payable out of earnings or earned surplus legally available for the payment of dividends under the laws of the corporate domicile of the Company) or other distribution, or any right to subscribe for or purchase any evidences of its indebtedness, any shares of stock of any class or any other securities or property, or to receive any other right, (B) there shall be any capital reorganization of the Company, any reclassification or recapitalization of the capital stock of the Company or any consolidation or merger of the Company with, or any sale, transfer or other disposition of all or substantially all the property, assets or business of the Company to, another corporation or entity, or (C) there shall be a voluntary or involuntary dissolution, liquidation or winding up of the Company; then, in any one or more of such cases, the Company shall give to the Holder at least 30 days’ prior written notice of the date on which a record date shall be selected for such dividend, distribution or right or for determining rights to vote in respect of any such reorganization, reclassification, merger, consolidation, sale, transfer, disposition, dissolution, liquidation or winding up, and, in the case of any such reorganization, reclassification, merger, consolidation, sale, transfer, disposition, dissolution, liquidation or winding up, at least 30 days’ prior written notice of the date when the same shall take place. Such notice in accordance with the foregoing clause also shall specify (Y) the date on which any such record is to be taken for the purpose of such dividend, distribution or right, the date on which the holders of Common Stock shall be entitled to any such dividend, distribution or right, and the amount and character thereof, and (Z) the date on which any such reorganization, reclassification, merger, consolidation, sale, transfer, disposition, dissolution, liquidation or winding up is to take place and the time, if any such time is to be fixed, as of which the holders of Common Stock shall be entitled to exchange their shares of Common Stock for securities or other property deliverable upon such reorganization, reclassification, merger, consolidation, sale, transfer, disposition, dissolution, liquidation or winding up. Each such written notice shall be sufficiently given if addressed to the Holder at the last address of the Holder appearing on the books of the Company and delivered in accordance with Section 0.

 

 
4

 

 

2.4.2     The Holder shall be entitled to the same rights to receive notice of corporate action as any holder of Common Stock.

 

SECTION 3.     Representations, Warranties and Covenants of the Company.

 

3.1     Representations and Warranties. As of the date hereof, the Company represents and warrants to the Holder that:

 

(A)     it has the corporate power to enter into, perform and deliver, and has taken all necessary action to authorize its entry into, and performance and delivery of, this Warrant and the transactions contemplated by this Warrant;

 

(B)     this Warrant constitutes the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with its terms, subject to (i) the effect of bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or other similar laws now or hereinafter in effect relating to or affecting the rights and remedies of creditors and (ii) the effect of general principles of equity, including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific performance or injunctive relief regardless of whether considered in a proceeding in equity or at law;

 

(C)     the execution of this Warrant and the performance of the Company’s obligations hereunder do not conflict with, result in a breach or violation or imposition of any lien, charge or encumbrance upon any property or assets of the Company’s or any of its subsidiaries pursuant to: (i) the Company’s organizational documents; (ii) the terms of any indenture, contract, lease, mortgage, deed of trust, note agreement, loan agreement or other agreement, obligation, condition, covenant or instrument to which the Company or any of its subsidiaries is a party or bound or to which its or their property is subject; or (iii) any statute, law, rule, regulation, judgment, order or decree of any court, regulatory body, administrative agency, governmental body, arbitrator or other authority having jurisdiction over it or any of its subsidiaries or any of its or their properties; and

 

(D)     assuming the accuracy of the representations and warranties of the Holder contained in this Warrant, the sale and issuance of the Warrant Shares pursuant to this Warrant is intended to be exempt from the registration requirements of the Act, and neither the Company nor any person acting on its behalf has taken or will take any action hereafter that would cause the loss of such exemption.

 

 
5

 

 

3.2     Covenants of the Company. The Company covenants and agrees as follows:

 

(A)     at all times the Company shall reserve and keep available for the exercise of this Warrant such number of authorized shares of Common Stock as are sufficient to permit the exercise in full of this Warrant;

 

(B)     all Warrant Shares, when issued upon the exercise of this Warrant, will be duly and validly issued, fully paid, nonassessable and free of preemptive rights;

 

(C)     the Company shall, for so long as the Warrant remains outstanding, timely file all reports and other documents required to be filed by it pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In the event the Company no longer has reporting obligations under the Exchange Act, then the Company will deliver to the Holder:

 

(i)     as soon as available, but in any event within 90 days after the end of each fiscal year of the Company, a copy of the audited consolidated balance sheet of the Company and its subsidiaries as at the end of such year and the related audited consolidated statements of income and of cash flows for such year, setting forth in each case in comparative form the figures as of the end of and for the previous year, together with a narrative discussion and analysis of the financial condition and results of operations of the Company and its subsidiaries for such fiscal year as compared to the previous year, and reported on without a “going concern” or like qualification or exception, or qualification arising out of the scope of the audit, by the Company’s independent accountants;

 

(ii)     as soon as available, but in any event not later than 60 days after the end of each quarterly period of each fiscal year of the Company, the unaudited consolidated balance sheet of the Company and its subsidiaries as at the end of such quarter and the related unaudited consolidated statements of income and of cash flows for such quarter and the portion of the fiscal year through the end of such quarter, setting forth in each case in comparative form the figures as of the end of and for the corresponding period in the previous year, together with a narrative discussion and analysis of the financial condition and results of operations of the Company and its subsidiaries for such fiscal quarter and for the period from the beginning of the then current fiscal year to the end of such fiscal quarter, as compared to the comparable periods of the previous year; and

 

(iii)     within 10 business days after the time periods specified by the rules and regulations of the U.S. Securities and Exchange Commission (the “Commission”), information substantively of the type that would be required to be filed with the Commission in a Current Report on Form 8-K.

 

All such financial statements and information delivered pursuant to this Section 0 shall be complete and correct in all material respects and to be prepared in reasonable detail and in accordance with generally accepted accounting principles in the United States of America applied consistently throughout the periods reflected therein and with prior periods (except as approved by the Company’s independent accountants or chief financial officer, as the case may be, and disclosed therein, and quarterly financial statements shall be subject to normal year-end audit adjustments and need not be accompanied by footnotes); and

 

 
6

 

 

(D)     the Company shall not, for so long as any Warrants remain outstanding, by any action, including amending its organizational documents or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant. The Company will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of the Holder against impairment. Without limiting the generality of the foregoing, the Company will use its commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant.

 

SECTION 4.     Representations and Warranties of the Holder.

 

Each Holder of a Warrant represents and warrants to the Company as follows:

 

4.1     Acquisition of Warrant for Personal Account. The Holder is acquiring this Warrant and the Warrant Shares (collectively the “Securities”) for investment for its own account and not with a present view to, or for resale in connection with, any public resale or distribution thereof. The Holder understands that the Securities have not been registered under the Act by reason of a specific exemption from the registration provisions of the Act which depends upon, among other things, the bona fide nature of the investment intent as expressed herein. The Holder further understands that the Securities have not been passed upon or the merits thereof endorsed or approved by any state or federal authorities.

 

4.2     Rule 144. The Holder acknowledges that the Securities it is purchasing are characterized as “restricted securities” under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and must be held indefinitely unless an exemption from registration is available. The Holder represents that it is knowledgeable with respect to Rule 144 promulgated under the Act.

 

4.3     Accredited Investor. As of the date hereof, the Holder is an “accredited investor” within the meaning of Regulation D promulgated under the Act. The Holder is sophisticated in financial matters, and is able to evaluate the risks and benefits of an investment in the Securities for an indefinite period of time.

 

4.4     Opportunity to Discuss; Information. The Holder has been afforded the opportunity to ask questions of, and receive answers from, the officers and/or directors of the Company acting on its behalf concerning the terms and conditions of this transaction and to obtain any additional information, to the extent that the Company possesses such information or can acquire it without unreasonable effort or expense, necessary to verify the accuracy of the information furnished; and has availed itself of the opportunity to the extent the Holder considers appropriate in order to permit it to evaluate the merits and risks of an investment in the Company.

 

 
7

 

 

SECTION 5.     Other Matters.

 

5.1     Withholding. If the Company is required by law to deduct or withhold any tax in respect of the Holder as a direct result of any adjustment described in Section 2 being made to Warrants held by such Holder, then the Company shall be entitled to make such deduction or withholding and shall timely pay the full amount withheld or deducted to the relevant taxing authority in accordance with applicable law. Notwithstanding anything to the contrary in this Section 0, the Company shall notify the applicable Holder in writing of its intent to withhold or deduct any tax at least 30 days prior to withholding or deducting any tax, and the Company shall give such Holder a reasonable opportunity to establish (by the provision of applicable tax forms or otherwise) that no withholding or deduction is required. Any amounts withheld by the Company and paid over to the relevant taxing authority by the Company pursuant to this Section 0 shall, to the extent not reimbursed to the Company by the Holder, be treated as payment by the Holder of the exercise price for all purposes of this Warrant. Without limiting the generality of the foregoing, and without duplication, the Holder shall indemnify the Company for the full amount of any taxes (excluding interest, penalties and additions to tax) that the Company is required by law to deduct or withhold in respect of the Holder as a direct result of any adjustment described in Section 2 being made to Warrants held by such Holder.

 

5.2     Binding Effect. All the covenants and provisions of this Warrant by or for the benefit of the Company or the Holder shall bind and inure to the benefit of their respective successors and permitted assigns hereunder.

 

5.3     Notices. Notices or demands pursuant to this Warrant to be given or made by any Holder to or on the Company shall be sufficiently given or made if sent by certified or registered mail, return receipt requested, postage prepaid, or facsimile and addressed, until another address is designated in writing by the Company, as follows:

 

AmeriCann, Inc.

3200 Brighton Blvd., Unit 144

Denver, CO 80216  

Attention: Chief Executive Officer

 

Notices to the Holder provided for in this Warrant shall be deemed given or made by the Company if sent by certified or registered mail, return receipt requested, postage prepaid, and addressed to the Holder or each successor at its last known address as it shall appear on the books of the Company.

 

5.4     Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. This Warrant shall be governed by, and construed in accordance with, the internal laws of the State of New York, without reference to the choice of law provisions thereof.  The Company and, by accepting this Warrant, the Holder, each irrevocably submits to the exclusive jurisdiction of the courts of the State of New York for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Warrant and the transactions contemplated hereby.  Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Warrant.  The Company and, by accepting this Warrant, the Holder, each irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court.  The Company and, by accepting this Warrant, the Holder, each irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. EACH OF THE COMPANY AND, BY ITS ACCEPTANCE HEREOF, THE HOLDER HEREBY WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS WARRANT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

 

 
8

 

 

5.5     Parties Bound and Benefited. Nothing in this Warrant expressed and nothing that may be implied from any of the provisions hereof is intended, or shall be construed, to confer upon, or give to, any person or entity other than the Company and the Holder any right, remedy or claim under any promise or agreement hereof, and all covenants, conditions, stipulations, promises and agreements contained in this Warrant shall be for the sole and exclusive benefit of the Company and its successors and of the Holder and its successors and registered assigns.

 

5.6     Confidentiality. The Holder agrees to maintain, and to require its representatives to maintain, all confidential information obtained from the Company on a confidential basis, which, among other things, precludes the use of such confidential information for the purposes of trading on the Warrant Shares.

 

5.7     Identity of Transfer Agent. The transfer agent for the Common Stock is Island Stock Transfer, Inc.  Upon the appointment of any subsequent transfer agent for the Common Stock or other shares of the Company’s capital stock issuable upon the exercise of the rights of purchase represented by the Warrant, the Company will, within five (5) business days, mail to the Holder a statement setting forth the name and address of such transfer agent.

 

5.8     Amendment; Waiver. Any term of this Warrant may be amended or waived upon the written consent of both the Company and the Holder.

 

5.9     Assignment. Any assignment or transfer of any portion or all of this Warrant shall be made by surrender of this Warrant to the Company at its principal office with the form of assignment attached as Appendix A hereto duly executed.  In such event, the Company shall, without charge, execute and deliver a new Warrant in substantially identical form (other than the number of Warrant Shares) in the name of the assignee named in such instrument of assignment and the portion of this Warrant assigned to the assignee shall promptly be cancelled.

 

5.10     Holder as Owner. Prior to the surrender, transfer or assignment of this Warrant, the Company may deem and treat the Holder as the absolute owner of this Warrant (notwithstanding any notation of ownership or other writing hereon) for the purpose of any exercise hereof and for all other purposes, and the Company shall not be affected by any notice to the contrary.

 

5.11     Rights of Holder. Nothing contained in this Warrant shall be construed as conferring upon the Holder, prior to the exercise of this Warrant, the right to vote, consent or, except as provided by Section 0, receive notice as a shareholder in respect of any meetings of shareholders for the election of directors or any other matter, or as having any rights whatsoever as a shareholder of the Company.

 

 
9

 

 

5.12     Indemnification. The Company agrees to indemnify and hold harmless the Holder from and against any liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, attorneys’ fees, expenses and disbursements of any kind which may be imposed upon, incurred by or asserted against the Holder (other than any income tax due under federal, state or other law as a result of owning this Warrant or any Warrant Shares issued upon the exercise of this Warrant) in any manner relating to or arising out of (i) the Holder’s exercise of this Warrant or ownership of any Warrant Shares issued in consequence thereof, or (ii) any litigation to which the Holder is made a party in its capacity as a shareholder of the Company; provided, however, that the Company will not be liable hereunder to the extent that any liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, attorneys’ fees, expenses or disbursements are found in a final non appealable judgment by a court to have resulted from the Holder’s gross negligence, bad faith or willful misconduct in its capacity as a shareholder or warrantholder of the Company.

 

5.13     Remedies. The Holder and each holder of Warrant Shares, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive the defense in any action for specific performance that a remedy at law would be adequate.

 

5.14     Lost Certificates. If this Warrant is lost, stolen, mutilated or destroyed, the Company shall, on such reasonable terms as to indemnity as it may impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant in substantially identical form as, and in substitution for, this Warrant, which shall thereupon become void.  Any such new Warrant shall constitute an additional contractual obligation of the Company, whether or not the Warrant so lost, stolen, destroyed or mutilated shall be at any time enforceable by anyone.

 

5.15     Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Warrant.

 

5.16     Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of a Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. If the Company fails to make, when due, any payments provided for hereunder, or fails to comply with any other provision of this Warrant, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

 
10

 

 

5.17     Office of the Company; Maintenance of Books. As long as any of the Warrants remain outstanding, the Company shall maintain an office (which shall be the principal executive offices of the Company) where the Warrants may be presented for exercise, registration of transfer, division or combination as provided in this Warrant. The Company agrees to maintain, at its aforesaid office, books for the registration and the registration of transfer of the Warrants.

 

5.18     Section Headings. The section headings in this Warrant are for the convenience of the Company and the Holder and in no way alter, modify, amend, limit or restrict the provisions hereof.

 

[Signature pages follow.]

 

 
11

 

 

IN WITNESS WHEREOF, each of the Company and the Holder has caused this Warrant to be executed and delivered as of the Issue Date by an officer thereunto duly authorized.

 

 

AMERICANN, INC.

 

 

 

 

 

 

 

 

 

 

By:

/s/ Timothy Keogh

 

 

Name:

Timothy Keogh

 

 

Title:

Chief Executive Officer

 

 

 

 

 

MASSACHUSETTS MEDICAL PROPERTIES, LLC

 

 

 

 

 

 

 

 

 

 

By:

/s/ J.F. Barton

 

 

Name:

J.F. Barton

 

 

Title:

Manager

 

 

 

 

 

 

 
12 

 

 

APPENDIX A
ASSIGNMENT OF WARRANT

 

FOR VALUE RECEIVED, _______________________ hereby sells, assigns and transfers unto _____________________________ the Warrant, dated October 17, 2016 (the “Warrant”) and the rights represented thereby, and does hereby irrevocably constitute and appoint _______________________________ Attorney, to transfer said Warrant on the books of AmeriCann, Inc., with full power of substitution.

 

Dated:                                                                                           

 

Signed:                                                                                         

 

 

 

 
 

 

 

APPENDIX B
WARRANT EXERCISE FORM

 

 

To AmeriCann, Inc.:

 

The undersigned hereby irrevocably elects to exercise the right of purchase represented by the Warrant, dated October 17, 2016 (the “Warrant”), for, and to purchase thereunder by the payment of the Exercise Price (as defined in the Warrant) and surrender of the Warrant, ___________ shares of common stock, par value $0.0001 (“Warrant Shares”), of AmeriCann, Inc. provided for therein. The undersigned requests that the Warrant Shares be issued in book-entry form by the Company’s transfer agent as follows:

 

                                                                     

Name

                                                                     

Address

                                                                     

                                                                     

Federal Tax ID or Social Security No.

 

 

and, if the number of Warrant Shares shall not be all the Warrant Shares purchasable upon exercise of the Warrant, that a new Warrant in substantially identical form (other than the number of Warrant Shares) for the balance of the Warrant Shares purchasable upon exercise of this Warrant be registered in the name set forth below indicated and delivered to the address stated below.

 

                                                                     

Name (please print)

                                                                     

Address

                                                                    

                                                                     

Federal Identification or

Social Security No.

 

 

 

 

Dated: ___________________, ____

 

Signature: ______________________________

 

 
 

 

 

Exhibit D

 

FORM OF Deed TO COMPANY

 

(See attached.)

 

 

 

 

 

 

 

 

 

 

 

Exhibit D 

 
 

 

 

QUITCLAIM DEED

 

FREETOWN ACQUISITION COMPANY, LLC, a Massachusetts Limited Liability Company with its principal place of business at c/o Boston Beer Company, One Design Center Place, Suite 850, Boston Massachusetts 02110

 

for consideration paid, and in full consideration of Four Million Four Hundred Seventy Five Thousand and 00/100 ($4,475,000.00) Dollars, the receipt of which is hereby acknowledged, grants to

 

AMERICANN, INC., a Delaware corporation,

 

with QUITCLAIM COVENANTS

 

 

Lot 1A and New Lot 3A on a plan entitled “Campanelli Freetown Land LLC, Campanelli Drive, Freetown, Massachusetts, Approval Not Required Plan”, prepared by Kelly Engineering Group, Inc., dated September 11, 2006, recorded with the Bristol County Registry of Deeds in Book 00144, Page 12 on August 16, 2007.

 

 

Said premises are conveyed subject to all easements and restrictions of record, if any, insofar as any of the same may be now in force and applicable.

 

 

The Grantor has not elected to be treated as a corporation for federal tax purposes.

 


For Grantors Title see a Deed recorded in the Bristol County Registry of Deeds at Book 00144, Page 12.

 

 

 

 

 

 

 

[SIGNATURES APPEAR ON THE FOLLOWING PAGES]

 

 
 

 

 

 

Executed as an instrument under seal this 17th day of October, 2016

 

 

FREETOWN ACQUISITION COMPANY, LLC

 

 

By: /s/ Tara Heath                                   

       Name: Tara Heath

       Title: Authorized Signatory

 

 

 

COMMONWEALTH OF MASSACHUSETTS

 

SUFFOLK COUNTY, SS.

 

On this 17th day of October, 2016, before me, the undersigned notary public, personally appeared Tara Heath, in her capacity as Authorized Signatory of FREETOWN ACQUISITION COMPANY, LLC and proved to me through satisfactory evidence of identification being [X]  driver’s license or other state or federal governmental document bearing a photographic image; [  ]  oath or affirmation of a credible witness known to me who knows the above signatory, or    [  ]  my own personal knowledge of the identity of the signatory, to be the person whose name is signed above, and acknowledged to me that she signed the foregoing, as her free act and deed, voluntarily for its stated purpose, as Authorized Signatory of FREETOWN ACQUISITION COMPANY, LLC.

 

 

/s/___________________________     

Notary Public:

My Commission Expires:

 

 
 

 

 

Exhibit E

 

FORM OF Deed TO PURCHASER

 

(See attached.)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exhibit E

 
 

 

 

QUIT CLAIM DEED

 

AMERICANN, INC., a Delaware Corporation

 

for consideration paid, and in full consideration of less than One Hundred and 00/100 ($100.00) Dollars, the receipt of which is hereby acknowledged, grants to

 

Massachusetts Medical Properties, LLC, a Delaware limited liability company having a principal place of business at P. O. Box 558, Wood River, IL 62095

 

with QUITCLAIM COVENANTS

 

Lot 1A and New Lot 3A on a plan entitled “Campanelli Freetown Land LLC, Campanelli Drive, Freetown, Massachusetts, Approval Not Required Plan”, prepared by Kelly Engineering Group, Inc., dated September 11, 2006, recorded with the Bristol County Registry of Deeds in Plan Book 144, Page 12 on August 16, 2007.

 

Said premises are conveyed subject to all easements and restrictions of record, if any, insofar as any of the same may be now in force and applicable.

 


For Grantors Title, see Deed of Freetown Acquisition Company LLC recorded just prior hereto.

 

 

 

 

 

 

[SIGNATURES APPEAR ON THE FOLLOWING PAGES]

 

 
 

 

 

Executed as an instrument under seal this 17th day of October, 2016.

 

 

AMERICANN, INC.

 

 

By: /s/ Timothy Keogh                           

       Name: Timothy Keogh

       Title: Authorized Signatory

 

 

 

 

 

COMMONWEALTH OF MASSACHUSETTS

 

SUFFOLK COUNTY, SS.

 

On this 17th day of October, 2016, before me, the undersigned notary public, personally appeared Tim Keogh, in his capacity as Authorized Signatory of AMERICANN, INC. and proved to me through satisfactory evidence of identification being [X]  driver’s license or other state or federal governmental document bearing a photographic image; [  ]  oath or affirmation of a credible witness known to me who knows the above signatory, or    [  ]  my own personal knowledge of the identity of the signatory, to be the person whose name is signed above, and acknowledged to me that he signed the foregoing, as his free act and deed, voluntarily for its stated purpose, as Authorized Signatory of AMERICANN, INC.

 

 

/s/                                                                  

Notary Public:

My Commission Expires:

 

                              

 

 

 

 

 

 

 

 

AmeriCann Exh. 10.6 Share Purch Agree Mass. Med. 2-1-17

 

EX-23.1 13 ex23-1.htm EXHIBIT 23.1 ex3-2.htm

 

 

 

 

 

 

EXHIBIT 23.1

 

 

 

 

 

 

 
 

 

 

CONSENT OF ATTORNEYS

 

 

Reference is made to the Registration Statement of AmeriCann, Inc. on Form S-1 whereby certain selling shareholders propose to sell up to, 4,150,000 shares of the Company’s common stock. Reference is also made to Exhibit 5 included in the Registration Statement relating to the validity of the securities proposed to be issued and sold.

 

We hereby consent to the use of our opinion concerning the validity of the securities proposed to be issued and sold.

 

 

 

Very truly yours,

 

HART & HART, LLC

 

 

 

/s/ William T. Hart                                                      

William T. Hart

 

 

 

Denver, Colorado

 

 February 23, 2017

EX-23.2 14 ex23-2.htm EXHIBIT 23.2 ex3-2.htm

 

 

 

 

 

 

EXHIBIT 23.2

 

 

 

 

 

  

 
 

 

 

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

 

The Board of Directors of
AmeriCann, Inc.

 

 

We consent to the use in this Registration Statement on Form S-1 of our report of independent registered public accounting firm dated January 12, 2017 on the balance sheet of AmeriCann, Inc. as of September 30, 2015, and the related statement of operations, stockholders’ equity (deficit) and cash flows for the year ended September 30, 2015.

 

 

/s/ Hartley Moore Accountancy Corporation

 

Hartley Moore Accountancy Corporation

 

March 1, 2017

Irvine, California

 

 

 

 

 
 

 

 

 

 

 

 

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

 

We consent to the inclusion in this Registration Statement on Form S-1 of our report dated January 12, 2017 with respect to the audited balance sheet of AmeriCann, Inc. and for the year ended September 30, 2016, and the related statements of operations, changes in stockholders’ equity and cash flows for the year then ended. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.

 

We also consent to the references to us under the heading “Experts” in such Registration Statement.

 

/s/ MaloneBailey, LLP

www.malonebailey.com

Houston, Texas

March 1, 2017

 

 

 

GRAPHIC 15 ex23-2img001.jpg begin 644 ex23-2img001.jpg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